WorldWideScience

Sample records for mesylate iodine i131

  1. Radioactive Iodine (I-131) Therapy for Hyperthyroidism

    ... Physician Resources Professions Site Index A-Z Radioactive Iodine (I-131) Therapy Radioiodine therapy is a nuclear ... thyroid cancer. When a small dose of radioactive iodine I-131 (an isotope of iodine that emits ...

  2. Radiation exposure in I-131 iodine therapy

    Friedrich, W.

    1985-01-01

    In the past five years, the applied I-131 radioactivity quantity has doubled with a constant number of beds. In 1984, it was 925 GBq (25 Ci). Despite this development, no changes in the professional radiation exposure were made out. The evaluation shows a dose smaller than 0.04 man Sv/TBq (0.16 man rem/Ci) of I-131 applied. This value is below the traceability limit of the film badges. The incorporation load of the personnel (27 members) was determined by monthly body counter measurements. Only in one measurement thyroid gland activity of 5 kBq (140 nCi) was detected. Most measurements did not show any incorporation; and the few positive results were below 0.74 kBq (20 nCi). The environmental load due to unfiltered release from patients' rooms was determined at the fence of the nuclear research plant. The maximum was 0.24 mSv/a thyroid gland dose of a small child in 1982 taking into account the measured 90% partion of organic compound iodine. The waste water is decayed following chemical treatment in storage tanks. (orig./HP) [de

  3. Investigations on the retention of I-131 by an iodine filter of a pressurized water reactor

    Deuber, H.; Gerlach, K.

    1984-01-01

    The retention of I-131 by an equipment room exhaust filter of a German pressurized water reactor was determined by various methods to particularly obtain reliable results. Moreover, investigations were performed to clarify the reason for aging of the carbon contained in the iodine filter mentioned. The actual retention of the organic I-131, corresponding to a value of 99.9%, was limited by I-131 in the form of penetrating iodine compounds. It was lower than the retention of CH 3 I-131 under layout conditions by more than one order of magnitude. The aging was essentially caused by the adsorption of low-volatile organic compounds. (orig.) [de

  4. Status of urinary iodine and I-131 uptake after universal iodination of common salt

    Alam, F.; Begum, F.; Haque, M.; Karim, M.A.; Faruque, O.; Ali, L.; Khan, A.K.A.

    2002-01-01

    This work was carried out in the Institute of Institute of Nuclear Medicine (INM), Bangabandhu Sheikh Mujib Medical University and Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders, Dhaka. Here we have tried to explore present status of urinary iodine and uptake status in Bangabandhu. Period study was from 1998 to 2000. Total study population was 300, of them 84 was male and 216 was female. Populations of all social and economic strata have been studied, starting from bottoms to top-level income groups as well as urban, rural and suburban populations are included randomly. We studied I-131 uptake and urinary iodine. I-131 given orally in liquid form and the quantity accumulated by the thyroid gland at 24 hours intervals of time is measured using a gamma scintillation counter. Gamma-ray emission of 364 keV energy by I-131 is detected gamma scintillation counter. Urinary iodine is estimated by CIS-BIO kit. Urine is digested with chloric acid under mild conditions and determined manually by its catalytic role in the reduction of ceric ammonium sulfate in the presence of arsenious acid. The uptake was grouped into four categories according to their uptake percentage. Group-A; (lowest uptake group) 99 subject, have uptake between 0 to 4.9%, Group-B; 100 subjects, (relatively low uptake) who have uptake between 4.91-9.9%, group-C; 73 subjects, who have uptake between 10-30% and in-group D, there was 28 subjects their uptake was above 30%. We have also found in group-A median uptake is 3.0% and urinary iodine level is 43.31 μg/dl, in group-B median uptake is 7.0% and urinary iodine level is 33.95 μg/dl, in group-C median uptake is 23.0% and urinary iodine level is 12.97 μg/dl, in group-D median uptake is 34.0% and urinary iodine level is 9.35 μg/dl. We have found 1.04% have severe type low urinary iodine, 3.48% moderate type of low urinary iodine, 3.48%, 16.72% mild type of low urinary iodine and 78.74% have normal

  5. Model of iodine metabolism in a T3-thyrotoxic patient undergoing I-131 therapy

    Ahuja, S.; Price, R.; Brill, A.B.; Dobyns, B.M.; Berman, M.

    Data on radioactivity in the thyroid, urine, serum, butanol-extractable iodine (BEI) and chromatographic fractionations of BEI, obtained during four I-131 therapeutic treatments of a T 3 -thyrotoxic patient, have been analyzed and simulated with the help of a 7-compartment model. Good fits to most of the data can be obtained with both the dose-independent and dose-dependent models. A model with 3 or 4 compartments, which provides adequate fits to iodine kinetic data in most euthyroid and hyperthyroid patients is not satisfactory in the case of this patient. Thus, to represent iodine metabolism during T 3 -thyrotoxicosis therapy, we find that it is necessary to provide for separate biochemical pathways for the BEI components as well as the butanol-insoluble compounds released by the thyroid gland

  6. Model of iodine metabolism in a T3-thyrotoxic patient undergoing I-131 therapy

    Ahuja, S.; Price, R.; Brill, A. B.; Dobyns, B. M.; Berman, M.

    1975-06-01

    Data on radioactivity in the thyroid, urine, serum, butanol-extractable iodine (BEI) and chromatographic fractionations of BEI, obtained during four I-131 therapeutic treatments of a T3-thyrotoxic patient, have been analyzed and simulated with the help of a 7-compartment model. Good fits to most of the data can be obtained with both the dose-independent and dose-dependent models. A model with 3 or 4 compartments, which provides adequate fits to iodine kinetic data in most euthyroid and hyperthyroid patients is not satisfactory in the case of this patient. Thus, to represent iodine metabolism during T3-thyrotoxicosis therapy, we find that it is necessary to provide for separate biochemical pathways for the BEI components as well as the butanol-insoluble compounds released by the thyroid gland. (auth)

  7. A False Positive I-131 Metastatic Survey Caused by Radioactive Iodine Uptake by a Benign Thymic Cyst

    Avneet K. Singh

    2017-01-01

    Full Text Available Thyroid carcinoma is the most common endocrine malignancy in the United States with increasing incidence and diagnosis but stable mortality. Differentiated thyroid cancer rarely presents with distant metastases and is associated with a low risk of morbidity and mortality. Despite this, current protocols recommend remnant ablation with radioactive iodine and evaluation for local and distant metastasis in some patients with higher risk disease. There are several case reports of false positive results of metastatic surveys that are either normal physiologic variants or other pathological findings. Most false positive findings are associated with tissue that has physiologic increased uptake of I-131, such as breast tissue or lung tissue; pathological findings such as thymic cysts are also known to have increased uptake. Our case describes a rare finding of a thymic cyst found on a false positive I-131 metastatic survey. The patient was taken for surgical excision and the final pathology was a benign thymic cyst. Given that pulmonary metastases of differentiated thyroid cancer are rare, thymic cysts, though also rare, must be part of the differential diagnosis for false positive findings on an I-131 survey.

  8. Status of thyroidal radioiodine (I-131) uptake and urinary iodine in Bangladesh population: A re-look following implementation of universal iodination of salt

    Alam, F.; Sultana Haque, F.; Karim, M.A.; Faruque, O.; Ali, L.; Azad Khan, A.K.

    2007-01-01

    Iodide plays a central role in thyroid physiology and in the production of thyroid hormones, which are essential for normal vertebrate growth and development. Radioiodine uptake test is one of the oldest radionuclide investigations for evaluation of thyroid function. On the other hand useful information about the nutritional status of a population can be obtained by measuring the prevalence of deficiency in a population. The main aim of this study was to find out the present status of urinary iodine and thyroid uptake status of people living in and around Dhaka City (Bangladesh). The present study was carried out over a period of three years from 1999 to 2002 involving 300 subjects inclusive of 216 females and 84 males. Efforts were made to randomly include people from a broad spectrum of social and economic strata, starting from people belonging to the lowest to the highest income groups; as well as people representing the urban, rural and suburban populations. Urinary iodine levels and 24 hour percentage radioiodine uptake by the thyroid were estimated in all subjects included in this study. Subsequently patients were grouped into four categories based on the values of their percentage 24-hour radioiodine uptake; e.g., Group-A (N-99) with lowest uptake (0-5%), Group-B (N=100) with uptake ranging between 5-10%, Group-C (N=73) with uptake ranging between 10-30% and Group D (N=28) with uptake above 30%. The median 24 hours RAIU values in groups A, B, C and D were 3, 7, 23 and 34% respectively. The corresponding mean urinary iodine levels in the four groups were 43.31, 33.95, 12.97 and 9.35μgm/dl respectively. The results have shown that 1.04, 3.48, 16.72 and 78.74% people studied had levels of urinary iodine indicating severe, moderate, mild or no iodine deficiency respectively as per the WHO Criteria (Severe: <2 μgm /dl, Moderate: 2-4.9 μgm /dl, mild: 5.0-9.9μgm /dl, normal: ≥ 10 μgm /dl). It may be noted that the normal values of Thyroidal I-131 uptake were

  9. Iodine capsules in thyroid therapy: An individually controlled study of I-131 uptake kinetics as compared to liquid administration

    von Schulthess, G.K.; Seelentag, W.W.; Pfeiffer, G.; Blauenstein, P.; Bekier, A.

    1984-01-01

    The aim of this study was to determine the additional radiation dose sustained by parts of the patients gastric mucosa when given I-131 therapy in capsular rather than liquid form, and thus to establish the safety of this procedure. 16 patients with benign thyroid disease were studied by measuring serum radioactivity at 0, 5, 10, 20, 40, and 80 min. after administration of the capsule (120-200 MBq I131). These serum uptake values were compared to the uptake after administration of a liquid diagnostic dose of I-131 (2 MBq). From the resulting uptake curves the delay due to capsular dissolution was determined. The average dissolution time was found to be 12 min. with a large standard deviation of 7 min. Also, a theoretical curve was computed to indicate the dose rate as a function of the distance from the surface of the capsule. Based on this information the maximum dose to the gastric mucosa is of the order of 250 cGy for a therapeutic activity of 185 MBq, which is the maximum dose which may be given as single application to outpatients in Switzerland. By having the patient swallow some liquid during the first ten minutes, the capsule can be made to move around, and hence, the local radiation dose can be reduced substantially. The authors conclude, that I-131 in capsular form is a safe galenic form for therapeutic use in patients with thyroid disease. When large doses are given, administration of the dose in several capsules may be advisable

  10. Diet low in iodine as well as goitrogens (LILGD) enhanced radioiodine (I-131) uptake in treatment of differentiated thyroid cancer

    Aaro, Erik; Gebre-Medhin, Mehari; Lindahl, Sten-AAke

    2005-01-01

    Full text: Low iodine diet (LID) is accepted as an adjuvant to post-thyroidectomy radioiodine therapy of differentiated thyroid cancer since it is held to enhance radioiodine uptake in thyroid remnants and thyroid cancer tissue. However, in the few clinical investigations performed only an indirect and weak evidence of a positive effect of the LID has been demonstrated. Also we had discouraging experience in the application of a strict LID using the same design as in the present study. We therefore decided to investigate the effect of a diet low in iodine as well as in goitrogens (LILGD). Methods: Six patients with differentiated thyroid cancer entered the study and they were their own control. After thyroid hormone withdrawal (TSH > 30 m U/L) and on regular diet a diagnostic whole body scan was performed 24 h after administration of 50 MBq (1,4 mCi) 123 I. The day following diagnostic scan the patients were put on LILGD for 4 days prior and two days after radioiodine therapy. In LILGD beverages, fruits and vegetables containing flavonoids, glucosinolates, cyanides and thiocyanates were avoided and spices and smoking prohibited. Therapeutic radioiodine was administered one week after diagnostic procedures and in the morning after over-night fasting with an activity range of 3,7-5,4 GBq (100 -150 mCi) 131 I. A 24-h therapeutic whole body scan and calculations of percentage uptake U(24) were performed. Diagnostic (basal) D U(24)% and subsequent therapeutic T U(24)% uptake were compared and expressed as therapeutic/diagnostic uptake ratios T/D U(24). Results: A significant increase in therapeutic versus diagnostic uptake T/D U(24) was observed (mean 2,53, median 2,30, range 1,40 - 4,46, p 131 I uptake in radio-ablation of normal and thyroid cancer tissue. (author)

  11. Radiation exposure by radio-iodine release of the planned nuclear power plant Wyhl. Expert's opinion on thyroid exposure due to radioactive I-131

    Bleck-Neuhaus, J

    1981-01-01

    The radioecology of iodine-131 in the off-air of a nuclear power plant is subject to investigation of the critical exposure pathway air - pasture ground - cow - milk. According to the findings on the factors influencing the radiation exposure of man presented in scientific publication we have to deviate today from static equilibrium models. Such models can no longer satisfy at the present state of the art. The viewing of the short-term time behaviour of the radioecological parameter that is imperative with iodine-131 shows that the conventional calculation, chiefly with mean values of many years, does not satisfy the requirements to replace the calculation of the radiation exposure at the most unfavourable points of exposure demanded by the Radiation Protection Ordinance. This report proves that in a number of possible events under normal operating conditions the radiation exposure is far more important and the limiting dose rates are unmistakably exceeded. If favourable conditions coincide it can in fact be expected that the radiation exposure by radio iodine remains below the limiting close rate.

  12. Radiation exposure estimation from patient treated by I-131

    Lahfi, Y.; Anjak, O.

    2012-09-01

    Radioactive iodine is the main radiopharmaceutical substance in the nuclear medicine field which used in diagnosis and treatment of patients suffering from thyroid cancer; thus it can be considered as the main source of the public and patient relative exposure. In this study, 192 patients were selected randomly and their radiation dose rate was measured at different levels of the patient's body (thyroid, knee, bladder) after one, twenty four and forty eight hours from availing the prescript quantity of the I-131. The collected data may serve in estimating the worker and public exposure related to the patient treated by I-131. (authors)

  13. Comparison of thallium-201, Tc-99m MIBI and I-131 scan in the follow-up assessment after I-131 ablative therapy in differentiated thyroid cancer

    Kwon, Jae Sung; Lee, Sung Keun; Kim, Doe Min; Park, Sae Jong; Jang, Kyong Sun; Kim, Eun Sil; Kim, Chong Soon

    1999-01-01

    We conducted a comparative study to evaluate the diagnostic values of Tl-201, Tc-99m MIBI and I-131 scans in the follow-up assessment after ablative I-131 therapy in differentiated thyroid cancer. The study population consisted of 20 patients who underwent surgical removal of thyroid cancer and ablative radioactive iodine therapy, and followed by one or more times of I-131 retreatment (33 cases). In all patients, Tl-201, Tc-99m MIBI, diagnostic and therapeutic I-131 scans were performed and the results were analyzed retrospectively. Also serum thyroglobulin levels were measured in all patients. The final diagnosis of recurrent or metastatic thyroid cancer was determined by clinical, biochemical, radiologic and/or biopsy findings. Positive rates (PR) of Tc-99m MIBI, Tl-201, diagnostic and therapeutic I-131 scans in detecting malignant thyroid tissue lesions were 70% (19/27), 54% (15/28), 35% (17/48) and 63% (30/48), respectively. The PR in the group of 20 cases (28 lesions) who underwent concomitant Tl-201 and I-131 scans were in the order of therapeutic 131 scan 71%, Tl-201 scan 54% and diagnostic I-131 scan 36%. There was no statistically significant difference between Tl-201 and diagnostic I-131 scans (p>0.05). In the group of 20 cases (27 lesions) who underwent concomitant Tc-99m MIBI and I-131 scans, the PR were in the order of Tc-99m MIBI scan 70%, I-131 therapeutic scan 52% and I-131 diagnostic scan 33%. The PR of Tc-99m MIBI was significantly higher than that of diagnostic I-131 scan (p<0.05). Tc-99m MIBI scan is superior to diagnostic I-131 scan in detecting recurrent or metastatic thyroid cancer following ablation therapy in patients with differentiated thyroid cancer. Tl-201 scan did not showed significantly higher positive rate than diagnostic I-131 scan. Instead of diagnostic I-131 scan before the I-131 retreatment, Tc-99m MIBI scan without discontinuing thyroid hormone replacement would be a prudent and effective approach in the management of these

  14. Recurrent thyrotoxicosis after I-131 induced hypothyroidism

    Liu, L.; Borowski, G.D.; Shtasel, P.; Rose, L.I.

    1984-01-01

    The first clinically and biochemically documented case of recurrent thyrotoxicosis after I-131 induced hypothyroidism in a patient with Graves' disease is reported. Two months after the administration of 9.2 mCi of I-131, the subject developed hypothyroidism. One month later, the patient became euthyroid. Then, nine months following ablation, the patient again developed thyrotoxicosis. A second dose of I-131 of 12.5 mCi was required to finally produce permanent hypothyroidism. This case illustrates the recurrence of hypothyroidism after what had seemed to have been adequate I-131 radiation

  15. Treatment of Graves' disease with I131: Case Report

    Sanchez Povis, J.E.; Sandoval Okuma, J.C.; Contreras Carreno, S.E.; Cabello Morales, E.

    2006-01-01

    Objective: To describe the response and complications in children and teenagers suffering Graves' disease who received radioactive iodine therapy. Material and Methods: The clinical records of the patients attended at Paediatric Endocrinology Unit of Hospital Nacional Cayetano Heredia who received therapy with I 131 were reviewed. Demographic characteristics, thyroid weight, radioactive iodine uptake, I 131 dose and clinical and thyroid function evolution were registered. Results: We include thirteen patients: 1 male and 12 females. The mean thyroid weight obtained was 47.56 ± 10.70 gr. Initial calculated dose was 3.92 ± 0.95 mCi, with a total dose of 4.47 ± 1.66 mCi, and mean following period of 2.76 years. Ten patients received only one dose, 2 patients received two doses and one patient received three doses; all cases remitted. Patients who received only 1 dose showed disease remission at 13.13 weeks and mean remission period of the population was 24.62 weeks. Hypothyroidism prevalence up to six months from initiating treatment was 66.66%, and up to 257 weeks 83.33%. Conclusions: We conclude that I 131 was 100% effective in the treatment of children and adolescents suffering Graves' disease in this small series. (author)

  16. I131-meta-iodobenzylguanidine in the diagnosis and treatment of neural crest tumours

    Hoefnagel, C.A.; Hartog Jager, F.C.A. den; Taal, B.G.; Engelsman, E.; Kraker, J. de; Voute, P.A.

    1988-01-01

    Iodine-131-meta-iodobenzylguanidine (I-131-MIBG) was used for scintigraphic detection and therapy of neural crest tumours. The methodology of both techniques is described. Based upon experience with I-131-MIBG-scintigraphy in 170 patients with neural crest tumours, of whom 46 received multiple therapeutic doses of I-131-MIBG, and upon the cumulative reports in the literature, the role of I-131-MIBG in diagnosis and treatment of each of these diseases is indicated. I-131-MIBG-scintigraphy is one of the most sensitive and specific techniques for the diagnosis, staging and follow-up of phaeochromocytoma and neuroblastoma and I-131-MIBG-therapy may induce remission in a number of these patients. In carcinoid and medullary thyroid carcinoma the diagnostic sensitivity is less; however, once the diagnosis has been made, it is useful to establish that the tumour concentrates I-131-MIBG, to see if the patients at some point in time may be amenable to I-131-MIBG-therapy

  17. Clinical comparison of I-131 orthoiodohippurate and the kit formulation of Tc-99m mercaptoacetyltriglycine

    Taylor, A. Jr.; Ziffer, J.A.; Steves, A.; Eshima, D.; Delaney, V.B.; Welchel, J.D.

    1989-01-01

    Previous studies in animals and humans have shown that technetium-99m mercaptoacetyltriglycine (MAG3) purified by high-performance liquid chromatography is a renal tubular agent with characteristics similar to those of iodine-131 orthoiodohippurate (OIH). A kit formulation for Tc-99m MAG3 has been developed and compared with I-131 OIH in 17 patients with suspected renal dysfunction and three potential kidney donors. There were no adverse reactions. Tc-99m MAG3 images were of good quality and consistently better than I-131 OIH images. There was no significant difference in the relative renal uptake of Tc-99m MAG3 and I-131 OIH. The 30-minute urinary excretion of Tc-99m MAG3 was 36.4%, versus 40.4% for I-131 OIH. The average plasma clearance of Tc-99m MAG3 (138 mL/min +/- 117) was less than that of I-131 OIH (272 mL/min +/- 205) (P less than .001); however, there was good correlation between the Tc-99m MAG3 and I-131 OIH clearances (r = .87). The volume of distribution of Tc-99m MAG3 (5.96 L +/- 1.94) was less than that of I-131 OIH (9.41 L +/- 3.73) (P less than .001). These characteristics and the advantages of a simple kit formulation should lead to widespread clinical use

  18. The present status of I-131 therapy for Graves' hyperthyroidism in Japan. Survey by questionnaire

    Ikekubo, Katsuji; Kusakabe, Kiyoko; Kanaya, Shinichi; Nakada, Kunihiro; Mori, Yutaka

    2003-01-01

    A survey on the I-131 therapy of Graves' hyperthyroidism was undertaken by questionnaire in 1,246 hospitals of Japan. One thousand and ninety seven of them (88.0%) responded to the questionnaire. In this paper, we report the results and analysis of the replies to the questionnaire. In the 121 hospitals (11.03%) of the respondents, I-131 therapy is being performed for Graves' hyperthyroidism. A gradual increase was observed in the annual number of I-131 treated Graves' disease patients during the period of 1998-2001, from 1,740 to 2,484. I-131 treatment was selected mainly for the cases with side effects from antithyroid drug (ATD) therapy, followed by the cases with complication of heart or hepatic diseases, recurrences of hyperthyroidism after surgery, radioiodine treatment, and long-term ATD treatment. The 41% of respondents used I-131 in order to restore euthyroidism, 34% aimed for hyperthyroidism and 41% used the dose properly between the two according to the patients. Administration dosage of I-131 was estimated mainly on the basis of thyroid uptake and volume in 93% of the respondents and 48% calculated the radiation dose by also determining the effective half-life in the thyroid gland. Thyroid size was estimated by scintigram (51%), ultrasonography (US) (33%), CT (22%) and palpation (12%). ATD treatment was used before I-131 administration by 70% of the respondents and 34% after radioiodine therapy. A low-iodine diet was given to the patients for a week (46%) or two weeks (47%) before I-131 administration. However, after treatment only 46% of the respondents continued low-iodine diet for a week. (author)

  19. Radioiodine (I-131) therapy in thyroid cancer differentiated type (abstract)

    Khan, M.S.

    1999-01-01

    Carcinoma thyroid is not an uncommon malignancy in Pakistan because of its location in iodine deficient terrain. Painless palpable (solitary) thyroid nodule is the common presentation in majority (>90%) of the patients and > 25% cold nodules in females turned malignant on biopsy whereas in males >75% of cold nodules turned malignant on historical examination. The disease is more common in females as compared to males (3:1) and in females pure papillary carcinoma is more common whereas in males mostly follicular or mixed tumors are seen. Radical surgery (thyroidectomy) is not a routine surgical treatment in our country. In teaching hospitals the routine surgical procedure is lobectomy and Isthmectomy, whereas in DHQ Hospitals less surgical procedures, e.g. tumorectomy or partial labectomy etc. are done. Therefore, in view of limited/partial surgical ablation, I-131 ablation is mandatory for better and longer survival. We have treated 118 patients of thyroid carcinoma (Differential type) at our centre (AEMC) with therapeutic dose of Radioactive iodine (I-131) during the last 13 years with encouraging results (Disease free survival). (author)

  20. The electrophilic lodi nation with 125 I/ 131 I of gamma globulin: Comparison between a solid-phase oxidizing agent (Iodogen), chloramine-T, iodine mono chloride and N-Bromo succinimide

    El-Wetery, A.S.; Ayyoub, S.; El-Mohty, A.A.; Raieh, M.; Ghonaim, A.Kh.

    1997-01-01

    A new available oxidizing agent, 1, 3, 4, 6-tetra chloro-3α, diphenyl glycoluril(iodogen) was compared with chloramine-T (Ch-T), Iodine-mono chloride (I Cl) and N-Bromo succinimide (NBS) in the radio-iodination of gamma-globulin (γ-G) with 'no-carrier-added' (nca) Na 131 I (T 1/2=8 d). In Phosphate and acetate buffer solution, the optimum reaction conditions with respect to PH, concentration of oxidizing agent, reaction time and concentration of γ-G were determined. The optimum conditions which were found require 100μ l of buffer (pH 7.4, 0.025 M), 500μg γ-G (0.003 μmol), (10-40) μg of oxidizing agent and the desired amount of carrier-free radioiodine. Highest radiochemical yield (>85-90%) were obtained at pH 7.4. Separation and identification of the labelled products were achieved by means of high performance liquid chromatography (HPLC) and thin layer chromatography (TLC). 8 figs., 1 tab

  1. I-131 and thyroid-associated ophthalmopathy

    Rasmussen, Aase Krogh; Nygaard, Birte; Feldt-Rasmussen, Ulla

    2000-07-01

    Objective: Radioiodine (I-131) used to obtain euthyroidism in thyrotoxic patients is suspected of having a worsening or provoking effect on thyroid-associated ophthalmopathy (TAO), an autoimmune disease closely related to Graves' disease. Design: This review summarises the existing literature and describes risk factors influencing the course of TAO including thyroid function, cigarette smoking and treatment of Graves' hyperthyroidism especially I-131 therapy. Conclusion: It is recommended that patients who may be at a greater risk of worsening ophthalmopathy are considered when choosing the modality of therapy of hyperthyroidism and also in deciding whether prophylactic systemic glucocorticoid treatment is indicated.

  2. The physico-chemical I-131 species in the exhaust air of a boiling water reactor (BWR 5)

    Deuber, H.

    1984-02-01

    In a German boiling water reactor, the pysico-chemical I-131 species were determined in the plant exhaust and in the individual exhausts during four months. These measurements aimed in particular at determining the percentage and the source of the radiologically decisive elemental I-131 released to the environment. On an average 13% of the I-131 discharged with the plant exhaust consisted of elemental iodine. This was largely released with the exhausts from the reactor building and from the turbine building. The main component was organic-bound I. (orig./HP) [de

  3. Reducing radiation exposure during oral I-131 therapy administration

    Trujillo, J.; Krinsky, S.; Wilson, B.; Teague, E.

    1982-01-01

    A new, closed-system method to reduce air-, direct-, and incidental-contamination during therapeutic administration of oral I-131 was experimentally evaluated on twelve patients. We studied a standard control population using the routine practice of drinking the solution through a straw and compared results with our new technique. Various measurements were performed throughout all phases of dose administration to assess the relative difference of the two approaches. Using the closed system method before and during iodine administration revealed between 100 and 1000 times less activity per millimeter of air sample; whereas, the direct radiation exposure values were higher for the control population. Both the experimental and control methods had similar levels of incidental contamination

  4. Dosimetry prior to I-131-therapy of benign thyroid disease

    Haenscheid, Heribert; Lassmann, Michael; Reiners, Christoph

    2011-01-01

    The activity to be administered in I-131 therapy of benign thyroid disease is determined by the radiation absorbed dose necessary to cure the disease, the target mass, and the residence time of the I-131 in the target volume. Data from 73 patients with complete sets of uptake measurements 2, 6, 24, 48, and 96 (n = 53) or 120 (n = 20) hours after oral administration of 1 MBq I-131 were used to deduce residence times from subsets of 3, 2, or only 1 measurement for each individual. The values were compared to those obtained with the reference method, i.e. a fit of an uptake function based on a 2-compartment model to all 5 measurements, to quantify the errors introduced by the less demanding assessments. Deviations are less than 10% if the 2- compartment uptake function is fitted to only 3 values measured after 6, 24, and 96-120 h. Use of 2, 24, and 96-120 h data results in errors > 20% in individual patients. The effective half-lives as determined from 2 measurements after 24 and 96-120 h correlate well with those deduced from the reference method with larger deviations in individuals with slow iodine kinetics and late maximal uptake. Residence times determined from the 24 h uptake, assuming linear increase during the first day, and the effective half-life limited to maximum 8 days underestimate the actual values systematically in patients with long and short half-lives. These errors can be eliminated by a modification of the calculation method resulting in deviations less than 14% in all but one individual for this procedure. The accuracy of methods based on only one retention value increases with the time of measurement after the administration of I-131. While systematic errors up to a factor of two occur if the 24 h uptake is used for the estimate, deviations are less than 18% for measurements after 120 h. The results suggest that only one late uptake assessment warrants residence time estimates with an acceptable error. Given the high inherent uncertainties in the

  5. Estimation of foetal brain dose from I-131 in the foetal thyroid

    O'Hare, N.J.; Murphy, D.; Malone, J.F.; Gilligan, P.

    1997-01-01

    The ingestion of I-131 by pregnant women can have consequences for the developing foetus, in particular brain function. As the foetal thyroid accumulates iodine from the twelfth week of gestation onwards, the determination of foetal brain dose resulting from such I-131 accumulation is essential. Normal dosimetric methods fail to treat the case of the foetus. Using an approximation method based on the MIRD approach, a foetal dose estimation scheme is developed to allow the determination of foetal brain dose from foetal thyroid irradiation. Dose values are obtained for the foetus based on the maternal intake of I-131. It was found that the choice of biokinetic model for the mother/foetus has a large impact on the determined dose estimate. (author)

  6. False-positive I-131 scan by contaminated muffler in a patient with thyroid carcinoma

    Seo, Han Kyung; Kim, Min Woo; Jeong, Hwan Jeong; Sohn, Myung Hee [Chonbuk National University Hospital, Chonju (Korea, Republic of)

    2006-02-15

    A 39-year-old female patient who had undergone a total thyroidectomy for a papillary thyroid carcinoma underwent a whole body scan with I-131. The I-131 scan was performed 72 hours after administering 185 MBq (5 mGi) of an I-131 solution. The anterior image of head, neck, and upper chest showed multiple areas of increased uptake in the mediastinal area considering of functional metastasis. However, radioactivity was not evident in the image taken after removing her clothes and muffler. The image obtained after placing the muffler on the pallet showed that the radioactivity was still present. It is well known that artifacts on an I-131 scan can be produced by styling hair sputum, drooling during sleep, chewing gum, and paper or a cloth handkerchief that is contaminated with the radioactive iodine from either perspiration or saliva. This activity might be mistaken for a functional metastasis. Therefore, it is essential that an image be obtained after removing the patient's clothes. In this study, artifacts due to a contaminated muffler on the I-131 scan were found. These mimicked a functional metastasis of the mediastinal area in a patient with a papillary thyroid carcinoma.

  7. Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer. No additional value of higher scan dose

    Phan, T.T.H.; Tol, K.M. van; Links, T.P.; Piers, D.A.; Vries, E.G.E. de; Dullaart, R.P.F.; Jager, P.L.

    2004-01-01

    After initial treatment with total thyroidectomy and radio iodine ablation, most follow-up protocols for patients with differentiated thyroid carcinoma contain cyclic diagnostic I-131 imaging and serum thyroglobulin (Tg) measurements. The applied diagnostic I-131 doses vary between 37 and 370 MBq. The aim of this study was to determine the yield of a diagnostic scan with 370 MBq I-131 in patients with a negative diagnostic scan with 74 MBq I-131. Retrospective evaluation of 158 patients who received a high-dose diagnostic scan with 370 MBq I-131 because of a negative low-dose diagnostic scan with 74 MBq I-131. Special attention was paid to the patients with positive high-dose diagnostic scanning and undetectable serum Tg levels after thyroid hormone withdrawal. In 127 (80%) of patients the 370 MBq I-131 scan was negative, just like the preceding low-dose scan. In 31 (20%) of patients abnormal uptake was present on the 370 MBq diagnostic scan. In 19 of these 31 patients serum Tg was undetectable. In 15/19 the high-dose diagnostic scan proved either false positive or demonstrated clinically irrelevant minor ablation rests. In only four patients (2.5%) did the high-dose diagnostic scans reveal possibly relevant uptake caused by residual differentiated thyroid cancer. In 98% of patients a 370 MBq dose of I-131 for diagnostic whole-body scintigraphy (WBS) had no additional value. The combination of a low-dose diagnostic I-131 scan using only 74 MBq combined with a serum Tg level measurement proved sufficient for correct clinical decision making regarding whether the patient requires additional I-131 therapy. (authors)

  8. I-131 Dose Response for Incident Thyroid Cancers in Ukraine Related to the Chornobyl Accident

    Brenner, Alina V.; Tronko, Mykola D.; Hatch, Maureen; Bogdanova, Tetyana I.; Oliynik, Valery A.; Lubin, Jay H.; Zablotska, Lydia B.; Tereschenko, Valery P.; McConnell, Robert J.; Zamotaeva, Galina A.; O?Kane, Patrick; Bouville, Andre C.; Chaykovskaya, Ludmila V.; Greenebaum, Ellen; Paster, Ihor P.

    2011-01-01

    Background: Current knowledge about Chornobyl-related thyroid cancer risks comes from ecological studies based on grouped doses, case?control studies, and studies of prevalent cancers. Objective: To address this limitation, we evaluated the dose?response relationship for incident thyroid cancers using measurement-based individual iodine-131 (I-131) thyroid dose estimates in a prospective analytic cohort study. Methods: The cohort consists of individuals < 18 years of age on 26 April 1986 who ...

  9. Radiopharmaceutical potential of I-131 labelled diazepam

    Yurt, F.; Unek, P.; Asikoglu, M.; Baggi, S.; Erener, G.; Ozkilic, H.; Uluc, F.; Tuglular, I.

    1998-01-01

    In this study, diazepam is a derivative of the 1.4 benzodiazepine family that the most widely used drug as anticonvulsant agent has been labeled with I-131, as a new radiopharmaceutical and its radiopharmaceutical potential has been determined. Labeling of diazepam has been performed by iodogen method and optimum labeling conditions have been determined. Optimum reaction conditions are 1 mg for iodogen amount; 1-5 mg for diazepam amount, 15-20 minutes for reaction time and room temperature for reaction temperature. Specific activity of labeled compound was 0,15 Ci/mmol level. N-octanol/water ratio was found 1.9 for 131 IDZ ( 131 I labeled diazepam). In vivo experiments have been carried out to determine radiopharmaceutical potentials of labeled compound. Biodistribution studies on rats showed that 131 IDZ have accumulated in kidneys, liver, lungs and brain tissues. Scintigraphic results taken with gamma camera on rabbits agree with biodistribution results of rats. (author)

  10. Medically-derived I-131: a potential tool for understanding the fate of wastewater nitrogen in aquatic systems

    Rose, P. S.; Smith, J. P.; Aller, R. C.; Cochran, J. K.; Swanson, R. L.; Murthy, S. N.; Coffin, R. B.

    2010-12-01

    Iodine-131(t1/2 = 8 days) has been measured in Potomac River water and sediments in the vicinity of the Blue Plains Water Pollution Control Plant (WPCP), Washington, DC. The source of I-131 is medical, where it is commonly used to treat thyroid cancer and hyperthyroidism. Iodine is metabolized by patients and eliminated primarily in urine. While other medical radioisotopes may enter the environment via sewage effluent, the nature and quantity of treatments using I-131 cause it to account for much of the radioactivity in sewage effluent. Natural iodine in aquatic systems is biologically cycled similar to other nutrients, such as nitrogen. Iodine-131 concentrations measured in sewage effluent from Blue Plains WPCP and in the Potomac River suggest a relatively continuous discharge of this isotope. Dissolved I-131 shows a strong, positive correlation with δ15N values of nitrate in the river. The range of I-131 concentrations detected in surface waters is 0.18 ± 0.01 to 0.68 ± 0.02 Bq/L. Surface water δ15NO3 values ranged from 8.7 ± 0.3 to 33.4 ± 7.3 ‰ with NO3+NO2 concentrations between 0.38 ± 0.02 and 2.79 ± 0.13 mgN/L. Sediment profiles of particulate I-131 and δ15N indicate rapid mixing or sedimentation and in many cases remineralization of a heavy nitrogen source consistent with wastewater nitrogen. Iodine-131 concentrations in sediments ranged from 1.31 ± 0.8 to 117 ± 2 Bq/kg dry weight. Values of δ15N in sediments ranged from 4.7 ± 0.1 ‰ to 9.3 ± 0.1 ‰. We propose that I-131 coupled with δ15N can be an excellent tracer for the short-term fate of wastewater nitrogen in this system. However, the utility of I-131 as a tracer is not limited to use in the Potomac River. Other studies have documented the presence of I-131 in several aquatic systems and continuous discharges of this radioisotope in sewage effluent are likely to be widespread in urban environments.

  11. Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

    Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others

    2005-01-01

    Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20∼70 mg) immediately prior to administration of therapeutic dose (51.4∼152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted

  12. Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

    Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others [Korea University Medical School, Seoul (Korea, Republic of)

    2005-07-01

    Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20{approx}70 mg) immediately prior to administration of therapeutic dose (51.4{approx}152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted.

  13. Iodine

    ... Health Information Supplement Fact Sheets Frequently Asked Questions Making Decisions What you Need To Know About Supplements Dietary ... mild iodine deficiency and of iodine supplements on cognitive ... breasts. It mainly affects women of reproductive age but can also occur ...

  14. I-131 therapy for thyroid diseases: Doses, new regulations and patient advice

    Amaral, H.; Michaud, P.

    2001-01-01

    I-131 therapy has been widely used in the past 50 years. Its main applications are hyperthyroidism and functioning thyroid cancer. The indications, doses, regulations, precautions and guidelines differ in various centers. The following are recommended: 1. I-131 should be indicated in agreement of the endocrinologist and the nuclear physician with the patient consent; 2. Pre-treatment I-131 thyroid uptake must be performed; 3. The only contraindication for treatment is pregnancy, in children it might be used with caution; 4. For thyrotoxicosis both a calculated or an ablative dose (555 MBq) criteria are acceptable In this case secondary hypothyroidism must be considered an objective rather than a complication; 5. In uninodular toxic goiter a 1110 MBq dose is recommended; 6. Iodine free diet is indicated only for cancer patients; 7. Propylthiouracil (PTU) must be discontinued 5 days before treatment, it should be reinitiated 5 days later; 8. Prophylactic use of corticoid in Graves' disease still require more clinical data to support its use; 9. In treatment failure, wait six months for a new dose; 10. In intrathyroid cancer disease an ablative dose of 3700 MBq should be administered 4 weeks post-thyroidectomy or with a TSH level above 30 μUI/mL; 11. A whole body scan should be done one week later; 12. Follow-up whole body scan should be used only if there is clinical suspicion of metastasis. Thyroid hormone replacement must be discontinued for 30 days or with TSH value above 30 I/mL. For follow-up scan 185 MBq of I-131 are recommended to ovoid thyroid tissue stunning; 13. For metastases, 5700 to 7400 MBq dose is recommended if there are cervical lymphatic nodes or distant metastases. We recommended to adopt the criteria proposed by the United States Nuclear Regulatory Commission (NRC) published as 10 CFR 35.75 and the Regulatory Guide 8.39 for patients release after I-131 administration. (author)

  15. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.

    Khan, Shahbaz Ahmad; Khan, Muhammad Saqib; Arif, Muhammad; Durr-e-Sabih; Rahim, Muhammad Kashif; Ahmad, Israr

    2015-07-01

    To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients. Analytical series. Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013. Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted. Fifty four patients were given only single I-131 therapy dose ranging from 70 mCi (2590 MBq) to 150 mCi (5550 MBq). Thirty nine patients were treated with multiple I-131 radioisotope therapy doses ranging from 80 mCi (2960 MBq) to 250 mCi (9250 MBq). T-test was applied on the sample data showed statistically significant difference between the two groups with p-value (p < 0.01) less than 0.05 taken as significant. There were 68 females and 25 males with an age range of 15 to 80 years. Mean age of the patients were 36 years. Among the 93 cases of first time Radio Active Iodine (RAI) therapy, 59 cases (63%) were discharged after 48 hours. Among 39 patients who received RAI therapy second time or more, most were discharged earlier after achieving acceptable discharge dose rate i.e 25 µSv/hour; 2 out of 39 (5%) were discharged after 48 hours. In 58% patients, given single I-131 therapy dose, majority of these were discharged after 48 hours without any major complications. For well differentiated thyroid cancer patients, rapid dose rate reduction is seen in patients receiving second or subsequent radioiodine (RAI) therapy, as compared to first time receiving RAI therapy.

  16. Determination of I-131 in milk samples

    Fernandez G, I.; Rodriguez C, G.; Quevedo A, J. L.

    1996-01-01

    In our country, in the near future, an isotope center will be in operation, and due to its characteristics, it is possible the discharge of radionuclides to the atmosphere during its normal exploitation, as well as in case of accident. Considering the kind and the concentration of the radioactive material released to the atmosphere, the possible ways of contamination were determined, playing the milk the most significant role, because the Iodine-131 is in the radionuclide inventory of this center, being possible to pass to the food-chain soil-grass-milk, due to the fact that the center is located in a cattle zone. Owing to these facts, it is necessary to rely on a method for determining Iodine-131 that allows to control its presence in milk samples, when the isotope center start to operate. The direct absorption of Iodine-131 in an anionic exchange resin and the subsequent analysis of this resin for gamma spectrometry with a Nal (Tl) detector is a cheap, simple and fast method with a recovery average greater than the 95%. (authors). 5 refs., 3 tabs

  17. Is it safe to treat hyperthyroid patients with I-131 without fear of thyroid storm?

    Vijayakumar, V.; Nusynowitz, M.L.; Ali, S.

    2006-01-01

    Thyroid storm is extremely rare. However, hyperthyroid patients with severe thyrotoxicosis are frequently not treated immediately with I-131 for fear of thyroid storm but are placed on thiouracil drugs for varying periods of time. We demonstrate herein that it is safe to treat these patients with I-131, without pretreatment with thiouracil drugs, provided they do not have complicating intercurrent disease. Our definition of severe hyperthyroidism includes marked signs and symptoms of thyrotoxicosis, suppressed thyroid stimulating hormone (TSH), markedly elevated free T4 and/or free T3 and elevated radioactive iodine uptake (RAIU) (>30%) at 4 or 24 hours. Our diagnostic criteria for thyroid storm include two or more findings of fever (>38 deg C, 100 deg F), severe tachycardia, high pulse pressure, agitation with tremors, flushing, sweating, heart failure, nausea, vomiting, diarrhea, jaundice associated with high free T4 and/or free T3. Patients were selected retrospectively for the period between August 2003 and December 2004. One hundred and twenty-two patient visits were identified. These patients were treated with 370-740 MBq (10-20 mCi) of I-131 and were evaluated for any evidence of thyroid storm. Most of the patients were placed on beta blocker drugs at the time of initial I-131 therapy; these were continued for at least two months, when the first follow-up visit occurred. At the time of I-131 therapy, it is our policy to educate the patients to seek immediate medical attention for exacerbation of symptoms of thyrotoxicosis. Not one of these patients developed thyroid storm. A subset of 25% of these cases with higher potential for thyroid storm (RAIU more than 65%, very marked signs and symptoms, and very markedly elevated free T4 and/or free T3) also tolerated the I-131 therapy well with marked clinical improvement and no exacerbation of the thyrotoxic state. It is safe to administer I-131 to patients who are severely hyperthyroid without fear of thyroid

  18. The biodistribution and effect on hepatic parenchyma with intraarterial injected I-131 lipiodol into hepatic artery

    Kim, Dong Ik; Suh, Jung Ho; Yoo, Hyung Sik; Lee, Jong Tae; Kim, Ki Whang; Park, Chan Il; Kim, Byung Ro

    1989-01-01

    Iodized oil has been used as a contrast agent in lymphangiography. One of the commercially available compounds is Lipidol Ultra-fluid(LUF) which contains 38% iodine by weight. Nakakuma et al(1979) reported that LUF was selectively retained in the hypervascular hepatocellular carcinoma when injected directly into the ligated hepatic artery. Since that time, it has been widely utilized in the detection as well as the therapeutic attempts of hepatocellular carcinoma, where it has been mixed with chemotherapeutic agents or labeled with radioactive I-131. Like all significant advances, the mechanism of lipid retention within the hepatocellular carcinoma is not clearly understood, and also there is a lack of information about the biodistribution and kinetics of I-131 Lipiodol. The apparent safety of this technique require confirmation. The present study was aimed to assess the biodistribution and kinetics of intraarterially injected I-131 Lipiodol and the histologic changes in canine livers. It was also to verify the safety of this technique in clinical applications. Radioactive iodized oil was obtained by simple exchange method . 518 ± 19 MBq(14 mCi, about 1 mCi/kg body weight) of I-131 Lipiodol was injected intraarterially in 12 dogs as a experimental group. Serial count rates over the livers under gamma camera were measured, and then it was compared with quantitative analysis of radioactivities distributed in liver, lung, spleen, kidney, thyroid, bile and circulating blood using dose calibrator after sacrifice at various time intervals. Cumulative radiation doses were calculated by Quimby method. The effect of I-131 lipiodol on hepatic function were analysed by serial liver function tests after intrahepatic injection of I-131 Lipiodol and compared with preinjection values. Liver tissue obtained after sacrifice were stained with hematoxylin-eosin, Oil red-O, and also election microscopic examinations were performed. The results were summarized as follows; 1

  19. I-131 dose response for incident thyroid cancers in Ukraine related to the Chornobyl accident.

    Brenner, Alina V; Tronko, Mykola D; Hatch, Maureen; Bogdanova, Tetyana I; Oliynik, Valery A; Lubin, Jay H; Zablotska, Lydia B; Tereschenko, Valery P; McConnell, Robert J; Zamotaeva, Galina A; O'Kane, Patrick; Bouville, Andre C; Chaykovskaya, Ludmila V; Greenebaum, Ellen; Paster, Ihor P; Shpak, Victor M; Ron, Elaine

    2011-07-01

    Current knowledge about Chornobyl-related thyroid cancer risks comes from ecological studies based on grouped doses, case-control studies, and studies of prevalent cancers. To address this limitation, we evaluated the dose-response relationship for incident thyroid cancers using measurement-based individual iodine-131 (I-131) thyroid dose estimates in a prospective analytic cohort study. The cohort consists of individuals radioactivity measurements taken within 2 months after the accident, environmental transport models, and interview data. Excess radiation risks were estimated using Poisson regression models. Sixty-five incident thyroid cancers were diagnosed during the second through fourth screenings and 73,004 person-years (PY) of observation. The dose-response relationship was consistent with linearity on relative and absolute scales, although the excess relative risk (ERR) model described data better than did the excess absolute risk (EAR) model. The ERR per gray was 1.91 [95% confidence interval (CI), 0.43-6.34], and the EAR per 10⁴ PY/Gy was 2.21 (95% CI, 0.04-5.78). The ERR per gray varied significantly by oblast of residence but not by time since exposure, use of iodine prophylaxis, iodine status, sex, age, or tumor size. I-131-related thyroid cancer risks persisted for two decades after exposure, with no evidence of decrease during the observation period. The radiation risks, although smaller, are compatible with those of retrospective and ecological post-Chornobyl studies.

  20. Migration of radionuclide I-131 through a clayey porous matrix

    Hamlat, M.S.

    1996-01-01

    The chemical and physical behavior of the radiotracer I-131 through a porous matrix are described. The study was evaluated using the laboratory column, which contains porous soils. The collected activities have been measured by gamma counting with a NaI(Tl) detector. The indicators were observed and analyzed by using the one dimension mass transport equation. The solution was utilized to interpret the obtaining experimental data. The experimental values of I-131 are in agreement with those calculated by the model. However, the utilization of (I-131) in the punctual hydrogeological studies is proved. (author). 5 refs., 2 figs., 2 tabs

  1. Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and phaeochromocytoma patients

    Woodings, S.

    2004-01-01

    Iodine-131 patients pose a radiation risk to their family members, carers and colleagues. Doses from thyrotoxicosis and thyroid cancer patients undergoing standard treatments have been well characterised in the literature. However the resulting precautions cannot be easily adapted to circumstances where the patient has an unusual affliction, or an atypical family or occupational environment. In this study, a model for calculating dose from an I-131 patient is derived from first principles. The model is combined with existing results from the literature to determine a distance weighting factor between patients and family members. This technique reduces the uncertainty in the dose calculations by removing the need to guess the unknown patterns of close contact, a problem common to all previous dose calculation techniques. Data is presented for four unusual I-131 treatments; a child thyroid cancer patient, two thyroid cancer dialysis patients and a phaeochromocytoma patient. The model is used to calculate appropriate periods of restricted contact for these patients. The recommendations provide a useful guide for future unusual I-131 treatments. Copyright (2004) Australasian College of Physical Scientists and Engineers in Medicine

  2. Get the Facts About Exposure to I-131 Radiation

    ... Data Conducting Clinical Trials Statistical Tools and Data Terminology Resources NCI Data Catalog Cryo-EM NCI's Role ... affected by I-131 fallout from nuclear testing. Medical signs —A lump or nodule that an individual ...

  3. Development of gamma-photon/Cerenkov-light hybrid system for simultaneous imaging of I-131 radionuclide

    Yamamoto, Seiichi; Suzuki, Mayumi; Kato, Katsuhiko [Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine (Japan); Watabe, Tadashi; Ikeda, Hayato; Kanai, Yasukazu [Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine (Japan); Ogata, Yoshimune [Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine (Japan); Hatazawa, Jun [Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine (Japan)

    2016-09-11

    Although iodine 131 (I-131) is used for radionuclide therapy, high resolution images are difficult to obtain with conventional gamma cameras because of the high energy of I-131 gamma photons (364 keV). Cerenkov-light imaging is a possible method for beta emitting radionuclides, and I-131 (606 MeV maximum beta energy) is a candidate to obtain high resolution images. We developed a high energy gamma camera system for I-131 radionuclide and combined it with a Cerenkov-light imaging system to form a gamma-photon/Cerenkov-light hybrid imaging system to compare the simultaneously measured images of these two modalities. The high energy gamma imaging detector used 0.85-mm×0.85-mm×10-mm thick GAGG scintillator pixels arranged in a 44×44 matrix with a 0.1-mm thick reflector and optical coupled to a Hamamatsu 2 in. square position sensitive photomultiplier tube (PSPMT: H12700 MOD). The gamma imaging detector was encased in a 2 cm thick tungsten shield, and a pinhole collimator was mounted on its top to form a gamma camera system. The Cerenkov-light imaging system was made of a high sensitivity cooled CCD camera. The Cerenkov-light imaging system was combined with the gamma camera using optical mirrors to image the same area of the subject. With this configuration, we simultaneously imaged the gamma photons and the Cerenkov-light from I-131 in the subjects. The spatial resolution and sensitivity of the gamma camera system for I-131 were respectively ~3 mm FWHM and ~10 cps/MBq for the high sensitivity collimator at 10 cm from the collimator surface. The spatial resolution of the Cerenkov-light imaging system was 0.64 mm FWHM at 10 cm from the system surface. Thyroid phantom and rat images were successfully obtained with the developed gamma-photon/Cerenkov-light hybrid imaging system, allowing direct comparison of these two modalities. Our developed gamma-photon/Cerenkov-light hybrid imaging system will be useful to evaluate the advantages and disadvantages of these two

  4. Initial radioiodine remnant ablation success rates compared by diagnostic scan methods: I123 versus I131

    Choi, W.; Choi, E.; Yoo, I.; Kim, S.; Han, E.; Lee, S.; Lee, W.

    2015-01-01

    Full text of publication follows. Objective: to see if diagnostic whole body scan (DxWBS) performed with I-131 prior diminishes the success rate of initial radioiodine remnant ablation (RRA) compared to I-123 DxWBS in differentiated thyroid cancer patients. Material and methods: consecutive thyroid cancer patients who received total thyroidectomy for differentiated thyroid cancer and then high dose RRA (either 100 mCi or 150 mCi) within 6 months were included. DxWBSs were performed with I-123 or with I-131. Prior to the DxWBSs, all patients followed strict low iodine diet for 2 weeks and withdrew hormone to stimulate TSH above 30 mIU/l. Patients with extra-thyroidal extension of tumor, lymph node metastasis, or distant metastasis were excluded. The initial RRA was defined as successful if the next DxWBS done 6 months to 1 year later was negative and stimulated thyroglobulin level was below 2 ng/ml. Results: of 71 patients who had I-123 DxWBSs, 31 patients went on to receive RRA with 100 mCi and 40 patients received 150 mCi. Of 73 patients who had I-131 DxWBSs, 66 received 100 mCi and 7 patients received 150 mCi. The overall success rate was 79% for patients who had I-123 DxWBS prior to RRA (68% for 100 mCi and 86% for 150 mCi), and 68% for patient who had I-131 DxWBSs (68% for 100 mCi and 71% for 150 mCi). Conclusion: for patients who received 100 mCi, the RRA success rate was the same for I-123 DxWBS and I-131 DxWBS. For patients treated with 150 mCi, the success rate may be lower in patients who receive RRA following DxWBS with I-131 compared to DxWBS with I-123. (authors)

  5. Thyroid uptake of I-131 during anti-thyroid drug treatment

    Hoque, M.; Alam, F.; Haque, F.S.; Karim, M.A.; Fariduddin, M.

    2004-01-01

    Hyperthyroidism is a global ailment and its treatment is very promising either by ant-thyroid drug or by radioiodine. Iodine-131 uptake test is very important for evaluation of hyperthyroid in respect to its therapy and to exclude thyroiditis. This study was performed to observe the thyroid uptake pattern during intake of anti-thyroid medicine and workout the possibility to start I-131 therapy just after withdraw of antithyroid drug without waiting few days. In this study total 252 patient's I-131 uptake test is performed. Among the patient 135 (53.57%) were female, 117 (64.43%) were male. All this patients were hyperthyroid both clinically and biochemically. Thyroid uptake was taken to all patients at 24 hours after oral administration of 5 to 10 micro-curie of I -131. Uptake was taken by an uptake system and recorded as percentage uptake. These patients are grouped into three categories. Group-A-newly diagnosed cases, who have not taken antithyroid drug or I-131 therapy, there were 82 patients in this group, and their mean uptake was 37.12 ±18.5%. Group B - this group of patients were studied during intake of antithyroid medicine, there were 130 patients in this group and their mean uptake was 34.34±16.0%. Group-B patients were further divided in two sub-groups, patients having antithyroid drug for 1 to 3 weeks (group-B 1), group B1 have mean uptake 37±21% and those were taking antithyroid for 3 weeks to 2 years (group-B2), group B2 have uptake 34.34±20%. Group C- these patients are taken from those patients who had withdrawn antithyroid drug for 3 days to 3 months, there were 40 such patients. Group C further divided into two sub-group, group-C1 (stopped for 3-10 days) and group C2 (stopped for 11 days to 3 months). Group C1 had mean uptake 38±16% and group C2 had mean uptake 35±19%. From this study it is observed that Iodine-131 uptake percentage of untreated hyperthyroid; during antithyroid drug treatment and after withdraw of antithyroid drug almost

  6. Three cases of respiratory failure after I-131 radioiodine therapy

    Watanabe, Ken; Uchiyama, Masayuki; Fukuda, Kunihiko

    2016-01-01

    We report three cases of respiratory failure after I-131 radioiodine therapy. All cases involved relapsed cervical lesions, and two showed edema of the larynx. Emergency tracheostomy was performed to treat the respiratory failure in one case while the others were treated conservatively. All patients showed improvements without after-effects. Patients who undergo I-131 radioiodine therapy, especially those with cervical lesions, should be carefully monitored for this rare complication after treatment. (author)

  7. Iodine

    ... leg ulcers and reduce the chance of a future infection. Conjunctivitis (pinkeye). Research suggests that using eye ... National Institute of Medicine has set Adequate Intake (AI) of iodine for infants: 0 to 6 months, ...

  8. Post-Irradiation Behaviour of I131 in TeO2

    Jaćimović, Lj.; Stevović, J.; Veljković, S.R.

    1965-01-01

    The system I 131 in TeO 2 is interesting because little is known about thermal chemical changes in this target. Radioiodine was produced by neutron irradiation of TeO 2 in the reactor. Irradiated TeO 2 was dissolved in diluted NaOH. The analysis of the iodine valency forms was made by ion exchange techniques. The thermal and radiation stability of TeO 2 was studied by using the spectrophotometric method for the determination of tellurium. Post-irradiation annealing of I 131 in TeO 2 was studied in dependence on the time and temperature of the heating. The main tendency of annealing was the reduction of radioiodine. The time dependence of this process indicates a fast change at high temperatures. The curves are more complex at lower temperatures. The annealing may appear complex because of the variety of thermal reactions of iodine intermediary. It may react with products of the following processes: tellurium recoil and corresponding hot zone, beta transition of Te 131 and TeO 2 itself. The kinetics of these changes was considered and an estimation of the processes during annealing was made. The influence of the neutron flux on the kinetics of annealing was also studied. (author) [fr

  9. Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study

    Brinks, Peter; Van Gils, Koen; Dickerscheid, Dennis B.M.; Habraken, Jan B.A. [Department of Medical Physics, St. Antonius Hospital, Nieuwegein (Netherlands); Kranenborg, Ellen; Lavalaye, Jules [Department of Nuclear Medicine, St. Antonius Hospital, Nieuwegein (Netherlands)

    2017-06-15

    Radionuclide therapy using I-131 is commonly used for the treatment of benign thyroid diseases. The therapeutic dose to be administered is calculated based on the type of disease, the volume of the thyroid, and the measured uptake percentage. This methodology assumes a similar biological half-life of iodine, whereas in reality a large variation in biological half-life is observed. More knowledge about the actual biological half-life of iodine for individual patients will improve the quantification of the delivered radiation dose during radioiodine therapy and could aid the evaluation of the success of the therapy. In this feasibility study we used a novel measurement device [Collar Therapy Indicator (CoTI)] to measure the uptake curve of patients undergoing I-131 radioiodine therapy. The CoTI device is a light-weight wearable device that contains two independent gamma radiation detectors that are placed in a collar. By comparing results of thyroid uptake measurements with results obtained with a gamma camera, the precision of the system is demonstrated. Additionally, for three patients the uptake curve is measured during 48 h of admission in the hospital. The presented results demonstrate the feasibility of the new measurement device to measure the uptake curve during radioiodine therapy. (orig.)

  10. Methodology to administer therapeutic dose of I-131; Metodologia para administrar dosis terapeutica de I-131

    Basteris M, J.; Gomez D, R. [Universidad Autonoma de Yucatan, Facultad de Medicina, Merida, Yucatan (Mexico)

    2007-07-01

    The present work suggests the use of measures guided to eliminate the resulting chronic sialoadenitis of the treatment of the thyroid cancer with Iodine-131, as well as the use of citric fruits to stimulate the salivation, the post-dose administration of liquids to accelerate the gastric emptying avoiding the secondary effects as the vomit is included. (Author)

  11. Calculated activity incorporated in the therapy with I131

    Chica, L.G.; Puerta, J.A.

    1998-01-01

    By means of the product S(T→ S).A s (T e ), the absorbed dose to thyroid delivered by I 131 incorporated is calculated. Where S(T→ S) is the absorbed dose in the thyroid per nuclear transformation (tn.) of I 131 localized in the thyroid and as a potential function of the mass is expressed. A s (T e ) is the number of tn. of I 131 in the thyroid since the moment of the incorporation until the time T e (the effective middle time); to find A s (T e ) to normal as different pathological conditions, the metabolic model of the iodo proposed by the ICRP is used. Of the expressions of the doses, the incorporated activity, l o , is obtained

  12. Study of the therapeutic dose and the clinical effect on Graves' disease with I-131 treatment

    Dang, Y.

    2005-01-01

    Full text: Graves' disease is being treated with I-131 for more than 40 years in China. Previously the dose of I-131 used to be calculated using the 'Quimby' formula. We have now observed that the dose of I-131 administered to patients is now lower in recent years than the early years. The radioactive iodine uptake by the thyroid gland has also changed significantly over a period of time. In this paper we intend to explore these reasons and to research the relationship between the dose and the effect as well as the main cause of the incidence of the hypothyroidism. The parameters in 'Quimby' formula including I-131 uptake, effective half-life and thyroid weight were analyzed and compared with each year data from 1961 to 1988 and subjected to multiple regression analysis to determine the influence on the calculation of dose in 4465 patients. The therapeutic effects were compared with the data of the clinical follow-up of patients between 1961-1973 and 1978-1988 in 748 patients. The factors which might lead to the hypothyroidism were investigated with the non-condition logistic regression. The I-131 uptake was repeatedly measured within one week in 100 patients to identify the changing pattern of the I-131 uptake and its influence on the administered therapeutic dose. We observed an increase in the value of I-131 uptake. The value of I-131 uptake showed an increase after 1977, as well as a prolongation of effective half-life after 1973. The main reason for these changes being a replacement of the equipment in 1977 (G-M counter tube was replaced by scintillation counter), and the other reason being salt iodization in China in 1973. These two factors resulted in a significant reduction in the administered dose of I-131 during the period 1974-1988 as compared to the previous period 1961-1973; the mean administered doses being 168.35MBq and 330.33MBq respectively. The result of multiple regression analyses suggested that the thyroid weight and the effective half

  13. The Relative Frequency of Persistent Hyperthyroidism After I131Therapy

    Al-EID, M.A.

    1998-01-01

    517 patients with different types of hyperthyroidism who had treated by I 131 therapy were studied. The study demonstrated that diffuse toxic goiter was the most common type of hyperthyroidism. The relative frequency of persistent hyperthyroidism in all types after the first dose of I 131 utilizing our empirical regimen in estimation of therapy doses was low (9.5%). While high frequency of persistent hyperthyroidism among diffuse toxic goiter patients (14%), probably was due to many factors discussed in this paper. Some of these factors are impossible to be estimated precisely and therefore, can not be avoided. But careful dose estimation for each case with diffuse toxic goiter may reduce the rate of retreatment by I 131 . Antithyroid medication prior to I 131 therapy might be another factor resulted in increasing of retreatment of retreatment rate diffuse toxic goiter cases. Longer time interval (more than 5 days) of ceasing antithyroid medication prior therapy is suggested to avoid the effects of these drugs. Patients with other types of hyperthyroidism were not frequently required more than one dose and the frequency of persistent hyperthyroidism was almost negligible

  14. Experimental radioimmunotherapy with I-131-antibody against a differentiation antigen

    Badger, C.C.; Krohn, K.A.; Bernstein, I.D.

    1985-01-01

    The authors have previously shown that I-131-labeled antibodies (Ab) against the Thyl.l antigen can care AKR/Cu (Thyl.2+) mice bearing the AKR/J (Thy 1l.1+) SL2 T-cell lymphoma. The authors have now extended these studies to therapy with I-131-anti-Thyl.1 of SL2 lymphoma in AKR/J mice where Ab reacts with both tumor and normal cells. A 25 μg bolus was rapidly cleared from serum by binding to spleen cells (75% with Tl/2 <60 min.) and only low concentrations of Ab(<2% ID/gm) were present in tumor after infusion. Therapy of AKR/J mice bearing established s.c. lymphoma nodules with 1500 μCi I-131-anti-Thyl.1 resulted in complete regression of the nodule in 6/6 animals although tumor eventually regrew and all animals died of metastatic lymphoma. In contrast, I-131-irrelevant Ab given to produce the same amount of whole body radiation (750 μCi) did not affect tumor growth. These studies suggest that radiolabeled-AB against differentiation antigens may be useful for therapy in spite of binding to normal cell populations

  15. Comparison of four different protocols of I-131 therapy for toxic single thyroid nodule

    Zakavi, S.R.; Mousavi, Z.

    2007-01-01

    Full text: Aim: Radio-iodine therapy is the preferred method of treatment of toxic thyroid nodule, however there is no consensus on the dose of I-131 administered. The aim of this study was to compare 4 different dose protocols for treatment of these patients. Methods and patients: All patients with hyperthyroidism and single hot thyroid nodule were referred for I-131 therapy after thyroid physical examination, ultrasonography and measurements of 24 hours thyroid iodine uptake. They were randomly entered in one of 4 groups: fixed low dose (FLD), fixed high dose (FHD), calculated low dose (CLD) and calculated high dose (CHD). In fixed dose protocol, 13mCi of I-131 was administered for patients in FLD group and 22.5mCi was administered for patients in FHD group. Quimby formula was used for calculation of radio-iodine dose in calculated groups with 90-100uCi and 180-200uCi per gram of thyroid weight in CLD and CHD groups respectively. Patients were followed up for a mean of 2, 5, 10 , 22 and 50 months later and physical exam and measurements of thyroid values were done in each follow up. Results: One hundred and sixteen patients were studied. One 72 year old patient was decreased 2 months after treatment due to coronary artery disease and 18 other patients did not complete follow up. From 97 patients who completed follow- up 8 patients were male and 89 patients were female. Mean age of patients were 43.3 years (SD=13.4) and mean thyroid nodule weight was 51 grams (SD=19.2).Mean 24 hours thyroid uptake was 48.07% (SD=14.07). Follow up was done up to 85 months with a median follow up of 14 months. Twenty two patients were in CHD group, 23 patients in CLD, 25 patients in FLD and 27 patients in FHD group. No significant difference was noted in 4 groups regarding age, sex, thyroid uptake and thyroid weight. The mean administered dose was 10.5mCi (SD=3.2) and 18.7mCi (SD=5.3) in CLD and CHD groups respectively (P<0.001). In CHD group, hyperthyroidism was decreased from 33

  16. Methodology for Gamma cameras calibration for I-131 uptake quantification in Hyperthyroidism diseases

    Lopez Diaz, A.; Palau San Pedro, A.; Martin Escuela, J. M.; Reynosa Montejo, R.; Castillo, J.; Torres Aroche, L.

    2015-01-01

    Optimization and verification of Patient-Specific Treatment Planning with unsealed I-131 sources is a desirable goal from medical and radiation protection point of view. To obtain a practical protocol to combine the estimation of the related parameters with patient's specific treatment dose in hyperthyroidism disease, 3 equipment were studied (Iodine Probe, a Philips Forte Camera with pin-hole collimators and a Mediso Nucline with HEGP for planar and SPECT techniques) and crossed calibrated. The linear behaviour on diagnostic and therapeutic activity range was verified, showing a linear correlation fitting factor R 2 > 0.99. The differences between thyroid uptake determinations in all equipment were less than 6% for therapeutic activities and less than 1.1% in the diagnostic range. The combined protocol to calculate, with only one administration of I 131 , all the necessary parameters to the treatment dose estimation in 2D or 3D, avoiding wasting time with gamma cameras, was established and verified. Following this protocol the difference between apparent and calculated activities were less than 3%. (Author)

  17. Role of trophallaxis in the dispersal of radioactive I131 and of bacterial infections in the termite, Bifiditermes beesoni

    Khan, K.I.; Jafri, R.H.; Ahmad, M.

    1981-01-01

    Dispersal and localisation of radioactive iodine (I 131 ) through trophallaxis was studied in various organs of healthy or bacteria-infected pseudergates of Bifiditermes beesoni. The breakdown of the defence system by bacterial pathogens was also studied by means of I 131 . Individual groups of pseudergates of B. beesoni were infected by various bacterial pathogens, i.e. Thuricide-HP (commercial preparation of Bacillus thuringiensis), B. thuringiensis 11-toumanoffi, B. thuringiensis serotype 3a, 3b, Pseudomonas fluorescens and Serratia marcescens, respectively. Healthy pseudergates retained more radioactivity in their guts and less in their exoskeletons. However, bacteria-infected 'donor' and 'recipient' pseudergates and soldiers retained less radioactivity in their guts and more in their exoskeletons. The flow of radioactivity from gut towards exoskeleton or other parts of B. beesoni pseudergates occurred after destruction and breakdown of the inestinal defence system of the host. (orig.) [de

  18. Effective Half-life of I-131 in Patients with Differentiated Thyroid Cancer Treated by Radioactive I-131

    Park, Seok Gun [Dankook University, Cheonan (Korea, Republic of)

    2008-12-15

    Effective half life of I-131 (T{sub eff}) in patients with differentiated thyroid cancer treated by I-131 is must-know value for dose calculation and determination of release time from isolation room. There has been no report about T{sub eff} in Koreans. Thus, author tried to measure dose rate without radiation exposure to faculty members and calculated T{sub eff}. Probe of radiation survey meter was fixed at the wall of isolation room, and body of survey meter was placed outside the room. With this simple arrangement, author could measure radiation frequently without radiation exposure to faculty members in 68 patient (F=55, M=13, age=47{+-}13.7) treated by I-131 (3.7{approx}7.4 GBq) for differentiated thyroid cancer from Jan 2006 to Dec 2006. From this data, T{sub eff}, 48 hr retention rate, and the time necessary to whole body retention of I-131 become less than 1.1 GBq were calculated. Serum creatinine levels were measured before and after thyroid hormone withdrawal. T{sub eff} was 15.4{+-}4.3 hr (9.4{approx}32.5 hr). There was a loose correlation between T{sub eff} and serum creatinine concentration (r=0.45). 48hr retention was 4.9{+-}4.2% (1{approx}23%). Time necessary to whole body retention of I-131 become less than 1.1 GBq was calculated as 47.1{+-}13.2 hr for 9.25 GBq, 42.1{+-}11.9 hr for 7.4 GBq, 35.7{+-}10.0 hr for 5.55 GBq, and 26.7{+-}7.5 hr for 3.7 GBq dose of I-131. Author successfully measured radiation dose rates in isolated patients treated by high dose of I-131 without radiation exposure to the faculty members with simple arrangement of survey meter probe. Using those data, T{sub eff} and some other indices were calculated.

  19. Microwave assistance of labeling hippuric acid by I-131

    Sherlock Huang, Lin-Chiang; Wu, Kou-Hung; Ko, Pi-Wen; Hsieh, Cheng-Ying; Pao, Kuan-Chuan; Chou, Shih-Ching; Shieh, Fa-Kuen; Sureshbabu, Radhakrishnan; Hsu, Ming-Hua

    2014-01-01

    This work presents a novel approach for labeling hippuric acid with I-131 using microwaves. It utilizes copper(II) acetate as a catalyst of the labeling. The process involves the use of this catalytic copper(II) acetate at low dilutions that were nevertheless sufficient to produce labeled hippuric acid with high radiochemical purity in a short time. Therefore, the novel technique overcomes the limitations of previously reported conventional methods that involve heating. - Highlights: • We report the microwave assisted radiochemical labeling of hippuric acid by I-131. • Cu(OAc) 2 can be used as catalyst to get labeled product in lower dilution condition. • Advantages of our method are lesser time scale and high radiochemical purity.

  20. Present state of the I-131-MIBG therapy

    Fischer, M.

    1986-01-01

    Treatment of malignant pheochromocytoma and neuroblastoma stage III and IV is unsatisfactory. Locally invasive tumors may be cured by radical extirpation. The role of irradiation and/or chemotherapy in malignant pheochromocytoma is disappointing, in neuroblastoma in many cases debatable. From 1981 to the present we studied more than 250 patients by MIBG scintigraphy. 5 patients with malignant pheochromocytoma, one female patient with an intra-adrenal, probably benign pheochromocytoma and 3 children with neuroblastoma stage IV were treated with I-131-MIBG

  1. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with I-131 radiation dose and other characteristics

    Leeman-Neill, Rebecca J.; Brenner, Alina V.; Little, Mark P.; Bogdanova, Tetiana I.; Hatch, Maureen; Zurnadzy, Liudmyla Y.; Mabuchi, Kiyohiko; Tronko, Mykola D.; Nikiforov, Yuri E.

    2012-01-01

    Background Childhood exposure to I-131 from the 1986 Chernobyl accident led to a sharp increase in papillary thyroid carcinoma (PTC) incidence in regions surrounding the reactor. Data concerning the association between genetic mutations in PTCs and individual radiation doses are limited. Methods We performed mutational analysis of 62 PTCs diagnosed in a Ukrainian cohort of patients who were Chernobyl tumors and show different associations for point mutations and chromosomal rearrangements with I-131 dose and other factors. These data support the relationship between chromosomal rearrangements, but not point mutations, and I-131 exposure and point to a possible role of iodine deficiency in generation of RET/PTC rearrangements in these patients. PMID:23436219

  2. I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening

    Phuong Tran

    2010-01-01

    Full Text Available Graves' disease is a thyroid-specific autoimmune disorder in which the body makes antibodies to the thyroid-stimulating hormone receptor leading to hyperthyroidism. Therapeutic options for the treatment of Graves' disease include medication, radioactive iodine ablation, and surgery. Radioactive iodine is absolutely contraindicated in pregnancy as exposure to I-131 to the fetal thyroid can result in fetal hypothyroidism and cretinism. Here we describe a case of a female patient with recurrent Graves' disease, who inadvertently received I-131 therapy when she was estimated to be eight days pregnant. This was despite the obtaining of a negative history of pregnancy and a negative urine pregnancy test less than 24 hours prior to ablation. At birth, the infant was found to have neonatal Graves' disease. The neonatal Graves' disease resolved spontaneously. It was suspected that the fetal thyroid did not trap any I-131 as it does not concentrate iodine until 10 weeks of gestation.

  3. I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening

    Barrett Mark

    2010-03-01

    Full Text Available Graves' disease is a thyroid-specific autoimmune disorder in which the body makes antibodies to the thyroid-stimulating hormone receptor leading to hyperthyroidism. Therapeutic options for the treatment of Graves' disease include medication, radioactive iodine ablation, and surgery. Radioactive iodine is absolutely contraindicated in pregnancy as exposure to I-131 to the fetal thyroid can result in fetal hypothyroidism and cretinism. Here we describe a case of a female patient with recurrent Graves' disease, who inadvertently received I-131 therapy when she was estimated to be eight days pregnant. This was despite the obtaining of a negative history of pregnancy and a negative urine pregnancy test less than 24 hours prior to ablation. At birth, the infant was found to have neonatal Graves' disease. The neonatal Graves' disease resolved spontaneously. It was suspected that the fetal thyroid did not trap any I-131 as it does not concentrate iodine until 10 weeks of gestation.

  4. Distribution and Bioaccumulation of I-131 Within The Water-Fish System

    Darussalam, M; Wijaya, DGO; Sutrisno

    1996-01-01

    Distribution and Bioaccumulation of I-131 Within The Water-Fish System. As one of fission products, radioiodine I-131 potentially become a pollutant either resulted froma fallout or radioactive waste. Therefore, special interest has been given to handle I-131 starting from its production implementation and its waste management. The observations in this research have been focussed on distribution and bio accumulation of I-131 within the water-fish systems. Some number of Tilapia fish were put in aquaria containing I-131 contamined water with certain radioactivity concentration. Within time interval of 0, 6, 24, 48 and 72 hours after treatment the radioactivities of water media. fish and their organs have been measured. The results show that the radioactivity percentage different water media containing different I-131 concentration tend to have similar patterns. Meanwhile, the I-131 concentrations of fish and their organs were varied with similar patterns for different I-131 content in water media

  5. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant

    Lee, T.C.; Harbert, J.C.; Dejter, S.W.; Mariner, D.R.; VanDam, J.

    1985-01-01

    Vocal cord paralysis has been reported following I-131 therapy of thyrotoxicosis and following ablation of the whole thryoid. However, this rare complication has not previously been described following I-131 ablation of a postthyroidectomy remnant. The authors report a patient who required tracheostomy for bilateral vocal cord paralysis following I-131 ablation after near-total thyroidectomy for papillary thyroid carcinoma

  6. The anti-thyroid antibody and I-131 uptake in thyroid disorder patient

    Faridul Alam; Fatema Sultana Haque; Mohammad Abdul Karim; Liaquat Ali; Omer Faruque; Azad Khan, A.K.

    2004-01-01

    The problem of thyroid disorder is extensive in Bangladesh, even more than that of other developing countries. The high incidence rate of goiter is reduced after universal iodine supplement. This study has been undertaken to study the an-thyroid anti-body level among the thyroid disorder population (anti-TPO and anti-thyrogobulin antibody) and TSAb among Graves' disease and sub-acute thyroiditis. This study was performed over 300 persons of them 150 have some type of thyroid (patient) disorder and 150 have got no clinical thyroid disorder (volunteer). We also studied TSH receptor anti-body (TSAb) in 112 Graves' disease patients and 86 patients with sub-acute thyroiditis. All the patient had I-131 Uptake in 24 hours. Among the patient 42(28%) had elevated anti-TPO, 12(8%) had borderline and 96(64%) had normal anti-TPO. It was found the uptake percentage of this group of patient hade slight lower than average uptake of our population. 13±5% It was found that 28(18.6%) had elevated anti thyrogobulin anti-body, 9 (6.2%) had borderline and 113(75.3%) had normal level anti thyrogobulin anti-body. It was also that found the uptake percentage of this group of patient had slight lower than average uptake of our population. We also found that 21% patient had elevated both the antibodies. Among the normal volunteer 24(16%) had elevated anti-TPO, 8 (5.3%) had borderline and 118(78.7%) had normal level of anti-TPO. Thyroid 1-131 uptake was 15±4%. It was found that 14(9.3%) had elevated anti thyrogobulin anti-body, 6(4.1%) had borderline and 130 (76.6%) had normal level of anti thyrogobulin anti-body. Among the normal volunteer 6% had elevated both the antibodies. It was found 91% patient Graves' disease had positive TSAb and 92% of' sub-acute thyroiditis has negative TSAb, I-131 uptake was 31±8% among this group of patient.. Thyroid stimulating antibody is found in 91% of Graves' disease and very few patient with sub-acute thyroiditis. The uptake of I-131 in sub

  7. Calibration of filters for detection of airborne I-131 in the environment of nuclear power plant; Kalibracija filtrov za detekcijo I-131 v zraku okolja jedrske elektrarne

    Zupan, M; Miklavzic, U; Pucelj, B [Institut Jozef Stefan, Ljubljana (Yugoslavia)

    1982-07-01

    A simple and clean method for efficiency calibration of filters for collection of airborne I and corresponding Ge(Li) spectrometer is described. As the calibrated source of gaseous I-131 the radiopharmaceutical water solution of NaI is used. As calibration example the absolute activity distribution of I-131 measured in a charcoal filter is shown. (author)

  8. Preparation of Labelled I131 Rose-Bengal

    Mayani, Mbutyabo; Chabouri, Galaal.

    1978-01-01

    Rose bengal purified on a Sephadex G-25 column has been labelled with iodine-131. The exchange reaction has been undertaken in an ether - alcohol medium. The influence of different factors (iodine concentration, Psup(h), purity and chemical form of the substratum, reaction rate) on the labelling yield has been studied. Radiochemical yield of 90% have been obtained in some conditions instead of the normal 80% reported in the literature

  9. I-131 rose bengal excretion test is not dead

    Antico, V.F.; Denhartog, P.; Ash, J.M.; Gilday, D.L.; Houle, S.

    1985-01-01

    One hundred and thirty I-131 Rose Bengal Excretion Studies (RBI) were performed on 84 patients over nine years. In 90% (56/60) of cases with biliary atresia, the 72-hour RBI was less than or equal to 7%. In only 12.5% (3/24) of cases with neonatal hepatitis was the 72-hour RBI less than or equal to 7%. The accuracy of the test was 91% with a specificity of 88%. Thirty patients later were studied following a Kasai procedure. The RBI test reliably predicted the patency of the anastomosis. The authors conclude that the 72-hour RBI is a reliable test in the diagnosis of biliary atresia and in the documentation of biliary patency following surgery, provided adequate care is taken in stool collection and measurement

  10. Study of Iodine Prophylaxis Following Nuclear Accidents

    Sri Widayati; Tedjasari, R. S.; Elfida

    2007-01-01

    Study of iodine prophylaxis following nuclear accidents has been done. Giving stable iodine to a population exposed by I-131 is one of preventive action from internal radiation to the thyroid gland. Stable iodine could be given as Kl tablet in a range of dose of 30 mg/day to 130 mg/day. Improper giving of stable iodine could cause side effect to health, so then some factors should be considered i. e. dose estimation, age, dose of stable iodine to be given, duration of stable iodine prophylaxis and risk of health. (author)

  11. Novel method of producing radioactive iodine

    Shikata, E.; Amano, H.

    1976-01-01

    Radioactive iodine(I-131) is easily obtained by heating, at a temperature ranging from 600 0 C to 650 0 C, a tellurium oxide intermediate which was obtained by heating telluric acid or tellurium trioxide at a temperature from about 400 0 C to 560 0 C and was irradited with a neutron flux. Thus, pure I-131 is obtained without the complicated operations required in a conventional process for separation and/or purification of the product. 4 claims

  12. The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation

    Watanabe, Ken; Uchiyama, Mayuki; Fukuda, Kunihiko

    2017-01-01

    This article examines the outcome of radioactive iodine ablation therapy for thyroid cancer in nigh-risk patients and investigates background factors influencing ablation failure. We included 91 patients in this retrospective analysis and evaluated the ablation success rate. Successful ablation was defined as the absence of visible iodine-131 (I-131) accumulation in the thyroid bed after whole-body scans and thyroglobulin levels <2 ng/ml in a TSH-stimulated state after ablation. We extracted data on patients' age, sex, I-131 dose, pathology, resection stump findings, tumor T category and thyroglobulin levels, which could affect ablation outcome. Successful ablation was achieved in only 14 patients (15.4%). Pre-ablation serum thyroglobulin levels were significantly higher in the ablation failure group than in the success group (P < 0.001), while no significant differences were found for other factors between the groups. Furthermore, thyroglobulin levels >10 ng/ml were significantly related to ablation failure after multivariate analysis (odds ratio 27.2; 95% confidence interval 2.469-299.7; P = 0.007). The ablation success rate was very low because of high thyroglobulin levels, even with high-dose I-131. High-risk patients, especially those with high thyroglobulin levels (>10 ng/ml), are unlikely to reach levels low enough to meet successful ablation criteria. (author)

  13. The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation.

    Watanabe, Ken; Uchiyama, Mayuki; Fukuda, Kunihiko

    2017-09-01

    This article examines the outcome of radioactive iodine ablation therapy for thyroid cancer in high-risk patients and investigates background factors influencing ablation failure. We included 91 patients in this retrospective analysis and evaluated the ablation success rate. Successful ablation was defined as the absence of visible iodine-131 (I-131) accumulation in the thyroid bed after whole-body scans and thyroglobulin levels sex, I-131 dose, pathology, resection stump findings, tumor T category and thyroglobulin levels, which could affect ablation outcome. Successful ablation was achieved in only 14 patients (15.4%). Pre-ablation serum thyroglobulin levels were significantly higher in the ablation failure group than in the success group (P 10 ng/ml were significantly related to ablation failure after multivariate analysis (odds ratio 27.2; 95% confidence interval 2.469-299.7; P = 0.007). The ablation success rate was very low because of high thyroglobulin levels, even with high-dose I-131. High-risk patients, especially those with high thyroglobulin levels (>10 ng/ml), are unlikely to reach levels low enough to meet successful ablation criteria.

  14. Methodology for management of therapeutic dose of I-131

    Basteris M, J.; Gomez D, R.

    2007-01-01

    The present work suggests the use of measures guided to eliminate the resulting chronic sialoadenitis of the treatment previously described with a therapeutic dose bigger than ablative of Iodine 131, as well as the use of citric fruits to stimulate the salivation, the administration of liquid post-dose is included to accelerate the gastric emptying avoiding the secondary effects as the vomit. (Author)

  15. Methodology to administer therapeutic dose of I-131

    Basteris M, J.; Gomez D, R.

    2007-01-01

    The present work suggests the use of measures guided to eliminate the resulting chronic sialoadenitis of the treatment of the thyroid cancer with Iodine-131, as well as the use of citric fruits to stimulate the salivation, the post-dose administration of liquids to accelerate the gastric emptying avoiding the secondary effects as the vomit is included. (Author)

  16. Radioiodine (I-131) therapy and the influence of antithyroid medication

    Duldulao, M.

    2007-01-01

    Full text: Radioiodine therapy began to play a major role in the management of hyperthyroidism as early as 1941. It later evolved to become what it is today, the treatment of choice for majority of patients who are suffering from Graves' disease and toxic nodular goiter. It is generally considered safe, inexpensive, effective, and devoid of major side effects. Despite the extensive experience with radioactive therapy, the adjunctive role of antithyroid medication remains controversial. Some authors claim that it has a positive influence on the outcome of radioiodine therapy while others insist otherwise. The reasons behind the adjunctive use of antithyroid medication include a more rapid attainment of euthyroid state and a decrease in the rise of developing thyroid crisis. However, a higher treatment failure rate is observed compared to radioiodine alone. This is due to the reputed radioprotective effect of the antithyroid medication. As a result, higher doses of I-131 are needed in order to obtain the desired effect but, unfortunately, that would also increase the radiation exposure to the rest of the body. The majority of clinicians would require discontinuation of the medication a few days before therapy to overcome these undesirable effects but the question is, is this safe? The issue of when antithyroid medication is warranted is a big question to the clinician. For optimal use of radioiodine therapy, appropriate selection criteria and good clinical judgment concerning pretreatment with antithyroid medication are required. Otherwise, we may put some patients into unnecessary increased risk and added cost. (author)

  17. Methodology for management of therapeutic dose of I-131; Metodologia para administrar dosis terapeutica de I-131

    Basteris M, J.; Gomez D, R. [Universidad Autonoma de Yucatan, Facultad de Medicina, Merida, Yucatan (Mexico)

    2007-07-01

    The present work suggests the use of measures guided to eliminate the resulting chronic sialoadenitis of the treatment previously described with a therapeutic dose bigger than ablative of Iodine 131, as well as the use of citric fruits to stimulate the salivation, the administration of liquid post-dose is included to accelerate the gastric emptying avoiding the secondary effects as the vomit. (Author)

  18. Post-laryngectomy localization of I-131 at tracheostomy site on a total body scan

    Kirk, G.A.; Schulz, E.E.

    1984-01-01

    A post-thyroidectomy, post-I-131-therapy patient had a laryngectomy and neck dissection for recurrent papillary thyroid carcinoma. A subsequent I-131 total body scan revealed persistent anterior neck activity, which disappeared upon removal of the tracheostomy tube and dressings

  19. Experience in treatment of hyperthyroidism with I-131 diagnosis, patient preparation and therapeutic procedure

    Zhongyun, Pan

    2003-01-01

    Treatment of hyperthyroidism with I-131 diagnosis is being performed after clinical diagnosis of thyrotoxicosis based on clinical manifestations of hypermetabolic state, serumT3 and T4 determination; medical preparation of patients and therapeutic procedure is obtained for better efficacy, relieve symptoms and prevent aggravation of thyrotoxicosis after I-131 treatment

  20. Bioaccumulation factor for I-131 in aquatic biota II fish - tilapia (Tilapia Mossambica)

    Garcia, G.F.; Casyao, J.M.; Bautista, E.Rb.

    1982-01-01

    The study was undertaken to provide local values for an essential parameter in the estimation of the dose contribution of I-131 through ingestion of fresh water fish. The result showed that the tilapia used in the experiment did not vary significantly in weight and no definite conclusion can be derived as to the effect of body size to bioaccumulation of I-131. (ELC)

  1. Micronucleus induction as a measure of I-131 exposure

    Kasuba, V; Horvat, D [Inst. for Medical Recearch and Occupational Health, Zagreb (Croatia). Laboratory for Mutagenesis; Kusic, Z [Clinical Hospital Sestre Milosrdnice, Zagreb (Croatia). Dept. of Oncology and Nuclear Medicine; Vlatkovic, M [Clinical Hospital Centre, Zagreb (Croatia). Dept. of Nuclear Medicine and Radiation Protection

    1994-10-01

    The change of cell numbers in the peripheral blood following irradiation has been studied for many years, particularly in patients undergoing radiotherapy. Recently, attention is directed towards the use of cytogenetic-mutagenetic methods to estimate the biological effects of received radiation dose. The aim of our study was to identify the difference in number and distribution of micronucleus, depending of applied therapeutic dose of iodine-131. According to their diagnosis, six patients have received iodine-131 in range from 80 to 140 mCi, while in the other group of patients the dose values varied from 7 to 32 mCi. On in vitro peripheral blood lymphocyte cultures micronucleus test was applied. Micronucleus analyses were carried out before the treatment, 24, 48 and 96 hours after the oral application of radiopharmaceutical. The number of micronucleus is showing increase, depending on applied radioactivity of iodine-131 and duration of exposition. The clear dose response relationship was never found. These results illustrate the problem associated with the inhomogeneous distribution of dose which results from the concentration of incorporated radionuclide into thyroid or other tissues. (author).

  2. Preliminary report of a fetal-thyroid overexposure case due to the administration of I-131 during the second trimester of pregnancy

    Gimenez, J.C.; Gutierrez, S.; Alcaraz, G.

    1992-01-01

    Sixty to eighty percent of patients with Graves's disease have antibodies directed against thyroglobulin or against thyroid microsomes. A contemporary interpretation is that thyroid stimulatory inmunoglobuline TSI mimics the action of TSH and stimulate the synthesis and release of thyroid hormone. In patient whose thyroids are capable of responding to such a trophic stimulus, TSI may be the mediator of hyperthyroxinemia. TSI cross the placenta and cause transient hyperthyroidism in some neonates (0,5-1 %) born to mothers who have high circulating levels of the antibodies. As regards adults aged 25 and up, administering I-131 radioactive iodine seems to be a satisfactory treatment for Graves' disease. Such a treatment, however, is to be avoided when treating either pregnant or breast-feeding women due to the effects that irradiation is likely to cause to the fetus or the suckling child. Even though such effects depend on the intrauterine developmental stage, the principal effects are as follows: (a) The embryo may be lethally affected; (b) Malformations and structure changes, or changes in the child's development are likely to occur; (3) The child may be mentally retarded; (4) An induction to cancer and leukemia is possible, and (e) Hereditary effect, may be expected. Moreover, it is a well-known fact that the fetal thyroid is able to capture and integrate iodine as of the 10th/12th gestation week. Thus, administering I-131 according to prescribed doses may define or suppress the thyroid function. Therefore, the highest precautions must be taken in order not to carelessly administer I-131 therapeutic doses to pregnant women. Any woman within the reproductive capacity range should be strongly advised that the pregnancy test is to be performed to avoid her fetus being irradiated. Precisely, the present paper deals with the inadvertent administering an I-131 therapeutic dose to pregnant woman with Graves disease whose child -unexpectedly enough- turned out to be

  3. THE MANAGEMENT OF THYROID CARCINOMA--THE ROLE OF RADIO-IODINE (I-131)

    Workman, James B.

    1963-06-15

    Experience from the management of 156 patients with proven thyroid cancer, followed from 1 to 11 years, is reported. Although no sweeping conclusions can be drawn, it appears that radioiodine continues to have a place in the overall management of most cases of this malignant disease. (auth)

  4. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

    2018-05-15

    Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage IV Thyroid Gland Follicular Carcinoma; Stage IV Thyroid Gland Papillary Carcinoma; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma

  5. Long-term follow-up study of I-131 therapy for Graves' disease

    Kusakabe, Kiyoko; Nakano, Keiko; Maki, Masako

    1990-01-01

    We have studied the follow-up of thyroid function in the patients with late-onset hypothyroidism and euthyroidism after I-131 therapy of hyperthyroidism. Thirty three patients who did not need the thyroid treatment until ten years after I-131 therapy were classified as euthyroid group. And eleven patients who needed the thyroid supplement of thyroid hormone for late-onset hypothyroidism were classified as hypothyroid group. Patients in both groups who required only a single dose of I-131 for successful treatment of hyperthyroidism had similar age, gland size, 24 hour I-131 uptake, pretreatment serum T 3 uptake level and T 4 concentration, and I-131 treatment dose. Subclinical hypothyroidism occurred in 28.6% of euthyroid group and 66.7% of hypothyroid group four months after I-131 therapy. The levels of T 3 were recovered to higher than normal range at 6 months in euthyroid group, while the levels of T 3 were kept within the normal range in the seventy percent of hypothyroid group. Patients who were still lower in the level of T 3 uptake than normal range at 6 months had a higher incidence of late-onset hypothyroidism. Our observation showed no significant difference in the course of follow-up studies after I-131 therapy between the patients with late-onset hypothyroidism and euthyroidism. (author)

  6. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy

    Nakajo, M.; Shapiro, B.; Copp, J.; Kalff, V.; Gross, M.D.; Sisson, J.C.; Beierwaltes, W.H.

    1983-01-01

    The scintigraphic distribution of m-[ 131 I]iodobenzylguanidine (I- 131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I- 131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The ''normal'' adrenal glands were seldom seen and faintly imaged in 2% at 24 hr after injection and in 16% at 48 hr, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extraadrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I- 131 MIBG uptake at 24 through 72 hr

  7. Normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man; evaluation by scintigraphy

    Nakajo, M.; Shapiro, B.; Copp, J.; Kalff, V.; Gross, M.D.; Sisson, J.C.; Beierwaltes, W.H.

    1983-01-01

    The scintigraphic distribution of m-[ 131 I]iodobenzylguanidine (I-131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I-131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The normal adrenal glands were seldom seen and faintly imaged in 2% at 24 h after injection and in 16% at 48 h, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extra-adrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I-131 MIBG uptake at 24 through 72 h

  8. Influence of radiolysis and gas-liquid partition of I-131 in accumulated water on late phase source terms at Fukushima NPP accident

    Hidaka, Akihide

    2014-01-01

    In the process of core cooling at Fukushima Daiichi nuclear power plants accident, large amount of contaminated water was accumulated in the basements of the reactor buildings at Units 1 to 4. The present study estimated the quantities of I-131 and Cs-137 in the water as of late March based on the press-opened data. The estimated ratios of I-131 and Cs-137 quantities to the core inventories are 0.51%, 0.85% at Unit 1, 74%, 38% at Unit 2 and 26%, 18% at Unit 3, respectively. According to the Henry's law, certain fraction of iodine in water could be released to atmosphere due to gas-liquid partition and contribute to increase in the release to environment. A lot of evaluations for I-131 release have been performed so far by severe accident codes such as MELCOR or the reverse estimation with atmospheric dispersion code such as SPEEDI using the monitoring data. The SPEEDI reverse predicted significant release until March 26 while no prediction in MELCOR after March 17. The present study showed that iodine release from accumulated water due to radiolytic conversion from I - to I 2 and gas-liquid partition of I 2 may explain the release between March 17 and 26. This strongly suggests a need for improvement of current MELCOR approach which treats the release only from containment breaks for several days after the core melt. The study also indicates that the release of radioactive iodine from accumulated water in the basements of reactor buildings could become a great concern for the consequence of Fukushima accident. (author)

  9. Dosimetric contribution of the organs of the I123, I124 and I131 bio-kinetics in the dose estimate for euthyroid adults

    Vasquez, A. M.; Rojas, A. R.; Castillo, D. C.; Idrogo, C. J.; Flores, U. H.

    2011-10-01

    Using the formalism MIRD and the representation of Crysty-Eckerman for the thyroid adult, is demonstrated that the dosimetric contributions of source organs of the biokinetics of the radiopharmaceuticals I 123 , I 124 and I 131 (iodine) are not significant in the dose estimate. Therefore, the total absorbed dose by the gland is its auto-dose. Equally, the reported results do not present significant differences to the results found by the Marinelli scheme (auto-dose) for the thyroid represented by a sphere of 20 grams. (Author)

  10. Evaluation of detectors for blood bioanalysis in Lu-177 and I-131 therapies for bone marrow dosimetry; Avaliacao de detectores para bioanalise de sangue em terapias com Lu-177 and I-131 para dosimetria de medula ossea

    Degenhardt, Amilie Louize

    2016-10-01

    The measures traceability is mandatory for minimizing uncertainties in internal dosimetry for radiopharmaceuticals clinical studies and ensures the quality of the standard. Equipment should have resolution and efficiency compatible with radionuclides energies and, additionally, be able to quantify variations in human bodies' activities samples since the initial administration near the minimum residual activities. For testing three equipment (ionization chamber Capintec 25R, sodium iodine scintillator LTI Genesys Gamma-1 and high hyperpure germanium detector Canberra), they were prepared Lu-177 and I-131 radiation sources simulating patient's blood samples activities by adopting the following hypothesis: (1) initial activities according the Brazilian protocols; (2) blood volume in the whole body (5.3 L for adult men and 1.4 L for 5 years-old children); (3) effective half-lives (1.61 h and 42.9 h for Lu-177 bi-exponential adjustment and 15.7 h for I-131 mono-exponential adjustment); (4) sampling between 30 min and 168 h; (v) blood density adjustments. The standard sources were measured in the secondary standard ionization chamber Centronics IG11 at the Laboratorio Nacional de Metrologia das Radiacoes Ionizantes. The Capintec ionization chamber efficiencies ranged, respectively for I-131 and Lu-177, between (111.58±0.02)% and (102.27±0.01)% and HPGe semiconductor detector efficiencies ranged, respectively, between (89.40±0.03)% and (87.80±0.04)%. For the NaI detector, when the Lu-177 sources were positioned inside the detector the efficiencies ranged between (12.66±0.01)% and (11.54± 0.07)% and when the sources were positioned at 5 cm and 10 cm from the detector the efficiencies decreased to less than 5%. For I-131 sources positioned inside the detector, the efficiencies ranged between (29.76±0.21)% and (30.20±0.04)% and they decreased to less than 5% when they were positioned at 5 cm and 10 cm from the detector (deviation greater than 95

  11. Software for dosimetry hypothyroid patients treated with I131 pick up and using probe gamma camera

    Jimenez Felstrom, D.; Luis simon, J.; Reyes Garcia, R.; Derecho Torres, P.; Herrador Cordoba, M.

    2015-01-01

    In this communication the process recently implemented in our hospital for pre and post treatment of patients treated with I-131 in benign diseases of the thyroid gland internal dosimetry is described. We have developed a proprietary software that facilitates the process of dosimetry. Through scans Planar or pictures Spect be determines the mass of the gland thyroid. In function of the mass, is calculated by Monte Carlo the media power absorbed by disintegration of the I-131 in said gland endocrine. (Author)

  12. False Positive Findings on I-131 WBS and SPECT/CT in Patients with History of Thyroid Cancer: Case Series

    Zeina C. Hannoush

    2017-01-01

    Full Text Available Introduction. Although whole body scan (WBS with I-131 is a highly sensitive tool for detecting normal thyroid tissue and metastasis of differentiated thyroid cancer (DTC, it is not specific. Additional information, provided by single photon emission computed tomography combined with X-ray computed tomography (SPECT/CT and by the serum thyroglobulin level, is extremely useful for the interpretation of findings. Case Presentation. We report four cases of false positive WBS in patients with DTC: ovarian uptake corresponding to an endometrioma, scrotal uptake due to a spermatocele, rib-cage uptake due to an old fracture, and hepatic and renal uptake secondary to a granuloma and simple cyst, respectively. Conclusions. Trapping, organification, and storage of iodine are more prominent in thyroid tissue but not specific. Physiologic sodium-iodine symporter expression in other tissues explains some, but not all, of the WBS false positive cases. Other proposed etiologies are accumulation of radioiodine in inflamed organs, metabolism of radiodinated thyroid hormone, presence of radioiodine in body fluids, and contamination. In our cases nonthyroidal pathologies were suspected since the imaging findings were not corroborated by an elevated thyroglobulin level, which is considered a reliable tumor marker for most well-differentiated thyroid cancers. Clinicians should be aware of the potential pitfalls of WBS in DTC to avoid incorrect management.

  13. Evaluation of detectors for blood bioanalysis in Lu-177 and I-131 therapies for bone marrow dosimetry

    Degenhardt, Amilie Louize

    2016-01-01

    The measures traceability is mandatory for minimizing uncertainties in internal dosimetry for radiopharmaceuticals clinical studies and ensures the quality of the standard. Equipment should have resolution and efficiency compatible with radionuclides energies and, additionally, be able to quantify variations in human bodies' activities samples since the initial administration near the minimum residual activities. For testing three equipment (ionization chamber Capintec 25R, sodium iodine scintillator LTI Genesys Gamma-1 and high hyperpure germanium detector Canberra), they were prepared Lu-177 and I-131 radiation sources simulating patient's blood samples activities by adopting the following hypothesis: (1) initial activities according the Brazilian protocols; (2) blood volume in the whole body (5.3 L for adult men and 1.4 L for 5 years-old children); (3) effective half-lives (1.61 h and 42.9 h for Lu-177 bi-exponential adjustment and 15.7 h for I-131 mono-exponential adjustment); (4) sampling between 30 min and 168 h; (v) blood density adjustments. The standard sources were measured in the secondary standard ionization chamber Centronics IG11 at the Laboratorio Nacional de Metrologia das Radiacoes Ionizantes. The Capintec ionization chamber efficiencies ranged, respectively for I-131 and Lu-177, between (111.58±0.02)% and (102.27±0.01)% and HPGe semiconductor detector efficiencies ranged, respectively, between (89.40±0.03)% and (87.80±0.04)%. For the NaI detector, when the Lu-177 sources were positioned inside the detector the efficiencies ranged between (12.66±0.01)% and (11.54± 0.07)% and when the sources were positioned at 5 cm and 10 cm from the detector the efficiencies decreased to less than 5%. For I-131 sources positioned inside the detector, the efficiencies ranged between (29.76±0.21)% and (30.20±0.04)% and they decreased to less than 5% when they were positioned at 5 cm and 10 cm from the detector (deviation greater than 95

  14. Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment.

    Tsai, Chi-Jung; Cheng, Cheng-Yi; Shen, Daniel Hueng-Yuan; Kuo, Shou Jen; Wang, Lien-Yen; Lee, Chiang-Hsuan; Wang, Jhi-Joung; Chang, Ming-Che; Huang, Wen-Sheng

    2016-02-01

    The aim of this study was to evaluate the clinical role of technetium-99m pertechnetate (Tc-99m) imaging in thyroidectomized differentiated thyroid cancer patients immediately before radioiodine-131 (I-131) treatment (Tx). Eighty-six consecutive post-total-thyroidectomy patients (15 men, 71 women; mean age: 46.8 years) with pathologically diagnosed differentiated thyroid cancer were retrospectively studied. Tc-99m imaging immediately before I-131 Tx using both patient-based and lesion-based measurements were analyzed and were further compared with those of post-Tx I-131 whole-body scans. For patients with unequivocally positive Tc-99m uptake, the sensitivity was 77% (patient-based) and 59% (site-based). The positive predictive value (PPV) was 100% for both patient-based and site-based measurements. If equivocal Tc-99m uptake was counted as positive, the sensitivity was 83 and 67%, and the PPV was 100 and 99% for patient-based and site-based measurements, respectively. (a) To increase sensitivity yet maintaining high PPV, equivocal Tc-99m uptake should be considered a positive finding. (b) The nearly 100% PPV of Tc-99m imaging immediately before I-131 Tx for remnant detection suggests that Tc-99m imaging not only serves as an alternative to low-dose I-131 scanning in the low-risk post-thyroidectomy patients but also provides a clue for the subsequent I-131 therapeutic dosage and even for the outcome prediction.

  15. Efficacy of different I-131 doses for thyroid remnant ablation

    Nguyen, X.C.; Thiep, T.V.; Hung, N.C.

    2007-01-01

    Full text: Radioactive iodine 131 I has been widely used as a treatment modality of differentiated thyroid carcinoma. The need for high dose radioiodine ablation of thyroid remnant is still in question. The aim of this prospective study was to assess the efficacy of 131 I different single and fractionated doses in ablation of post-operative thyroid remnant. Patients and methods: One hundred-twelve patients were included in this study. Sixty-one patients with TSH≥30 μU/ml were treated 30 mCi in group 1 (36 patients) or 100 mCi in group 2 (25 patients). Fifty one patients with TSH 131 I high dose of 100 mCi and no severe adverse effect in the other groups. Conclusion: Single high dose (100 mCi) may be more efficient than single low dose (30 mCi) for post-operative remnant ablation with serum TSH≥30 μU/ml and the efficacy of low fractionated doses (30+30 mCi) was comparable with high-fractionated dose (30+100 mCi) for post-operative remnant ablation with low serum TSH in differentiated thyroid carcinoma. (author)

  16. A simple low-cost of liquid I-131 dispenser for routine radiopharmaceutical dispensing at nuclear medicine department, Institut Kanser Negara

    Said, M. A.; Suhaimi, N. E. F. [Fakulti Sains dan Teknologi, Universiti Kebangsaan Malaysia, 43600 UKM, Bangi Selangor (Malaysia); Ashhar, Z. N., E-mail: aminhpj@gmail.com [Institut Kanser Negara, No 4, Jalan P7, Presint 7, 62250 Putrajaya (Malaysia); Zainon, R. [Advanced Medical & Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Pulau Pinang (Malaysia)

    2016-01-22

    In routine radiopharmaceutical Iodine-131 ({sup 131}I) dispensing, the amount of radiation dose received by the personnel depends on the distance between the personnel and the source, the time spent manipulating the source and the amount of shielding used to reduce the dose rate from the source. The novel iRAD-I131 dispenser using recycle {sup 131}I liquid lead pot will lead into low cost production, less maintenance and low dose received by the personnel that prepared the {sup 131}I. The new fabricated of low cost {sup 131}I dispenser was tested and the dose received by personnel were evaluated. The body of lead material is made from 2.5 cm lead shielded coated with epoxy paint to absorb the radiation dose up to 7.4 GBq of {sup 131} I. The lead pot was supported with two stainless steel rod. The Optically Stimulated Luminescence (OSL) nanodot was used in this study to measure the dose rate at both extremities for every personnel who prepared the {sup 131}I. Each OSL nanodot was attached at the fingertip. Three different personnel (experienced between one to ten years above in preparing the radiopharmaceuticals) were participated in this study. The average equivalent dose at right and left hand were 122.694 ± 121.637 µSv/GBq and 77.281 ± 62.146 µSv/GBq respectively. This study found that the dose exposure received using iRAD-I131 was less up to seven times compared to the conventional method. The comparison of experimental data using iRAD-I131 and established radiopharmaceutical dispenser was also discussed. The innovation of {sup 131}I dispenser is highly recommended in a small radiopharmaceutical facility with limited budget. The novel iRAD-I131 enables implementation of higher output liquid dispensing with low radiation dose to the personnel.

  17. The radio-iodine therapy of the functional autonomy. Indications, findings, risks

    Reiners, C.

    1990-01-01

    The functional autonomy of the thyroid is a disorder, which appears in connection with iodine deficit and befalls the complete organ. An absolute indication for a radio-iodine-therapy is given in case of hyperthyreoidism (these are 25 % of all at the functional autonomy). Contrary to the operation method the advantage of the I-131-therapy is, that all of the functional autonome-cells can be reached. The risk at the I-131-therapy is low. (Botek)

  18. Study on the change of hepatic fibrosis indicators in serum before and after I-131 treatment in Graves' Patients

    Li, L.

    2007-01-01

    Full text: Objective: To explore the change of hepatic fibrosis indicators, i.e., PC-III (type III procollagen), IV-C (type IV collagen), HA (hyaluronic acid), LN (laminin) levels in serum of Graves' patients before and after I-131 treatment. Methods: Control group were 40 healthy cases (female 25, male 15, aged 18-60 years) with normal serum levels of those indicators by medical examination in our hospital. Fifty-five Graves' patients (female 32, male 23, aged 17-58) were diagnosed by thyroid function indicators (TT3, TT4, FT3, FT4, TSH) tests, thyroid iodine intake and clinical symptoms and signs, with normal hepatic function indicators and without combined history of hepatic disease, cardiac disease, diabetes, and rheumatic disease. Three to six months after I-131 treatment these were completely recovered (back to normal thyroid function, shrunken thyroid gland volume from swelling, and disappeared clinical symptoms and signs). In both controls and Graves' patients, 2 ml venous blood was taken at early morning from each case with limosis respectively before and after I- 131 treatment. RIA method was adopted for detection of each serum indicator with reagents kit. Data were analyzed by t test in the SPSS statistical software pack. Results: 1. In Graves' patients, before treatment PC- III (type III procollagen) levels were statistically higher than that in controls (p 0.05). 2. In Graves' patients, PC-III significantly decreased to a lower level after treatment than before (p 05). 3. In Graves' patients, after treatment there is no significant difference of indicator levels when compared with controls (p>0.05). Conclusion: Graves' patients had certain degree of hyperplasia of hepatic connective tissue, and this pathogenesis recovered with healing of Graves' disease. PC-III positive rate and thyroid function indicator positive rate may be better in accordance with the disease process than IV-C, Ha and LN indicators. These data showed that of four serum hepatic

  19. Iodine behaviour in the SLOWPOKE nuclear reactor

    Bekeris, P A; Evans, G J [Toronto Univ., ON (Canada). Dept. of Chemical Engineering and Applied Chemistry

    1994-12-31

    The purpose of this project is to measure and attempt to explain the presence and volatility of iodine isotopes present as fission products in the SLOWPOKE-2 reactor. Liquid sampling and extraction procedures developed indicated that approximately 40% of the reactor iodine is in the form of iodate (IO{sub 3}{sup -}), and 60% is in the form of iodide (I{sup -}). No appreciable amount in non-polar forms such as molecular iodine (I{sub 2}) or organic iodides (RI) were detected. This goes contrary to past expectations that all of the iodine in the liquid phase would be in the form of I{sup -}. In addition partition coefficients for I-131 were determined as 2-6x10{sup 6} at a neutral pH. Kr-88 is suspected as a possible interfering isotope in the measurement of I-131 in the liquid and gas phases. (author). 9 refs., 2 tabs., 2 figs.

  20. Iodine 131 and 133 as Fission Indicators

    Broda, E.

    1944-07-01

    This report was written by E. Broda at the Cavendish Laboratory (Cambridge) in September 1944 and is about the possible use of Iodine 131 and 133 as fission indicators. Additionally, the description of the chemical procedure for I 131 and I 133 and the corresponding results can be found in this report. (nowak)

  1. Clinical Significance of Diffuse Intrathoracic Uptake on Post-Therapy I-131 Scans in Thyroid Cancer Patients

    Choi, Hyun Su; Kim, Sung Hoon; Park, Sonya Youngju; Park, Hye Lim; Seo, Ye Young; Choi, Woo Hee

    2014-01-01

    The purpose of this study was to identify the frequency and possible cause of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients. We retrospectively reviewed 781 post-therapy scans of 755 thyroid cancer patients who underwent total thyroidectomy and radioactive iodine therapy between January and December 2010. Diffuse intrathoracic uptake on post-therapy scans was examined, and clinical patient characteristics including sex, age, regimen for thyroid-stimulating hormone (TSH) stimulation (thyroid hormone withdrawal or recombinant human TSH injection), TSH, thyroglobulin (Tg) and anti-thyroglobulin antibody (anti-Tg Ab) levels, therapeutic dose of radioactive iodine therapy and prior history of radioactive iodine therapy were recorded.Scan findings were correlated with chest CT, chest radiographs, laboratory tests and/or clinical status. Diffuse intrathoracic uptake without evidence of pathologic condition was categorized as indeterminate. The association between clinical characteristics and intrathoracic uptake were analyzed for negative intrathoracic uptake and indeterminate uptake groups. Diffuse intrathoracic uptake on post-therapy scans was demonstrated in 39 out of 755 (5.2 %) patients, among which 3 were confirmed as lung metastasis. The 14 patients that showed high Tg or anti-Tg Ab levels were considered to be at risk of having undetected micrometastasis on other imaging modalities. The remaining 22 were indeterminate (2.9 %). Upon comparison of negative intrathoracic uptake and indeterminate uptake groups, TSH stimulation by thyroid hormone withdrawal was shown to be significantly correlated with diffuse intrathoracic uptake (p <0.05). The frequency of diffuse intrathoracic uptake on post-therapy scans was 5.2 % and could be seen in thyroid cancer patients with underlying lung metastasis as well as those without definite pathologic condition. In the latter, there was a higher frequency for diffusely increased intrathoracic

  2. I131-MIBG in early diagnose of neuroblastoma in symptomatic children

    Saddadi, F.S.; Kargarzadeh, F.K.; Yaghoobi, N.Y.

    2002-01-01

    Aim: Neuroblastoma is the second most common solid tumors in childhood which derivates from neural crest. It is very malignant and almost always patient comes with metastasis. However there are some diagnostic tools to detection of lesion in the early stage of tumor. We decided to have a review with using I-131 MIBG in patients suspected and/or proved to have neuroblastoma. Material and Methods: 300-500 μci I 131 MIBG was injected intravenously in patients (5 patients with age range 4 years old) referred for their bone pain and pelvic mass(detected with anatomical tools). Images were obtained 24 to 72 hours throughout the body with ADAC gamma camera and SPECT was performed in each local abnormal uptake. Each patient has already had a WBBS with TcMDP. Results: All abnormal tracer uptakes were seen in bone scan were revealed clearly in I131 MIBG. However, three to five other abnormal tracer activities were only seen in MIBG scan. The main tumoral lesions were showed perfectly in pelvic,that was not seen in WBBS. With a statistical analysis, I131 MIBG has 94% sensitivity 85-100% specificity, compare to Tc99m-MDP that was 78% and 51% respectively. Conclusions: We found that I131 MIBG is the most useful method to diagnose of patients with neuroblastoma and reproved that it has a competitive role in management, follow-up of these tumors especially in detection of metastasis

  3. A case report of hyperfunctioning metastatic thyroid cancer and rare I-131 avid liver metastasis

    Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Chotipanich, Chanisa

    2016-01-01

    Thyroid cancer is usually, relatively hypofunctional; most patients with thyroid cancer are clinically euthyroid. The combination of thyroid cancer and thyrotoxicosis is not common. We herein, report a case of follicular thyroid cancer with hyperfunctioning metastasis in a 43-year-old woman who presented with thyrotoxicosis, a cold right thyroid nodule, and low I-131 uptake at the thyroid bed. An additional total body scan with I-131 revealed a large radioiodine avid osteolytic bone metastasis with soft tissue masses and liver metastasis. The patient received treatment with total thyroidectomy, methimazole, and I-131 at a cumulative dose of 600 mCi along with recombinant human thyroid-stimulating hormone before the first I-131 treatment and palliative radiation. The patient had normal liver function test and experienced a mild degree of bone marrow suppression after I-131. At the 2-year follow-up, the patient was still alive with the progression of bone metastases but was doing well with less severe thyrotoxicosis, good ambulation, and an Eastern Cooperative Oncology Group performance status of 2. Clinicians should be aware of the unusual concurrent presentation of thyrotoxicosis and thyroid cancer, a differential diagnosis in patients with thyrotoxicosis and low or normal radioiodine uptake over the neck and also potential pitfalls during radionuclide treatment

  4. A prospective randomized study of the efficacy and cost-effectiveness of high and low dose regimens of I-131 treatment in hyperthyroidism.

    Pusuwan, Pawana; Tuntawiroon, Malulee; Sritongkul, Nopamol; Chaudakshetrin, Pachee; Nopmaneejumruslers, Cherdchai; Komoltri, Chulalak; Thepamongkhol, Kullathorn; Khiewvan, Benjapa; Tuchinda, Pongpija; Sriussadaporn, Sutin

    2011-03-01

    To compare the efficacy and cost-effectiveness of high and low dose regimens of I-131 treatment in patients with hyperthyroidism. One hundred fifty patients with proven hyperthyroidism were randomly allocated into the high (74 patients) and low (76 patients) dose regimen of I-131 treatment. Four patients of the high dose group and one patient of the low dose group were excluded because of lost follow-up. A gland-specific dosage was calculated on the estimated weight of thyroid gland and 24-hour I-131 uptake. The high and low I-131 dose regimens were 150 microCi/gm and 100 microCi/gm, respectively. The first mean radioiodine activity administered to the high and low dose group was 10.2 and 8 mCi, respectively. Repeated treatment was given to 25 patients of the high dose group and 40 patients of the low dose group. Clinical outcome and calculated costs for outpatient attendances, and laboratory tests together with initial and subsequent treatments were evaluated for one year after I-131 treatment. Elimination of hyperthyroidism that resulted in either euthyroidism or hypothyroidism was classified as therapeutic success. The cost effectiveness was also compared. At 6 months after treatment, 45 (64.3%) patients receiving high dose and 59 (78.7%) patients receiving low dose were hyperthyroidism. Clinical outcome at one year showed persistence of hyperthyroidism in 21 (30%) patients of the high dose regimen and 36 (48%) patients of the low dose regimen. At one year post treatment, it was demonstrated that the high dose regimen could eliminate hyperthyroidism in a significantly shorter time than the low dose regimen, i.e., 259.6 days and 305.5 days, respectively, p = 0.008). For the persistent hyperthyroid patients, the average total cost of treatment in the low dose group was significantly higher than that of the high dose group, i.e., 13,422.78 baht and 10,942.79 baht, respectively; p = 0.050). A high dose regimen of radioactive iodine treatment is more effective than

  5. Evaluation of systematic I-131 thyroid measurements for nuclear medicine workers

    Puscalau, M.A.

    2002-01-01

    In Nuclear Medicine, I-131 is used intensively for the diagnosis and for the treatment of the different severities maladies of the thyroid. This radionuclide generates an important internal contamination to the patients, because of its oral administration, and, also, through inhalation, to the workers involved in the radiopharmaceuticals production , to the nursing staff and to the physicians that care and treat the patients in the hospitals. The paper presents the data obtained by systematically thyroid monitoring of the physicians and nurses from the Endocrinology Hospital, that are contaminated by I-131 inhalation because of their permanent relation with the patients treated with 3.7 MBq I-131 for investigation and with activities in the range 1100 MBq - 4000 MBq for therapy. The measurements were carried out with our Body Counter equipped with a NaI(Tl) scintillation detector, 50 mm thickness and 40mm diameter. Values of the estimated committed equivalent doses are, also, reported

  6. Testicular impact of the treatment with I-131 in patients with differentiated thyroid carcinoma

    Chebel, G.; Gutierrez, S.; Fadel, A.; Suarez, S.; Levalle, O.

    2007-01-01

    Young patients carriers differentiated thyroid carcinoma (DTC) are treated with high doses of I-131 for much of his life with very good prognosis and projects with paternity. However, there is scarce information on the effect of radioiodine on the male gonad and their future fertility. This therapy may compromise on a temporary and / or definitively the role of the germinal cells. The testicular irradiation depends on the blood flow, the dose of I-131 administered and of the presence or absence of metastasis pelvic near to the gonads. A single dose of 100 mCi of I-131 throws an absorbed dose at gonadal level of 50-150 cGy. It has been reported that absorbed doses of 50 cGy can produce transitory decrease spermatogenesis and higher doses can also affect the function of the Leydig cells [es

  7. Calculation of the activity incorporated in the therapy with I 131

    Chica, L.G.; Puerta, J.A.

    1998-01-01

    By means of the product S(T--S). A-s-(T-e-). the absorbed dose to thyroid delivered by I-131 incorporated is calculated. Where S(T--S) is the absorbed dose in the thyroid per nuclear transformations (tn.) of I-131 localized in the thyroid and as a potential function of the mass is expressed. A-s-(T-e-) is the number of tn. of I-131 in the thyroid since the moment of the incorporation until the time T-e- (the effective middle time); to find A-s-(T-e-) to normal as different pathological conditions, the metabolic model of the iodo proposed by the ICRP is used. Of the expression of the doses, the incorporated activity, I-o- is obtained

  8. Iodine-131 in milk 1961-62 and in thyroid glands of cattle and sheep 1962

    Hvinden, T.; Lillegraven, A.

    1976-03-01

    Cases of late effects from radioactive iodine uptake in children have renewed interest in this contaminant. I-131 data collected in Norway during periods following the nuclear weapons test series in 1961 and 1962 have been re-examined and collated with more recent data on natural iodine in the milk and thyroid glands from domestic animals. Some of the measured values may be interpreted as indications of an inverse relationship between the level of natural iodine and the uptake of I-131, but the material is too small and inconsistent to draw any conclusions. Obviously the uptake and concentration of I-131 in animal milk and thyroid glands are influenced by many factors besides the fallout amounts; at present it is not possible to determine their relative importance and set up a satisfactory model for the I-131 uptake. (Auth.)

  9. The therapeutic use of I-131 meta-iodobenzylguanidine (MIBG) in neuroblastoma

    Hartmann, O.; Lumbroso, J.D.; Lemerle, J.; Schlumberger, M.; Parmentier, C.; Ricard, M.; Aubert, B.; Coornaert, S.; Merlin, L.

    1988-01-01

    Despite the use of intensified conventional chemotherapy the complete response rate of advanced neuroblastoma remains low. The use of high-dose chemo-radiotherapy followed by bone marrow transplantation (BMT) improved the duration of disease free survival but, even after these high-dose regimens the relapse rate remains high. Metaiodobenzylguanidine (MIBG) labelled with I-131 or I-123 can be used for scintigraphic imaging of neuroblastoma. In order to evaluate the therapeutic role of I-131-MIBG in the treatment of neuroblastoma patients, a phase II study was performed in 12 patients. Results are presented in this paper

  10. Personalization of restrictions and recommendations for patients heated with I-131. Experience during two years (2000-2001)

    Rivas Ballarin, M. A.; Ruiz Manzano, P.; Hernandez Vitoria, A.; Lozano Flores, F.; Ortega Pardina, P.

    2002-01-01

    The aim of this study is to set criteria for discharging patients treated with I-131, bearing in mind their familiar, social and working status according to the new Spanish legislation on radiological protection and European Guides related to the subject. A mathematical development and a normal contact pattern are proposed to calculate the period of restriction Tcr on the behaviour of the patients, so that the dose to their family friends and colleagues, both in thyroid carcinoma and hyperthyroidism, is within the dose constraints established in the European Guide Radiation Protection following iodine-131 therapy (exposures due to auto-patient or discharged in-patients) published in 1998. This systems has been applied ruing the last two years in Hospital Clinico Universitario Lozano Blesa of Zaragoza where the mean dose rate at 1 meter was 16,6 μSv/h on the day of discharge, after being in hospital for about 48 hours. Some results obtained for the three types of treatment are presented. (Author)

  11. Recurrence rates following I-131 therapy of differentiated thyroid carcinoma: results of meta-analysis

    Obaldo, J.M.

    1990-01-01

    To examine the efficacy of I-131 therapy in decreasing recurrence rates after surgery for differentiated thyroid carcinoma, a research tool called meta-analysis was used. Data were pooled from five published studies which evaluated recurrences following at least sub-total thyroidectomy with or without I-131 ablation of remnants. Of 1332 patients managed surgically only 202 (15%) developed recurrences compared to 36 of 339 (11%) treated with radioiodine. This difference was statistically significant at p<.05. When a separate analysis of only those studies which directly compared the two modes of management was conducted, recurrence rates for patients treated by surgery alone was higher at 18% (185 of 1034) compared with those who had subsequent I-131 therapy with a rate of 9% (27 of 297). This difference was again significant at p <.001. This meta-analysis strongly suggests that the use of I-131 for ablation of post-surgical thyroid remnants significantly reduces recurrence rates in patients with differentiated thyroid carcinoma. (Auth.). 34 refs., 1 tab.; 1 fig

  12. Renal I-131-hippurate clearance overestimates true renal blood flow in the instrumented conscious dog

    Visscher, CA; DeZeeuw, D; Navis, G; VanZanten, AK; DeJong, PE; Huisman, RM

    We evaluated renal I-131-hippurate clearance (ERPF(hip)) as a measure of renal blood flow (RBF) in chronically instrumented conscious dogs. When adjusted for renal hippurate extraction (E(hip), 0.77 +/- 0.01) and hematocrit (Hct, 39.7 +/- 1%), calculated RBF(hip) (656 +/- 37 ml/min) markedly

  13. 76 FR 81517 - Agency Information Collection Activities: Form I-131, Revision of an Existing Information...

    2011-12-28

    ... information collection. (2) Title of the Form/Collection: Application for Travel Document. (3) Agency form... DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services Agency Information...-Day Notice of Information Collection Under Review: Form I- 131, Application for Travel Document. The...

  14. 77 FR 15787 - Agency Information Collection Activities: Form I-131, Revision of an Existing Information...

    2012-03-16

    ... the Form/Collection: Application for Travel Document. (3) Agency Form Number, if any, and the... DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services Agency Information...-Day Notice of Information Collection Under Review: Form I- 131, Application for Travel Document. The...

  15. Control system of liquid effluents generated in treatment with I-131; Sistema de control de efluentes liquidos generados en el tratamiento con I-131

    Garcia M, T.; Ruiz C, M. A.; Angeles C, A.; Ramirez S, R., E-mail: teodoro.garcia@inin.gob.mx [ININ, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2015-09-15

    In recent years, nuclear medicine has developed greatly in our country and around the world. Techniques for both medical diagnosis and therapy have increased the use of radiopharmaceuticals, notably the I-131. In Mexico there are around 150 nuclear medicine establishments authorized by the Comision Nacional de Seguridad Nuclear y Salvaguardias. Most of these establishments do not have an appropriate facility for the treatment of radioactive liquid effluents, to ensure compliance with the concentration limits established in the regulations. The Instituto Nacional de Investigaciones Nucleares (ININ) developed and implemented successfully, a control system of radioactive effluents (named SACEL) from a nuclear medicine facility. This system ensures an effective compliance with regulations and also better management and control of these radioactive effluents. Calculations and design of SACEL were made with respect to I-131, because is one of the most commonly used in radiotherapy and medical diagnostics, besides its half-life is greater in relation to other radionuclides. SACEL is comprised of four storage tanks and decay and a fifth tank for measuring the concentration of I-131 and later discharge to the drain; these tanks are connected to an automated system that controls the effluents passage. The calculation to determine the volume of the tanks was carried out according to the demand that has the hospital, to the maximum activity being poured in effluents and time required to decay. In this paper the design and installation of SACEL system, in addition to functioning as a facility that enables the Hospital meet the required standards is presented. Dose calculations performed with MCNPX and the methodology used in the calibration of the detection system is also presented. (Author)

  16. Evaluation of results of more than 20 years treating hyperthyroidism by I-131

    Phan, S.A.; Mai, T.K.; Tran, D.H.

    2001-01-01

    The authors have summarized their works of more than 20 years using I-131 for treatment and close observation of 723 patients with hyperthyroidism in 1000 ones in the Nuclear Medicine Department, Bach Mai University Hospital in Hanoi to collect data and draw experience for the report. Patient selection for the treatment is based on clinical features and laboratory tests results by the Nuclear Medicine Department such as thyroid uptake, scintigraphy and RIA determinations of thyroid hormones. I-131 dose is determined in compliance with a prevailing formula. The average dose is 6.2 ± 1.1 mCi (that is 233.1 ± 40.7 MBq). The average number of times is 1.3 time for one patient. The results are as follows: Euthyroid status after 4- year following- up from date of I-131 dose administration: 72.3%; Persistent or recurrent hyperthyroidism: 20.0%; Hypothyroid complications: appear 4 to 12 months after date of I-131 administration: 3.0%; appear 4 years after date of I-131 administration: 7.7%; appear 6 years after date of I-131 administration. 14.0%; so the cumulative hypothyroid rate is 2.3% per year. No occurrence of other serious complications by all the observed patients. This is therefore a safe, efficient treatment method to be applied on a large scale including adolescents and children. However, much more study has still to be made on the dose due to high rate of recurrence of the therapeutic method although the hypothyroid complications cases are not serious. Hyperthyroidism is a common health problem in Viet Nam. Previously, only anti-thyroid drugs and surgery were used. Use of I-131 was firstly introduced to Viet Nam in the Nuclear Medicine Department in Bach Mai in 1974 and afterwards applied larger nationwide. Initial therapeutic results have been published in national medical magazines. This is a general study aiming at analyzing the way to carry out the work and get experience and recommendation from gained results for further work in the future. (author)

  17. Efficiency of radioiodine therapy with a fix dose of I-131 in toxic thyroid adenoma

    Petrovski, Z

    2004-01-01

    Purpose: The aim of this study was to estimate the results obtained using a fix dose of I-131 in the treatment of the solitary toxic thyroid adenoma. Material and Methods: We have performed radioiodine therapy m 64 patients, 49 female (50+ 1 7 yrs) and 15 male (43+-15 yrs) with solitary toxic thyroid adenoma. 45 patients received fix dose I-131 of 850 MBq, while 19 patients were treated with calculated (MBq/gr) dose 555-1100 MBq Previously 39(64%) patients were clinically hyperthyreotic and received thyreostatic meditication which were interruptecf one week before the administration of I-131. Those patients who were euthyreotic, TSH was suppressed(<0.25 MU/m1). 61(95.3%) patients received a single dose, while 3(4, 7%) patients needed two doses. Resulting thyroid matabolism and volume of nodules were evaluated 6-48 months after treatment. Results: From 45 radioiodine treated patients with fix dose 6(9, 8%) became hypothyroidism, 36(85, 3%) euthyroidism and 3(4, 9%) recurrent hyperthyroidism, in comparison with 19 treated patients with calculated I-131 dose: 2(10, 5%) hypothyroidism, 16(84, 3%) euthyroidism and 1(5, 2%) recurrent hyperthyroidism. The size of the nodules became unpalpable m 17(26, 2%), decreased evidently in 33(52, 5%) and remained unchanged in 14(21, 3%) of the treated patients. Conclusion: A fix dose of I-131 is simple, safe and efficient in the treatment of solitary toxic thyroid adenoma. There was not significant different in incidence of late follow-up results of hypothyroidism and recurrent hyperthyroidism between fix dose and calculated MBq/gr dose. (authors)

  18. Radioiodine (I-131) treatment for uncomplicated hyperthyroidism: An assessment of optimal dose and cost-effectiveness

    Paul, A.K.; Rahman, H.A.; Jahan, N.

    2002-01-01

    Aim: Radioiodine (I-131) is increasingly being considered for the treatment of hyperthyroidism but there is no general agreement for the initial dose. To determine the cost-effectiveness and optimal dose of I-131 to cure disease, we prospectively studied the outcome of radioiodine therapy of 423 patients. Material and Methods: Any of the fixed doses of 6, 8, 10, 12 or 15 mCi of I-131 was administered to the patients relating to thyroid gland size. The individual was excluded from this study who had multinodular goitre and autonomous toxic nodule. Patients were classified as cured if the clinical and biochemical status was either euthyroid or hypothyroid at one year without further treatment by antithyroid drugs or radioiodine. The costs were assessed by analyzing the total cost of care including office visit, laboratory testing, radioiodine treatment, average conveyance and income loss of patient and attendant and thyroxine replacement for a period of 2 years from the day of I-131 administration. Results: The results showed a progressive increase of cure rate from the doses of 6, 8 and 10 mCi by 67%, 76.5% and 85.7% respectively but the cure rate for the doses of 12 and 15 mCi was 87.9% and 88.8% respectively. Cure was directly related to the dose between 6 and 10 mCi but at higher doses the cure rate was increased marginally at the expense of increased total body radiation. There was little variation in total costs, but was higher for low dose-therapy and the cost proportion between the 6 mCi regimen and 10 mCi regimen was 1.04:1. Conclusion: We could conclude that an initial 10 mCi of I-131 may be the optimal dose for curing hyperthyroidism and will also limit the total costs

  19. Estimation of ingestion dose due to I-131 in the initial month by using food-monitoring data after the Fukushima nuclear disaster in Japan

    Yamaguchi, Ichiro [National Institute of Public Health, Department of Environmental Health, Wako, Saitama (Japan)

    2012-11-15

    The committed equivalent dose to the thyroid caused by I-131 and the effective dose caused by I-131, Cs-134 and Cs-137 due to ingestion immediately after the accidental releases following the Fukushima nuclear disaster in March 2011 were estimated retrospectively by using measured food data. A food monitoring dataset provided by the Ministry of Health, Labour and Welfare (MHLW) up to April 18, 2011 (N=1,752) was used for this study. Information on food consumption by 99 food categories was made available by using the original data of the Japanese National Food Consumption Survey, which was conducted in 2009 (N=9,942). Food concentration every 4 days and food consumption in each food category was randomly picked up (N=100,000). The levels of radioactive iodine and cesium were summed for one month and then converted to equivalent doses to the thyroid and effective doses. These doses in the first month after the Fukushima nuclear power plant accident were evaluated by using the food monitoring dataset provided by the MHLW. Assuming that food was randomly extracted from monitored food samples and food restrictions were fully implemented, the 90%tile of the equivalent doses to the thyroid and the effective doses in 1- to 6-year-old children were estimated to be around 1 mSv and 0.07 mSv, respectively. Several different methods should be considered to reduce limitations of this estimation. (author)

  20. Preparation of a radioactive boron compound (B-I-131-lipiodol) for neutron capture therapy of hepatoma

    Chou, F.I.; Chung, H.P.; Chung, R.J.; Wen, H.W.; Wei, Y.Y.; Kai, J.J.; Lui, W.Y.; Chi, C.W.

    2000-01-01

    In our research, a radioactive boron compound, B-I-131-lipiodol, that can be selectively retained in hepatoma cells was prepared. Combining the effect of α particles produced by boron neutron capture reaction with the β particles released by radionuclides in the radioactive boron compounds will produce a synergistic killing effect on cancer cells. Human hepatoma HepG2 cell cultures were used to examine the stability and the intracellular distribution of the radioactive boron drug. Microscopes were used to examine the interaction and retention of B-I-131-lipiodol globules in the individual hepatoma cell. Moreover, ICP-AES and NaI scintillation counter were performed to determine boron concentrations and I-131 radioactivity, respectively. Results showed that B-I-131-lipiodol with a boron concentration and a specific radioactivity ranged from 500-2000 ppm and 0.05-10 mCi/mL respectively was stably retained in serum. The radiochemical purity of B-I-131-lipiodol was 98%. After supplement with a medium containing B-I-131-lipiodol, the HepG2 cells had intracellular B-I-131-lipiodol globules in the cytoplasm as seen by inverted light microscope, the I-131 and boron can be stably retained in HepG2 cells. (author)

  1. Differentiated Thyroid Carcinoma After I-131-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases

    van Santen, Hanneke M.; Tytgat, Godelieve A. M.; van de Wetering, Marianne D.; van Eck-Smit, Berthe L. F.; Hopman, Saskia M. J.; van der Steeg, Alida F.; Nieveen van Dijkum, Els J. M.; van Trotsenburg, A. S. Paul

    2012-01-01

    Background: It is well known that the thyroid gland is sensitive to the damaging effects of irradiation (X-radiation or I-131(-)). For this reason, during exposure to I-131-metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), the thyroid gland is protected against radiation damage by

  2. Indication of doxorubicin cardiotoxicity by impairment of pIPPA I 131 utilization

    Lenzhofer, R.; Dudczak, R.

    1986-01-01

    The present study was designed to evaluate if doxorubicin (D) can impair myocardial fatty acid utilization. To this end we studied the myocardial utilization of pIPPA I 131 in untreated (Co, n=6) and D (20 mg/kg intraperitoneal) treated rats. D was given 24 h (24 D, n=6) and 48 hours (48 D, n=6) before tracer administration. One min after i.v. pIPPA I 131 (50 μCi) injection, the hearts were rapidly removed, frozen in liquid nitrogen, weighed, and counted. Following lipid extraction of homogenized heart extracts 131 I radioactivity distribution was analyzed by thin-layer chromatographity (TLC). In additional rat experiments, high energy phosphates (12 rats/group) and carnitine (20 rats/group) were determined enzymatically in heart extracts. The mean pIPPA uptake in rat heart (%dose/g) was 2.49 in Co, 1.74 in 24 D, and 2.36 in 48 D rats. Usually five peaks were separated by TLC, that with a mean Rf value of 0.92 corresponding to pIPPA I 131, the remaining four representing catabolites of pIPPA metabolism. The mean relative amount of unmetabolized pIPPA I 131 as compared to the sum of pIPPA I 131 catabolites was less in Co than in 24 D or 48 D rats (P<0.05) (anti x: 46.5% vs 72.4% vs 59.4%, respectively). The mean carnitine content of H extracts was higher in Co (0.55 μM/g) than in D treated rats (24 D, 0.42 μM/g; 48 D, 0.46 μM/g) (P<0.05). The total amount of higher energy phosphates was not different between the groups. However the mean ATP/AMP ratio was higher in Co (35.9) than in 24 D (22.3) or 48 D (27.1) rats (P<0.05). We conclude that D therapy is accompanied by a partial reversible impairment in myocardial pIPPA utilization, possibly mediated by carnitine deficiency. Thus, pIPPA I 131 might be useful in patients on D therapy to evaluate eventual D-induced effects on myocardial fatty acid utilization. (orig.)

  3. Comparison of F-18 FDG PET and I-131 whole body scan in diagnosis of suspicious metastatic thyroid carcinoma

    Seok, Ju Won; Chung, June Key

    2005-01-01

    There are several reports about the usefulness of F-18 FDG PET in thyroid cancer. The aim of this study was to evaluate the effectiveness of F-18 FDG PET and I-131 whole body scan in suspicious metastatic thyroid cancer. There were 46 patients (11 men, 35 women; age range, 18-74yr; mean age, 47.3yr) with suspicious metastatic thyroid cancer after total thyroidectomy who performed FDG PET and I-131 scan. The interval of FDG PET and I-131 scan was within 6 months. An overall clinical evaluation was performed including cytology, thyroglobulin level, sonography, MRI and CT. Metastatic regions were divided into four areas: neck, mediastinum, lung and bone. Among 46 patients, the number of patients, metastatic lesions were detected, totaled 36 (78.3%). Twenty-nine patients (63.0%) were detected by FDG PET and 18 patients (39.1%) were detected by I-131 scan. Twenty-one patients were detected in neck by two methods. Nineteen patients (90.5%) were detected by FDG PET and 7 patients (33.3%) were detected by I-131 scan. Eighteen patients were detected in mediastinum by two methods. Ten patients (55.5%) were detected by FDG PET and 10 patients (55.5%) were detected by I-131 scan. Ten patients were detected in lung by two methods. Nine patients (90.0%) were detected by FDG PET and 3 patients (30.0%) were detected by I-131 scan. Three patients were detected in bone by two methods. Three patients (100%) were detected by FDG PET and 0 patients (0%) were detected by I-131 scan. These data indicate that for detecting metastatic lesions, F-18 FDG PET and I-131 whole body scan may provide complementary information. Thus, the combination of FDG PET and I-131 scan is the method of choice for detecting suspicious metastatic thyroid cancer after total thyroidectomy

  4. Measurement Of I-131 In Air Using A Portable Gamma Spectrometer

    Bunawas; Dadong Iskandar; Wahyudi; U, Wiwik

    2000-01-01

    Aerosol contamination of I-131, radioactive emitting gamma radiation, can be directly measured by using a portable gamma spectrometer which used GC2020 Canberra HPGe detector. Assuming constant concentration of I-131 in the infinite space of semi spherical, calibration factor, and detection limits determined using standard CH 3 I gas. The results showed that the detection limits for 1 hour counting period was 3.06 Bq/m exp.3 for confidence level of 95% (2σ). Field measurements are conducted on several rooms with uncertainties variation between 0.34 and 60.11% compare with true values. Qualitative discussion of the factors contributing to the uncertainty in the in situ result is included

  5. A feasibility study of thyroid cancer among patients treated with I-131

    Anderson, T.W.

    1984-04-01

    This study examined the feasibility of conducting a Canada-wide follow-up study of persons receiving I-131 before 1970, to see if current estimates of induction of thyroid cancer are well founded. It is concluded that such a study is not feasible due to the widespread destruction of old records, and the limited quantity of personal identifying information on those records that do still exist

  6. I-131 attraction by thyroid during first hours following its oral administration

    Franquiz, J.M.; Cardenas, R.; Blanco, J.; Garcia, M.

    1982-01-01

    From radioisotopic investigations used to study thyroid function, that of I-131 attraction results to be one of the most known and used in medical practice. In the authors' laboratory measurement of I-131 activity upon the gland has been for long adopted at 24 hours after administration; however, current needs compel to look for an early time (within the first six hours) for measuring it. In the paper results of I-131 attraction by thyroid in a group with more than 200 patients at 2,4 and 24 hours following its administration are presented in order to assess a 24 hours attraction representativeness by an early attraction. Results demonstrate early attraction is representative of an attraction at 24 hours and with the same diagnostic usefulness. Normal and doubtful ranks for attraction in our medium are determined at 2 and 6 hours, being adopted as proceeding for those cases whose value should be found within doubtful rank, a measurement at 24 hours in order to determine functional condition of the gland. (author)

  7. Chemical Process for Treatment of Tellurium and Chromium Liquid Waste from I-131 Radioisotope Production

    Zainus-Salimin; Gunandjar; Dedy-Harsono; Hendro; Sugeng-Purnomo; Mohammad-Faruq; Zulfakhri

    2000-01-01

    The I-131 radioisotope is used in nuclear medicine for diagnosis and therapy. The I-131 radioisotope is produced by wet distillation at Bandung Nuclear Research Center and generated about 4,875 Itr of liquid waste containing 2,532.8 ppm of tellurium and 1,451.8 ppm chromium at pH 1. Considering its negative impact to the environment caused by toxic behaviour of tellurium and chromium, it is necessary to treat chemically that's liquid waste. The research of chemical treatment of tellurium and chromium liquid waste from I-131 radioisotope production has been done. The steps of process are involved of neutralisation with NaOH, coagulation-flocculation process for step I using Ca(OH) 2 coagulant for precipitation of sulphate, sulphite, oxalic, chrome Cr 3+ , and coagulation-flocculation process for step II using BaCI 2 coagulant for precipitation of chrome Cr 6+ and tellurium from the supernatant of coagulation in step I. The best result of experiment was achieved at 0.0161 ppm of chromium concentration on the supernatant from coagulation-flocculation of step I using 3.5 g Ca(OH) 2 for 100 ml of liquid waste, and 0.95 ppm of tellurium concentration on the final supernatant from coagulation-flocculation by of step II using 0.7 g BaCI 2 for supernatant from coagulation of step I. (author)

  8. Recurrence of pheochromocytoma in 11 years old school child, diagnosed by I-131 MIBG

    Jara Yorg, J. A; Arias, Cohl; Gimenez, J; Rodriguez, E; Ortiz, L; Mendieta, B; Ayala, R. M; Rodriguez, C; Delgadillo, J. L

    2000-01-01

    Pheocromocytoma is a paraganglioma with an incidence of arterial hypertension approximately of 1%,but its diagnosis has several important issues from the clinical point of view. 1-The tumor resection frequently cure the hypertension. 2.-Its manifestations might simulates other diseases like carcinoid Sx, hypertiroidism,etc. 3.-It is a familiar disease transmitted by an autosomic dominant way. It is 10% bilateral,10%extraadrenal,10% occur in children and 10% are malignant. We present a case of pheochromocytoma recurrency in a young girl,11 y.o. operated 8 months before, at the Clinical Hospital, National University of Paraguay, School of Medicine for a right suprarenal gland pheochromocytoma of 2cms of diameter, who consults the Pediatric Department for arterial hypertension and cefalea. She also had a Von Hippel Sx and Glaucoma. Nuclear Medicine is a non invasive method that use the I-131 Methayodobencylguanidine(MIBG-I-131) with high accuracy to diagnose and treat both neuroblastoma and pheochromocytoma I-131 MIBG is the gold standard for the diagnosis of both entities with a sensitivity between 94-100%6-7 and specificity of 100% being the best method to evaluate these diseases in the pre and post operatory (Au)

  9. Radioanalytical studies of iodine behaviour in the environment

    Evans, G.J.; Hammad, K.A.

    1995-01-01

    The behaviour of iodine in the environment is of interest both in relation to radioecology and human nutrition. Radiochemical techniques were used to evaluate various aspects of the behaviour of iodine in the environment. The natural iodine content of plant, water and soil samples collected from three sites was determined using preconcentration neutron activation analysis (PNAA). The effect of initial chemical speciation on the distribution of iodine between various soils, sediments and waters was evaluated using I-131 tracer. Iodide was found to adsorb more extensively than iodate, although four most of the solid/water systems examined, a substantial portion of the iodate was slowly reduced to iodide. Experiments involving gamma irradiation suggest that much of the sorption of iodide and reduction of iodate involved microbial processes. Distribution coefficients measured using I-131 were comparable with values based on the natural I-127 content. (author) 18 refs.; 5 tabs

  10. The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer

    Hung Guanguei; Lee Kwowhei; Liao Peiyung; Yang Liheng; Yang Kwangtao

    2008-01-01

    18F-fluorodeoxyglucose positron emission tomography (FDG-PET) [or PET/computed tomography (CT)] is more likely to show false-negative results when it is performed shortly after chemotherapy and/or radiotherapy because of ''metabolic stunning''. The present study aimed to evaluate the influence of I-131 therapy on FDG uptake and the detection of recurrence or metastasis of differentiated thyroid cancer (DTC). We retrospectively enrolled 16 consecutive FDG-PET/CT studies which had been performed in patients with DTC with elevated thyroglobulin (TG) but negative I-131 whole-body scan. All studies were performed under L-thyroxine suppression. The patients were divided into groups A and B for PET/CT performed within 4 months of I-131 therapy or no such therapy, respectively. Each lesion identified on PET/CT was characterized using a 5-point scale by visual analysis: 0=definitely benign, 1=probably benign, 2=equivocal, 3=probably malignant, and 4=definitely malignant. The maximum standardized uptake value (SUV max ) in each lesion was also measured for semiquantitative analysis. We compared the visual grading and SUV max of the lesion of highest FDG uptake between groups A and B. For visual analysis, group B had significantly more patients with an uptake score of 3 or 4 than group A (80% vs. 17%, P=0.01). In addition, there were significantly more equivocal results from group A than from group B (67% vs. 10%, P=0.02). If the patients with the highest uptake scores of 2, 3, and 4 were considered to be positive for local recurrence or metastasis, there would be no significant difference between the positive rates of groups A and B (83% vs. 90%, P=0.7). However, the mean SUV max of positive results was significantly lower for group A than for group B (3.1±0.9 and 6.6±3.5 respectively, P=0.02). The preliminary results suggested that FDG uptake in DTC may be negatively influenced by I-131 therapy within 4 months, resulting in lower FDG uptake and more equivocal results

  11. Radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages

    Chaudakshetrin, P.; Pusuwan, P.; Sritongkul, N.; Tuntawiroon, M.

    2007-01-01

    Full text: Therapeutic doses of I-131 for treatment of thyroid cancer are administered orally in liquid or capsule form. During the last few years, a total number of patients loaded in our isolation ward increased from 4 to 10 patients per week. When considering radiation safety precautions for attending technologists, it is preferable to use the dose in capsules. The purpose of this study is to compare radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages in capsules and in liquid form in a closed system. Materials and Methods: Three year radiation exposure to technologists during I-131 administration was analyzed. From January 2004 to June 2005 dose administration was in liquid form (n=263) and from July 2005 to February 2007 in capsules (n=541). Radiation dose assessment was performed with an electronic personal dosimeter (PDM 112). The dose rate in μSv and time spent per patient were recorded. Results: Dose received per patient when I-131 was given in a liquid was 3.50 ± 1.67 μSv and 1.17 ± 0.66 μSv when given in capsules. Compared with the use of a liquid, capsules significantly reduced radiation dose to technologists by 66% (P < 0.001). These doses received depended not only on the administered activity but also on the time, distance and shielding. Time spent per patient, including a brief visit before the time of dosing to explain the procedure and answer questions was reduced slightly from 4.4 ± 2.2 to 3.7 ± 1.8 minutes (P < 0.01). These correspond to a reduction in a yearly dose to 1 technologist by 40%, from 0.63 mSv to 0.38 mSv from dosing to 175 and 325 patients respectively. Conclusions: The measured doses clearly showed that handling of I-131 therapy dosages either in a liquid form or capsules are not the major contributors to the technologist's radiation exposure in routine clinical practice. However, one has to be cautious and follow good work practice to avoid risk of radiation exposure and radioiodine

  12. Radioimmunotherapy of Nude Mice Bearing Human Colon Carcinoma with I-131 Labeled Anti-carcinoembryonic Antigen

    Kim, Byung Tae; Lee, Kyung Han; Kim, Sang Eun; Choi, Yong; Chi, Dae Yoon; Chung, June Key; Lee, Myung Chul; Koh, Chang Soon; Chung, Hong Keun

    1995-01-01

    This study was designed to evaluate the effects of various factors on the therapeutic effect of the I-l3l labeled anti-carcinoembryonic antigen monoclonal antibody(anti-CEA antibody). Tetrazolium-based colorimetric assay (MTT) was used to compare in vitro cytotoxicity of 3 Korean colon cancer cell lines (SNU-C2A, SNU-C4, SNU-C5) for selection of proper 2 cell lines in this study. The changes of the size of tumor which was xenografted to nude mice (balb/c nu/nu) were compared in 4 groups (group treated I-131 labeled anti-CEA antibody, group treated with non-radiolabeled anti-CEA antibody, group treated with I-131. labeled anti-human chorionic gonadotropin monoclonal antibody (anti-hCG antibody) as nonspecific antibody, and group injected with normal saline as a control). Immunohistochemical staining and in vivo autoradiography were performed after excision of the xenografted tumor. The results were as below mentioned. The in vitro cytotoxic effect of I-131 labeled anti-CEA antibody is most prominent in SNU-C5 cell line between 3 cancer cell lines. The changes of xenografted tumor size in both SNU-C4 and SNU-C5 cell tumors at the thirteenth day after injection of the antibodies were smallest in the group treated with I-131 labeled anti-CEA antibody (SNU-C4/SNU-C5; 324/342%) comparing with other groups, group treated with anti-CEA antibody (622/660%), group treated with I-131 anti-hCG antibody (538/546%), and control group(1030/724%) (p<0.02 in SNU-C4 and p<0.1in SNU-C5 at the 13th day after injection of antibodies). On the thirteenth day after injection of the antibodies nude mice were sacreficed to count the radiouptake of tumor and to check the changes of tumor size. Correlations between radiouptake and change of tumor size were calculated in each groups and significant negative correlation was only obtained in the group treated with I-131 anti-CEA antibody (p<0.05). There were no correlations between antigenic expression of carcinoembryonic antigen and

  13. Iodine-125 safety procedures in a biochemical laboratory

    1989-01-01

    Radioactive isotopes of iodine are of considerable importance in biochemical research and this 14 minute videotape is designed to give workers an introduction to the radiation safety aspects of their use. It deals with I-125, which is now generally used in preference to I-131, but the principles of safe working practice are the same for both isotopes. (author)

  14. Radioactively labelled iodinated insulin and method of preparation

    Geiger, R; Teetz, V; Eckert, H G

    1977-10-20

    Suitable tracers for RIA and substrates for pharmacokinetic investigations are insulin derivatives where B1 phenylalanine is substituted by a tyrosine derivative and part of the iodine is in the form of I-125 or I-131. The preparation of the insulin derivatives is described.

  15. Control system of liquid effluents generated in treatment with I-131

    Garcia M, T.; Ruiz C, M. A.; Angeles C, A.; Ramirez S, R.

    2015-09-01

    In recent years, nuclear medicine has developed greatly in our country and around the world. Techniques for both medical diagnosis and therapy have increased the use of radiopharmaceuticals, notably the I-131. In Mexico there are around 150 nuclear medicine establishments authorized by the Comision Nacional de Seguridad Nuclear y Salvaguardias. Most of these establishments do not have an appropriate facility for the treatment of radioactive liquid effluents, to ensure compliance with the concentration limits established in the regulations. The Instituto Nacional de Investigaciones Nucleares (ININ) developed and implemented successfully, a control system of radioactive effluents (named SACEL) from a nuclear medicine facility. This system ensures an effective compliance with regulations and also better management and control of these radioactive effluents. Calculations and design of SACEL were made with respect to I-131, because is one of the most commonly used in radiotherapy and medical diagnostics, besides its half-life is greater in relation to other radionuclides. SACEL is comprised of four storage tanks and decay and a fifth tank for measuring the concentration of I-131 and later discharge to the drain; these tanks are connected to an automated system that controls the effluents passage. The calculation to determine the volume of the tanks was carried out according to the demand that has the hospital, to the maximum activity being poured in effluents and time required to decay. In this paper the design and installation of SACEL system, in addition to functioning as a facility that enables the Hospital meet the required standards is presented. Dose calculations performed with MCNPX and the methodology used in the calibration of the detection system is also presented. (Author)

  16. Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.

    Roa, W H; Yaremko, B; McEwan, A; Amanie, J; Yee, D; Cho, J; McQuarrie, S; Riauka, T; Sloboda, R; Wiebe, L; Loebenberg, R; Janicki, C

    2013-02-01

    The physical properties of I-131 may be suboptimal for the delivery of therapeutic radiation to bone marrow metastases, which are common in the natural history of neuroblastoma. In vitro and preliminary clinical studies have implied improved efficacy of I-125 relative to I-131 in certain clinical situations, although areas of uncertainty remain regarding intratumoral dosimetry. This prompted our study using human neuroblastoma multicellular spheroids as a model of metastasis. 3D dose calculations were made using voxel-based Medical Internal Radiation Dosimetry (MIRD) and dose-point-kernel (DPK) techniques. Dose distributions for I-131 and I-125 labeled mIBG were calculated for spheroids (metastases) of various sizes from 0.01 cm to 3 cm diameter, and the relative dose delivered to the tumors was compared for the same limiting dose to the bone marrow. Based on the same data, arguments were advanced based upon the principles of tumor control probability (TCP) to emphasize the potential theoretical utility of I-125 over I-131 in specific clinical situations. I-125-mIBG can deliver a higher and more uniform dose to tumors compared to I-131 mIBG without increasing the dose to the bone marrow. Depending on the tumor size and biological half-life, the relative dose to tumors of less than 1 mm diameter can increase several-fold. TCP calculations indicate that tumor control increases with increasing administered activity, and that I-125 is more effective than I-131 for tumor diameters of 0.01 cm or less. This study suggests that I-125-mIBG is dosimetrically superior to I-131-mIBG therapy for small bone marrow metastases from neuroblastoma. It is logical to consider adding I-125-mIBG to I-131-mIBG in multi-modality therapy as these two isotopes could be complementary in terms of their cumulative dosimetry.

  17. Radioactive Iodine

    ... order to limit radiation exposure to others (see chart). I-131 may occasionally cause mild pain in ... Statement on Thyroid Shielding During Diagnostic Medical and Dental Radiology By ATA | 2013 News Releases , News Releases , ...

  18. A preliminary study of radioimmunoimaging of ovarian malignancy with I-131 labelled CEA monoclonal antibody

    Hu Likuan

    1988-01-01

    Ten cases of ovarian cancers have been detected with I-131 labelled CEA McAb and computer assisted clual radionuclide subtraction technique. The lesions (both primary and secondary) are clearly visualized and proved by surgical and pathohistological findings. 30 of 31 metastatic lesions are localized with a positive rate 97%. It seems to be a sensitive and specific procedure for early diagnosis of ovarian cancer so far. It is also valuable for staging clinical course and making decision on treatment, assessing the prognosis of ovarian cancer as well

  19. Myocardial distribution of I131-labeled hexadecenoic acid in relation to the dog local coronary flow

    Riche, F.; Busquet, G.; Pilichowski, P.; Wolf, J.E.; Mathieu, J.P.; Comet, M.; Pernin, C.; Vidal, M.; Vincens, M.; Godart, J.

    1981-01-01

    20 anesthetized and thoracotomized dogs are studied. The local myocardial blood flow is measured with sup(99m)Tc human albumin microspheres. The intramyocardial distribution of the 16-I(131)-9-hexadecenoic acid in relation to local blood flow is studied in basal conditions (7 dogs), after experimental infarction (6 dogs) and postischemic reactive hyperhemia (7 dogs). We conclude that during basal condition, after infarction but not during reactive hyperhemia, the distribution of the labeled fatty acid reflect the local variations of blood flow [fr

  20. Septal penetration correction in I-131 imaging following thyroid cancer treatment

    Barrack, Fiona; Scuffham, James; McQuaid, Sarah

    2018-04-01

    Whole body gamma camera images acquired after I-131 treatment for thyroid cancer can suffer from collimator septal penetration artefacts because of the high energy of the gamma photons. This results in the appearance of ‘spoke’ artefacts, emanating from regions of high activity concentration, caused by the non-isotropic attenuation of the collimator. Deconvolution has the potential to reduce such artefacts, by taking into account the non-Gaussian point-spread-function (PSF) of the system. A Richardson–Lucy deconvolution algorithm, with and without prior scatter-correction was tested as a method of reducing septal penetration in planar gamma camera images. Phantom images (hot spheres within a warm background) were acquired and deconvolution using a measured PSF was applied. The results were evaluated through region-of-interest and line profile analysis to determine the success of artefact reduction and the optimal number of deconvolution iterations and damping parameter (λ). Without scatter-correction, the optimal results were obtained with 15 iterations and λ  =  0.01, with the counts in the spokes reduced to 20% of the original value, indicating a substantial decrease in their prominence. When a triple-energy-window scatter-correction was applied prior to deconvolution, the optimal results were obtained with six iterations and λ  =  0.02, which reduced the spoke counts to 3% of the original value. The prior application of scatter-correction therefore produced the best results, with a marked change in the appearance of the images. The optimal settings were then applied to six patient datasets, to demonstrate its utility in the clinical setting. In all datasets, spoke artefacts were substantially reduced after the application of scatter-correction and deconvolution, with the mean spoke count being reduced to 10% of the original value. This indicates that deconvolution is a promising technique for septal penetration artefact reduction that

  1. Financial impact of outpatient clinic radioiodine therapy with sodium iodide I-131 for the treatment of patients with differentiated low-risk thyroid carcinoma in relation to hospital doses

    Berenguer, P.F.; Chang, T.M.C.; Silva, R.A.M.; Neto, A.H.D.; Belo, I.B.; Santos, M.A.P.

    2017-01-01

    Differential thyroid carcinoma (CDT) is the most prevalent endocrine malignancy in the world, with an excellent prognosis and a 10-year survival rate of over 95%. By 2013, the lowest activity of I-131 authorized by the Brazilian Unified Health System (SUS) in the therapy of patients with low-risk CDT was 3,700 MBq, requiring hospitalization. Recent studies have shown similar effectiveness between low and high doses of I-131 in the treatment of low-risk CDT. In 2014, the Ministry of Health included in the list of SUS procedures the use of lower activities (1,110 MBq and 1,850 MBq) for this purpose. The Brazilian National Nuclear Energy Commission (CNEN) also authorized the outpatient use of activity up to 1,850 MBq of I-131. Objective: To evaluate the financial impact of the adoption of ambulatory radioiodine therapy in patients with CDT of low-risk when compared to the hospital dose. Methods: Analysis of patients with CDT low-risk who were treated with an outpatient dose of I-131 from August / 2014 to January / 2017 at a nuclear medicine service in Recife, PE, Brazil. The cost of outpatient versus hospital doses was calculated. Results: A total of 289 patients underwent low doses of iodine therapy were evaluated, resulting in a savings of R$227,793.80. Conclusion: Outpatient radioiodine therapy in the treatment of patients with CDT of low-risk resulted in a 61.10% reduction in SUS expense, in addition to enabling faster care

  2. Financial impact of outpatient clinic radioiodine therapy with sodium iodide I-131 for the treatment of patients with differentiated low-risk thyroid carcinoma in relation to hospital doses; Impacto financeiro da radioiodoterapia ambulatorial com iodeto de sódio I-131 para tratamento de pacientes com carcinoma diferenciado da tireóide de baixo risco em relação às doses hospitalares

    Berenguer, P.F.; Chang, T.M.C.; Silva, R.A.M.; Neto, A.H.D.; Belo, I.B., E-mail: pricilaberenguer@gmail.com [Instituto de Medicina Integral Professor Fernando Figueira, Recife, PE (Brazil). Serviço de Medicina Nuclear; Santos, M.A.P. [Centro Regional de Ciências Nucleares do Nordeste (CRCN-NE/CNEN-PE), Recife (Brazil). Coordenação de Radioproteção

    2017-07-01

    Differential thyroid carcinoma (CDT) is the most prevalent endocrine malignancy in the world, with an excellent prognosis and a 10-year survival rate of over 95%. By 2013, the lowest activity of I-131 authorized by the Brazilian Unified Health System (SUS) in the therapy of patients with low-risk CDT was 3,700 MBq, requiring hospitalization. Recent studies have shown similar effectiveness between low and high doses of I-131 in the treatment of low-risk CDT. In 2014, the Ministry of Health included in the list of SUS procedures the use of lower activities (1,110 MBq and 1,850 MBq) for this purpose. The Brazilian National Nuclear Energy Commission (CNEN) also authorized the outpatient use of activity up to 1,850 MBq of I-131. Objective: To evaluate the financial impact of the adoption of ambulatory radioiodine therapy in patients with CDT of low-risk when compared to the hospital dose. Methods: Analysis of patients with CDT low-risk who were treated with an outpatient dose of I-131 from August / 2014 to January / 2017 at a nuclear medicine service in Recife, PE, Brazil. The cost of outpatient versus hospital doses was calculated. Results: A total of 289 patients underwent low doses of iodine therapy were evaluated, resulting in a savings of R$227,793.80. Conclusion: Outpatient radioiodine therapy in the treatment of patients with CDT of low-risk resulted in a 61.10% reduction in SUS expense, in addition to enabling faster care.

  3. Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients

    Gül Ege Aktaş

    2015-10-01

    Full Text Available Objective: Geriatric patient population has special importance due to particular challenges. In addition to the increase in incidence of toxic nodular goiter (TNG with age, it has a high incidence in the regions of low-medium iodine intake such as in our country. The aim of this study was to evaluate the overall outcome of high fixed dose radioiodine (RAI therapy, and investigate the particular differences in the geriatric patient population. Methods: One hundred and three TNG patients treated with high dose I-131 (370-740 MBq were retrospectively reviewed. The baseline characteristics; age, gender, scintigraphic patterns and thyroid function tests before and after treatment, as well as follow-up, duration of antithyroid drug (ATD medication and achievement of euthyroid or hypothyroid state were evaluated. The patient population was divided into two groups as those=>65 years and those who were younger, in order to assess the effect of age. Results: Treatment success was 90% with single dose RAI therapy. Hyperthyroidism was treated in 7±7, 2 months after RAI administration. At the end of the first year, overall hypothyroidism rate was 30% and euthyroid state was achieved in 70% of patients. Age was found to be the only statistically significant variable effecting outcome. A higher ratio of euthyroidism was achieved in the geriatric patient population. Conclusion: High fixed dose I-131 treatment should be preferred in geriatric TNG patients in order to treat persistent hyperthyroidism rapidly. The result of this study suggests that high fixed dose RAI therapy is a successful modality in treating TNG, and high rates of euthyroidism can be achieved in geriatric patients.

  4. Calibration of the Accuscan II In Vivo System for I-131 Thyroid Counting

    Orval R. Perry; David L. Georgeson

    2011-07-01

    This report describes the March 2011 calibration of the Accuscan II HpGe In Vivo system for I-131 thyroid counting. The source used for the calibration was an Analytics mixed gamma source 82834-121 distributed in an epoxy matrix in a Wheaton Liquid Scintillation Vial with energies from 88.0 keV to 1836.1 keV. The center of the detectors was position 64-feet from the vault floor. This position places the approximate center line of the detectors at the center line of the source in the thyroid tube. The calibration was performed using an RMC II phantom (Appendix J). Validation testing was performed using a Ba-133 source and an ANSI N44.3 Phantom (Appendix I). This report includes an overview introduction and records for the energy/FWHM and efficiency calibrations including verification counting. The Accuscan II system was successfully calibrated for counting the thyroid for I-131 and verified in accordance with ANSI/HPS N13.30-1996 criteria.

  5. Evaluation for Preparation of I-131-MIBG for Diagnosis and Therapy Neuroblastoma

    Laksmi Andri A; Purwoko; Sri Setyowati; Maskur; Cahya Nova Ardianto; Adang Hardi G

    2012-01-01

    Evaluation for preparation of 131 I-MIBG have been carried out. Production/preparation of 131 I-MIBG was carried out by labeling MIBG with I-131, the radiochemical purity of 131 I-MIBG was analysed using TLC/paper chromatography. The stability in the human body by using fresh human plasma, at room temperature and at 8°C was carried out. The chemical purity of synthesized MIBG was found to be > 95%, the labeled MIBG with I-131 was analysed using TLC/paper chromatography. The radiochemical purity of 131 I-MIBG was obtained at higher than 95 %. The stability of labeled MIBG in fresh human plasma and at 8°C was stable up to 141 hours, while at room temperature was stable up to 120 hours. The results of labeling of 131 I-MIBG from 2010-2012 showed that these products were colorless clear solution with pH between 5.5.0-7.0, sterile and pyrogen-free, radiochemical purity > 95%. The quality control results were found to be met with the requirements of 131 I-MIBG injection solution used for diagnosis and therapy of neuroblastoma in Hospital. (author)

  6. Effects of changed working methods on personnel doses at a I-131 and afterloading therapy ward

    Lange, D.; Wolf, G.; Georgi, P.; Bauer, M.

    1985-01-01

    The external load of the personnel from I-131 therapy can be kept small (almost 'neglectable') by appropriate behaviour without keeping patients 'under-lock and key'. The marked decrease in personnel doses is due to improved radiation protection for afterloading therapy (gynecological Ra-therapy, Cs-137-therapy) by technical equipment. This therapy is now possible but with the door of the application room closed; when the door is opened, the instruments automatically go back to their original position. From 1975 through 1982, there were remote control errors forcing the personnel to withdraw the instruments to the safe manually. Despite working regulations the personnel was able to go into the room without prior instrument withdrawal. The personnel doses so received were within the tolerance limits, however markedly above the inevitable values. Because of regular thyroid gland examination of the personnel there is proof for the fact that the radiation load of this organ from I-131 is probably smaller than 2% (6 mSv/a=600 mrem/a) of the annual limit value of 0.3 Sv (30 rem) which corresponds to 6 times the value of normal load. (orig./HP) [de

  7. SU-F-T-222: Dose of Fetus and Infant Following Accidental Intakes of I-131 by the Mother

    Wang, Y [The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan (China); Hu, P [Fudan University Shanghai Cancer Center, Shanghai, Shanghai (China)

    2016-06-15

    Purpose: To estimate the calculation of absorbed dose to the fetus and infants from intakes of I-131 by the mother. Thus provide some advice to the radioprotection of radioactive accident. Methods: In this clinical case, a staff of nuclear medicine accidently intake I-131 during (10–12 weeks) and after pregnancy. The infant was born at full term, but both lobes of the thyroid gland were found to be absent (bilobar thyroid agenesis). It was suspected that the fetal thyroid agenesis may be related with mother’s contamination of I-131 during pregnancy. Urine samples for 24h were collected at different times after administered and radioactivity were measured to calculate the dose of intake I-131. Calculate the intake I-131 by the results of personal TLD dosimeter. We adopted the mean of two calculated results as the I-131 intake. According to the dose of intake I-131 by the mother, effective dose and absorbed dose of thyroid for mother, fetus and infant were calculated. Results: The intake of I-131 was estimated for 8.18 mCi. I-131 intake was calculated for 7.9 mCi based on data of TLD dosimeter. We adopted the mean of two results as the I-131 intake. The final result was 8.0 mCi. Effective dose and absorbed dose of thyroid for mother were 7.3Sv and 164 Gy, effective dose and absorbed dose of thyroid for fetus were 2.035 Sv and 40.7 Gy, effective dose and absorbed dose of thyroid for infant were 16.25 Sv and 355Gy. Conclusion: The intake during pregnancy was about 1mCi. The absorbed dose of thyroid of the mother was 19.5Gy, whereas the effective of infant was estimated for 40.7Gy. The function of the mother’s thyroid was normal after diagnosis. But the infant was diagnosed as bilobar thyroid agenesis.

  8. Internal Dosimetry Of I-131 For Radiation Workers Based On Analysis Of The Human Urine And Liquid Scintillation Counting

    Nguyen Van Hung; Pham Hung Thai; Le Van Ngoc

    2011-01-01

    Internal dosimetry of I-131 for radiation workers based on analysis of the human urine, measuring radioactivity by the liquid scintillation system, and dose calculation by the specialized code has been firstly studied at the Nuclear Research Institute. Urine samples from the subjects internally contaminated with I-131 through respiratory ways were collected, chemically processed, measured beta radioactivities of I-131 by the liquid scintillation system of ALOKA-LSC-6100, and then thyroid doses and effective ones for whole-body were calculated by using the specialized code of LUDEP 2.0. Based on chemically separation procedure for I-131 in urine samples and the low background HPGe gamma spectrometer of Canberra for measuring radioactivity, efficiency for chemical separation was determined to be (86.1 ± 5.0)%. The experimental results for 9 subjects with urine samples to be collected during 4 operating courses of Dalat nuclear reactor with production of I-131 (from June to September, 2010) were shown that thyroid doses and effective ones for whole-body for each course of I-131 production were in ranges of from 0.11 to 13.00 mSv and from 0.01 to 0.71 mSv, respectively. Therefore, totally average doses per year for thyroid and whole-body were less than the correlative levels of permissible doses. Besides, the liquid scintillation method was also compared experimentally with the gamma spectrometry (measuring directly urine samples by the gamma spectrometer to be carried out at the Institute before) was shown that errors on dosimetric results between them were less than 12%. This was proved the dosimetry has had a confidence, and it could be applied for internal dosimetry for radiation workers contacting with unsealed sources of I-131 in radiation installations as well as for diagnostic and therapeutic patients in health ones. (author)

  9. Quantitative detection of I-131 at the inlet and outlet of the Giessen municipality sewage works

    Leib, J.; Crecelius, R.; Pfeiff, H.; Faengewisch, G.L.

    1985-01-01

    During the sampling time, the mean quantities of the radioactive iodine delivered to the sewage works were measured to be 66 p.c. at the inlet and 28 p.c. at the outlet. Error sources of the procedure adopted for the study are assessment only of the overall inflow to the sewage treatment plant during sampling time, and lacking exactness of values for the detention period of the radioactive iodine in the sewage plant. Dispersion calculations made in addition to water examinations showed that the mean radiation dose as a result of the iodine discharges is far below the limits set by the Radiation Protection Ordinance. (orig./PW) [de

  10. Iodine Deficiency

    ... Fax/Phone Home » Iodine Deficiency Leer en Español Iodine Deficiency Iodine is an element that is needed ... world’s population remains at risk for iodine deficiency. Iodine Deficiency FAQs WHAT IS THE THYROID GLAND? The ...

  11. Radioimmunoscintigraphy with I-131-labelled anti-CEA monclonal antibody in colorectal cancer patients

    Xie Tianhao

    1988-01-01

    Twenty three colorectal carcinoma and two benign polyposis patients with operatively and histologically proven were studied by radioimmunoscintigraphy, using anti-CEA monoclonal antibodies (C14-17 and C50) radiolabeled with I-131 . Computer assisted processing for the subtraction of Tc-99m background radioactivity was used to enhance the detection and localization of tumor which is visualized by immune scintigraphy. The size of tumor and the ratios of tumor to nontumor (T/NT) are two very important factors for the external immunoscintigraphy. The antibody uptake and retention in tumor are likely to depend on the degree of vascularity and diffusion into the viable tumor mass. Based upon the obtained results, the sensitivity of the method (true-poditive) was 91%, its specificity (true-negative) was 100%. This study thus indicates that radioimmunoscintigraphy of cancer with radioactive anti-CEA monoclonal antibody is very uaeful in the diagnoses of patients with CEA-containing neoplasms

  12. Simultaneous treatment of toxic diffuse goiter with I-131 and antithyroid drugs: a prospective study

    Steinbach, J.J.; Donoghue, G.D.; Goldman, J.K.

    1979-01-01

    We report a prospective study to evaluate the effect of antithyroid drugs containing the sulfhydryl radical on the outcome of I-131 (RAI) therapy. Twenty-four male patients with toxic diffuse goiter were assigned randomly into two treatment groups: Group A received RAI treatment while on antithyroid drugs after attainment of euthyroidism; Group B received no antithyroid drugs before, or when, RAI was given. Patients in each group received a dose of RAI calculated to deliver approximately 5000 rads per treatment. The incidence of hypothyroidism at 12 mo was 8% for Group A and 36% for Group B (p 0.45). The improved therapeutic outcome of patients in Group A suggests that further validation of the method in a larger patient population, including females, is warranted

  13. Tests of some methods to remove I-131 from contaminated tap water

    Tagami, Keiko; Uchida, Shigeo

    2011-01-01

    Following the Fukushima Daiichi Nuclear Power Plant accident, iodine-131 concentrations in tap water higher than 100 Bq L"-"1 were reported by several local governments in the Kanto Plain in March 2011. To remove iodine-131 from tap water, five methods were tested in this study, that is, (1) boiling, (2) adding charcoals from oak or bamboo, (3) activated charcoals, (4) water purifiers, and (5) reverse osmosis (RO) treatments. Boiling was shown to be not effective in removing iodine-131 from tap water; indeed even higher concentrations may result from the liquid-volume reduction accompanying this process. Adding charcoals and activated charcoal treatment could not remove iodine-131, because no reduction of iodine-131 was observed in tap water samples after these treatments. Only limited effect was found with water purifiers with first several portions; no effect was expected with further water treatment. On the other hand, the RO showed high iodine-131 removal percentage of more than 95%, although the method needs about 5-10 L water to obtain 1 L of RO treated water. (author)

  14. Calibration of CDTN-whole body counter for in vivo measurements of I-131

    Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L.

    2009-01-01

    Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

  15. Calibration of CDTN-whole body counter for in vivo measurements of I-131

    Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN/MG), Belo Horizonte, MG (Brazil)], e-mail: cmo@cdtn.br

    2009-07-01

    Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

  16. Thyroid dose of I-131 absorbed by the internal organs of a pregnant woman; Dosis tiroidea de I-131 absorbida por los organos internos de una embarazada

    Arcos P, A; Manzanares A, E; Vega C, H R; Leon, C.L. de . [Cuerpo Academico de Radiobiologia de la Universidad Autonoma de Zacatecas (Mexico)

    2007-07-01

    The use of nuclear techniques, for diagnosis or treatment, generates stress in the patient and its relatives. During the pregnancy some sufferings related with the thyroid gland can be presented. If the patient is pregnant, OEP or NOEP, the stress comes from the fear to that the product can it turns affected. The dose is calculated that the Iodine 131, captured by the thyroid of a woman with three months of pregnancy, it deposits in the brain, stomach, heart, kidneys, liver, lungs, ovaries, pancreas, thymus, spleen and in the uterus. The thymus is the organ that receives the biggest dose. (Author)

  17. Thyroid Dose Estimation Using WBC and I-131 Concentration in Working Area of Radioisotope Production at Normal Operation; Perkiraan Dosis Thyroid Melalui Pengukuran WBC dan Perhitungan dengan Konsentrasi I-131 Di Daerah Kerja Pada Operasi Normal Produksi Radioisotop

    Tedjasari, R S; Lubis, E [Radioactive-Waste Management Technology Centre, National Atomic Energy Agency of Indonesia(Indonesia)

    1996-07-01

    Thyroid dose estimation at Radioisotope Production Centre workers using WBC and calculation based on I-131 concentration in working area has been done. The aim of this research is to get the relation between WBC result and calculation using I-131 concentration in working area. The result indicates differences in a range of 3,2% to 53,2%. These differences caused of parameters which influence the calculation are not accurate. These results also indicate that dose estimation using WBC is relatively batter and more accurate but need to have certain information about time of intake.

  18. LAM Pilot Study with Imatinib Mesylate (LAMP-1)

    2017-10-01

    AWARD NUMBER: W81XWH-14-1-0132 TITLE: LAM Pilot Study with Imatinib Mesylate (LAMP-1) PRINCIPAL INVESTIGATOR: Charlie Strange, MD...regarding imatinib mesylate (imatinib) in the treatment of Lymphangioleiomyomatosis ( LAM ) sufficient to power and design a phase 3 imatinib vs. placebo...clinical trial. The hypothesis is that imatinib will be equivalent to rapamycin in short term efficacy and safety. Currently, most LAM patients are

  19. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: Preliminary experience

    Larson, S.M.; Carrasquillo, J.A.; McGuffin, R.W.

    1985-01-01

    High molecular-weight antigen (HMWA) is tumor-associated proteoglycan of human malignant melanoma. I-131 labeled Fab fragments of these specific antibodies were used for preliminary feasibility studies for radioimmunodetection and therapy of human subjects who had inoperable metastatic melanoma. Ten patients received tracer doses of I-131 (anti-HMWA) Fab. All patients (8/8) who had melanoma lesions greater than 1 cm by correlative diagnosis methods had one or more lesions that had localization to tumor of the radiolabelled Fab. In all, 17 of 23 (74%) documented metastases were seen. Two patients who had avid uptake received potentially radiotherapeutic doses. For both of these patients, whole imaging studies showed that the localization of the high dose I-131 Fab was predominantly in tumor. On whole body images, the anti-Fab HMWA appears to be more tumor selective than Fab preparations that target the p97 antigen for melanoma, and there is less uptake in liver

  20. A significant discrepancy of uptake between I-131 MIBG and F-18 FDG in a patient with malignant paraganglioma

    Kim, Jong Su; Kim, Hyun Keun; Choi, Kyu Young; Park, Hyung Ki; Kim, Eun Sil; Kim, Yun Kwon; Kim, So Yon [National Police Hospital, Seoul (Korea, Republic of)

    2007-06-15

    A 38-year-old man who was diagnosed with malignant paraganglioma underwent computed tomography (CT) and I-131 metaiodobenzylguanidine (MIBG) scan. CT showed extensive lymph node enlargement in right iliac area and retroperitoneum with severe hydronephrosis and mass on posterior bladder wall. However, I-131 MIBG scan didn't showed abnormal uptake. He also underwent F-18 fluorodeoxyglucose (FDG) positron emission tomography/CT for localizing accurate tumor site. F-18 FDG PET/CT showed multiple metastases of left supraclavicular, hilar, mediastinal para-aortic, inguinal, right iliac lymph nodes, lung, vertebrae, and pelvis. There are a few reports showing that the F-18 FDG PET/CT is helpful for staging and localizing tumor site of patients who are diagnosed with negative on the MIBG scans. Thus, we report a case with paraganglioma which showed negative I-131 MIBG scan, but revealed multiple intense hypermetabolic foci in F-18 FDG PET/CT.

  1. Source of Iodine-131 in Europe Identified

    2011-01-01

    Full text: The IAEA has received information from the Hungarian Atomic Energy Authority (HAEA) that the source of the iodine-131 (I-131) detected in Europe was most probably a release to the atmosphere from the Institute of Isotopes Ltd., Budapest. The Institute of Isotopes Ltd. produces radioisotopes for healthcare, research and industrial applications. According to the HAEA, the release occurred from September 8 to November 16, 2011. The cause of the release is under investigation. As previously mentioned, the levels of I-131 that have been detected in Europe are extremely low. There is no health concern to the population. If any member of the public were to breathe iodine for a whole year at the levels measured in European countries, then they would receive a dose in the range of 0.01 microsieverts for the year. To put this into perspective, the average annual background is 2 400 microsieverts per year. The IAEA was first notified of the presence of trace levels of I-131 by authorities from the Czech Republic on 11 November. Since this notification, the IAEA contacted several member states throughout the region to determine the cause and origin. The IAEA also worked with the World Meteorological Organization (WMO) to conduct air dispersion modelling, as part of efforts to determine the source. (IAEA)

  2. The Assessment of I-131 Internal Doses of Nuclear Medicine Workers in Korea Using Thyroid uptake system

    Bahn, Young Kag; Oh, Gi Back; Lee, Chang Ho; Lee, Jong Doo; Yeom, Yu Sun; Hwang, Young Muk

    2012-01-01

    There are possibilities the radiation workers could intake the radiation when workers deal with radiation-materials. Therefore, internal radiation doses of radiation workers need to be assessed. Although an application of the nuclear medicine is continuously increased in Korea, there is not a proper tool and form to monitor the internal doses of nuclear medicine workers. However, it is possible to attain the internal doses of I-131 to evaluate using thyroid uptake and well count system. In this study, we measured and evaluated the I-131 internal doses of nuclear medicine workers in Korea using thyroid uptake and well count system and performed an air sampling

  3. Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer

    Okamoto, Shozo; Shiga, Tohru; Uchiyama, Yuko; Manabe, Osamu; Kobayashi, Kentaro; Yoshinaga, Keiichiro; Tamaki, Nagara

    2014-01-01

    It is sometimes difficult to assess I-131 lung uptake at the initial I-131 therapy because of strong artifacts from I-131 uptake in the thyroid bed. The aim of this study was to analyze the lung uptake at the second I-131 therapy for lung metastasis in patients who did not have lung uptake at the initial therapy from differentiated thyroid carcinoma (DTC). Then, we also analyzed the relationship between the initial lung uptake and short-term outcome after I-131 therapies. This study included 62 DTC patients with lung metastasis. The patients were classified into 2 groups according to the lung uptake at the initial I-131 therapy such as patients with lung uptake (positive uptake group n=31) and those without lung uptake (negative uptake group n=31). The lung uptake was analyzed at the second therapy in both groups. The short-term outcome was also analyzed based on the CT findings of lung metastasis size and serum thyroglobulin level between the two groups. The positive uptake group showed positive lung uptake at the second therapy in 23 patients (74%), whereas none of negative uptake group showed any lung uptake at the second therapy (P < 0.01). The positive uptake group significantly decreased in the size of lung metastasis from the initial therapy to the second therapy (20.0 ± 11.7 to 16.6 ± 9.6 mm, P < 0.01) with further decrease after the second therapy (P < 0.05). The serum thyroglobulin level was also significantly decreased from the initial therapy to the second therapy (4348 ± 7011 to 2931 ± 4484 ng/ml, P < 0.05). In contrast, the negative uptake group significantly increased in the size of lung metastasis from the initial therapy to the second therapy (17.3 ± 12.2 to 19.9 ± 14.3 mm, P < 0.01) with further increase after the second therapy (P < 0.01). No patients without lung uptake at the initial I-131 therapy showed lung uptake at the second therapy, or showed treatment effect. Therefore, second I-131 therapy for these patients with initially

  4. Iodine species in reactor effluents and in the environment. Final report

    Voilleque, P.G.

    1979-12-01

    The air-to-vegetation transfer velocity, an important parameter in evaluating dose to man from I-131 in the environment, has been used to establish an environmental reactivity ranking for the radioiodine species. In these terms, the hierarchy of reactivities is I 2 > particulate > HOI > organic iodides. Previous measurements showing that the least reactive forms, HOI and organic iodides, comprise 50% or more of the total I-131 release from boiling water reactors were confirmed in this study. Measurements of the chemical forms of I-131 and stable iodine in the environment were made using radioiodine species sampler media and a stable iodine species sampler. The compound HOI-131 was observed in the environment 1.5 km from the plant release point. Organic forms were prevalent in environmental samples. Organic iodide residence times calculated using the measured variability of ambient concentrations are > 80 days

  5. A new and simple test for the exocrinic function of the pancreas: Analysis of the urine after oral application of a I-131 labeled triglyceride

    Kropp, J.; Schmidt, S.; Wunderlich, G.; Schendtke, K.U.; Breidert, M.; McPherson, D.; Knapp, F.F. Jr.

    2002-01-01

    Aim: A simple non-invasive test for the exocrine function of the pancreas would be attractive to diagnose various diseases of this organ. 1,2-dipalmitoyl-3-[(15-p-[I-131]-iodophenyl)pentadecan-1-oyl]rac-glycerol (MIPPAG) has been evaluated for this purpose. Materials and Methods: After oral administration, IPPA is released from the triglyceride by the action of pancreatic lipases followed by intestinal absorption and subsequent metabolism. Radioiodinated phenylpropenoic acid as the final metabolite of IPPA is then conjugated and excreted into the urine. We investigated 7 normal volunteers, 13 patients without signs of pancreatic disease and 23 patients with pancreatic insufficiency (PI). About 1 MBq Iodine-131-MIPPAG were administered orally with subsequent urine collection for two 24 h periods. Blood samples were withdrawn after 1, 3, 6, and 24 hours. TLC analysis was performed on the serum lipid extracts. As a reference method for PI measurement of the elastase concentration in the feces was used. Results: Healthy subjects excreted 44.9% (SD: 7.5%) of the administered dose in the first 24 h and after 48 h this value cumulated to 61.9 % (SD: 8.1%) whereas patients with PI excreted 27.5% (SD: 15.4%) and 35.0% (SD: 18.7%), respectively. These values were statistically highly significant (p<0.00001) compared to normals. The TLC's showed two major peaks which corresponded to the standards iodine benzoic acid (IBA) and tripalmitin (TP). The IBA/TP ratio increased with time. The sensitivity and specificity of this new test was 78.3% and 100%, respectively. Sensitivity of the elastase test was only 54%. Conclusion: MIPPAG showed the expected physiologic behavior and a pancreatic insufficiency might be diagnosed by a simple urine analysis after oral application of this new tracer

  6. Medical evaluations of ionizing radiation effects during I131 therapy in patients after thyroid carcinoma surgery

    Hermida, J.C.

    1996-01-01

    This study shows the para-clinical studies on a 39 years old patient who was operated on of a thyroid carcinoma and who, under the beirwaltes medical record (in use in our country), received in the post surgical stage, a Iodine-131 dose of about 2960 MBq (80 mCi) for ablation, having been noted subsequently her pregnancy condition. (author). 6 refs

  7. Use of Br-82 and I-131 radionuclides in studies of goitrogenic effects of exogenous bromide

    Pavelka, Stanislav

    2012-01-01

    Roč. 291, č. 2 (2012), s. 379-383 ISSN 0236-5731 R&D Projects: GA ČR(CZ) GA304/08/0256 Institutional research plan: CEZ:AV0Z50110509 Keywords : bromide * goitrogenic effect * iodine radionuclides * thyroid hormone Subject RIV: ED - Physiology Impact factor: 1.467, year: 2012

  8. Iodine volatility

    Beahm, E.C.; Shockley, W.E.

    1984-01-01

    The ultimate aim of this program is to couple experimental aqueous iodine volatilities to a fission product release model. Iodine partition coefficients, for inorganic iodine, have been measured during hydrolysis and radiolysis. The hydrolysis experiments have illustrated the importance of reaction time on iodine volatility. However, radiolysis effects can override hydrolysis in determining iodine volatility. In addition, silver metal in radiolysis samples can react to form silver iodide accompanied by a decrease in iodine volatility. Experimental data are now being coupled to an iodine transport and release model that was developed in the Federal Republic of Germany

  9. Planar and SPECT Monte Carlo acceleration using a variance reduction technique in I131imaging

    Khosravi, H. R.; Sarkar, S.; Takavar, A.; Saghari, M.; Shahriari, M.

    2007-01-01

    Various variance reduction techniques such as forced detection (FD) have been implemented in Monte Carlo (MC) simulation of nuclear medicine in an effort to decrease the simulation time while keeping accuracy. However most of these techniques still result in very long MC simulation times for being implemented into routine use. Materials and Methods: Convolution-based forced detection (CFD) method as a variance reduction technique was implemented into the well known SlMlND MC photon simulation software. A variety of simulations including point and extended sources in uniform and non-uniform attenuation media, were performed to compare differences between FD and CFD versions of SlMlND modeling for I 131 radionuclide and camera configurations. Experimental measurement of system response function was compared to FD and CFD simulation data. Results: Different simulations using the CFD method agree very well with experimental measurements as well as FD version. CFD simulations of system response function and larger sources in uniform and non-uniform attenuated phantoms also agree well with FD version of SIMIND. Conclusion: CFD has been modeled into the SlMlND MC program and validated. With the current implementation of CFD, simulation times were approximately 10-15 times shorter with similar accuracy and image quality compared with FD MC

  10. I-131 therapy for hyperthyroidism in carbimazole induced acute aplastic anaemia

    Jenkin, B.A.; Van Every, B.; Kelly, M.J.

    1998-01-01

    Full text: We present a case of a 39 year old previously well woman who developed carbimazole-induced acute aplastic anaemia. Following 6 weeks of carbimazole for Grave's disease she presented with fever, sore throat and lethargy and was found to be pancytopaenic. Haemoglobin fell to 79g/l (normal>120g/l), neutrophils to an undetectable level and platelets to 4,000/ml (normal>150,000/ml). From the MIRD schema it was estimated that a therapeutic dose of 444 MBq (12mCi) to treat her hyperthyroidism would deliver a red marrow radiation dose of about 30 mSv, at least an order of magnitude below any expected demonstrable deleterious effect on the marrow. Subsequently a dose of 444 MBq of I-131 was given and within 2 weeks the marrow had begun to recover, eventually to normal. This case would support the use of 1-131 for hyperthyroidism in carbimazole-induced marrow aplasia, even in profoundly depressed marrow

  11. Estimation dose in organs of hyperthyroidism patients treated with I-131

    Farias de Lima, F.; Khoury, H.C.; Bertelli Neto, L.; Hazin, C.

    1997-01-01

    Full text: The absorbed dose in organs of hyperthyroidism patients, which received 370 MBq and 555 MBq of I-131 were estimated, using the MIRDOSE computational program and data of the ICRP-53 publication. The calculus were done considering an equal uptake to 45% and an effective half life of 5 days, these values are closed to the average values found in 17 studied patients. The thyroidal masses were previously determined by the physicians and varied between 40 g and 80 g The results showed that the dose in the thyroid, for an activity of 370 MBq, varied between 99 Gy and 49,5 Gy for the masses of 40 g and 80 g respectively. In the case of the administration of 555 MBq the patients had thyroidal masses between 60 g and 80 g and the doses varied between 99 Gy and 74,2 Gy, respectively. These values showed that the absorbed doses in thyroid are within limits expected for the hyperthyroidism therapy, which are of 506 Gy to 100 Gy. The 100 Gy dose would be exceeded, if the patients with thyroidal mass of 40 g had received a therapeutic dose of 555 MBq. The estimated media doses in others organs were relatively low, with inferior values of 0,1 Gy in kidneys, bone marrow and ovaries and of 0,19 Gy in stomach

  12. I-131 therapy for hyperthyroidism in carbimazole induced acute aplastic anaemia

    Jenkin, B.A.; Van Every, B.; Kelly, M.J. [Alfred Hospital, Prahran, VIC (Australia). Nuclear Medicine Department

    1998-06-01

    Full text: We present a case of a 39 year old previously well woman who developed carbimazole-induced acute aplastic anaemia. Following 6 weeks of carbimazole for Grave`s disease she presented with fever, sore throat and lethargy and was found to be pancytopaenic. Haemoglobin fell to 79g/l (normal>120g/l), neutrophils to an undetectable level and platelets to 4,000/ml (normal>150,000/ml). From the MIRD schema it was estimated that a therapeutic dose of 444 MBq (12mCi) to treat her hyperthyroidism would deliver a red marrow radiation dose of about 30 mSv, at least an order of magnitude below any expected demonstrable deleterious effect on the marrow. Subsequently a dose of 444 MBq of I-131 was given and within 2 weeks the marrow had begun to recover, eventually to normal. This case would support the use of 1-131 for hyperthyroidism in carbimazole-induced marrow aplasia, even in profoundly depressed marrow

  13. Risk from ionizing radiation to the clinical staff and incidental public in the course of therapy with I-131

    Chas, J.; Janiak, M.K.; Kowalczyk, A.; Siekierzynski, M.; Dziuk, E.

    1997-01-01

    The aim of the study was to assess the risk to the personnel and neighbouring patients exposed to ionizing radiation during their stay at the Isotopic Therapy Clinic in Warsaw where therapeutic applications of I-131 are routinely performed. To this end, thermoluminescent dosimeters were deposited in various places throughout the Clinical ward and the absorbed doses were read after 125 days of the exposition. Additionally, exposure dose rates were determined at the skin surface over the thyroid gland at 0.5 and 1.0 m away from 71 patients treated with I-131 for hyperthyroidism or thyroid cancer (as a supplementary therapy after thyroidectomy) and the potential dose equivalents were calculated. From these values ''restriction times'', i.e., the amounts of time needed for the potential dose equivalents to decline below the limit recommended for occupational or public exposures to ionizing radiation were derived. The results indicate that - a) the probability to exceed the recommended annual dose limit by the personnel (50 mSv y -1 ) and neighbouring patients not subjected to radiotherapy (1 mSv y -1 ) during their exposition at the Isotopic Therapy Clinic to the I-131 treated patients is practically equal to zero; b) no restrictions in terms of limiting the duration of contact with the I-131-treated patients are necessary during the occupational exposures of the personnel of the Clinic; and c) the treated patients may incur some risk to the general public only when injected with high doses of I-131 and/or only within about 3 days upon the application of the radionuclide. (author)

  14. Maximal safe dose therapy of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma

    Lee, Jong Jin; Seok, Ju Won; Uh, Jae Sun

    2005-01-01

    In patients with recurrent or metastatic differentiated thyroid carcinoma, residual disease despite repetitive fixed dose I-131 therapy presents an awkward situation in terms of treatment decision making. Maximal safe dose (MSD) administration base on bone marrow radiation allows the delivery of a large amount I-131 to thyroid cancer tissue within the safety margin. We investigated the efficacy of MSD in differentiated thyroid cancers, which had persisted after conventional fixed dose therapy. Forty-six patients with differentiated thyroid carcinoma who had non-responsible residual disease despite repetitive fixed dose I-131 therapy were enrolled in this study. The postoperative pathology consisted of 43 papillary carcinomas and 3 follicular carcinomas. MSD was calculated according the Memorial Sloan Kettering Cancer Center protocol using blood samples. MSDs were administered at intervals of at least 6 months. Treatment responses were evaluated using I-131 whole body scan (WBS) and serum thyroglobulin measurements. Mean calculated MSD was 12.5±2.1 GBq. Of the 46 patients, 6 (13.0%) showed complete remission, 15 (32.6%) partial response, 19 (41.3%) stable disease, and 6 (13.0%) disease progression. Thus, about a half of the patients showed complete or partial remission, and of these patients, 14 (67%) showed response after a single MSD administration and 6 (29%) showed response after the second dose of MSD administrations. Twenty-nine patients (63%) experienced transient cytopenia after therapy, and recovered spontaneously with the exception of one. MSD administration is an effective method even in the patients who failed to be treated by conventional fixed dose therapy. MSD therapy of I-131 can be considered in the patients who failed by fixed dose therapy

  15. Manual on therapeutic uses of iodine-131. Incorporating: Applications guide, procedures guide, basics guide

    1992-01-01

    This booklet contains information about procedures to protect hospital staff and visitors and families of patients treated with iodine 131 from exposure to radiation from I-131. It also includes a basic guide to the principles of the production of ionizing radiation and to methods of radiation protection and dosimetry

  16. No impact of dietary iodine restriction in short term development of hypothyroidism following fixed dose radioactive iodine therapy for Graves' disease.

    Jacob, Jubbin Jagan; Stephen, Charles; Paul, Thomas V; Thomas, Nihal; Oommen, Regi; Seshadri, Mandalam S

    2015-01-01

    The increased incidence of autoimmune thyroid disease with increasing dietary iodine intake has been demonstrated both epidemiologically and experimentally. The hypothyroidism that occurs in the first year following radioactive iodine therapy is probably related to the destructive effects of the radiation and underlying ongoing autoimmunity. To study the outcomes at the end of six months after fixed dose I, (131)therapy for Graves' disease followed by an iodine restricted diet for a period of six months. Consecutive adult patients with Graves' disease planned for I(131) therapy were randomized either to receive instructions regarding dietary iodine restriction or no advice prior to fixed dose (5mCi) I(131) administration. Thyroid functions and urinary iodine indices were evaluated at 3(rd) and 6(th) month subsequently. Forty seven patients (13M and 34F) were assessed, 2 were excluded, 45 were randomized (Cases 24 and Controls 21) and 39 patients completed the study. Baseline data was comparable. Median urinary iodine concentration was 115 and 273 μg/gm creat (p = 0.00) among cases and controls respectively. Outcomes at the 3(rd) month were as follows (cases and controls); Euthyroid (10 and 6: P = 0.24), Hypothyroid (3 and 5: P = 0.38) and Hyperthyroid (7 and 8: P = 0.64). Outcomes at the end of six months were as follows (cases and controls); Euthyroid (10 and 5: P = 0.12), Hypothyroid (3 and 5: P = 0.38) and Hyperthyroid (7 and 9: P = 0.43). Of the hypothyroid patients 5 (cases 1 and controls 4: P = 0.13) required thyroxine replacement. There was no statistical significant difference in the outcome of patients with dietary iodine restriction following I(131) therapy for Graves' disease.

  17. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].

    Ruiz Franco-Baux, J V; Borrego Dorado, I; Gómez Camarero, P; Rodríguez Rodríguez, J R; Vázquez Albertino, R J; Navarro González, E; Astorga Jiménez, R

    2005-01-01

    This study aimed to evaluate the role of Fluorine-18-fluorodeoxyglucose positron emission tomography (PET-FDG) in patients with elevated serum thyroglobulin (hTg) levels where thyroid cancer tissue does not concentrate radioiodine, rendering false-negative results on I-131 scanning. Whole-body PET imaging using FDG was performed in 54 patients (37 female, 17 male) aged 17-88 years: 45 with papillary tumors and 9 with follicular tumors who were suspected of having recurrent thyroid carcinoma due to elevated thyroglobulin levels (hTg > 2 ng/ml) under thyroid-stimulating hormone (TSH > or = 30 microIU/ml) in whom the iodine scan was negative. All whole body scans were obtained with diagnostic doses (185 MBq). Whole body PET imaging was performed in fasting patients following i.v. administration of 370 MBq FDG while the patients were receiving full thyroid hormone replacement. Before PET, 99mTc methoxyisobutylisonitrile scintigraphy (99mTc-MIBI) was done in 14 patients and morphologic imaging in 26 by CT scan. Positive PET results confirmed the presence of hypermetabolic foci in 25/54 patients (46.29 %). Positive findings were found for PET-FDG in patients with hTg levels higher than 10 ng/ml receiving full thyroid hormone replacement. 99mTc-MIBI demonstrated lesions in 7/14 patients (50 %). PET-FDG and 99mTc-MIBI had congruent positive results in 4/7 patients. All the lesions found by CT were detected by PET-FDG, while recurrent disease was found in 12/21 patients with previous negative CT. These results suggest that PET-FDG seems to be a promising tool in the follow-up of thyroid cancer and should be considered in patients suffering from differentiated thyroid cancer with suspected recurrence and/or metastases by elevated thyroglobulin levels, and negative I-131 whole body scans. PET-FDG might be more useful at hTg levels > 10 ng/ml.

  18. A practical guideline for the release of patients treated by I-131 based on Monte Carlo dose calculations for family members

    Han, Eun Young; Lee, Choonsik; Mcguire, Lynn; Bolch, Wesley E

    2014-01-01

    We recently published effective doses per time-integrated activity (mSv MBq −1  s −1 ) for paediatric and adult family members exposed to an adult patient released from hospital following I-131 therapy. In the present study, we intend to provide medical physicists with a methodology to estimate family member effective dose in daily clinical practice because the duration of post-radiation precautions for the patient–family member exposure scenario has not been explicitly delineated based on the effective dose. Four different exposure scenarios are considered in this study including (1) a patient and a family member standing face to face, (2) a patient and a family member lying side by side, (3) an adult female patient holding a newborn child to her chest and (4) a one-year-old child standing on the lap of an adult female patient following her I-131 therapy. The results of this study suggest that an adult female hyperthyroidism (HT) patient who was administered with 740 MBq should keep a distance of 100 cm from a 15-year-old child for six days and the same distance from other adults for seven days. The HT female patient should avoid holding a newborn against her chest for at least 16 days following hospital discharge, and a female patient treated with 5550 MBq for differentiated thyroid cancer should not hold her newborn child for at least 15 days following hospital discharge. This study also gives dose coefficients allowing one to predict age-specific effective doses to family members given the measured dose rate (mSv h −1 ) of the patient. In conclusion, effective dose-based patient release criteria with a modified NRC two-component model provide a site medical physicist with less restrictive and age-specific radiation precaution guidance as they fully consider a patient’s iodine biokinetics and photon attenuation within both the patient and the exposed family members. (note)

  19. Comparison of I-131 MIBG scintigrapy and F-18 FDG PET in neuroblastoma

    Pai, M.; Lee, S.; Yoo, E

    2004-01-01

    The purpose of this preliminary study was to compare the utility of metaiodobenzylguanidine(MIBG) scintigraphy and F-18 FDG PET for the detection of primary and metastatic lesions of neuroblatoma. F-18 FDG PET and I-131 MIBG scan or SPECT were performed with in 1 month of each other in 4 patients (age: 4-5, all female) with known neuroblastoma after primary treatment. In 3 of 4 patients with confirmed neuroblastoma, FDG PET and MIBG scans were concordant for the presence or absence of diseased sites. In two cases, residual abdominal masses less than 1cm in which the X -ray computed tomography showed no change in tumor volume had a simultaneous negative uptake in both MIBG scan and FDG PET. In a patient with histologic evidence of bone marrow involvement, there was no skeletal uptake of both MIBG and FDG but Tc-99m HDP bone scan revealed disseminated bone marrow involvement, while a large mediastinal primary mass of this patient showed intense MIBG and FDG uptake. In one patient whose large abdominal mass of neuroblastoma failed to accumulate FDG, MIBG uptake in the tumor was intense. We concluded that FDG PET could reveal metabolic state of primary or residual neuroblastoma as much as MIBG in majority of our cases but it did not show any advantages over MIBG or even bone scan. FDG PET had an obvious defect in detection of residual viable disease in one patient. FDG PET may not replace MIBG or bone scan for evaluation of primary or metastatic disease of neuroblastoma in the diagnostic and staging procedure from INSS recommendation

  20. Comparison of I-131 MIBG scintigrapy and F-18 FDG PET in neuroblastoma

    Pai, M.; Lee, S.; Yoo, E [Seoul National University College of Medicine, Seoul (Korea, Republic of)

    2004-07-01

    The purpose of this preliminary study was to compare the utility of metaiodobenzylguanidine(MIBG) scintigraphy and F-18 FDG PET for the detection of primary and metastatic lesions of neuroblatoma. F-18 FDG PET and I-131 MIBG scan or SPECT were performed with in 1 month of each other in 4 patients (age: 4-5, all female) with known neuroblastoma after primary treatment. In 3 of 4 patients with confirmed neuroblastoma, FDG PET and MIBG scans were concordant for the presence or absence of diseased sites. In two cases, residual abdominal masses less than 1cm in which the X -ray computed tomography showed no change in tumor volume had a simultaneous negative uptake in both MIBG scan and FDG PET. In a patient with histologic evidence of bone marrow involvement, there was no skeletal uptake of both MIBG and FDG but Tc-99m HDP bone scan revealed disseminated bone marrow involvement, while a large mediastinal primary mass of this patient showed intense MIBG and FDG uptake. In one patient whose large abdominal mass of neuroblastoma failed to accumulate FDG, MIBG uptake in the tumor was intense. We concluded that FDG PET could reveal metabolic state of primary or residual neuroblastoma as much as MIBG in majority of our cases but it did not show any advantages over MIBG or even bone scan. FDG PET had an obvious defect in detection of residual viable disease in one patient. FDG PET may not replace MIBG or bone scan for evaluation of primary or metastatic disease of neuroblastoma in the diagnostic and staging procedure from INSS recommendation.

  1. Aplicaciones clínicas del radioyodo 131 (I131 en las enfermedades del tiroides Clinical applications of radioiodine 131 (I131 in the thyroid diseases

    Levi González Rivero

    2012-12-01

    Full Text Available El radioyodo 131 es un isótopo radioactivo que se emplea exitosamente en el diagnóstico y tratamiento de las enfermedades benignas y malignas del tiroides. Su propiedad de integrarse selectivamente al metabolismo del tiroides y emitir una señal, le permite describir el funcionamiento glandular mediante estudios de captación, y delimitar la morfología y localización de los tejidos que capten yodo, a través de la gammagrafía. Es además una radioterapia sencilla, segura y coste-efectiva, usada como primera línea terapéutica en el control del hipertiroidismo, cuya dosis y momento de aplicación debería individualizarse según la etiología y la clínica de cada paciente. El radioyodo 131 ofrece una alternativa eficaz para reducir el tamaño del bocio no tóxico; además, respalda el tratamiento quirúrgico del carcinoma diferenciado del tiroides, y destruye a dosis ablativa los restos tisulares y las lesiones metastásicas que puede identificar durante el seguimiento gammagráfico. El empleo de radioyodo 131 está sujeto al cumplimiento de regulaciones de protección contra la radioactividad.Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of gammagraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses

  2. Clinical outcome during the peri-operative (thyroidectomy) period of severely hyperthyroid patients with normalized pre-operative free-T4 levels: Importance of I-131 therapy as a part of pre-operative preparation

    Siguan-Crisaldo, M.A.L.; Mercado-Asis, L.B.

    2005-01-01

    Thyroidectomy is performed for hyperthyroidism on patients who do not respond to or are not compliant with medical therapy and in patients with very large goiters causing compressive symptoms. All thyrotoxic patients undergoing thyroidectomy usually are first treated with anti-thyroid drugs to normalize free thyroid hormone levels and render them euthyroid before surgery in order to prevent complications particularly thyroid storm and circulatory collapse. In this case series, we describe the clinical outcome during the perioperative (thyroidectomy) period of three severely hyperthyroid patients, two females and one male, with ages ranging from 13 to 38 years. All patients had grade III goiter, and only one had exophthalmos. The mean duration of goiter was 3.6 years. All of them were given preoperative treatment consisting of propylthiouracil (PTU) at 450-600 mg/day; iodone, 3 tablets daily and propranolol at 30-120 mg/day for one month. All of them had normalized preoperative thyroid function tests. In addition to the preoperative medications mentioned above, all three patients received radioactive iodine therapy before surgery. The first two patients received relatively low doses of 8.0 and 7.5 mCi of I-131 respectively. Unfortunately the first patient had supraventricular tachycardia (SVT), post skin cutting and the other one went into thyroid storm. The third patient who received a cumulative dose of 23.5 mCi of I-131 before surgery had an uneventful postoperative course. It is concluded that normalization of thyroid hormone parameters, especially free T4 is not sufficient for an uneventful and uncomplicated peri-thyroidectomy period in severely hyperthyroid patients with large goiters. Effective radioactive iodine therapy might prove to be helpful in inducing thyroid tissue fibrosis, thus leading to true clinical euthyroidism and excellent clinical course postoperatively. (author)

  3. Exposure of employees engaged on the production and quality control of radiopharmaceuticals labelled with Tc-99m and I-131

    Trtic, T.; Jovanovic, M.; Vranjes, S.; Vucina, J.; Vuksanovic, Lj.

    1995-01-01

    In this paper, the analysis is presented, of exposure control of employees in the Laboratory for radioisotopes, of the Vinca Institute of nuclear sciences, engaged in the production and quality control of the Tc-99m generator and radiopharmaceuticals labelled with Tc-99m and I-131. Effective doses equivalent (mSv) was measured by personal thermoluminescent dosimeter in the Laboratory for radiation and environmental protection each month. We calculated effective dose equivalents for each year in the period 1986-1990. Thirty one employees were analysed. They were separated into the groups both on the basis of radioisotope which they worked with and the kind of the professional work. The highest average effective doses equivalent were received in the group producing of Tc-99m generator (4-12.5 mSv) and in the group producing I-131 radiopharmaceuticals (3.55-13.73 mSv). (author)

  4. Autonomous Functioning Thyroid Nodule in a 4-year-old Male Child Treated with Radioiodine (I-131)

    Khare, Abhishek; Bhutani, Puneet; Chauhan, Suneel

    2013-01-01

    Autonomous functioning thyroid nodules that cause toxic manifestations (toxic adenomas) are benign monoclonal tumors characterized by their capacity to grow and produce thyroxine (T4) and triiodothyronine (T3) autonomously, i.e. in the absence of thyrotropin thyroid stimulating hormone. Toxic adenomas are a rare presentation of hyperthyroidism in the pediatric population. Radioiodine (I-131) has been widely used for therapy of patients with toxic adenomas and is now accepted as a safe and effective treatment even in the pediatric age group. The authors here present a case of a 4-year-old boy with a solitary hyperfunctioning thyroid nodule, who was successfully treated with radioiodine (I-131) and is presently on follow-up

  5. Evaluation of absorbed dose in studies of renal function due to 123I/131I (hippuran) e 111In (DPTA)

    Vasquez, M.V.; Castillo, C.E.; Rojas, R.; Cabrera, C.; Abanto, D.; Morgan, A.; Diaz, E.E.

    2015-01-01

    The absorbed dose of the kidneys during renal function studies of adult patients is estimated through biokinetics of radiopharmaceuticals containing the 123 I/ 131 I (hippuran) e 111 In (DPTA). Using the methodology MIRD and representation Cristy-Eckerman for adult kidneys, it is shown that dosimetric contributions of organs of biokinetics 123 I/ 131 I (hippuran) e 111 In (DPTA) are significant, in estimative of dose for renal function studies. Dosimetric contributions (body and whole bladder, kidneys excluding) are given by 11.90% (for 123 I), 4.97% (for 131 I) and 28.32% (for 111 In). In all cases, the dosimetric contributions are mainly due to photons issued by the whole body

  6. The uptake of radioactive iodine in rat intact Graafian follicles

    Lieberman, L.M.; Lieberman, G.L.; Lieberman, M.E.

    1984-01-01

    The concentration of iodine-131 in the ovaries of mammals has important implications in the use of I-131 for the diagnosis and treatment of thyroid disease in women. The authors studied the I-131 uptake in whole ovaries and in isolated Graafian follicles of sexually mature rats. Adult female Sprague-Dawley rats, in groups of 5-6 animals, were injected IP with 10-50 μCi of I-131, at 3, 12, and 24 hrs prior to the day of proestrus and killed on the day of proestrus. The thyroid gland and ovaries were removed intact and these organs, as well as eight other tissue specimens, were weighed. The large preovulatory follicles (6-9/ovary) were then isolated under a dissecting microscope and the remaining ovary weighed. All samples were counted in a gamma well counter and the % dose/g estimated. The thyroid gland showed 23.7% dose/organ at 24 hrs. Blood decreased from 1.6% dose/g at 3 hrs to 0.5% dose/g at 24 hrs with the uterus showing 1.1% dose/g and 0.4% dose/g at the same times. Ovarian tissue was 0.5, 0.1, and 0.1% dose/g at 3,12, and 24 hrs respectively, while the intact Graafian follicles had from one-tenth to one-third the concentration of the ovary at the same times. (0.05, 0.03, and 0.03% dose/g). The authors found that the intact Graafian follicle concentrates approximately one-thirtieth to one-sixteenth of the I-131 in the blood and one-tenth to one-third of the I-131 in the ovary. This suggests that there is no active uptake of I-131 in the follicle or follicular fluid

  7. Guide for the putting int practice the control of internal contamination due to I-131 in hospitals

    1988-01-01

    The generalized use of radioactive installations in different branches of the Economy and Medicine makes essential the existence of a radiological surveillance systems that guarantees that exposure are kept within the limits established. Nuclear medicine workers in hospitals that handle I-131 constitutes a professional group that can be internally contaminated the aim of this guide is to give the entity the general instructions and the necessary methodology to fulfill the control of the internal contamination by this radionuclide

  8. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans

    Park, Eun-Kyung; Lee, Dong Soo; Lee, Myung Chul; Chung, June-Key; Lim, Il Han; Park, Do Joon; Cho, Bo Youn

    2009-01-01

    Serum Tg and I-131 WBS have been used to detect recurrent and metastatic thyroid cancers postoperatively. Tg is known to be more sensitive than I-131 WBS, and therefore, false-negative WBS cases with elevated Tg levels are frequently found. However, the clinical characteristics of false-negative Tg cases with positive WBS have not been clarified. The authors evaluated 824 postoperative patients with differentiated thyroid carcinoma who underwent post-ablation/therapy I-131 WBS. Tg negativity was defined as a Tg level of ≤2 ng/mL without TgAb under thyroid-stimulating hormone stimulation. Remission, recurrence, and metastasis were confirmed using pathologic or clinically findings. Fifty-two patients (6.3%) with functioning metastasis and negativity for TgAb were Tg-negative and posttherapy I-131 WBS-positive (TgN group), and 128 patients with functioning metastases were Tg positive and WBS positive (TgP group). The TgN group consisted of 45 cases of cervical/mediastinal lymph node metastases (86.5%) and seven cases of distant metastasis to lung or bone by follow-up WBS. The TgN group demonstrated significantly higher profiles of regional involvement than the TgP group (P < 0.029). In 47 patients in the TgN group, metastatic uptake disappeared in 33, ameliorated in four, and persisted in ten during follow-up. A significant number of differentiated thyroid cancer patients were Tg-/TgAb-negative despite a positive WBS finding. Cervical and mediastinal lymph nodes were predominant sites of metastasis in the TgN group. WBS should be undertaken routinely as a complementary modality to detect functioning recurrence and metastasis regardless of serum Tg results. (orig.)

  9. Off-shore contamination by I-131 and Cs-137 from the Fukushima Daiichi nuclear power station accident

    Pereira, Wagner de Souza; Kelecom, Patrick Vicent; Miyashita, Erika; Universidade Federal Fluminense; Kelecom, Alphonse

    2011-01-01

    On March 11, 2011 the biggest earthquake ever registered in Japan severed off-site power supply to the Fukushima Daiichi Nuclear Power Station. Backup diesel generators began providing electricity to pumps circulating coolant to the reactors, but were knocked out by a large tsunami and the nuclear site lost the ability to maintain proper reactor cooling. This was the beginning of a huge nuclear accident that was assigned an INES maximum rating of 7. On March 21, Japanese authorities reported that the Tokyo Electric Power Company (TEPCO) had detected radioactive materials in seawater. Radioactivity started to be measured by the Japan Atomic Energy Agency every two days in sea water from eight locations, 30km from the coastline. I-131 and Cs-137 were analyzed among other radionuclides. It is the aim of this paper to gather all this information and to discuss the evolution of the radioactive marine contamination during the first month of the accident. Results indicate for surface seawater concentrations ranging from 24.9 to 161.0 Bq/L for I-131 and 11.2 to 186.0 Bq/L for Cs-137, and for deep waters of 1.59-15.0 Bq/L (I-131) and 0.0-11.4 Bq/L (Cs-137). The I-131 concentrations in superficial waters were at or above Japanese regulatory limits in the first days, then lowered during one week to increase again above limits when TEPCO released contaminated water into the ocean, to finally reach not detectable values the last week of April. With the exception of point 4, on April 15, the Cs-137 levels were always well below regulatory limits. (author)

  10. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma

    Lee, Jong-Jin; Chung, June-Key; Kim, Sung-Eun; Kang, Won-Jun; Park, Do-Joon; Lee, Dong-Soo; Cho, Bo-Youn; Lee, Myung-Chul

    2008-01-01

    The maximal safe dose (MSD) on the basis of bone marrow irradiation levels allows the delivery of a large amount of I-131 to thyroid cancer tissue. The efficacy of MSD therapy in differentiated metastatic thyroid cancers that persisted after conventional fixed dose therapy is investigated. Forty-seven differentiated thyroid carcinoma patients with non-responsive residual disease despite repetitive fixed dose I-131 therapy were enrolled in this study. Their postoperative pathologies were 43 papillary carcinomas and 4 follicular carcinomas. The MSD was calculated with the Memorial Sloan-Kettering Cancer Center protocol using serial blood samples. The MSDs were administered at intervals of 6 months. Treatment responses were evaluated using I-131 whole-body scans and serum thyroglobulin measurements. The mean calculated MSD was 12.5±2.1 GBq (339.6±57.5 mCi). Of the 46 patients, 7 (14.9%) showed complete remission, 15 (31.9%) partial remission, 19 (40.4%) stable disease, and 6 (12.8%) disease progression. Of the patients who showed complete or partial remission, 15 (65%) showed response after the first MSD session and 6 (26%) showed response after the second session. Twenty-nine patients (62%) experienced transient cytopenia after therapy, but three did not recover to the baseline level. The maximal safe dose provides an effective means of treatment in patients who failed to respond adequately to conventional fixed dose therapy. I-131 MSD therapy can be considered in patients who fail fixed dose therapy. (author)

  11. Thyroid dose of I-131 absorbed by the internal organs of a pregnant woman

    Arcos P, A.; Manzanares A, E.; Vega C, H.R.; Leon, C.L. de

    2007-01-01

    The use of nuclear techniques, for diagnosis or treatment, generates stress in the patient and its relatives. During the pregnancy some sufferings related with the thyroid gland can be presented. If the patient is pregnant, OEP or NOEP, the stress comes from the fear to that the product can it turns affected. The dose is calculated that the Iodine 131, captured by the thyroid of a woman with three months of pregnancy, it deposits in the brain, stomach, heart, kidneys, liver, lungs, ovaries, pancreas, thymus, spleen and in the uterus. The thymus is the organ that receives the biggest dose. (Author)

  12. Dosimetric comparison fixed-individualized activity in the treatment of serious disease with I -131

    Melgar Perez, J.; Orellana Salas, A.; Santaella, Y.; Arrocha Acevedo, J. F.

    2013-01-01

    The iodine-131 therapy has become the treatment with radiopharmaceuticals more frequent in our country, as well as the largest source of exposure to ionizing radiation for members who surround the patient. The aim of this article is to analyse the recommendations of radiological protection which are delivered to the patient receiving radiation discharge, in terms of the duration of the same time, taking into account the radiopharmaceutical dose, the time of entry, the dose rate measured at one meter and the family environment among others. (Author)

  13. Iodine Deficiency

    Zimmermann, M.B.

    2009-01-01

    Iodine deficiency has multiple adverse effects in humans, termed iodine deficiency disorders, due to inadequate thyroid hormone production. Globally, it is estimated that 2 billion individuals have an insufficient iodine intake, and South Asia and sub-Saharan Africa are particularly affected.

  14. Radionuclide Basics: Iodine

    ... Centers Radiation Protection Contact Us Share Radionuclide Basics: Iodine Iodine (chemical symbol I) is a chemical element. ... in the environment Iodine sources Iodine and health Iodine in the Environment All 37 isotopes of iodine ...

  15. External dose measurements for patients receiving therapeutic I-131 for thyroid cancer

    Molfetas, M.; Kottou, S.

    2002-01-01

    Iodine-131 is a well established and effective treatment, supplementing surgery, in differentiated thyroid carcinoma. Iodine-131 except from its β-emission, that generates a cell-killing effect in a small area, has also a γ-emission irradiating distant tissues and even people who are close enough with the treated patient. The International Commission on Radiation Protection, ICRP has estimated the probability of a radiation-induced fatal cancer for the whole population at 5.0 % per sievert for low doses and at low dose rates and at 1.3 % for serious genetic diseases. For elderly people the probability seems to be 3 to 10 times lower, whereas for children up to the age of 10 years, 2-3 times higher. These findings led the ICRP to recommend new dose limits, lower than the previous ones. The European Union has endorsed the ICRP recommendations and the Council issued two directives, with which the Greek legislation complied recently. The current annual public dose limit is 1 mSv, while in the new Greek legislation the concept of dose constrains (0.5 m Sv in Greece) has also been proposed as a goal to reach whenever possible

  16. Radioiodine (I-131) application in the management of differentiated thyroid cancer (DTC) audit

    Nanayakkara, D.

    2005-01-01

    Full text: Differentiated thyroid cancer (DTC) remains one of the curable of all cancers. All literature reviews and clinical experiences regarding I 131 use in DTC conclude the beneficial effects, better prognosis, longer survival time and an assurance for cure. The Overall prognosis of patients with DTC is excellent if treat scientifically, adequately and timely. The management of thyroid cancer depends on the resources available in different institutions. Nuclear Medicine unit (NMU), Faculty of Medicine Peradeniya, Sri Lanka is in the process of uplifting the services for thyroid cancer management. Clinical audit was carried out in NMU on patients who utilized the Nuclear Medicine facilities in the management of DTC. It is important to identify deficiencies in current practice to improve our services. During January 2004 to March 2005, 126 DTC patients were referred for radioiodine Whole body scan (WBS) and therapy. Their age, sex, histology, extent of surgery, adequacy of thyroxine suppression treatment, monitoring with serum thyroglobulin levels (Tg), WBS results and radioiodine therapy were analyzed. There were 104(82.5%) females and 22(17.5%) males giving sex ratio of 4.7: 1. The Mean age was 35.5 years (range 9-58 years). The commonest histological types were papillary carcinoma 55.5% (n=70), follicular carcinoma 35% (n=44) and follicular variant of papillary carcinoma 9.5% (n=12). Seventy five percent (n=95) had total thyroidectomy (TT), 17 %(n=21) had near total thyroidectomy (NTT) and 8%(n=10) had subtotal thyroidectomy (STT). Sixty-nine patients (54.8%) were on thyroid suppression therapy. Thirty-six patients (28.6%) were referred to the WBS soon after surgery without initiation of thyroxine treatment. Another twenty-one patients (16.6%) were not on thyroxine therapy since surgery. Serum thyroglobulin was assessed on 20.6% (n=26). WBS done using 3-4 mCi liquid radioiodine showed residual functioning thyroid tissues in 41% (n=52). Lymph nodes or bone

  17. No hypothyroidism after I-131 therapy in pts with toxic nodular goiter, treated under combined thyreostatic, thyreomimetic medication

    Giubbini, R.; Panarotto, M.B.; Paghera, B.; Pagliaini, R.; Pajoro, U.; Pizzocaro, C.; Rossini, P.L.; Terzi, A.; Maira, G.

    2002-01-01

    Background. Treatment of toxic nodular goiter with 131-I is generally satisfactory and will cause a reversion of hyperthyroidism. To avoid the risk of thyrotoxic storm I-131 therapy is usually performed after pre-treatment with antithyroid drugs, which causes a TSH increase and functional recruitment of previously inhibited normal thyroid tissue. In this functional state both autonomous nodule(s) and normal tissue are irradiated after I-131 administration. This may be the reason of late hypothyroidism occurring in 15-25% of Pts. Aim of the study was the evaluation of a different pre-treatment modality with combined methimazole (10-20 mg) and Triiodo-thyronine (T3 - 60 μg) in order to treat pts in euthyroid state with suppressed TSH. Study protocol. After diagnosis of hyperthyroidism with autonomous functioning tissue the pts were put under thyreostatic medication. Two months later TSH was checked and if >0.5% U.I the T3 treatment was associated. After two more months, the TSH level was checked again and, if suppressed, the pt received I-131 therapy. Study population. 93 pts (74f, 19m - age 75±10) were consecutively enrolled. 24 pts had a toxic nodular goiter and 69 a multi nodular one, respectively; they were evaluated at diagnosis, at pre-treatment, two months after therapy and at late follow-up (3.1 ± 3.5 yrs). Methods: 557±225 MBq of I-131 (according to uptake determinations and gland weight) were administered. Methymazole was discontinued 3 days before treatment whereas T3 was maintained during I-131 therapy. Results: Euthyroidism was achieved after the first treatment in 71% of pts. At late follow-up TSH values over the normal range were observed in only 4 pts (4.3% - however all 4 pts had TSH level below 6 I.U.). Summaries of FT3 and FT4 values are presented. Conclusions: The treatment of toxic nodular goiter under combined thyreostatic-thyreomimetic treatment is a safe, well tolerated and effective procedure allowing a 71% success at the first treatment

  18. Evaluation of different substrates for inkjet printing of rasagiline mesylate

    Genina, Natalja; Janßen, Eva Maria; Breitenbach, Armin

    2013-01-01

    The main goal of the present study was to evaluate applicability of the different model substrates, namely orodispersible films (ODFs), porous copy paper sheets, and water impermeable transparency films (TFs) in preparation of the inkjet-printed drug-delivery systems. Rasagiline mesylate (RM...

  19. Safety pharmacology of sibutramine mesylate, an anti-obesity drug.

    Kim, Eun-Joo; Park, Eun-Kyung; Suh, Kwee-Hyun

    2005-03-01

    Sibutramine mesylate is a new anti-obesity drug. It is a crystalline salt of sibutramine developed to improve the solubility of sibutramine hydrochloride. Methanesulfonic acid was used as a salt-forming acid instead of hydrochloric acid, resulting in a greatly improved solubility of 1000 mg/mL in water. Sibutramine mesylate was administered orally to ICR mice, Sprague-Dawley rats, and beagle dogs at dose levels of 1.15, 3.45, and 11.50 mg/kg to measure its effects on the central nervous system (CNS), general behaviour, cardiovascular-respiratory system and the other organ systems. Following administration of sibutramine mesylate, spontaneous locomotor activity was significantly increased from 120 min to 24 hours at 3.45 mg/kg and from 30 min to 24 hours at 11.50 mg/kg. Furthermore, there were a decrease in hexobarbital-induced sleep time, an increase in respiratory rate at 120 min, increases in intestinal transport capacity and gastric pH at 11.50 mg/kg, and decreases in gastric volume and total acidity at 3.45 and 11.50 mg/kg. However sibutramine mesylate caused no effects on general behaviour, motor coordination, body temperature, analgesia, convulsion, blood pressure, heart rate, electrocardiogram, cardiac functions of the isolated rat heart, isolated smooth muscles and renal function. Based on the above results, it was concluded that sibutramine mesylate caused effects on the spontaneous locomotor activity, hexobarbital-induced sleep time, respiration, gastrointestinal transport, and gastric secretion at a dose level of 3.45 mg/kg or greater but caused no effects on other general pharmacological reactions.

  20. Fixed dose of I-131 therapy for the treatment of Graves' hyperthyroidism

    Li Lin; Lee, K.

    2004-01-01

    Objectives: To evaluate short-term (6 month) efficacy of fixed-dose (555 MBq, 15 mCi) approach in the treatment of Graves' hyperthyroidism and analyze the relationship between clinical outcome (hyperthyroidism, hypothyroidism, and euthyroidism) and variances (patient age, thyroid weight, absorbed activity per gram of thyroid tissue, and radioactive iodine uptake value). Methods: 38 patients of Graves' hyperthyroidism were treated with 555MBq of radioactive iodine (in the form of capsule). Follow-up was done 3 and 6 months post therapy and the following clinical outcome was monitored: persistent hyperthyroidism, hypothyroidism, and euthyroidism. Statistical analysis was performed with SPSS software (version 11.5). P<0.05 was taken as indicating a statistically significant effect. Results: Of the 38 subjects, 14 (36.8%) were identified as euthyroidism, 18 (47.4%) hypothyroidism, and 6 (15.8%) hyperthyroidism. Cure rate (euthyroidism+hypothyroidism) was 84.2%. Statistical analysis revealed that there is a statistically significant difference of absorbed activity per gram of thyroid tissue and thyroid weight (F=17.639, P=0.000; F=28.453, P=0.000), but there is no statistically significant difference in terms of patient age and RAIU (F=1.375, P-0.266; F=2.453, P=0.101) among euthyroidism, hypothyroidism, and hyperthyroidism patients. Conclusion: We concluded that fixed-dose approach is very effective in the quickly restoration of thyroid function. There is a statistically significant difference of absorbed activity per gram of thyroid tissue and thyroid weight, but there is no statistically significant difference in terms of patient age and RAIU among euthyroidism, hypothyroidism, and hyperthyroidism patients. (authors)

  1. Exhalation of I-131 after radioiodine therapy: time dependence and chemical form

    Schomaecker, K.; Fischer, T.; Eschner, W.; Gaidouk, M.I.; Schicha, H.

    2001-01-01

    Aim: The change of both amount and chemical forms of radioiodine exhaled in the air of rooms with patients on the therapy ward should be investigated depending on radioactivity applied, time after application, and kind of thyroid disease. Methods: The air of ward-rooms of 62 patients with thyroid carcinoma, Graves' Disease, and autonomy which received different therapy doses, was investigated with an portable constant air flow sampler. Different chemical iodine species (organic, elemental, aerosol bound) were collected during 8 hr in various filters until 3 days after application of the radioiodine capsule, according to their chemical form. The radioactivity in the filters was measured with a well counter on defined time points after application. Results: The radioactivity exhaled was between 0,008 and 0,03% related to activity of radioiodine applied. The percentage of radioiodine exhaled related to the activity applied, differed significantly depending on disease and changed as follows: Grave's disease > autonomy > carcinoma. The exhalation of radioiodine became stronger with increasing applied activities and showed an exponential decrease with time. The most part of radioiodine was present in organic bound form. This organic portion decreased with time in favour of the other iodine species. Conclusion: The degree of accumulation of radioiodine orally applied within thyroid seems to be in direct proportion to the extend of its exhalation. Further measurements directly in the breathing air of RIT-patients are necessary, in order to clarify the relationship between degree of thyroid uptake and quantity as well as chemical form of radioiodine exhaled. (orig.) [de

  2. Survey of iodine metabolism in man illustrated by an iodide load investigation

    Bassoee, C.-F.; Langaasdalen, H.

    1977-12-01

    The first part of this report deals with the human metabolism of iodine, its sources, serum iodine, uptake in the thyroid, hormonal thyroid secretion and iodine excretion. The thyroid hormones are discussed as is the regulating of the iodine metabolism. The second part consists of a study performed on six healthy persons over two days. These were given 5mg iodine in aqueous solution rally and series of blood tests taken. Two persons were also given 100mg and 200mg respectively per day for 3weeks. The results are tabulated and discussed. In the third and final section the radiation hygiene aspects are treated. The basis is the uptake of large amounts of I - 131 from radioactive fallout. Carcinogenesis and hypothyroidism following this are discussed and therapy and iodine prophylaxis are described. (JIW)

  3. Fallout and drinking water contamination by I-131 and Cs-134, 137 in Japan, from the Fukushima Daiichi NPS accident

    Kelecom, Alphonse; Miyashita, Erika; Kelecom, Patrick Vicent

    2011-01-01

    The earthquake followed by a tsunami in Japan, on last March 11, seriously damaged four of the six reactors of the Fukushima Daiichi nuclear power station (NPS). Radioactive smokes and highly contaminated water were released for weeks to the environment. Since March 12, when the plant operator TEPCO and Japan's nuclear agency (NISA) confirmed the presence of radionuclides near the NPS, a giant environmental monitoring operation was set up, covering the entire Japanese territory. Daily thousands measurements are realized. We here analyze data released during 60 days on I-131 and Cs-134,137 radioactive concentrations in drinking water and fallout for 45 prefectures. Miyagi and Fukushima, that requires a separate study, are not considered here. Drinking water contamination by I-131 was observed in 13 prefectures, including Tokyo. The most impacted one was Tochigi (maximum of 110 Bq/l, March 24). This value turned water not drinkable for infants and babies. Cs-137 was detected in drinking water in 8 prefectures, with a maximum level of 18 Bq/l in Ibaraki. These levels do not affect potability of tap water. I-131 was observed in fallout in 27 prefectures, with level reaching 93 kBq/m2 in Ibaraki and 36 kBq/m 2 in Tokyo on March 21 and 23 respectively. Fallout of Cs-137 was observed in 19 prefectures. The maximum deposition occurred again in Ibaraki (13kBq/m 2 , March 21) and in Tokyo (5.3 kBq/m2, March 22). Since mid April, only trace contamination has been observed for both radionuclides in drinking water. Sporadically medium levels of Cs-137 are still observed in fallout. (author)

  4. Fallout and drinking water contamination by I-131 and Cs-134, 137 in Japan, from the Fukushima Daiichi NPS accident

    Kelecom, Alphonse; Miyashita, Erika; Kelecom, Patrick Vicent [Universidade Federal Fluminense (UFF), Niteroi, RJ (Brazil)

    2011-07-01

    The earthquake followed by a tsunami in Japan, on last March 11, seriously damaged four of the six reactors of the Fukushima Daiichi nuclear power station (NPS). Radioactive smokes and highly contaminated water were released for weeks to the environment. Since March 12, when the plant operator TEPCO and Japan's nuclear agency (NISA) confirmed the presence of radionuclides near the NPS, a giant environmental monitoring operation was set up, covering the entire Japanese territory. Daily thousands measurements are realized. We here analyze data released during 60 days on I-131 and Cs-134,137 radioactive concentrations in drinking water and fallout for 45 prefectures. Miyagi and Fukushima, that requires a separate study, are not considered here. Drinking water contamination by I-131 was observed in 13 prefectures, including Tokyo. The most impacted one was Tochigi (maximum of 110 Bq/l, March 24). This value turned water not drinkable for infants and babies. Cs-137 was detected in drinking water in 8 prefectures, with a maximum level of 18 Bq/l in Ibaraki. These levels do not affect potability of tap water. I-131 was observed in fallout in 27 prefectures, with level reaching 93 kBq/m2 in Ibaraki and 36 kBq/m{sup 2} in Tokyo on March 21 and 23 respectively. Fallout of Cs-137 was observed in 19 prefectures. The maximum deposition occurred again in Ibaraki (13kBq/m{sup 2}, March 21) and in Tokyo (5.3 kBq/m2, March 22). Since mid April, only trace contamination has been observed for both radionuclides in drinking water. Sporadically medium levels of Cs-137 are still observed in fallout. (author)

  5. Outcomes of pregnancy in function of radiation dose to ovaries following a treatment with I131 for a differentiated thyroid cancer

    Garsi, J.P.; Rubino, C.; Labbe, M.; Vathaire, F. de; Garsi, J.P.; Schlumberger, M.; Rubino, C.; Ricard, M.; Labbe, M.; Vathaire, F. de; Garsi, J.P.; Rubino, C.; Labbe, M.; Vathaire, F. de; Schvartz, C.; Henri-Amar, M.; Bardet, S.; Ceccarelli, C.

    2008-01-01

    Radiations are mutagen. During a treatment for a differentiated cancer of thyroid, the minimal activity of I 131 given to the patient is 3700 MBq producing a radiation dose to ovaries estimated to 140 mGy. In spite of the importance of this dose, few data on the outcomes of the pregnancy after irradiation are available. After our study it appears that the exposure to I 131 has no harmful effect on the outcomes of these pregnancies. (N.C.)

  6. Estimation of parameters biokinetics from the resolution of a model compartment for I-131. Application to a patient with thyroid carcinoma hemodialysis

    Garcia, R.; Jimenez Feltstrom, D.; Luis dimon, F. J.; Sanchez Carmona, G.; Herrador Cordoba, M.

    2013-01-01

    This work aims to define a biokinetic model for the I-131, and solve it for different conditions of the patient or person affected (normal, with cancer of the thyroid or hyperthyroid). Solve the model in the case of a patient treated with I-131 for ablation of thyroid remnants with undergoing renal insufficiency and hemodialysis . Get the parameters Biokinetic this model for different situations. (Author)

  7. Evaluation of absorbed dosis during studies of renal function due AI 123I / 131I (Hippuran) and 111 In (DPTA)

    Arteaga, Marcial V.V.; Diestra, Carlos E.C.; Villanueva, Raul A.S.; Alegria, Roberto R.; Salvatierra, Carlos C.; Rosales, Jorge M.; Gonzalez, Denis A.; Cruz, Carlos A.M.

    2014-01-01

    Using the MIRD methodology and Cristy-Eckerman representation for for adult kidneys, it proves that the dosimetric contributions of bodies of the biokinetics of 123 I / 131 I (Hippuran) and 111 In (DTPA) are significant, in the estimated of dose, during studies of renal function. Dosimetric contributions (whole body and urinary bladder, kidney excluding) are given by 11.90% (for 123 I), 4.97% (for 131 I) and 28.32% (for 111 In). In all cases, the dosimetric contributions are mainly due to photons emitted by the entire body

  8. Our first experience in the application of I-131 MIBG in a patient with neuroblastoma (A case report)

    Samarina, G.; Poksi, A.

    2005-01-01

    Full text: Neuroblastomas (NB) belong to a group of neuroendocrine tumors that are thought to arise from cells in the neural crest from the pelvis to neck, produce high levels of the urinary catecholamines vanillylmandelic acid (VMA) or homovanillic acid (HVA) in more than 90% of cases, and often metastasize to bones, bone marrow (BM), lymph nodes, and the liver. I-123 MIBG and I-131 MIBG are clinically important radiopharmaceuticals, which are routinely used for diagnostic imaging and treatment of NB. 90% percent of NB takes up the MIBG. If, however, the MIBG cannot successfully attach to a patient's tumor, it cannot be used to find or treat it. A 20-month-old girl presented with a 6-month history of a rapidly growing tumor mass 3.5 cm in diameter in the left orbital region. The first CT scan revealed a soft tissue tumor 22 x 28 mm, extending from the inferolateral wall of the left orbit and destroying the surrounding bone (os zygomaticus). CT scans of the chest and abdomen were negative. Histopathology showed high malignancy (G3) of NB (immunohistochemical reactions: NSE positive, CgA positive, SY positive, Ki-67 70% of tumor cells positive). First BM histological examination revealed no pathological findings. Urinary VMA and HVA levels were within the normal range. Tc-99m MDP scans showed increased uptake of radiopharmaceutical in the bones around the left orbital region but no evidence of skeletal metastases. 123 I-MIBG studies revealed a hypermetabolic focus in the left orbital region, concordance with the CT and bone scans. The child was treated with preoperative chemotherapy, but without any results: the CT-scan performed four months later showed that the tumor had grown to 45 x 37 x 40 mm. The clinical test demonstrated the progress of the disease and the tumor at that stage was inoperable. Clinicians decided to change the chemotherapy regimen and a CT study carried out three months later showed that the tumor had decreased to 26 x 10 x 30 mm. The patient

  9. Differences in the dry deposition of gaseous elemental I-131 to several leafy vegetable species

    Shinonaga, T.; Heuberger, H.; Tschiersch, J.

    2004-01-01

    The height of the dry deposition of gaseous elemental 131 I to leafy vegetable is quite uncertain because of the different habit, surface texture and leaf uptake of the different plant species. There is no comparative data on the deposition to various species, but leafy vegetables are taken as reference plants for the estimation of the height of contamination of vegetable foods after a nuclear accident. Therefore new chamber experiments were performed to determine under homogeneous and controlled conditions the dry deposition of gaseous elemental 131 I on mature leafy vegetable. The simultaneous exposition of endive, head lettuce, red oak leaf lettuce and spinach (spring leafy vegetable) rsp. curly kale, white cabbage and spinach (summer leafy vegetable) was arranged. The sample collective of each species was such large that for the expected variation of the results a statistically firm analysis was possible. Significant differences were observed for the 131 I deposition on spring vegetable: the deposition on spinach was roughly 3 times that on leaf lettuce, 4 times that on endive and 9 times that on head lettuce. All summer vegetables showed differences in deposition. For Iodine, the deposition on spinach was roughly 3 times (6 times) that on curly kale and 35 times (100 times) that on white cabbage in the 2 experiments. Washing by deionised water could reduce the contamination only by about 10% for 131 I. (author)

  10. Clinical applications of radioiodine 131 (I131) in the thyroid diseases

    Gonzalez Rivero, Levi; Turcios Trista, Silvia Elena; Velasco Mirabal, Milagros

    2012-01-01

    Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of scintigraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses the tissular remains and the metastatic lesions that can be detected during the gammagraphic follow-up. Radioiodine 131 depends on the fulfillment of safety regulations against radioactivity

  11. Clinical applications of radioiodine 131 (I131) in the thyroid diseases

    Gonzalez, Rivero Levi; Turcios Trista, Silvia Elena; Velasco Mirabal, Milagros

    2012-01-01

    Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of gammagraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses the tissular remains and the metastatic lesions that can be detected during the gammagraphic follow-up. Radioiodine 131 depends on the fulfillment of safety regulations against radioactivity

  12. I-131 Therapy in patients with hyperthyroidism 11- year follow-up

    Radeva, M.

    2007-01-01

    Full text: Radioiodine therapy is a well-established method for the treatment of patients with various forms of hyperthyroidism and is preferred in many countries as the first line therapy. Traditionally, it has been applied in Bulgaria in low doses, mainly in elderly patients with contraindications for surgery or after long-term antithyroid drug therapy. No systematic follow up of these patients has ever been done in the country. Materials and Methods: 571 subjects aged 34 to 79 years (mean 64, 7), 108 males with mean age of 68.61 years (54 to 76 yrs) and 463 females with mean age of 68.89 years (34 to 84 yrs). Mean disease duration was 73±5 months. The study included 296 patients with toxic nodular goiter, 220 patients with Graves- Basedow disease and Hashitoxicosis and 55 patients with adenoma toxicum. 256 females and 40 males with toxic nodular goiter, 158 females and 62 males with Graves- Basedow disease and Hashitoxicosis, 49 females and 6 males with adenoma toxicum. The disease duration is 48.19 months in females and 22.5 months in males. Methods: 131-iodine scan and uptake before the treatment and on follow-up visits at months 6,12,18 and 24 with a dose of 1.48 MBq 131-I for the both tests, given orally as a water solution. Uptake was measured at hours 2, 4 and 24; thyroid scan -at hour 24, thyroid ultrasound, FNB cytology if suspicious of malignancy, thyroid hormones -TSH (normal range 0.3-4.0 mU/l), FT4 (normal range 8-17 pmol/l) Results: 131-iodine therapy was administered to subjects with 131-I uptake over 25% at hour 24. Doses between 148- 370MBq were given depending on diagnosis and thyroid volume. A single radioiodine dose, mean value 189.07 MBq is applied in 246 (87, 85%) patients, second dose, mean value 183, 5 MBq is required in 30 (10, 72%) and third dose, mean value 148 MBq received 4 (1, 43%) patients. Effect of 131-iodine therapy-the change in radioiodine uptake is a marker for complex assessment of the result of the 131-iodine therapy. In

  13. Prospective randomized trial for the evaluation of the efficacy of low vs. high dose I-131 for post operative remnant ablation in differentiated thyroid cancer

    Barrenechea, E.A.; Laureta, E.G.; Gaston, J.C.; Al-Nahhas, A.; Padhy, A.K.

    2005-01-01

    The study was done under the auspices of the IAEA to evaluate the efficacy of low dose (50-60mCi) vs. High dose (100 mCi) for the post-operative remnant ablation of differentiated thyroid cancer and to determine other factors associated with successful ablation. There were eighty-six patients included in the study with a diagnosis of papillary, follicular or mixed type of thyroid cancer. They all have undergone near total thyroidectomy or total thyroidectomy and without any evidence of metastatic disease. Four to six weeks after the surgery and without thyroid hormone maintenance as well as iodine free diet and drugs, they underwent a total body scan and uptake using 1-3 mci of I-131. Serum TSH and thyroglobulin were also taken. Randomization was made thru the IAEA and the patients either got a low dose or a high dose depending on such randomization. Of the 86 patients included, there were a total of 76 evaluable cases. There were three dropouts because of other medical conditions as upper GI bleeding, lung cancer and leg fracture. The 7 other patients have not completed their follow-up body scan. Among these patients were 67 females and 19 males whose age range was 19 to 84 years old. There were 65 cases with histologic type of papillary cancer, 15 follicular and 6 mixed varieties. Forty-one patients were randomized to the high dose group while 35 patients were assigned to the low dose therapy group. These patients were confined till their radiation activity was below 2mR/hr. Monitoring of the patients were done during their hospital stay. Post-therapy body scan was done but not with all patients. Most of the side effects noted were sialitis, mild neck pains, nausea and occasional vomiting as well as ageusia. These patients were maintained on thyroid hormone depending on their sensitivity but almost all were given 200-300mgs per day. The older patients tolerated only around 150mcgs/day. After four to six months, serum TSH, thyroglobulin and total body scan were

  14. Comparison of chromatography and Sep-pak methods for estimating the radiochemical purity of I-123 and I-131 labelled meta-iodobenzylguanidine (mIBG), synthesised in house

    Kumar, V.

    1998-01-01

    Full text: Radioiodine (I-123 or I-131) labelled mlBG has been prepared routinely in-house in a number of radiopharmacy laboratories. The radiochemical purity can be estimated by several methods. Available literature suggests that the results of chronatographic analysis are comparable with electrophoresis and high pressure liquid chromatography (HPLC) methods which are considered as gold-standard procedures. However, due to the cost involved with these equipments most of the radiopharmacy laboratories are not fortunate enough to have them. The present study compares the validity of reverse-phase Sep-pak cartridge method against chromatographic technique. We analysed twenty four preparations of mIBG by both Sep-pak and chromatography methods (20 batches of I-123 mD3G and 4 batches of I-131 mIBG). Chromatographic analysis, which takes >2hrs, was performed with Whatman No 1/ n-butanol: acetic acid: water (60:15:25 v/v) and the activity associated with the peaks for free iodine and I-123 mD3G were measured. Sep-pak cartridge method, which takes less than 10 min, was performed as follows: the cartridge was activated by injecting 5 mL ethanol (200% pure) followed by flushing with 5mL distilled water. A sample (0.1mL) of radioiodine labelled mD3G was applied to the column and was eluted with 5mL distilled water. Subsequently two aliquots of 5mL solution containing tetrahydrofuran: (0.1M) sodium dihydrogen phosphate (25:75v/v) were passed through and the activity in each elute was measured. Analysing the results by Student's paired t-test for I-123 mlBG using the Sep-pak method gave a mean + SD of 98.8+ 0.6 % which correlated well (r 2 = 0.780) with the results obtained by the chromatographic method 99.3+0.5% (p <0.05). The results obtained for free I-123 by the two methods were 1.09 + 0.56% and 0.6 + 0.5% (p <0.05) respectively. The parameters did not differ significantly when I-131, instead of I-123, was used to synthesise mIBG. The results clearly indicate that the Sep

  15. Radiation Dose to Family Member of Hospitalized Patient Receiving I-131 Therapy for Thyroid Cancer: Case Study

    Tuntawiroon, M; Chaudakshetrin, P; Sritongkul N; Thongprapal, T

    2009-07-01

    Full text: During high-dose I-131 therapy, hospitalized patient who is unable to walk to the bathroom is at risk of radiation burden to comforter from excreted urine. Foley catheter is usually placed in the patient before I-131 administration. The urine was collected and housed in lead shielding, emptied every 4 to 6 hours on the first day, and every 8 to 10 hours on subsequent days. After specific instructions with regard to radiation safety, family member designed as the caregiver of patient was provided an electronic personal dosimeter to directly measure radiation dose for three days in isolated hospitalization and two more weeks at home. The caregiver recorded time spent in contact with the patient and activities performed during these times. Total accumulative dose for 16 days was 650 μSv of which 44% (288 μSv) was from the first 24 hours and more than 70% (462 μSv) during the first 72 hours, and about 25% (162 μSv) from emptying urine bags. Most of the dose received (488 μSv) was from attending time spent in the vicinity of the patients. However, this was not exceeding the constraints of 1 mSv/y and well below the limit of 5 mSv in any one year for exposed caregiver and comforter

  16. Effect of decicurie doses of radioactive iodine 131 on parathyroid function

    Glazebrook, G.A.

    1987-01-01

    Although parathyroid deficiency has been reported after administration of relatively small doses of iodine 131, reports of such deficiency after the much larger doses given in the management of thyroid cancer are notable by their absence in the literature. We observed one such patient, then instituted a prospective study. We observed a 58 percent incidence of apparently diminished parathyroid reserve among 53 patients given high doses of I 131. Susceptibility does not appear to be related to age, sex, extent of thyroid operation, operative technique, the amount of thyroidal I 131 uptake, the use of external radiation to the neck, or to the presence of parathyroid glands or of Hashimoto's disease in the operative specimen; however, susceptibility may be related to the anatomic location of the parathyroid glands in relation to the thyroid gland. The administered dose of I 131 almost reached significant levels (p = 0.1) in the present study. The initial pretreatment serum calcium levels were consistently lower among affected patients (p = 0.01), suggesting the presence of a preexisting latent impairment of parathyroid reserve which was subsequently unmasked after the administration of I 131. Thyroid cancer is compatible with very long-term survival, and therefore, there is a considerable risk of delayed chronic hypocalcemia among patients who have received large doses of I 131, particularly female patients in the premenopausal age group. These patients deserve special management surveillance

  17. Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

    Daiki Kayano

    2015-01-01

    Full Text Available Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG via a NE transporter. Since iodine-131 (I-131 MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective response was poor. In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with other radionuclide formations of MIBG, and in combined use with other therapeutic agents.

  18. Iodinated bleomycin

    Lunghi, F.; Riva, P.; Assone, F.; Villa, M.; Plassic, G.

    1978-01-01

    Bleomycin was labelled with iodine-131 by the iodine monochloride method. Iodination did not alter the chemical and chromatographic features and ''in vitro'' stability studies on freeze-dried 131 I-Bleomycin having a specific activity of 1 mCi/mg, stored at different temperatures, showed no appreciable variation of the free-iodine content. Tissue distribution of 131 I-Bleomycin has been evaluated in tumor bearing rats. Patients have been injected with 0.5-1.0 mCi of 131 I-Bleomycin corresponding to a maximum of 1.5 mg. No adverse reactions have been observed. Total body scans have been performed at 2, 6, 24 and 48 hours after injection. The iodinated Bleomycin was rapidly distributed and cleared from the body and showed an early uptake in the neoplastic tissue. A diagnostic accuracy of 90% has been observed in malignant deseases, while no false positive results have been, at the moment, recorded. (author)

  19. Thyrotoxicosis caused by functioning metastatic thyroid carcinoma. A rare and elusive cause of hyperthyroidism with low radioactive iodine uptake

    Ober, K.P.; Cowan, R.J.; Sevier, R.E.; Poole, G.J.

    1987-01-01

    A patient with progressively worsening thyrotoxicosis, refractory to medical therapy, is described. Repeated measurements of thyroidal RAI uptake over a 13 month period were low consistently and could not be explained by iodine ingestion, thyroiditis, or administration of exogenous thyroid hormone. An I-131 scan ultimately revealed striking activity at the base of the skull, reflecting ectopic excessive production of thyroid hormone by a solitary functioning metastatic thyroid carcinoma. The thyrotoxic state resolved after large doses of therapeutic I-131. Typical features of this rare cause of hyperthyroidism are discussed

  20. An experiment to use medical I-131 as tracer in a city sewer system

    Ulbrich, Susanne; Fischer, Helmut W. [University of Bremen, Institute of Environmental Physics, Otto-Hahn-Allee 1, D-28359 Bremen (Germany)

    2014-07-01

    City sewer systems have to reliably carry residential and industrial wastewater to treatment plants, often mixed with rainwater. Transport in the sewer system is regularly modelled in order to predict sewerage levels, transport velocities and volume discharges. Radioisotopes would be interesting tracers, as they can be detected quickly and without the need of applying wet chemistry. Medical isotopes are released in large quantities (many MBq) by excretion from patients either at the location of administration or from elsewhere, most probably the patient's home. Depending on diagnostic or treatment modality, isotopes of different physical characteristics are used, often bound to compounds of specific metabolic behaviour. Routine environmental surveillance regularly detects the most common diagnostic ({sup 99m}Tc) and therapeutic ({sup 131}I) isotopes in city wastewater samples. Except for {sup 131}I in the case of a nuclear emergency, no contributions from sources other than medical are expected. Medical isotopes therefore might be used for tracing purposes, provided individual inputs can be identified and separated. A field experiment has been designed involving {sup 131}I releases from a single patient who had undergone radioiodine thyroid ablation therapy. This modality is applied after thyroid cancer surgery in order to destroy residual thyroid tissue. Activities up to 5 GBq of {sup 131}I are used which are excreted within few days, as no iodine-retaining thyroid tissue remains. In Germany, about 20,000 of these treatments are performed yearly. For a sewer system of 500,000 inhabitants, about 150 cases would be expected per year, making it quite improbable to have interference between individual patient releases in the same region of the city sewer system. Practically, the radiometric laboratory was informed of the expected release of an (anonymous) patient from the collaborating radiotherapy unit several days in advance, plus the approximate location of

  1. Optimizing a single fixed dose of Iodine-131 in Graves' Disease (An Experience)

    Khan, S.H.

    2007-01-01

    Full text: Kashmir is a Himalayan mountain state of India enclosed by high snow capped ridges of Pir Panjal Mountains at an average height of 4000-5000 meters above the sea level. For most of the 4 million inhabitants in this land locked valley, agriculture horticulture and handcrafts are the main source of income. Due to long and severe winters the terraced farming on the mountain slopes yield just a single crop of rice which is barely sufficient to meet the local needs of this staple diet. People are relatively poor with low annual per capita income. Goiter is endemic in the Valley of Kashmir. In a published report the overall prevalence of goiter among the school going children in Kashmir between the ages of 5 years is 45.2% (+ SEM) with urinary iodine excretion of 49 + 3.55 μg per gram of creatinine. The extremely shy people of Kashmir are casual towards the aesthetic aspects of their goiters but nevertheless seek medical advice when associated with physical symptoms. In a published study of 203 patients of thyrotoxicosis from Kashmir, Graves' disease was the commonest cause, accounting for 63% of patients. One hundred and twentyone patients of Graves' disease were prospectively studied for their response to a single fixed dose of I-131. Patients were randomly treated with two different fixed doses of I- 131. Sixty four patients belonging to Group-I received a fixed dose of 185 MBq (Low Dose) and 57 patients belonging to Group -2 received 370 MBq (High Dose) of I- 131. Following therapy all patients were evaluated at 3 months. Patients with normal or reduced thyroid hormone levels were termed as responders and those with persistently elevated levels of thyroid hormone were termed as non responders. The response rates among the two groups were analyzed for their statistical significance. Patients treated with the high fixed dose of 370 MBq revealed good response to therapy achieving a rate of 91.22%, while the response rate in the group of patients treated with

  2. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid. A comparison of ablation success with different activities of radioiodine (I-131)

    Prpic, M.; Dabelic, N.; Stanicic, J.; Jukic, T.; Kusic, Z.; Milosevic, M.

    2012-01-01

    The objective of this study was to assess efficiency of various I-131 activities on thyroid remnant ablation in thyroid cancer patients. The significance of patients' characteristics, pathologic features and levels of Tg were analyzed. This study included 259 consecutive differentiated thyroid cancer patients, with disease confined to the thyroid, treated with I-131 after total thyroidectomy. Patients were divided into the three groups: 80 patients receiving low [1110-1850 MBq (30-50 mCi)], 121 intermediate [2775 MBq (75 mCi)] and 58 high [3700 MBq (100 mCi)] postoperative I-131 activities. Six to eight months after the application of radioiodine, measurements of TSH, Tg, anti-Tg antibodies (in hypothyroid state) together with ultrasound exam and whole-body scintigraphy were performed. The ablation was significantly more effective (after the first application) in patients receiving 100 mCi of I-131-89.7% than in patients receiving lower activities (P=0.016). There was no significant difference in ablation rate between the 30-50 mCi (77.5%) and 75 mCi (70.2%) groups. In the group receiving 30-50 mCi, patients with solitary tumors had significantly higher ablation rate (P=0.038). In patients receiving 75 mCi ablation rates were higher among older patients (P=0.005), with infiltration of the single lobe (P=0.005), and with solitary tumor (P=0.012). The rates of successful ablation after the second application of I-131 (after 12-16 months) amounted to 96, 97 and 96% in the 30-50, 75 and 100 mCi groups, respectively. The activity of I-131 and age were independent factors for thyroid ablation failure after the first application of I-131 (model of binary logistic regression). The results of remnant ablation were satisfactory with all activities applied. Although after the first application of I-131 the activity of 100 mCi is significantly more effective in thyroid ablation than the administration of 30-50 mCi and 75 mCi, the ablation rates between all the three groups are

  3. Pd-Catalyzed Cross-Coupling Reactions of Amides and Aryl Mesylates

    Dooleweerdt, Karin; Fors, Brett P.; Buchwald, Stephen L.

    2010-01-01

    A catalyst, based on a biarylphosphine ligand, for the Pd-catalyzed cross-coupling reactions of amides and aryl mesylates is described. This system allows an array of aryl and heteroaryl mesylates to be transformed into the corresponding N-arylamides in moderate to excellent yields. PMID:20420379

  4. Iodine poisoning

    ... Iodine is also used during the production of methamphetamine. Note: This list may not be all inclusive. ... breathing machine (ventilator) Blood and urine tests Chest x-ray EKG (electrocardiogram, or heart tracing) Fluids through a ...

  5. Reproductive function and biological dosimetry prospective study of young thyroid differentiated cancer patients treated with I-131

    Di Giorgio, M.; Vallerga, M.B.; Taja, M.R.; Radl, A.; Chebel, Graciela; Fadel, Ana Maria; Gutierrez, Silvia; Normandi, Eduardo; Levalle, Oscar; Kundt, Miriam

    2011-01-01

    The administration of I-131 in the management of differentiated thyroid cancer (DTC) is a well established practice. As the spermatogonia is highly sensitive to radiation, large doses of internal radiation could result in adverse effects on reproductive function such as oligo/azoospermia and infertility. During spermiogenesis, mammalian chromatin undergoes replacement of nuclear histones by protamines, which yields a DNA sixfold more highly condensed in spermatozoa than in mitotic chromosomes. The structure of this highly packaged chromatin shows a low binding capacity for several fluorochromes and dyes such as chromomycin A3 (CMA3). The aim of this study is to assess the correlation between reproductive function (endocrine and exocrine testicular function, and levels of CMA3 stainability) and biological dosimetry in a prospective study of 4 young DTC patients treated with I-131. In this context, a background level of CMA3 binding in mature human sperm was established. It revealed a variable accessibility of CMA3 to the DNA that is dependant on packaging quality and thus, indicative of protamine deficiency. The identification of altered stainability suggests DNA damage as well as epigenetic effects, which may be indicators of male infertility. Transient impairment of spermatogenesis associated with an increase in FSH, an altered spermiogram and even azoospermia was observed after the administration of cumulative activities. Overall, testosterone levels were preserved, except in one case, which presented a drastically diminished value associated with an increase in LH level. As peripheral blood lymphocytes and spermatogonia have equivalent radiosensitivity (interphase death) we hypothesize that the knowledge of DNA damage recovery in peripheral lymphocytes could correlate with spermatogonia recovery and with FSH evolution. (authors)

  6. Reproductive function and biological dosimetry prospective study of young thyroid differentiated cancer patients treated with I-131

    Di Giorgio, Marina; Vallerga, Maria B.; Taja, Maria R.; Radl, Analia; Chebel, Graciela; Fadel, Ana M.; Gutierrez, Silvia; Normandi, Eduardo; Levalle, Oscar; Kundt, Miriam

    2008-01-01

    Full text: The administration of I-131 in the management of differentiated thyroid cancer (DTC) is a well established practice. As the spermatogonia is highly sensitive to radiation, large doses of internal radiation could result in adverse effects on reproductive function such as oligo/azoospermia and infertility. During spermiogenesis, mammalian chromatin undergoes replacement of nuclear histones by protamines, which yields a DNA sixfold more highly condensed in spermatozoa than in mitotic chromosomes. The structure of this highly packaged chromatin shows a low binding capacity for several fluoro chromes and dyes such as chromo mycin A 3 (CMA 3 ). The aim of this study is to assess the correlation between reproductive function (endocrine and exocrine testicular function, and levels of CMA 3 stainability) and biological dosimetry in a prospective study of 4 young DTC patients treated with I-131. In this context, a background level of CMA 3 binding in mature human sperm was established. It revealed a variable accessibility of CMA 3 to the DNA that is dependant on packaging quality and thus, indicative of protamine deficiency. The identification of altered stainability suggests DNA damage as well as epigenetic effects, which may be indicators of male infertility. Transient impairment of spermatogenesis associated with an increase in FSH, an altered spermiogram and even azoospermia was observed after the administration of cumulative activities. Overall, testosterone levels were preserved, except in one case, which presented a drastically diminished value associated with an increase in LH level. As peripheral blood lymphocytes and spermatogonia have equivalent radiosensitivity (interphase death) we hypothesize that the knowledge of DNA damage recovery in peripheral lymphocytes could correlate with spermatogonia recovery and with FSH evolution. Therefore, a prospective study on the decline of unstable chromosome aberrations is being conducted, considering the damage

  7. High-dose I-131 MIBG treatment for young children with high-risk neuroblastoma, and its practical problem. From the experience of the youngest case in Japan

    Araki, Raita; Nishimura, Ryosei; Mase, Shintaro

    2012-01-01

    High-dose I-131 MIBG (metaiodobenzylguanidine) therapy combined with auto- or allo-hematopoietic stem cell transplantation is becoming a potential treatment for patients with high-risk neuroblastoma worldwide. However, only older children, who can perform personal care, had been given high-dose I-131 MIBG treatment to avoid the needless radiation exposure to caregivers and medical staff in Japan. In this case report, we have used the high dose MIBG therapy followed by autologous PBSCT (peripheral blood stem cell transplantation) for a 1-year-old boy with a newly diagnosed high-risk neuroblastoma with MYCN amplifications. The total radiation exposure to all parties involved was very limited, even in the youngest case in Japan, probably due to adequate preparations. This encouraging experience may remove the age limit for high-dose I-131 MIBG treatment for the patients with high-risk neuroblastoma in Japan. (author)

  8. Radiation of the thyroid during examination of patients with thyroid diseases using radioactive iodine

    Zvonova, I.A.; Likhtarev, A.A.; Nikolaeva, A.A.

    1984-02-01

    Basing on 131I uptake functions in the thyroid of 109 patients irradiation doses of this organ were evaluated for persons with normal iodine metabolism and in the following diseases: hypothyrosis, moderate thyrotoxicosis, nodular toxic and nontoxic goiter, vegetative neurosis. Maximum tolerant doses of 123I, 125I, 131I and 132I are recommended for diagnostic examination of thyroid function and scanning of this organ.

  9. Tirilazad mesylate protects stored erythrocytes against osmotic fragility.

    Epps, D E; Knechtel, T J; Bacznskyj, O; Decker, D; Guido, D M; Buxser, S E; Mathews, W R; Buffenbarger, S L; Lutzke, B S; McCall, J M

    1994-12-01

    The hypoosmotic lysis curve of freshly collected human erythrocytes is consistent with a single Gaussian error function with a mean of 46.5 +/- 0.25 mM NaCl and a standard deviation of 5.0 +/- 0.4 mM NaCl. After extended storage of RBCs under standard blood bank conditions the lysis curve conforms to the sum of two error functions instead of a possible shift in the mean and a broadening of a single error function. Thus, two distinct sub-populations with different fragilities are present instead of a single, broadly distributed population. One population is identical to the freshly collected erythrocytes, whereas the other population consists of osmotically fragile cells. The rate of generation of the new, osmotically fragile, population of cells was used to probe the hypothesis that lipid peroxidation is responsible for the induction of membrane fragility. If it is so, then the antioxidant, tirilazad mesylate (U-74,006f), should protect against this degradation of stored erythrocytes. We found that tirilazad mesylate, at 17 microM (1.5 mol% with respect to membrane lecithin), retards significantly the formation of the osmotically fragile RBCs. Concomitantly, the concentration of free hemoglobin which accumulates during storage is markedly reduced by the drug. Since the presence of the drug also decreases the amount of F2-isoprostanes formed during the storage period, an antioxidant mechanism must be operative. These results demonstrate that tirilazad mesylate significantly decreases the number of fragile erythrocytes formed during storage in the blood bank.

  10. Iodine in diet

    Diet - iodine ... Many months of iodine deficiency in a person's diet may cause goiter or hypothyroidism . Without enough iodine, ... and older children. Getting enough iodine in the diet may prevent a form of physical and intellectual ...

  11. Daily variation of I-131, Cs-134 and Cs-137 activity concentrations in the atmosphere in Osaka during the early phase after the FDNPP accident

    Zijian Zhang; Kazuhiko Ninomiya; Naruto Takahashi; Atsushi Shinohara

    2015-01-01

    To investigate the time variations of radionuclides discharged from the Fukushima Daiichi nuclear power plants accident, we started collecting aerosol samples in Osaka, Japan, using a high-volume sampler from March 15 to May 1, 2011. Atmospheric radioactivity concentrations of I-131, Cs-134 and Cs-137 were measured with germanium semi-conductor detectors. Only I-131 was detected in the early phase and two Cs-134.137 peaks were found in Osaka in April. Using the HYSPLIT model, we concluded that direct transportation of the air mass from the Fukushima area was responsible for such events. (author)

  12. Potassium iodide (KI) to block the thyroid from exposure to I-131: current questions and answers to be discussed

    Reiners, Christoph; Schneider, Rita [Hospital of the University of Wuerzburg, Department of Nuclear Medicine, German WHO-REMPAN Collaboration Center, Wuerzburg (Germany)

    2013-05-15

    Thyroid cancer in children and adolescents has to be considered as the most severe health consequence of a nuclear reactor emergency with release of radioiodine into the atmosphere. High doses of potassium iodide are effective to block radioiodine thyroid uptake and to prevent development of thyroid cancer years later. However, there are controversies concerning thyroid cancer risk induced by radioiodine exposure in adults. Further, the interaction of nutritional supply of potassium iodide and radioiodine uptake as well as the interaction of radioiodine with certain drugs has not been addressed properly in existing guidelines and recommendations. How to proceed in case of repeated release of radioiodine is an open, very important question which came up again recently during the Fukushima accident. Lastly, the side effects of iodine thyroid blocking and alternatives of this procedure have not been addressed systematically up to now in guidelines and recommendations. These questions can be answered as follows: in adults, the risk to develop thyroid cancer is negligible. In countries, where nutritional iodine deficiency is still an issue, the risk to develop thyroid cancer after a nuclear reactor emergency has to be considered higher because the thyroid takes up more radioiodine as in the replete condition. Similarly, in patients suffering from thyrotoxicosis, hypothyroidism or endemic goitre not being adequately treated radioiodine uptake is higher than in healthy people. In case of repeated or continued radioiodine release, more than one dose of potassium iodide may be necessary and be taken up to 1 week. Repeated iodine thyroid blocking obviously is not harmful. Side effects of iodine thyroid blocking should not be overestimated; there is little evidence for adverse effects in adults. Newborns and babies, however, may be more sensitive to side effects. In the rare case of iodine hypersensitivity, potassium perchlorate may be applied as an alternative to iodine for

  13. Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on I-131 in the thyroid

    Lamart, Stephanie; Simon, Steven L; Lee, Choonsik; Bouville, Andre; Eckerman, Keith F; Melo, Dunstana

    2011-01-01

    The S values for 11 major target organs for I-131 in the thyroid were compared for three classes of adult computational human phantoms: stylized, voxel and hybrid phantoms. In addition, we compared specific absorbed fractions (SAFs) with the thyroid as a source region over a broader photon energy range than the x- and gamma-rays of I-131. The S and SAF values were calculated for the International Commission on Radiological Protection (ICRP) reference voxel phantoms and the University of Florida (UF) hybrid phantoms by using the Monte Carlo transport method, while the S and SAF values for the Oak Ridge National Laboratory (ORNL) stylized phantoms were obtained from earlier publications. Phantoms in our calculations were for adults of both genders. The 11 target organs and tissues that were selected for the comparison of S values are brain, breast, stomach wall, small intestine wall, colon wall, heart wall, pancreas, salivary glands, thyroid, lungs and active marrow for I-131 and thyroid as a source region. The comparisons showed, in general, an underestimation of S values reported for the stylized phantoms compared to the values based on the ICRP voxel and UF hybrid phantoms and relatively good agreement between the S values obtained for the ICRP and UF phantoms. Substantial differences were observed for some organs between the three types of phantoms. For example, the small intestine wall of ICRP male phantom and heart wall of ICRP female phantom showed up to eightfold and fourfold greater S values, respectively, compared to the reported values for the ORNL phantoms. UF male and female phantoms also showed significant differences compared to the ORNL phantom, 4.0-fold greater for the small intestine wall and 3.3-fold greater for the heart wall. In our method, we directly calculated the S values without using the SAFs as commonly done. Hence, we sought to confirm the differences observed in our S values by comparing the SAFs among the phantoms with the thyroid as a

  14. Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on I-131 in the thyroid

    Lamart, Stephanie; Bouville, Andre; Simon, Steven L.; Eckerman, Keith F.; Melo, Dunstana; Lee, Choonsik

    2011-11-01

    The S values for 11 major target organs for I-131 in the thyroid were compared for three classes of adult computational human phantoms: stylized, voxel and hybrid phantoms. In addition, we compared specific absorbed fractions (SAFs) with the thyroid as a source region over a broader photon energy range than the x- and gamma-rays of I-131. The S and SAF values were calculated for the International Commission on Radiological Protection (ICRP) reference voxel phantoms and the University of Florida (UF) hybrid phantoms by using the Monte Carlo transport method, while the S and SAF values for the Oak Ridge National Laboratory (ORNL) stylized phantoms were obtained from earlier publications. Phantoms in our calculations were for adults of both genders. The 11 target organs and tissues that were selected for the comparison of S values are brain, breast, stomach wall, small intestine wall, colon wall, heart wall, pancreas, salivary glands, thyroid, lungs and active marrow for I-131 and thyroid as a source region. The comparisons showed, in general, an underestimation of S values reported for the stylized phantoms compared to the values based on the ICRP voxel and UF hybrid phantoms and relatively good agreement between the S values obtained for the ICRP and UF phantoms. Substantial differences were observed for some organs between the three types of phantoms. For example, the small intestine wall of ICRP male phantom and heart wall of ICRP female phantom showed up to eightfold and fourfold greater S values, respectively, compared to the reported values for the ORNL phantoms. UF male and female phantoms also showed significant differences compared to the ORNL phantom, 4.0-fold greater for the small intestine wall and 3.3-fold greater for the heart wall. In our method, we directly calculated the S values without using the SAFs as commonly done. Hence, we sought to confirm the differences observed in our S values by comparing the SAFs among the phantoms with the thyroid as a

  15. Iodine-131 therapy for the treatment of hyperthyroidism

    Enkhtuya, B.; Tsevelmaa, L.; Erdenechimeg, S.

    2005-01-01

    Full text: Since 1997, radioactive iodine (I-131) has become the most widely used therapy for patients with hyperthyroidism cased by Graves' disease in the Mongolia. Our seven years clinical experience was reviewed to evaluate the efficacy of the therapy. We treated 150 patients (119 female and 31 male) with hyperthyroidism with I-131 (mean dose 8.2 mCi) between 1997 and 2004. The dose calculation was based on 24 hours thyroid uptake, thyroid gland size and degree of toxicity. We determined their thyroid status after 1 year in relation to age, pretreatment with an antithyroid drug, pretreatment thyroid size and whether or not there are thyroid nodules. Out of the 150 patients, 87(58%) were euthyroid, 30 (20%) hypothyroid at 1 year after treatment, and 33 patients (22%) had persistent hyperthyroidism and required second treatment. The patients who had persistent hyperthyroidism were younger in age, had larger thyroid glands, some of them had thyroid nodules and 27 patients (81%) pretreatment with anti-thyroid drugs for more than 6 months. Our results showed that the majority of patients with Graves' hyperthyroidism had a effective treatment. However, 22% of patients with younger age, larger thyroid glands, patients with thyroid nodules and who had anti-thyroid drugs for more than 6 months had undergone repeated treatment. A higher dose of I-131 maybe advisable in such patients. In order to establish correct treatment dose we may need more precise dosimetry study. (author)

  16. Iodine-131: optimal therapy for hyperthyrodism in children and adolescents

    Freitas, J.E.; Swanson, D.P.; Gross, M.D.; Sisson, J.C.

    1979-01-01

    To assess the medium- to long-term effects of I-131 therapy of hyperthyroidism in children and adolescents, we studied 51 patients (age range 6 to 18; 8 boys, 43 girls) treated with I-131 for Graves' disease with hyperthyroidism at the University of Michigan Medical Center (1951 to 1972). Patients received total doses ranging from 3 to 81.6 mCi. The mean followup period was 14.6 +- 7.9 yr. Hyperthyroidism was effectively treated in 49 within 1 to 12 months. One patient failed to respond to three treatment doses, and hyperthyroidism recurred in two patients: 2 and 11 yr after initial therapy. Of these three patients, two were treated by thyroidectomy and was retreated successfully with I-131. There were no cases of thyroid cancer, other malignancies or leukemia. The patients' reproductive histories and the health of their offspring were as in the general population. At the time of study, the prevalence of hypothyroidism was 92%, with no recurrent goiters or thyroid nodules. Iodine-131 is found to be safe and effective treatment of hyperthyroidism in children and adolescents and should be the preferred mode of therapy

  17. Radiation protection instrumentation. Monitoring equipment. Atmospheric radioactive iodine in the environment

    1995-01-01

    This international standard applies to portable or installed equipment for the monitoring of radioactive iodine (such as I-131 or I-125) in air in the environment of nuclear installations during normal operation, during design basis events, and in emergency situations. The monitoring involves continuous sample trapping and, where adequate, automatic start of sampling. The document deals with radioactive iodine monitor design, testing procedures, and documentation. Appended tables refer to the reference and normal testing conditions, tests in normal testing conditions, tests during changes of the affecting quantities, and tests of changes in the air circuit. (P.A.)

  18. Uptake of Iodine-131 in mussel (Mytilus smaragdinns) and algae (caulerpa racemosa)

    Sombrito, E.Z.; Banzon, R.B.; de la Mines, A.S.; Bautista, E.Rb.

    1982-01-01

    The behavior of radionuclides in the environment has been the subject of research. Iodine-131, a beta emitter as one of the radionuclides has been studied. This study describes Iodine-131 uptake in mussel and algae. The bioaccumulation factor C was determined which gave the relationship between the concentration of radioactivity in biota relative to the water environment. Results of the experiments showed that the mussels steadily accumulated I-131 from radioactive medium. Much higher bioaccumulation factor was obtained in algae than in mussel. No attempt was made to measure activity in the soft parts. (ELC)

  19. Radiation exposure from liquid discharges from I-131 therapy rooms into the piping system of a hospital building

    Tuntawiroon, M.; Sritongkul, N.; Pusuwan, P.; Chaudakshetrin, P.

    2008-01-01

    Over 80% of the activity from patients undergoing radioiodine therapy for thyroid cancer is eliminated during the first three days. In our I-131 therapy unit, the number of hospitalized patients has increased from less than 200 in 2004 to more than 300 in 2006. The total amount of radio activity used is about 1,800 GBq per year, and the estimated amount excreted is calculated to be about 1,500 GBq. This results in significant volume of contaminated liquid discharges into the piping system. In this study, we monitored external dose rates in non-radiation use areas adjacent to pipeline connections in the building to ensure that the dose to non-occupational workers who reside in offices below the unit does not exceed 1 mSv per year. Exposure rates in areas adjacent to the pipeline junction connections were measured periodically from April 2006 to February 2007 five floors below the therapy unit. The measurements were made inside the wall at contact with the junction, outside the wall and in hallways at 1 meter from the wall, using a GM detector or an ionization chamber. The results were recorded in μSv/h and the dose received was estimated for members of the public. Significant increases in dose rates were detected in three floors below the unit. They were 20--30, 10--30 and 5--15 μSv/h at contact with the pipeline connections, 9--15, 10--15 and 3--5 μSv/h outside the wall, and 3--6, 4--6 and 2--5 μSv/h in hallways on floors 1, 2 and 3 respectively. After appropriate wall shielding has been provided, dose rate outside the wall was reduced to 1.4 μSv/h, and to 0.5.3 μSv/h in hallways. By using an occupancy factor 1/4 for hallways, the calculated dose now meets the public dose limits of 1 mSv per year. Therapeutic application of I-131 for the treatment of thyroid cancer generates a significant amount of contaminated liquid waste into the sewers. These wastes originate mainly from toilets, showers, wash basins and floor drains. Although waste discharges can be

  20. Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    2017-11-15

    Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma

  1. Spatial distribution of Iodine-129 in surface soil around the Fukushima Daiichi Nuclear Power Plant

    Miyake, Yasuto; Tagi, Kazuhiro; Matsuzaki, Hiroyuki; Fujiwara, Takeshi; Saito, Takumi; Yamagata, Takeyasu; Tsuchiya, Yoko; Nakano, Chuichiro; Honda, Maki

    2011-01-01

    Due to the accident at the Fukushima Daiichi nuclear power plant, which was caused by the Great East Japan Earthquake, a lot of radioactive materials were released into the environment. Among them, Iodine-131, which has a short half-life of 8 days, is thought to be hardly detected after the accident is concluded. It is very important to research how leaked out Iodine-131 was diffused in order to estimate the health impact of radiation at the time of the accident. On the other hand, Iodine-129, which was leaked out and was thought to act chemically-identically as Iodine-131, has an extremely long half-life of 15.7 million years and we are able to measure it equally after the accident. By following the trail of Iodine-129, it is considered to estimate the distribution of Iodine-131. To do this, at first, it is essential to measure simultaneously Iodine-131 and Iodine-129 in the same sample picked from near-the Fukushima Daiichi nuclear power plant and examine the relation between them (for example, the isotopic ratio of Iodine derived from the nuclear power plant (I-129/I-131)). At this study, we measured Iodine-129 in surface soil within 60 kilometers of the Fukushima Daiichi nuclear power plant, which was picked by research team of Nuclear Engineering Research Laboratory, Faculty of Engineering, the University of Tokyo. We discuss Iodine-129 derived from the nuclear power plant by considering the concentration range, the relation of a distance or a direction from the nuclear power plant, and the relation between I-129 and other radioactive nuclides (Cs-134, Cs-137, I-131). Since Iodine-129, which had been leaked out from the nuclear fuel reprocessing plant in Europe, was already transferred to Japan by way of the atmospheric transportation before the accident, it is important to distinguish between Iodine-129 from this accident and from the reprocessing plant. Then, we want to obtain the I-129/I-131 ratio originating in the accident precisely and discuss the

  2. The effect of newer water-soluble contrast media on I-131 uptake by the thyroid gland

    Starinsky, R.; Horne, T.; Barr, J.; Ramot, Y.

    2006-01-01

    The aim of this study was to evaluate the effect of two water-soluble contrast media (nonionic and Dimer) on iodine uptake by the thyroid gland. Twenty-eight euthyroid patients (16 females and 12 males) were subjected to 24hrs radioiodine uptake (RAIU) studies following brain CT examinations using the above cited two water-soluble contrast media. Radioiodine uptake studies were done at one (Group-1), two (Group-2) and four (Group-3) weeks following performance of contrast enhanced CT scans. The effect of both contrast media on the thyroid uptake was found to be identical. The radio active iodine uptake (RAIU) was observed to be suppressed in 30% of patients in Group-1, 33% of patients in Group-2 and in none of the patients belonging to Group-3. On the basis of this pilot study on a limited number of patients it was concluded that dimer and non-ionic water soluble contrast media cause suppression of radio iodine uptake by the thyroid gland in a significant proportion of patients. It has also been observed that both contrast media have similar suppressive effects on radio iodine uptake by the thyroid gland. This effect is transient and does not persist beyond a period of four weeks following the administration of the contrast media. (author)

  3. Preoperative F-18-FDG PET for the detection of metastatic cervical lymph nodes in recurrent papillary thyroid carcinoma patients with negative I-131 whole body scans

    Byun, Byung Hyun; Urn, Sang Moo; Cheon, Gi Jeong; Choi, Chang Woon; Lee, Byeong Cheol; Lee, Guk Haeng; Lee, Yong Sik; Shim, Youn Sang

    2007-01-01

    We evaluated the diagnostic performance of FDG-PET for the detection of metastatic cervical lymph nodes in recurrent papillary thyroid carcinoma patients with negative I-131 scan. All patients had total thyroidectomy and following I-131 ablation therapy. In the follow-up period, FDG-PET showed suspected cervical lymph nodes metastases and neck dissection was performed within 3 months after FDG-PET. It had shown for all patients the negative I-131 scan within 3 months before FDG-PET or negative I-131 scan during the period of cervical lymph nodes metastases suspected on the basis of FDG-PET, CT, or ultrasonography until the latest FDG-PET. Preoperative FDG-PET results were compared with the pathologic findings of lymph nodes specimens of 19 papillary thyroid carcinoma patients. Serum Tg, TSH, and Tg antibody levels at the time of latest I-131 scan were reviewed. The size of lymph node was measured by preoperative CT or ultrasonography. In 45 cervical lymph node groups dissected, 31 lymph node groups revealed metastasis. The sensitivity and specificity of FDG-PET for metastasis were 74.2% (23 of 31) and 50.0% (7 of 14), respectively. Except for patients with elevated Tg antibody levels, all patients showed the elevated serum Tg levels than normal limits at the TSH of =30uIU/ml. 8 lesions without suspected metastatic findings on FDG-PET revealed metastasis (false negative), and none of them exceeded 8mm in size (4 to 8mm, median= 6mm). On the other hand, 23 true positive lesions on FDG-PET were variable in size (6 to 17mm, median=9mm). FDG-PET is suitable for the detection of metastatic cervical lymph nodes in patients with recurrent papillary thyroid carcinoma. However, false positive or false negative should be considered according to the size of lymph node

  4. Iodine Satellite

    Kamhawi, Hani; Dankanich, John; Martinez, Andres; Petro, Andrew

    2015-01-01

    The Iodine Satellite (iSat) spacecraft will be the first CubeSat to demonstrate high change in velocity from a primary propulsion system by using Hall thruster technology and iodine as a propellant. The mission will demonstrate CubeSat maneuverability, including plane change, altitude change and change in its closest approach to Earth to ensure atmospheric reentry in less than 90 days. The mission is planned for launch in fall 2017. Hall thruster technology is a type of electric propulsion. Electric propulsion uses electricity, typically from solar panels, to accelerate the propellant. Electric propulsion can accelerate propellant to 10 times higher velocities than traditional chemical propulsion systems, which significantly increases fuel efficiency. To enable the success of the propulsion subsystem, iSat will also demonstrate power management and thermal control capabilities well beyond the current state-of-the-art for spacecraft of its size. This technology is a viable primary propulsion system that can be used on small satellites ranging from about 22 pounds (10 kilograms) to more than 1,000 pounds (450 kilograms). iSat's fuel efficiency is ten times greater and its propulsion per volume is 100 times greater than current cold-gas systems and three times better than the same system operating on xenon. iSat's iodine propulsion system consists of a 200 watt (W) Hall thruster, a cathode, a tank to store solid iodine, a power processing unit (PPU) and the feed system to supply the iodine. This propulsion system is based on a 200 W Hall thruster developed by Busek Co. Inc., which was previously flown using xenon as the propellant. Several improvements have been made to the original system to include a compact PPU, targeting greater than 80 percent reduction in mass and volume of conventional PPU designs. The cathode technology is planned to enable heaterless cathode conditioning, significantly increasing total system efficiency. The feed system has been designed to

  5. Incidence of symptomatic salivary disease in patients with differentiated thyroid cancer treated with radioactive iodine

    Goni E, Ignacio; Selt A, Guillermo Vander; Ruiz A, Catalina; Leon R, Augusto; Solar G, Antonieta; Orellana B, Catalina

    2015-01-01

    Background: The radioactive iodine therapy for differentiated thyroid cancer can produce severe and frequent salivary symptoms, during the treatment or later. Aim: To analyze the incidence, severity and characteristics of the salivary signs and symptoms in these patients. Patients and Method: Retrospective and descriptive anal isis of 106 patients with confirmed diagnosis of differentiated thyroid cancer, treated with surgery and radioactive iodine, that completed a telephonic survey for the evaluation of salivary symptoms. Results: 26 (24.52%) patients presented with salivary symptoms or signs after the radioactive iodine therapy (mean 5 months). The average doses of I 131 was 128,5 mCi. Xerostomy, pain, xeroftalmy, inflammation, sialoadenitis and dysgeusia, were the most frequent clinical symptoms. Conclusions: After radioactive iodine therapy the salivary symptoms and signs incidence is high. We conclude that the indication for this treatment must be selective, but in accordance with the oncological risk of each patient

  6. Successful Treatment For Chronic Eosinophilic Leukemia (CEL With Imatinib Mesylate

    Rayane da Silva Souza

    2017-12-01

    Full Text Available We report a case of a patient with Chronic Eosinophilic Leukemia (CEL with mutation in alfa PDGFR gene exhibiting a satisfactory response to treatment with imatinib mesylate. A 25-year-old man presented in a hematology service with a persistent cough and hemogram alterations. His blood count showed a hemoglobin level of 12.5 g/dL and a white blood cell count of 94,030/mm3, eosinophils were 68% of all cells. Bone marrow aspiration and biopsy showed hypercellularity with marked eosinophilia (77% and erythroid differentiation series was hypocellular with normoblast maturation. The immunohistochemically of the bone biopsy was positive for myeloperoxidase and negative for CD34/CD99, consistent with CEL. Fluorescence in situ hybridization (FISH for the beta-fraction of platelet-derived growth factor (PDGFRβ and Philadelphia chromosome (Ph 1 were negative and the alfa PDGFR (Platelet-Derived Growth Factor was positive and showed heterozygosis in c.2531T>C on 18 Exon and homozygous in C.2562+1G>A at the region of the splicing site at the 18 intron. Treatment was initiated and maintained by administering 400mg/day imatinib mesylate. Laboratory findings returned to normal ranges, with clinical improvement and a hematological response observed after the second month of therapy. Currently, the patient’s blood count shows the white blood cell count (5,400 total leukocytes, eosinophils (8.6/mm3, hemoglobin (15.5 g/dl, hematocrit (45.4% and platelets (298,000/mm3 within normal ranges. The mutation search was negative in in peripheral blood one year after the initial treatment. Our work corroborates other studies on the efficacy of imatinib mesylate in the treatment of patients with CSF PDGFR alpha positive. We emphasize the importance of molecular studies, considering its relevance for the correct staging of the disease. Since CEL is a rare disease, it is important to define its etiology and anticipate its treatment, thus minimizing the damage induced by

  7. Transient hypothyroidism in iodine-131 treated thyrotoxicosis - a review of cases from 1970-1984 at JRRMMC

    Reyes, E.B.; de la Cruz, C.; Gonzales, V.L.

    1988-01-01

    This review was conducted to determine the minimum dose of radioactive iodine necessary to show signs and symptoms of thyrotoxicosis among Filipinos, to determine the incidence of hypothyroidism secondary to radioactive treatment and to determine if some cases of hypothyroidism following radioactive iodine treatment are only transient and replacement therapy could be withheld or not. A total of 212 patients who had I-131 therapy was evaluated (177 female and 35 male). Of this number 19 or 8.9% developed hypothyroidism. After three years, 14 or 74% of the hypothyroids were noted. Easy fatigability ranked first of the patients complaints, followed by dry skin, sleepiness, numbness of extremities, and joint pains. Results of this study indicate that there is a definite, although low incidence of hypothyroidism following I-131 therapy (8.9%). (ELC). 6 refs.; 6 tabs

  8. Comparison of radiolabeling efficiency of peptides containing the RGD domain using the Tc-99M and I-131 radioisotopes

    Sobral, Danielle V.; Cabral, Francisco Romero; Malavolta, Luciana

    2017-01-01

    Full text: Introduction: Radiolabeled peptides have become very important in nuclear medicine and oncology in recent years mainly because they represent the molecular basis for in vivo imaging and radiopharmaceutical therapy with high specificity and affinity for over expressed receptors in tumors (Thno 2(5):481-501, 2012 / Drug Discov. Today. 7:1224-1232, 2012). In this context, peptides containing the RGD domain which possess high affinity for the αvβ3 integrin receptor have become an important tool in a wide variety tumor, including glioblastoma (Exp. Opin. Drug Deliv. 8:1041- 1056, 2011). Objective: The goal of this work was to compare the radiolabeling efficiency of the GRGDYV and GRGDHV peptides when radiolabeled with the 131 I and 99m Tc radioisotopes, respectively, as well as, to evaluate the features of synthesized complexes. Methods: The GRGDYV and GRGDHV fragments were manually synthesized by peptide synthesis in solid phase accordingly to the Fmoc protocol and purified by preparative HPLC. The GRGDYV and GRGDHV peptides were radiolabeled with the I-131 and Tc-99m radioisotopes respectively, through of the direct method of radiolabeling. The radioiodination was evaluated and optimized using the methodology of Chloramine-T and for the peptide containing the histidine aminoacid the tricarbonyl method was used. Radiochemical yield analyses of [ 131 I]-GRGDYV and [ 99m Tc]-GRGDHV peptides were performed by thin layer chromatography on silica gel TLC-SG (Al) in ACN 95%. The radiolabeled peptides were purified by using solid phase extraction (Sep-Pak C18 filter). The stability studies were realized at 2, 24, 48 and 72 hours in room temperature and refrigerate (4 deg C) for [ 131 I]-GRGDYV and up to 6 hours for the fragment [ 99m Tc]-GRGDHV. Partition coefficient was determinate for both radiopeptides. Results: The peptides [ 131 I]-GRGDYV and [ 99m Tc]-GRGDHV were efficiently synthesized, radiolabeled and showed radiochemical yield of 91.02% ± 1.68 (n=5

  9. Comparison of radiolabeling efficiency of peptides containing the RGD domain using the Tc-99M and I-131 radioisotopes

    Sobral, Danielle V.; Cabral, Francisco Romero; Malavolta, Luciana [Santa Casa de São Paulo, SP (Brazil). Faculdade de Ciências Médicas; Durante, Ana C. Ranucci; Miranda, Ana C. Camargo; Barbosa, Marycel R. F.Figols de [Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, SP (Brazil)

    2017-07-01

    Full text: Introduction: Radiolabeled peptides have become very important in nuclear medicine and oncology in recent years mainly because they represent the molecular basis for in vivo imaging and radiopharmaceutical therapy with high specificity and affinity for over expressed receptors in tumors (Thno 2(5):481-501, 2012 / Drug Discov. Today. 7:1224-1232, 2012). In this context, peptides containing the RGD domain which possess high affinity for the αvβ3 integrin receptor have become an important tool in a wide variety tumor, including glioblastoma (Exp. Opin. Drug Deliv. 8:1041- 1056, 2011). Objective: The goal of this work was to compare the radiolabeling efficiency of the GRGDYV and GRGDHV peptides when radiolabeled with the {sup 131}I and {sup 99m}Tc radioisotopes, respectively, as well as, to evaluate the features of synthesized complexes. Methods: The GRGDYV and GRGDHV fragments were manually synthesized by peptide synthesis in solid phase accordingly to the Fmoc protocol and purified by preparative HPLC. The GRGDYV and GRGDHV peptides were radiolabeled with the I-131 and Tc-99m radioisotopes respectively, through of the direct method of radiolabeling. The radioiodination was evaluated and optimized using the methodology of Chloramine-T and for the peptide containing the histidine aminoacid the tricarbonyl method was used. Radiochemical yield analyses of [{sup 131}I]-GRGDYV and [{sup 99m}Tc]-GRGDHV peptides were performed by thin layer chromatography on silica gel TLC-SG (Al) in ACN 95%. The radiolabeled peptides were purified by using solid phase extraction (Sep-Pak C18 filter). The stability studies were realized at 2, 24, 48 and 72 hours in room temperature and refrigerate (4 deg C) for [{sup 131}I]-GRGDYV and up to 6 hours for the fragment [{sup 99m}Tc]-GRGDHV. Partition coefficient was determinate for both radiopeptides. Results: The peptides [{sup 131}I]-GRGDYV and [{sup 99m}Tc]-GRGDHV were efficiently synthesized, radiolabeled and showed

  10. Optimizing the number of equivalent iterations of 3D OSEM in SPECT reconstruction of I-131 focal activities

    Koral, Kenneth F.; Kritzmaan, James N.; Rogers, Virginia E.; Ackermann, Robert J.; A Fessler, Jeffrey

    2007-01-01

    To externally estimate the radiation dose to a tumor during therapy with I-131 radiopharmaceuticals, and its distribution, one must accurately estimate activity, and its distribution, by means of SPECT imaging. Our objective is to characterize the quantification of the total activity in focal targets and in their uniform background, and of the activity distribution within the targets, after 3D Ordered Subsets Expectation Maximization (OSEM) reconstruction with attenuation and scatter correction and no post smoothing, in the good-counting-statistics case. A cylindrical phantom containing seven spheres simulating tumors, ranging in volume from 209 to 4.2 cm 3 , and filled with an I-131 water solution containing background, was imaged. A Siemens Symbia SPECT/CT scanner was used to acquire 128x128 projection images, employing 60 angles over 360 o . With dynamic SPECT, 10 sequential acquisitions of 15 min duration each were obtained and each was reconstructed with particular values of the number of subsets and the number of iterations. Let the product of the number of subsets times the number of iterations equal the equivalent number of iterations, EI. The counts-to-activity conversion factor was derived from the average ratio of total count divided by true activity for the largest sphere at the largest value of EI. Then, for the activity of each sphere at each of the values of EI, we evaluated (1) the fractional variance (variance in estimate over true activity), (2) the fractional bias (average estimate bias over true activity) and (3) the fractional error (the root mean square error (RMSE) in the estimate divided by the true activity). The fractional bias and fractional variance were smaller for the larger spheres compared to the smaller (the fractional bias decreased faster with an increase in the fractional variance for them as well). The RMSE was dominated by the bias. The fractional error decreased as EI increased for all sphere sizes. The minimum average value

  11. Immunoscintigraphy of human pancreatic carcinoma in nude mice with I-131-F(ab')/sub 2/-fragments of monoclonal antibodies

    Senekowitsch, R.; Maul, F.D.; Wenisch, H.J.C.; Kriegel, H.; Hor, G.

    1985-01-01

    In the present study radioiodinated F(ab')/sub 2/-fragments of CA19-9 and antibody that reacts specifically with human gastrointestinal cancer were examined for their ability to detect human pancreatic carcinoma hosted in nude mice. Tumor-bearing mice received 80μCi of I-131-F(ab')/sub 2/ with a specific activity of 1.8μCi/μg. All mice were imaged after the injection and every 24hr up to 6 days. The retained radioactivity was also registered with a whole-body counter immediately after imaging. As a control F(ab's)/sub 2/ of a nonspecific antibody were administered in parallel to another group of animals bearing the same tumor. Three animals of each group were killed at 1,2,4 and 8 days for determination of the distribution of both labeled antibody-fragments. On scintigraphic images obtained with the CA19-9-F(ab')/sub 2/ the tumors could be visualized 24hr after injection, the best dilineation however was achieved 96hr p.i.. The biodistribution data exhibited a more rapid blood clearance for the specific fragments compared to that for the unspecific ones. Tumors showed an increase in uptake up to 48hr reaching 1.7% of the injected dose per gram, declining to values of 0.08%/g at day 6 p.i.. The highest tumor-to-blood ratios were found after 96h. They were 7 for the CA19-9-fragments compared to 1.5 for the unspecific fragments. The whole body counting revealed a more rapid excretion for the fragments of the specific monoclonal antibodies than for the unspecific ones. In summary the authors were able to show that CA19-9-F(ab')/sub 2/-fragments can be used for immunodetection of human pancreatic carcinoma hosted in nude mice

  12. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

    Reardon, David A; Egorin, Merrill J; Quinn, Jennifer A; Rich, Jeremy N; Rich, Jeremy N; Gururangan, Sridharan; Gururangan, Idharan; Vredenburgh, James J; Desjardins, Annick; Sathornsumetee, Sith; Provenzale, James M; Herndon, James E; Dowell, Jeannette M; Badruddoja, Michael A; McLendon, Roger E; Lagattuta, Theodore F; Kicielinski, Kimberly P; Dresemann, Gregor; Sampson, John H; Friedman, Allan H; Salvado, August J; Friedman, Henry S

    2005-12-20

    We performed a phase II study to evaluate the combination of imatinib mesylate, an adenosine triphosphate mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients on enzyme-inducing antiepileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs. Assessments were performed every 28 days. The primary end point was 6-month progression-free survival (PFS). Thirty-three patients enrolled with progressive disease after prior radiotherapy and at least temozolomide-based chemotherapy. With a median follow-up of 58 weeks, 27% of patients were progression-free at 6 months, and the median PFS was 14.4 weeks. Three patients (9%) achieved radiographic response, and 14 (42%) achieved stable disease. Cox regression analysis identified concurrent EIAED use and no more than one prior progression as independent positive prognostic factors of PFS. The most common toxicities included grade 3 neutropenia (16%), thrombocytopenia (6%), and edema (6%). There were no grade 4 or 5 events. Concurrent EIAED use lowered imatinib mesylate exposure. Imatinib mesylate clearance was decreased at day 28 compared with day 1 in all patients, suggesting an effect of hydroxyurea. Imatinib mesylate plus hydroxyurea is well tolerated and associated with durable antitumor activity in some patients with recurrent GBM.

  13. Phentolamine mesylate: It′s role as a reversal agent for unwarranted prolonged local analgesia

    Harpreet Singh Grover

    2015-01-01

    Full Text Available Administration of local anesthesia is an integral procedure prior to dental treatments to minimize the associated pain. It is learned that its effect stays more than the time required for the dental procedure to be completed. This prolonged soft tissue anesthesia (STA can be detrimental, inconvenient, and unnecessary. Phentolamine mesylate, a Food and Drug Administration-approved drug essentially serves the purpose of faster recovery from numbness at the site of local anesthesia. This article reviews the development of the drug phentolamine mesylate and its indication as a local anesthetic reversal agent. A literature search for phentolamine mesylate as a STA reversal agent was conducted in PubMed using the terms "dental local anesthesia reversal, phentolamine mesylate" up to March 2014. The search was limited to articles published in English. The search revealed 13 PubMed indexed articles stating the development and application of phentolamine mesylate. Phentolamine mesylate is an important step in the progress of developing patient care as well as an aid to the dental clinician.

  14. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy. Regulatory considerations on release of patients after unsealed radioiodine therapy

    Kusakabe, Kiyoko; Yokoyama, Kunihiko; Ito, Koichi

    2012-01-01

    This study was undertaken to measure the radiation exposure level of caregivers following outpatient NaI (I-131) 1,110 MBq therapy for remnant thyroid ablation after total thyroidectomy in patients with differentiated thyroid cancer, and to evaluate the influence of activities of daily living on radiation exposure level, with the goal of proposing an optimum method of I-131 therapy. The study included 37 patients with differentiated thyroid cancer, who had undergone total thyroidectomy and received outpatient based remnant thyroid ablation using NaI (I-131) 1,110 MBq, who were satisfying the following requirements: patients who have no evidence of distant metastases, whose living environments were appropriate for outpatient I-131 (1,110 MBq) therapy, and patients who gave written informed consent. The dose rate at a distance of 1 m from the body surface of the patient at the moment of release was measured using survey meters of the GM type or ionization chamber type. The dose level for the caregiver was measured with a personal dosimeter in all cases. The dose rate at a distance of 1 m from the patient's body surface 1 h after I-131 administration was in the range of 29-115 μSv/h (mean 63.8 μSv/h). The 7-day cumulative effective dose of caregivers was 0.11±0.08 mSv, on an average, in 34 dosimeters. In 31 of 34 dosimeters, cumulative effective dose of caregivers was below 0.2 mSv. Dose levels exceeding 0.2 mSv were recorded in 3 cases (0.21, 0.35 and 0.43 mSv in one case each). These results suggest that the exposure level of family members (caregiver and others) was minimal and is lower than the radiation levels affecting human environments. Outpatient-based remnant thyroid ablation with I-131 (1,110 MBq) performed after total thyroidectomy in patients with differentiated thyroid cancer is safe if applied in accordance with the appropriate supervision and guidance by experts with certain qualifications. (author)

  15. Dosimetric comparison fixed-individualized activity in the treatment of serious disease with I -131; Comparacion dosimetrica actividad fija-actividad individualizada en el tratamiento de la enfermedad de graves con I-131

    Melgar Perez, J.; Orellana Salas, A.; Santaella, Y.; Arrocha Acevedo, J. F.

    2013-07-01

    The iodine-131 therapy has become the treatment with radiopharmaceuticals more frequent in our country, as well as the largest source of exposure to ionizing radiation for members who surround the patient. The aim of this article is to analyse the recommendations of radiological protection which are delivered to the patient receiving radiation discharge, in terms of the duration of the same time, taking into account the radiopharmaceutical dose, the time of entry, the dose rate measured at one meter and the family environment among others. (Author)

  16. Using ion-selective electrode for determining iodine-131 preparation specific activity

    Melnik, M.I.; Nazirova, T.E.

    2002-01-01

    A pilot facility was developed in 2000 for the production of iodine-131. The parameters of the preparation are as follows: chemical form: sodium iodide solution (NaI-131) in a carbonate-bicarbonate buffer (or in 0.001M NaOH); specific activity: carrier free (> 5 Ci/mg); solution pH: 7-10; radionuclide purity: > 99.9%; radiochemical purity: > 97%; bulk activity: 0.15 Ci/ml. The experimental results of investigation aimed at the determination of the specific activity of the I-131 preparation using a iodine-selective electrode are described. The method enables the analytical concentration of iodide ions in the carbonate-bicarbonate buffer (pH = 8-11) and NaOH solution (0.01 mol/l, pH = 8-11) to be determined. A micro-cell has been developed for the analysis of the I-131 solution allowing the sample volume to be reduced to below 0.3 ml. The relative error of determination of the analytical concentration of iodide (10 -6 to 10 -1 mol/l) does not exceed 1%

  17. Behavior of radioactive iodine and technetium in the spray calcination of high-level waste

    Knox, C. A.; Farnsworth, R. K.

    1981-08-01

    The Remote Laboratory-Scale Waste Treatment Facility (RLSWTF) was designed and built as a part of the High-Level Waste Immobilization Program (now the High-Level Waste Process Development Program) at the Pacific Northwest Laboratory. In facility, installed in a radiochemical cell, is described in which installed in a radiochemical cell is described in which small volumes of radioactive liquid wastes can be solidified, the process off gas can be analyzed, and the methods for decontaminating this off gas can be tested. During the spray calcination of commercial high-level liquid waste spiked with Tc-99 and I-131 and 31 wt% loss of I-131 past the sintered-metal filters. These filters and venturi scrubber were very efficient in removing particulates and Tc-99 from the the off-gas stream. Liquid scrubbers were not efficient in removing I-131 as 25% of the total lost went to the building off-gas system. Therefore, solid adsorbents are needed to remove iodine. For all future operations where iodine is present, a silver zeolite adsorber is to be used.

  18. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results

    Kuecuek, N.O.; Kulak, H.A.; Aras, G.

    2006-01-01

    The aim of this study was to evaluate the potential contribution of Tc-99m-MIBI scintigraphy to the follow-up of patients with differentiated thyroid carcinoma, who had elevated Tg levels and negative I-131 whole-body scan (WBS) results. In this retrospective study, we evaluated 28 patients with differentiated thyroid carcinoma, who had total or near total thyroidectomy followed by an ablative dose of I-131 at various time intervals (15 women, 13 men; mean age 43±17 years). All patients were treated with T4 suppression. After a mean follow-up period of 6.1 years (range 3-15) all patients were determined to have a high serum Tg concentrations (>2 ng/ml) and previous negative I-131 WBS results. All patients were examined for metastatic sites using Tc-99m-MIBI scan. Scans were visually evaluated for detecting lymph node metastases and/or local recurrence, lung metastases and skeletal metastases. Tc-99m-MIBI scan demonstrated lesions in 23 patients (83.3%). In five patients with negative Tc-99m-MIBI scan findings (FN results): Chest CT showed small-sized mediastinal LN metastases in 2 patients and lung metastases in another 2 patients (<1 cm); Neck CT showed small-sized cervical LN involvement in 1 patient. The sensitivity of detection for neck was 94.4%, for lung 63.6%, and for bone lesions 100%. For all scan sites taken together, the sensitivity of disease detection was 83.3%, the specificity was 50%, positive predictive value (PPV) was 96.2%, and finally negative predictive value (NPV) was 16.7%. We concluded that Tc-99m-MIBI scan should be considered as a supplementary scintigraphic method for the follow-up of patients with high serum Tg levels and negative I-131 WBS results, and it can help clinicians in making the decision to treat these patients. (author)

  19. Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid: case report

    Thom, Anneliese Rosmarie Gertrud Fischer; Hamerschlak, Nelson; Osawa, Akemi; Santos, Fabio Pires de Souza; Pasqualin, Denise da Cunha; Wagner, Jairo; Yamaga, Lilian Yuri Itaya; Cunha, Marcelo Livorsi da; Campos Neto, Guilherme de Carvalho; Funari, Marcelo Buarque de Gusmao; Teles, Veronica Goes

    2014-01-01

    The authors report the case of a 70-year-old male patient with chronic lymphoid leukemia who presented subsequently a papillary carcinoma of the thyroid with metastases to regional lymph nodes. The patient was treated with surgical thyroidectomy with regional and cervical lymph node excision and radioiodine therapy (I-131). The protocolar control scintigraphy 4 days after the radioactive dose showed I-131 uptake in both axillae and even in the inguinal regions. PET/CT showed faint FDG-F-18 uptake in one lymph node of the left axilla. An ultrasound guided fine needle biopsy of this lymph node identified by I-131 SPECT/CT and FDG-F-18 PET/CT revealed lymphoma cells and was negative for thyroid tissue and thyroglobulin content. The sequential blood counts done routinely after radiation treatment showed a marked fall until return to normal values of leucocytes and lymphocytes (absolute and relative), which were still normal in the last control 19 months after the radioiodine administration. Chest computed tomography showed a decrease in size of axillary and paraaortic lymph nodes. By immunohistochemistry, cells of the lymphoid B lineage decreased from 52% before radioiodine therapy to 5% after the procedure. The authors speculate about a possible sodium iodide symporter expression by the cells of this lymphoma, similar to some other non-thyroid tumors, such as breast cancer cells. (author)

  20. Three-dimensional noninvasive monitoring iodine-131 uptake in the thyroid using a modified Cerenkov luminescence tomography approach.

    Hu, Zhenhua; Ma, Xiaowei; Qu, Xiaochao; Yang, Weidong; Liang, Jimin; Wang, Jing; Tian, Jie

    2012-01-01

    Cerenkov luminescence tomography (CLT) provides the three-dimensional (3D) radiopharmaceutical biodistribution in small living animals, which is vital to biomedical imaging. However, existing single-spectral and multispectral methods are not very efficient and effective at reconstructing the distribution of the radionuclide tracer. In this paper, we present a semi-quantitative Cerenkov radiation spectral characteristic-based source reconstruction method named the hybrid spectral CLT, to efficiently reconstruct the radionuclide tracer with both encouraging reconstruction results and less acquisition and image reconstruction time. We constructed the implantation mouse model implanted with a 400 µCi Na(131)I radioactive source and the physiological mouse model received an intravenous tail injection of 400 µCi radiopharmaceutical Iodine-131 (I-131) to validate the performance of the hybrid spectral CLT and compared the reconstruction results, acquisition, and image reconstruction time with that of single-spectral and multispectral CLT. Furthermore, we performed 3D noninvasive monitoring of I-131 uptake in the thyroid and quantified I-131 uptake in vivo using hybrid spectral CLT. Results showed that the reconstruction based on the hybrid spectral CLT was more accurate in localization and quantification than using single-spectral CLT, and was more efficient in the in vivo experiment compared with multispectral CLT. Additionally, 3D visualization of longitudinal observations suggested that the reconstructed energy of I-131 uptake in the thyroid increased with acquisition time and there was a robust correlation between the reconstructed energy versus the gamma ray counts of I-131 (r(2) = 0.8240). The ex vivo biodistribution experiment further confirmed the I-131 uptake in the thyroid for hybrid spectral CLT. Results indicated that hybrid spectral CLT could be potentially used for thyroid imaging to evaluate its function and monitor its treatment for thyroid cancer.

  1. The usefulness of I-131 MIBG scintigraphy in assessing the staging of neuroectodermal tumors in children - Our experience

    Budlewski, T.; Rogowski, F.; Luczynski, W.; Krawczuk-Rybak, M.

    2004-01-01

    Full text: Neuroendodermal tumors include pheochromocytoma, paraganglioma, medullary thyroid cancer and neuroblastoma. These malignant tumors derive from the primitive neural crest, which develops to sympathic nervous system. The tumors consist of cells that are capable of incorporating the amine precursors such as I-131 MIBG. The most common malignant tumor in childhood is neuroblastoma. The tested group included patients with neuroblastoma and one with pheochromocytoma treated in the Department of Oncology at the Paediatric University Hospital in Bialystok. There were 8 patients between the ages of 2 and 13. They have all undergone standard whole body scanning with a tomographic Nucline X-Ring camera made by Mediso, fitted with high-energy all purpose parallel hole collimator, a scan speed 5cm/ min and static images of 250,000 counts or 10 min per image. The study was performed 24-48 h after I-131 MIBG injection of 35 MBq activity. The results were obtained by antero-posterior and posterio-anterior projections (a whole body scan) and, if necessary, additional static images of chest and abdomen, skull, pelvis, and lower limbs. Clinical Characteristics of the Group: M.E. 12-year-old child with a right suprarenal tumor with morrow metastases. HP-neuroblastoma. The child was treated with a preoperative chemotherapy, operated and given postoperative chemotherapy (palliative therapy). The MIBG scintigraphy showed hypermetabolic focus in the pelvis and in the left vertex bone. Clinical test pointed to the progress of the disease. M.J. 6-year-old child with infiltrative retroperitoneal on both sides of celiac trunk with a metastases to mediastinum and bone marrow. HP-neuroblastoma. The first MIBG scintigraphy performed after Tsishidy operative procedure was negative. The second MIBG scintigraphy, one year later showed metastases to thigh bone, spine, and sacroiliac joint. Clinically proven progress of the disease. G.G. 2-year-old child with facial skeleton tumor and

  2. The prevalence of thyroid tissue along the thyroglossal tract on SPECT/CT following I131 ablation therapy after total thyroidectomy for thyroid cancer

    Barber, T.W.; Cherk, M.H.; Yap, K.S.K.; Kalff, V.; Topliss, D.J.; Serpell, J.W.

    2015-01-01

    Full text of publication follows. Aim: the aims of this study are first to determine the prevalence of thyroid tissue along the thyroglossal tract on SPECT/CT and secondly to assess the contribution of this tissue to total neck I-131 activity in patients treated with I-131 ablation therapy after total thyroidectomy for thyroid cancer. Materials and methods: a total of 63 consecutive patients with well differentiated thyroid cancer treated with total thyroidectomy underwent whole body planar imaging and SPECT/CT of the neck 48 hours following ablative I-131 therapy. On SPECT/CT, thyroglossal tract thyroid tissue was defined as radioiodine activity in the anterior neck, superior to the thyroid bed in close proximity to the midline without evidence of localisation to lymph nodes. On planar imaging, thyroglossal tract thyroid tissue was defined as linear radioiodine activity in the midline of the neck superior to the thyroid bed. SPECT/CT and planar images were classified by two independent reviewers as positive, negative or equivocal with interobserver agreement quantified using a Kappa score. Disagreement was resolved using a third reviewer. Quantitation of thyroglossal tract thyroid tissue and total neck I-131 activity was performed using region of interest analysis on planar imaging following localisation on SPECT/CT. Results: thyroglossal tract thyroid tissue was present in 31/63 (49%; 95% CI: 37-61%) patients on SPECT/CT. In these 31 patients, thyroglossal tract thyroid tissue contributed to an average of 49% of total neck activity. Interobserver agreement was substantial on SPECT/CT (Kappa = 0.76; 95% CI: 0.61-0.91) and fair on planar imaging (Kappa = 0.31; 95% CI: 0.15-0.47). Conclusion: thyroid tissue along the thyroglossal tract was present in one half of patients in our study population and can contribute to a significant amount of total neck I-131 activity. Given the high prevalence of thyroglossal tract thyroid tissue, our results suggest that total neck

  3. New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate.

    Cui, Jihong; Hollmén, Maija; Li, Lina; Chen, Yong; Proulx, Steven T; Reker, Daniel; Schneider, Gisbert; Detmar, Michael

    2017-01-03

    Cancer stem cells (CSCs) play major roles in cancer initiation, metastasis, recurrence and therapeutic resistance. Targeting CSCs represents a promising strategy for cancer treatment. The purpose of this study was to identify selective inhibitors of breast CSCs (BCSCs). We carried out a cell-based phenotypic screening with cell viability as a primary endpoint, using a collection of 2,546 FDA-approved drugs and drug-like molecules in spheres formed by malignant human breast gland-derived cells (HMLER-shEcad cells, representing BCSCs) and control immortalized non-tumorigenic human mammary cells (HMLE cells, representing normal stem cells). 19 compounds were identified from screening. The chemically related molecules benztropine mesylate and deptropine citrate were selected for further validation and both potently inhibited sphere formation and self-renewal of BCSCs in vitro. Benztropine mesylate treatment decreased cell subpopulations with high ALDH activity and with a CD44+/CD24- phenotype. In vivo, benztropine mesylate inhibited tumor-initiating potential in a 4T1 mouse model. Functional studies indicated that benztropine mesylate inhibits functions of CSCs via the acetylcholine receptors, dopamine transporters/receptors, and/or histamine receptors. In summary, our findings identify benztropine mesylate as an inhibitor of BCSCs in vitro and in vivo. This study also provides a screening platform for identification of additional anti-CSC agents.

  4. Iodine and Pregnancy

    Yarrington, Christina; Pearce, Elizabeth N.

    2011-01-01

    Iodine is a necessary element for the production of thyroid hormone. We will review the impact of dietary iodine status on thyroid function in pregnancy. We will discuss iodine metabolism, homeostasis, and nutritional recommendations for pregnancy. We will also discuss the possible effects of environmental contaminants on iodine utilization in pregnant women.

  5. Iodine intake in Denmark

    Pedersen, K.M.; Noehr, S.B.; Laurberg, P.

    1997-01-01

    Iodine deficiency with a high frequency of goitre and, in severely affected areas, cretinism is common in some areas of the world. In Denmark the iodine intake as evaluated by urinary iodine excretion has been at a stable low level for many years, except for the part of the population now taking iodine supplementation as part of vitamin/mineral preparations. The iodine intake is lowest in the western part to the country where an epidemiological study of elderly subjects has demonstrated a high frequency of goitre and hyperthyroidism in women. This supports the suggestion of a controlled moderate increase in iodine intake via an iodine supplementation program. (au) 40 refs

  6. Imatinib mesylate--gold standards and silver linings.

    Peggs, K

    2004-09-01

    Imatinib mesylate represents the first of a new generation of molecularly targeted therapies engineered to disrupt signal transduction pathways. It is a tyrosine kinase inhibitor with relatively selective activity against the Abelson (ABL) proto-oncogene, platelet-derived growth factor receptor, and c-KIT receptor. Deregulated tyrosine kinase activity has been implicated as a central pathogenic event in a number of human malignancies, most notably chronic myeloid leukemia. In this myeloproliferative disorder the t(9;22) reciprocal translocation results in the generation of a novel fusion oncoprotein, BCR-ABL, with constitutive tyrosine kinase activity. Imatinib inhibits this activity, inducing remarkable rates of hematological and cytogenetic remission in excess of those seen with alternative medical therapies. Following a large phase III study comparing its efficacy with the combination of interferon alpha and low-dose cytarabine, it has emerged as the current gold standard therapy for patients with chronic-phase disease without a potential bone marrow donor and those considered unsuitable for bone marrow transplantation. Its integration into the management of those patients who might be considered for transplantation, which has historically been considered the only potentially curative approach, remains a major challenge. The increasing recognition and subsequent molecular characterization of resistance mechanisms has reinforced the need to exercise caution against deferring a proven curative therapy in favor of a treatment approach that is still investigational, with the spectre of increased numbers of patients progressing to sudden-onset blast crisis remaining the potential dark cloud in the silver lining for imatinib.

  7. Iodine intake in Ireland

    Smith, P.P.A.; Hetherton, A.M.; O'Carroll, D.; Smith, D.F.; O'Halloran, M.J.; O'Donovan, D.K.

    1988-01-01

    A study of urinary iodine excretion and thyroid gland uptake of radioactive iodine 131 I was undertaken in the Dublin area with a view to providing data on the current iodine status in Ireland. A mean urinary iodine excretion of 118±82μg/gram creatinine (Median 96) obtained from 821 subjects attending general hospital outpatient clinics in the Dublin area in 1987, while excluding severe iodine deficiency in this particular cohort, obscured the fact that 250 (30%) had iodine excretion values ≤70 μ/g creatinine, a value approximating to the minimum daily iodine requirement. The results provide sufficient evidence of sporadic iodine deficiency to justify a more widespread study of the iodine status of the Irish population with a view to making recommendations on the possible need for iodine prophylaxis

  8. Studies of iodine concentration in steel and transition metals

    Kormann, C.; Kozlowski, W.; Oleksi-Frenzel, J.; Nachtigall, K.; Neste, A. van; Welsh, M.; Titze-Zaeske, B.; Plieth, W.

    1990-01-01

    Radioactive iodine which originates from nuclear fuel reprocessing plants as a fission product and consists mainly of the radioactive isotopes 129 I, 131 I, and of the inactive 127 I, must be quantitatively adsorbed at the end of the process for the purpose of safe waste disposal. Inspite of using high-alloy austenitic chrome nickel steels, major corrosion effects were observed at tubes and containers of the PASSAT dissolver waste gas purifier. This research project serves to clarify the question in which parts of the installation iodine concentration is to be expected under certain conditions. Furthermore it serves to identify the redox state of iodine in the various installation components. For this purpose steel (1.4306esu and 1.4563N), zirconium and titanium were studied in nitric iodic media. With the objective of calculating iodine adsorption isotherms, the following methods were used to obtain qualitative and quantitative data: FTIR, ellipsometry, 131 I radiotracer method, cyclo-voltametry, closed circuit potential measurements, ion chromatography. (orig./DG) [de

  9. Solution-mediated phase transformation of haloperidol mesylate in the presence of sodium lauryl sulfate.

    Greco, Kristyn; Bogner, Robin

    2011-09-01

    Forming a salt is a common way to increase the solubility of a poorly soluble compound. However, the solubility enhancement gained by salt formation may be lost due to solution-mediated phase transformation (SMPT) during dissolution. The SMPT of a salt can occur due to a supersaturated solution near the dissolving surface caused by pH or other solution conditions. In addition to changes in pH, surfactants are also known to affect SMPT. In this study, SMPT of a highly soluble salt, haloperidol mesylate, at pH 7 in the presence of a commonly used surfactant, sodium lauryl sulfate (SLS), was investigated. Dissolution experiments were performed using a flow-through dissolution apparatus with solutions containing various concentrations of SLS. Compacts of haloperidol mesylate were observed during dissolution in the flow-through apparatus using a stereomicroscope. Raman microscopy was used to characterize solids. The dissolution of haloperidol mesylate was significantly influenced by the addition of sodium lauryl sulfate. In conditions where SMPT was expected, the addition of SLS at low concentrations (0.1-0.2 mM) reduced the dissolution of haloperidol mesylate. In solutions containing concentrations of SLS above the critical micelle concentration (CMC) (10-15 mM), the dissolution of haloperidol mesylate increased compared to below the CMC. The solids recovered from solubility experiments of haloperidol mesylate indicated that haloperidol free base precipitated at all concentrations of SLS. Above 5 mM of SLS, Raman microscopy suggested a new form, perhaps the estolate salt. The addition of surfactant in solids that undergo solution-mediated phase transformation can add complexity to the dissolution profiles and conversion.

  10. Doses to the hand during the administration of radiolabeled antibodies containing Y-90, Tc-99m, I-131, and Lu-177

    Barber, D.E. [Minnesota Univ., Minneapolis, MN (United States). School of Public Health; Carsten, A.L.; Kaurin, D.G.L.; Baum, J.W. [Brookhaven National Lab., Upton, NY (United States)

    1997-02-01

    Exposure of the hands of medical personnel administering radiolabeled antibodies (RABs) was evaluated on the basis of (a) observing and photo-documenting administration techniques, and (b) experimental data on doses to thermoluminescent dosimeters (TLDs) on fingers of phantom hands holding syringes, and on syringes, with radionuclides in the syringes in each case. Actual exposure data for I-131 and Lu-177 were obtained in field studies. Variations in handling and administration techniques were identified. Dose rates measured using TLDs on the surface of loaded syringes were adjusted for differences in electronic stopping power, absorption coefficients, and attenuation between dosimeters and tissue to estimate dose-to-skin averaged over 1 cm{sup 2} at 7 mg cm{sup {minus}2} depth for Y-90, Tc-99m, I-131, and Lu-177. Dose rate coefficients to the skin, if in contact with the syringe wall, were 89, 1.9, 3.8, and 0.41 {micro}Sv s{sup {minus}1} per 37 MBq (1 mCi) for Y-90, Tc-99m, I-131, and Lu-177, respectively. For dose reduction, when using Y-90 the importance was clearly indicated of (a) avoiding direct contact with syringes containing RABs, if practical, and (b) using a beta-particle shield on the syringe. In using a syringe for injection, doses can best be approximated for the geometry studied by (a) wearing a finger dosimeter on the middle finger, toward the outside of the hand, on the hand operating the plunger, and (b) wearing finger dosimeters on the inner (palm) side of the finger on the hand that supports the syringe for energetic beta-particle emitters, such as Y-90 and Re-188.

  11. Multiple model testing using Chernobyl fallout data of I-131 in forage and milk and Cs-137 in forage, milk, beef and grain. Pt. 1

    Koehler, H.; Peterson, S.R.; Owen Hoffman, F.

    1991-03-01

    Comprehensive measurements of I-131 and Cs-137 in the environment after the Chernobyl accident provided a unique opportunity for the collection of environmental transfer data sets. These come from 13 locations in the northern hemisphere which experienced levels of contamination that spanned approximately three orders of magnitude. Data have been compiled for radionuclide concentrations in air, rain, pasture vegetation, milk, beef and grain. In addition background information has been collated for factors such as prevailing meteorological conditions, location description, and local agricultural practices. Participants were asked to predict radionuclide concentrations in forage, milk, beef and grain from radionuclide concentrations in air, the daily amounts of precipitation and other pertinent information. This was a blind test in that the locations to which the input data referred were not revealed to the participants until after they had submitted their predictions. Twenty-three models were involved in the study. This report compares observations and predictions for deposition, time- integrated concentrations in forage, milk, beef and grain, to help assess understanding of individual processes, time-dependent concentrations in forage, milk and beef. In general, predictions of time-integrated concentration of I-131 and Cs-137 in forage, milk (normalized for forage) and beef are within a factor of 10 of the observations. About 50% of the predictions of I-131 and Cs-137 in forage and just over 30% of the predictions of those nuclides in milk (normalized for forage) fall within a factor of 2 of the observations. Documentation of the measurements, models, methods of analysis and model results is presented in the appendices. (au) (75 refs.)

  12. Doses to the hand during the administration of radiolabeled antibodies containing Y-90, Tc-99m, I-131, and Lu-177

    Barber, D.E.

    1997-02-01

    Exposure of the hands of medical personnel administering radiolabeled antibodies (RABs) was evaluated on the basis of (a) observing and photo-documenting administration techniques, and (b) experimental data on doses to thermoluminescent dosimeters (TLDs) on fingers of phantom hands holding syringes, and on syringes, with radionuclides in the syringes in each case. Actual exposure data for I-131 and Lu-177 were obtained in field studies. Variations in handling and administration techniques were identified. Dose rates measured using TLDs on the surface of loaded syringes were adjusted for differences in electronic stopping power, absorption coefficients, and attenuation between dosimeters and tissue to estimate dose-to-skin averaged over 1 cm 2 at 7 mg cm -2 depth for Y-90, Tc-99m, I-131, and Lu-177. Dose rate coefficients to the skin, if in contact with the syringe wall, were 89, 1.9, 3.8, and 0.41 microSv s -1 per 37 MBq (1 mCi) for Y-90, Tc-99m, I-131, and Lu-177, respectively. For dose reduction, when using Y-90 the importance was clearly indicated of (a) avoiding direct contact with syringes containing RABs, if practical, and (b) using a beta-particle shield on the syringe. In using a syringe for injection, doses can best be approximated for the geometry studied by (a) wearing a finger dosimeter on the middle finger, toward the outside of the hand, on the hand operating the plunger, and (b) wearing finger dosimeters on the inner (palm) side of the finger on the hand that supports the syringe for energetic beta-particle emitters, such as Y-90 and Re-188

  13. Software for dosimetry hypothyroid patients treated with I131 pick up and using probe gamma camera; Software para la dosimetria de pacientes hipertiroideos tratados con 131I utilizando sonda de captacion y gammacamara

    Jimenez Felstrom, D.; Luis simon, J.; Reyes Garcia, R.; Derecho Torres, P.; Herrador Cordoba, M.

    2015-07-01

    In this communication the process recently implemented in our hospital for pre and post treatment of patients treated with I-131 in benign diseases of the thyroid gland internal dosimetry is described. We have developed a proprietary software that facilitates the process of dosimetry. Through scans Planar or pictures Spect be determines the mass of the gland thyroid. In function of the mass, is calculated by Monte Carlo the media power absorbed by disintegration of the I-131 in said gland endocrine. (Author)

  14. The initial investigation of radiation dose rate at X-ray department and patients treating thyroid by I-131 at nuclear medicine department

    Nguyen Van Kinh; Vo Thanh Cuong

    2000-01-01

    Survey meter NSM 150 Fuji with detector Geiger Muller has been used to assess for average annual exposure dose which affect radiographer ≤ 2 mSv per year, the staff involved with Fluoroscopy ≤ 19 mSv per year. Dose rate in waiting area of patient is a range from 0.2 to 0.8 μSv/h. Patients who have been treated by radioiodine, may be only discharged when the remaining activity is 400.2 ±368.8 MBq. Radioactivity of I-131 and Tc-99m in the sewage system of hospital is 0.4x10 -11 Ci/l. (author)

  15. Clinical experience of 2-hour I-131 thyroid uptake significance in considering the radioiodine Graves' disease treatment dose: A retrospective study

    Al-Shammeri, I.; Al-Deen Mahmood, S.; Al-Mohannadi, S.; Ballani, N.

    2015-01-01

    Purpose: It has been noticed that Graves' disease patients with high turnover are likely to experience under dosage when calculating the radioiodine therapeutic dose. We aim to demonstrate our clinical experience of 2-h I-131 uptake% value in estimating the radioiodine dose for Graves' disease patients with rapid washout. Material and methods: We reviewed the medical records for 2080 Graves' disease patients who received radioiodine treatment(s). Patients were distinguished by 2-h I-131 thyroid uptake%: 249 patients (group I) exhibited a rapid washout (>25%), and 250 patients (group II control group) demonstrated normal uptake (6–15%); the age and sex were balanced for both groups. These cases were reviewed for the time taken to control the condition clinically (ideally 3 months is the time needed), the time taken to achieve hypothyroidism (average time is 6 months), and the number of repeated treatments for recurrent thyrotoxicosis or failure of treatment. Results: In 152/249 (61%) patients, the condition was not controlled in the 3 month period post treatment and subsequently they needed more frequent and closer follow up, as opposed to 47/250 patients (19%) in the control group-II. At 6 months, 119/249 (48%) patients in group-I had not achieved hypothyroidism, as opposed to 28/250 patients (11%) in group-II. Seventy-seven patients in group-I (31%) needed a second or third therapeutic dose, as opposed to 10/250 patients (4%) in group-II. Conclusion: We believe that a higher radioiodine dose with significant rapid washout in the thyroid gland of Graves' disease patients would give a greater treatment success rate. - Highlights: • We present our clinical experience of 2-h I-131 uptake% value in Graves' disease. • We reviewed records of hyperthyroid patients who received radioiodine treatment. • Two patients' groups were distinguished by normal and high 2-h I-131 uptake%. • The two groups showed different radioiodine treatment

  16. Validated UV-Spectrophotometric Methods for Determination of Gemifloxacin Mesylate in Pharmaceutical Tablet Dosage Forms

    R. Rote Ambadas

    2010-01-01

    Full Text Available Two simple, economic and accurate UV spectrophotometric methods have been developed for determination of gemifloxacin mesylate in pharmaceutical tablet formulation. The first UV-spectrophotometric method depends upon the measurement of absorption at the wavelength 263.8 nm. In second area under curve method the wavelength range for detection was selected from 268.5-258.5 nm. Beer’s law was obeyed in the range of 2 to 12 μgmL-1 for both the methods. The proposed methods was validated statistically and applied successfully to determination of gemifloxacin mesylate in pharmaceutical formulation.

  17. The retention of iodine in stainless steel sample lines

    Evans, G.J.; Deir, C. [Univ. of Toronto (Canada); Ball, J.M. [Whiteshell Laboratories, Pinawa (Canada)

    1995-02-01

    Following an accident in a multi-unit CANDU nuclear generating station, decontamination of air vented from containment would play a critical role in minimizing the release of iodine to the environment. The concentration of gas phase iodine in containment air would be measured using the post accident radiation monitoring system, requiring that air samples be passed through a considerable length of tubing to a remote location where the desired measurements could safely be made. A significant loss of iodine, due to adsorption on the sample line surfaces, could greatly distort the measurement. In this study, the retention of I{sub 2}(g) on stainless steel was evaluated in bench scale experiments in order to evaluate, and if possible minimise, the extent of any such line losses. Experiments at the University of Toronto were performed using 6 inch lengths of 1/4 inch stainless steel tubing. Air, containing I-131 labelled I{sub 2}(g), ranging in concentration from 10{sup {minus}10} to 10{sup {minus}6} mol/dm{sup 3} and relative humidity (:RH) from 20 to 90 %, was passed through tubing samples maintained at temperatures ranging from 25 to 90{degrees}C. Adsorption at low gas phase iodine concentrations differed substantially from that at higher concentrations. The rate of deposition was proportional to the gas phase concentration, giving support to the concept of a first order deposition velocity. The surface loading increased with increasing relative humidity, particularly at low RH values, while the deposition rate decreased with increasing temperature. Surface water on the steel may play an important role in the deposition process. The chemisorbed iodine was located primarily in areas of corrosion. Furthermore, water used to wash the steel contained Fe, Mn and iodine in the form of iodide, suggesting that I{sub 2} reacted to form metal iodides. The deposition of I{sub 2} was also found to depend on the initial surface condition.

  18. Radioactive Iodine Treatment for Hyperthyroidism

    ... Balance › Radioactive Iodine for Hyperthyroidism Fact Sheet Radioactive Iodine for Hyperthyroidism April, 2012 Download PDFs English Zulu ... prepare for RAI or surgery. How does radioactive iodine treatment work? Iodine is important for making thyroid ...

  19. Iodine and thyroid function

    Hye Rim Chung

    2014-03-01

    Full Text Available Severe iodine deficiency causes hypothyroidism that results in impaired somatic growth and motor development in children. Mild and moderate iodine deficiencies cause multifocal autonomous growth of thyroid, which results in thyrotoxicosis. On the other hand, iodine excess is associated with the development of hypothyroidism and thyroid autoimmunity. In areas of iodine deficiency, a sudden increase in iodine intake is associated with transient hyperthyroidism. Recent studies demonstrated that long-term thyroid function of subjects who experienced both iodine deficiency and iodine excess during childhood tended to be abnormal despite optimization of their current iodine intake. Iodine status in the Korean Peninsula is very unique because people in the Republic of Korea have been shown to have predominantly excessive iodine levels, whereas the Democratic People's Republic of Korea is known to be an iodine-deficient area. Further research is warranted to verify the optimal ranges of iodine intake and to clarify the effects of iodine intake on thyroid disorders in the Korean Peninsula.

  20. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I131 during Adolescence and Young Adulthood

    Melanie Metallo

    2016-01-01

    Full Text Available Introduction. Differentiated thyroid cancer (DTC is rare and confers good prognosis. Long-term health related quality of life (HRQoL and pregnancy outcomes are not well known in subjects treated during adolescence and young adulthood. Methods. Cross-sectional analysis of HRQoL and global self-esteem, using SF-36 and ISP-25 surveys, and of pregnancy outcomes in female survivors of DTC treated by total thyroidectomy and I131 before age of 25 years. Results. Forty-five of 61 patients (74% responded to the survey. Cumulative I131 activity was ≤3.85 GBq in 18 subjects and >3.85 GBq in 27 subjects. Mean time from diagnosis was 7.6 ± 5.2 years for the group ≤ 3.85 GBq versus 16.9 ± 11.6 years for the group > 3.85 GBq (P 3.85 GBq and 10 in patients from the group ≤ 3.85 GBq. Frequency of miscarriages was of 17% (group > 3.85 GBq and 10% (group ≤ 3.85 GBq with 9 and 24 live births, respectively. No congenital malformations or first year mortality was noted. Conclusion. Long-term HRQoL, global self-esteem, and pregnancy outcomes are not affected in young female survivors of DTC.

  1. The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

    Wurdiyanto, G; Candra, H

    2016-01-01

    The standardization of radioactive sources ( 125 I, 131 I, 99m Tc and 18 F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125 I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125 I, 131 I, 99m Tc and 18 F respectively, by about 5 to 6% of the expanded uncertainties. (paper)

  2. The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

    Wurdiyanto, G.; Candra, H.

    2016-03-01

    The standardization of radioactive sources (125I, 131I, 99mTc and 18F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125I, 131I, 99mTc and 18F respectively, by about 5 to 6% of the expanded uncertainties.

  3. Evaluation of the absorbed dose during studies of the renal function due to I123 / I131 (hippuran) and In111 (DTPA)

    Vasquez, M.; Castillo, C.; Sarachaga, R.; Rojas, R.; Zelada, L.; Melendez, J.; Gomez, M.; Diaz, E.

    2014-08-01

    Using the methodology MIRD and representation Cristy-Eckerman for kidneys, bladder, and whole body as organs of the bio-kinetics of I 123 / I 131 (hippuran) and the In 111 (D PTA), the absorbed dose for studies of the renal function of adults due to the I 123 is 0,0071 mGy/MBq where 88.16% corresponds to its auto-dose and 11,96% to the organs of their bio-kinetics; while for the I 131 their dose is 0,032 mGy/MBq where 95,03% corresponds to its auto-dose and 4,97% to the organs of their bio-kinetics. For the In 111 their dose is 0,0168 mGy/MBq where 71,68% corresponds to their auto-dose and 28,32% to the organs of their bio-kinetics. In all the cases the dosimetric contributions of the organs of the bio-kinetics (whole body and urinary bladder) are very significant, and this fundamentally is due to the photons of the whole body. (Author)

  4. Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid: case report; Normalizacao da contagem de linfocitos apos dose ablativa de I-131 em um paciente com leucemia linfoide cronica e carcinoma papilifero da tireoide: relato de caso

    Thom, Anneliese Rosmarie Gertrud Fischer; Hamerschlak, Nelson; Osawa, Akemi; Santos, Fabio Pires de Souza; Pasqualin, Denise da Cunha; Wagner, Jairo; Yamaga, Lilian Yuri Itaya; Cunha, Marcelo Livorsi da; Campos Neto, Guilherme de Carvalho; Funari, Marcelo Buarque de Gusmao, E-mail: afthom@einstein.br [Hospital Israelita Albert Einstein, Sao Paulo, SP (Brazil); Teles, Veronica Goes [Sociedade Brasileira de Diabetes, Sao Paulo, SP (Brazil)

    2014-07-01

    The authors report the case of a 70-year-old male patient with chronic lymphoid leukemia who presented subsequently a papillary carcinoma of the thyroid with metastases to regional lymph nodes. The patient was treated with surgical thyroidectomy with regional and cervical lymph node excision and radioiodine therapy (I-131). The protocolar control scintigraphy 4 days after the radioactive dose showed I-131 uptake in both axillae and even in the inguinal regions. PET/CT showed faint FDG-F-18 uptake in one lymph node of the left axilla. An ultrasound guided fine needle biopsy of this lymph node identified by I-131 SPECT/CT and FDG-F-18 PET/CT revealed lymphoma cells and was negative for thyroid tissue and thyroglobulin content. The sequential blood counts done routinely after radiation treatment showed a marked fall until return to normal values of leucocytes and lymphocytes (absolute and relative), which were still normal in the last control 19 months after the radioiodine administration. Chest computed tomography showed a decrease in size of axillary and paraaortic lymph nodes. By immunohistochemistry, cells of the lymphoid B lineage decreased from 52% before radioiodine therapy to 5% after the procedure. The authors speculate about a possible sodium iodide symporter expression by the cells of this lymphoma, similar to some other non-thyroid tumors, such as breast cancer cells. (author)

  5. Our experience of high dose I-131 therapy in 75 patients with well differentiated carcinoma thyroid followed up over 5 years

    Dougall, P.; Kumar, A.; Ashok, P.; Chinwan, B.P.; Khan, B.; Pandey, D.; Joshi, N.D.

    2005-01-01

    Thyroid cancer is the most common endocrine malignancy. The epidemiology of thyroid cancer is variable, depending on the geographic location of the patient population. Well differentiated thyroid cancer (WTC), is responsive to high dose I-131 treatment, and is the most accepted form of therapy, even though the dose administered for ablation of residual thyroid tissue maybe controversial. At our centre, 75 patients of WTC, mean age 42.4 years, 22 males and 53 females (M:F 1:2.4), were treated with high dose oral I-131 therapy with a Total Mean Dose (TMD) of 263.6 mCi, 4 - 6 weeks post thyroidectomy. They were followed up over a period of 6 years. Twenty ( 26.7%) patients had follicular cancer (FC), 47 (62.7%) papillary cancer (PC) and 8 (10.7%) were mixed (MC), on histopathology, at presentation. 38 (50.7%) patients had only residual thyroid tissue (RTT) on I-131 whole body bone scan (WBS) and 37 (49.3%) presented with metastatic disease (MD) at the time of therapy. Of the 37 patients with MD, 21 (56.8%) had metastases to the lymph nodes, 6 (16.2%) to the lungs, 4 (10.8%) to bone, 3 (8.1%) to bone and lung, and 4 (10.8%) to lung plus lymph nodes. Twenty-three patients (7 FC , 13 - PC and 3 MC; 6 RTT, 17 - MD) , received more than one dose of I-131 with a TMD of 422.7 mCi (Range 88 1590 mCi ). 52 patients (13 FC, 34 PC, 5 MC; 20 MD and 32 RTT) received a single TMD of 104.4 (Range 39.5 219 mCi). On follow-up, 3 patients of FC with MD (2 lung metastasis and 1 with extensive lymph node metastasis), died within 3 months 2 years of therapy. 3 patients of MD (2 FC, 1-MC; 2 bone metastasis and 1 bone with lung metastasis) died after 5 .5 years, Of the 6 patients who died, 5 were FC and only 1 was MC. 2 patients with MD to lungs and bone had received a single dose and were lost to follow up. All patients with PC and FC with only RTT, were surviving at the end of 5 years. None of the patients with MD to lymph nodes died at the end of 5 years, either receiving single or

  6. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

    Bérengère Gobin

    Full Text Available Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods. Imatinib mesylate (Gleevec, Novartis Pharma, a tyrosine kinase inhibitor, was originally developed for the treatment of chronic myeloid leukemia. Several studies revealed that imatinib mesylate inhibits osteoclast differentiation through the M-CSFR pathway and activates osteoblast differentiation through PDGFR pathway, two key cells involved in the vicious cycle controlling the tumour development. The present study investigated the in vitro effects of imatinib mesylate on the proliferation, apoptosis, cell cycle, and migration ability of five osteosarcoma cell lines (human: MG-63, HOS; rat: OSRGA; mice: MOS-J, POS-1. Imatinib mesylate was also assessed as a curative and preventive treatment in two syngenic osteosarcoma models: MOS-J (mixed osteoblastic/osteolytic osteosarcoma and POS-1 (undifferentiated osteosarcoma. Imatinib mesylate exhibited a dose-dependent anti-proliferative effect in all cell lines studied. The drug induced a G0/G1 cell cycle arrest in most cell lines, except for POS-1 and HOS cells that were blocked in the S phase. In addition, imatinib mesylate induced cell death and strongly inhibited osteosarcoma cell migration. In the MOS-J osteosarcoma model, oral administration of imatinib mesylate significantly inhibited the tumour development in both preventive and curative approaches. A phospho-receptor tyrosine kinase array kit revealed that PDGFRα, among 7 other receptors (PDFGFRβ, Axl, RYK, EGFR, EphA2 and 10, IGF1R, appears as one of the main molecular targets for imatinib mesylate. In the light of the present study and the literature, it would be particularly interesting to revisit therapeutic evaluation of imatinib mesylate in osteosarcoma according to the tyrosine-kinase receptor

  7. Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease.

    Rohrs, Henry J; Silverstein, Janet H; Weinstein, David A; Amdur, Robert J; Haller, Michael J

    2014-01-01

    Female, 11 FINAL DIAGNOSIS: Thyroid storm Symptoms: Diarrhea • tachycardia • tachypnea • tremor • wheezing - Clinical Procedure: - Specialty: - Rare disease. A growing number of pediatric endocrinologists treat Graves disease with radioactive iodine (RAI) therapy due to the typically definitive nature of I-131 therapy. Given the published benefits and perceived low risks of RAI when compared to surgery or long-term anti-thyroid medication, the trend towards therapy with RAI is likely to continue. Nevertheless, RAI is not without significant risk. An 11-year-old girl with newly diagnosed Graves disease received RAI for definitive treatment of her hyperthyroidism. Within 24 hours of receiving I-131, she developed increasing sleepiness and eventually became unresponsive. Upon arrival at the emergency department she had a tonic-clonic seizure and was diagnosed with thyroid storm. Despite best efforts to manage her hyperthyroidism, she suffered a stroke of the left cerebral hemisphere that left her with persistent neurological deficits. Although thyroid storm after thyroid ablation is rare, the significant morbidity and potential mortality of pediatric thyroid storm warrant further studies to determine if children with markedly elevated thyroid hormone concentrations at diagnosis should receive prolonged pretreatment with anti-thyroid drugs. While such an approach may reduce the efficacy of I-131 ablation, it can also reduce and hopefully eliminate the risk of post-ablative thyroid storm.

  8. Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.

    Spindeldreier, Kirsten; Thiesen, Judith; Lipp, Hans-Peter; Krämer, Irene

    2014-06-01

    The aim of this study was to determine the stability of commercially available eribulin mesylate containing injection solution as well as diluted ready-to-administer solutions stored under refrigeration or at room temperature. Stability was studied by a novel developed stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) assay with ultraviolet detection (detection wavelength 200 nm). Triplicate test solutions of eribulin mesylate containing injection concentrate (0.5 mg/mL) and with 0.9% sodium chloride solution diluted ready-to-administer preparations (0.205 mg/mL eribulin mesylate in polypropylene (PP) syringes, 0.020 mg/mL eribulin mesylate in polypropylene/polyethylene (PE) bags) were stored protected from light either at room temperature (25) or under refrigeration (2-8). Samples were withdrawn on day 0 (initial), 1, 3, 5, 7, 14, 21 and 28 of storage and assayed. Physical stability was determined by measuring the pH value once a week and checking for visible precipitations or colour changes. The stability tests revealed that concentrations of eribulin mesylate remained unchanged over a period of 28 days irrespective of concentration, container material or storage temperature. Neither colour changes nor visible particles have been observed. The pH value varied slightly over time but remained in the stability favourable range of 5-9. Eribulin mesylate injection (0.5 mg/mL) is physico-chemically stable over a period of 28 days after first puncture of the vial. After dilution with 0.9% NaCl vehicle solution, ready-to-administer eribulin mesylate injection solutions (0.205 mg/mL in PP syringe) and infusion solutions (0.02 mg/mL in prefilled PP/PE bags) are physico-chemically stable for a period of at least four weeks either refrigerated or stored at room temperature. For microbiological reasons storage under refrigeration is recommended.

  9. Radiation exposure from liquid discharges from I-131 therapy rooms into a piping system in the building

    Tuntawiroon, M.; Sritongkul, N.; Pusuwan, P.; Chaudakshetrin, P.

    2007-01-01

    Full text: Over 80% of the activity from patients undergoing radioiodine therapy for thyroid cancer is eliminated during the first three days. In our iodine therapy unit, numbers of hospitalized patients have increased from less than 200 in 2004 to more than 300 patients in 2006. The total amount of activity used is about 1,900 MBq, and the estimated amount excreted would then be about 1,800 MBq. This results in significant volume of liquid discharges into the piping system. In this study, we monitored external dose rates in non-radiation areas adjacent to pipeline connections in the building to ensure that the dose to any individual in these areas does not exceed 1 mSv per year. Materials and Methods: Exposure rates in areas adjacent to the pipeline junction connections were measured periodically from April 2006 to February 2007, five floors below the therapy unit. The measurements were made inside the wall in contact with the junction, behind the wall and in hallways 1 meter from the wall, using a GM detector or an ionization chamber. The results were recorded in μSv/h and the dose received was estimated for members of the public. Results: Significant increases in dose rates were detected in three floors below the unit. They were 2030, 1025 and 515 Sv/h at contact with the pipeline connections, 915, 1015 and 35 μSv/h behind the wall, and 36, 56 and 25 μSv/h in hallways on floors 1, 2 and 3 respectively. After appropriate wall shielding had been provided, dose rate behind the wall reduced to 23 μSv/h, and to 0.52 μSv/h in hallways. By using an occupancy factor 1/4 for hallways, the calculated dose meets the public dose limits of 1 mSv per year. Conclusions: Therapeutic application of 131 I for the treatment of thyroid cancer generates a significant amount of liquid waste into the sewers. These low activity wastes originate mainly from toilets, showers, wash basins and floor drains. Although waste discharges can be handled without exceeding the permissible

  10. Determination of intake and internal radiation dose for occupationally exposed workers to iodine 131

    Kharita, M. H.; Maghrabi, M.; Sadyya, A.

    2004-12-01

    Workers who prepare and inject radioactive Iodine I 131 doses at the medical centers in Syria are potentially exposed to the radioactive intake by ingestion or inhalation during preparation or injection processes. The received amount of the radioactive intake differs according to the amount of the I 131 that released during the preparation or injection processes, and to the work conditions and the applying ways of the radiation protection principles. Because of this radioactive intake, the thyroid gland may expose to amounts of I 131 which may negatively affect the health of the workers, so it is necessary to make routine monitoring for all workers who receive an intake of more than 10% of the annual intake limit which is (2*10 6 Bq/y) for I 131 . To make this monitoring process, it is necessary to use either the thyroid gland counter in order to know the concentrated amount of the radioactivity in the gland, or the analysis of a 24 hours urine sample of the exposed workers to determine the eliminated amount of the radioactivity using gamma spectrometry, also the two processes can be applied at the same time. Since the thyroid gland counter is not available, the analysis of urine sample was done to determine the concentrated amount of the radioactivity in urine, then to estimate the radioactive intake and the internal radioactive dose. The results of applying this method dictated that some workers work in safe conditions according to the radiation protection and there is no need for them to make routine monitoring . But the other workers receive a radioactive intake of about 10% yearly of the annual intake limit and that requires a routine periodical monitoring for those workers in addition to the necessity of applying the principles of the radiation protection during the work with I 131 . These principles and systems should indicate the basic requirement of radiation protection that must be available in the laboratory that deal with I 131 either for therapy or for

  11. Chromatographic separation of Iodine species for environmental studies

    Machado, E.C. [Universidade Federal Fluminense, Niteroi, RJ (Brazil). Dept. de Geoquimica]. E-mail: geoedin@vm.uff.br; Bellido, A.V.B. [Universidade Federal Fluminense, Niteroi, RJ (Brazil). Dept. de Fisico-Quimica]. E-mail: alf@risc2.rmn.uff.br; Bellido, L.F. [Comissao Nacional de Energia Nuclear (CNEN), Rio de Janeiro, RJ (Brazil)]. E-mail: lbellido@cnen.gov.br

    1999-07-01

    In this work a experimental method was developed to separate iodine species from environmental samples by using adsorption chromatography. The radionuclide {sup 123} I which has a half-life of 13 h and a convenient gamma ray of 159 keV was used to investigate a fast and efficient procedure for the separation of iodide and iodate ions in seawater from mangrove samples. The radio-iodine tracer technique is very useful, particularly in kinetic studies because it is easy to detect without any interference of concentration due to the small amount of tracer that is spiked. It is also possible to add two tracers (I-123 and I-131) in different oxidation states. Three chromatographic methods were studied: paper, thin layer and adsorption chromatography with silica and alumina. It was found that paper chromatography is very useful for checking the valence adjustment of the radioiodine species. Initially, several coefficient distributions of iodine species by adsorption in silica and alumina from NaOH, NaHCO{sub 3} and NaNO{sub 3} solutions (in the range 05. - 0.0001 m) were determined. The best separation so far was achieved by loading the sample (after adjusting the concentration to 0.1 NNaNO{sub 3}) into a chromatographic column with Al{sub 2} O{sub 3}. The iodide passes through the column and after washing the column, the iodate was removed by eluting with 1.0 M NaHCO{sub 3} solution. (author)

  12. Chromatographic separation of Iodine species for environmental studies

    Machado, E.C.

    1999-01-01

    In this work a experimental method was developed to separate iodine species from environmental samples by using adsorption chromatography. The radionuclide 123 I which has a half-life of 13 h and a convenient gamma ray of 159 keV was used to investigate a fast and efficient procedure for the separation of iodide and iodate ions in seawater from mangrove samples. The radio-iodine tracer technique is very useful, particularly in kinetic studies because it is easy to detect without any interference of concentration due to the small amount of tracer that is spiked. It is also possible to add two tracers (I-123 and I-131) in different oxidation states. Three chromatographic methods were studied: paper, thin layer and adsorption chromatography with silica and alumina. It was found that paper chromatography is very useful for checking the valence adjustment of the radioiodine species. Initially, several coefficient distributions of iodine species by adsorption in silica and alumina from NaOH, NaHCO 3 and NaNO 3 solutions (in the range 05. - 0.0001 m) were determined. The best separation so far was achieved by loading the sample (after adjusting the concentration to 0.1 NNaNO 3 ) into a chromatographic column with Al 2 O 3 . The iodide passes through the column and after washing the column, the iodate was removed by eluting with 1.0 M NaHCO 3 solution. (author)

  13. The presence of I-131 in different environmental factors from N W of Romania after the Fukushima disaster

    Cosma, C.; Iurian, A.R.; Nita, D.C.; Begy, R.; Cindea, C.

    2011-01-01

    The earthquake that hit Japan in March 11, 2011, entailed a high radioactive release from Fukushima NPP during the next days. Based on the results of the reactors analysis, the Nuclear and Industrial Safety Agency from Japan (NISA) estimated that a total amount of 1.3x10 17 Bq 131 I and 6.1x10 15 Bq 137 Cs have been released into the atmosphere. The aim of this study is to quantify the Fukushima radioactivity contamination in Cluj county and surrounding areas of Transylvania region. The concentration of the fission products has been analyzed in rainwater, milk, vegetation, eggs and pollen during the period 28th of March, 2011 - 19th of April, 2011. The measurements have been carried out by means of gamma-spectroscopy, using two ORTEC spectrometers with HpGE detectors with 34.2% and 30% relative efficiency, respectively . The 364.5 keV gamma line was analysed to obtain the 131 I concentrations and Maestro software has been used for the automatic spectrum evaluation. The 134 Cs and 137 Cs nuclides were also analysed as based on the gamma line from 604.7 keV and 661 keV, respectively. Some measurements were also performed for aerosol iodine collected on paper filters. The 131 I was the first radionuclide detected in rainwater from Cluj-Napoca, in 28th of March 2011. In April 5, 2011, the sheep milk registered a maximum activity of 9.22 ± 0.95 Bq/l in Cluj area. It seems that the maximum level of radioiodine concentration in the N W region of Romania has been reached at around 4th of April, 2011. The results obtained for rainwater at the beginning of April are in accordance with the measurements carried out in Pitesti area for radioiodine in air and wet depositions. The 134 Cs has been found only in rainwater at the beginning of March. The values recorded for 137 Cs in rainwater were close to the detection limit of the spectrometer, being subject of uncertainty due to the suspension in atmosphere of this artificial radionuclide also from Chernobyl accident release

  14. Iodination of phenol

    Christiansen, J.V.; Feldthus, A.; Carlsen, L.

    1990-01-01

    Phenol is iodinated in aqueous solution at pH 5 (acetate buffer) by elemental iodine or, if the iodine is present as iodide, enzymatically controlled by peroxidases. Generally mono-, di- and triiodophenols are obtained, the overall product composition being virtually identical for the two iodination modes. However, there is a tendency to a higher para to ortho ratio for the enzymatically controlled reaction. The mutual ratios of the single iodophenols depends on the initial concentration ratio between phenol and the iodinating species. The first step in the iodination leads preferentially to substitution in the ortho position rather than in the para position in contract to e.g. the corresponding bromination. The relative rates of the competive reactions in the combined iodination scheme has been derived. (author) 2 tabs., 3 ills., 15 refs

  15. Evaluation of radiation exposure of workers caring for the patient after administration of radionuclide I-131 based on the Monte Carlo

    Hudzietzova, J.; Sabol, J.; Fueloep, M.

    2013-01-01

    In the paper using the Monte Carlo method ( code MCNPX) were calculated absorbed doses in organs caregivers, from which thereafter was set the value of the equivalent dose in these organs by appropriate formulas and then effective doses in selected geometries using protective shielding devices. The results show that using of shielding aprons equivalent of 1 mm of lead will reduce the exposure of workers caring for patients after administration of the radionuclide I-131 by about 30%. If the caregiver without protective shielding aprons is located between two patients, the gamma rays will be reduced by about 18% due to averted body of caregiver, while the worker's personal dosimeter located at the chest will register approximately 40% lower value of personal dose equivalent. (authors)

  16. Multiple model testing using Chernobyl fallout data of I-131 in forage and milk and Cs-137 in forage, milk, beef and grain. Pt. 2

    1991-03-01

    BIOMOVS is an international study for testing and validating model predictions of the transfer of radionuclides and rare stable elements through the biosphere. The BIOMOVS A4 scenario was designed to test model prediction of the transfer of I-131 and Cs-137 from the atmosphere via pasture vegetation to milk and of the Cs-137 transfer from air to beef (via vegetation) and grain. This document is an appendix to the A4 report. It includes tables and figures of time-integrated results, a summary of a statistical analysis of time-dependent and representative figures of time-dependent results. The quantities to be predicted in this scenario were wet, dry and total deposition (Bq m -2 ) of I-131 and Cs-137, contamination of vegetation (Bq kg -1 d.w.), milk (Bq L -1 ), beef and grain (Bq kg -1 ). While with steady state models only time-integrated results for vegetation, milk and beef could be calculated, these quantities also were requested as time-series from users of dynamic models. A detailed description of the participating models is given in Appendix 3, while all collected observations are documented in Appendix 2 of the A4 report. A diskette with all observed data can be obtained from the Swedish National Institute of Radiation Protection, SSI, or from Harry Koehler, IAEA, Vienna, Austria. For time-integrated P/Os, graphs for all locations and all models and sometimes subsets of these are provided. For time-series, graphs are enclosed for the observations and some model results. These values are calculated across locations and across models for time-integrated predictions and for the P/O of entire time-series and subsets of these for the time-dependent predictions. (au)

  17. Imatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy

    Fiorentini Giammaria

    2006-01-01

    Full Text Available Background: Imatinib mesylate represents a real major paradigm shift in cancer therapy, targeting the specific molecular abnormalities, crucial in the etiology of tumor. Intra-arterial hepatic chemotherapy (IAHC followed by embolization, has been considered an interesting palliative option for patients with liver metastases from gastrointestinal stromal tumor (GIST, due to the typically hypervascular pattern of the tumor. Aims: We report our experience with IAHC followed by Imatinib mesylate, in order to show the superiority of the specific molecular approach in liver metastases from GIST. Materials and Methods: Three patients (pts with pretreated massive liver metastases from GIST, received IAHC with Epirubicin 50 mg/mq, every 3 weeks for 6 cycles. At the evidence of progression, they received Imatinib mesylate. Results: We observed progressive diseases in all cases. In 1998, one patient underwent Thalidomide at 150 mg orally, every day for 4 months, with evidence of stable disease and clinical improvement. In 2001, two patients received Imatinib mesylate at 400 mg orally, every day, with evidence of partial response lasting 18+ months and 16 months. One of them had grade 3 neutropenia, with suspension of therapy for 3 weeks. Conclusion: No patient treated with IAHC, reported objective responses, but two of them obtained partial response after the assumption of Imatinib mesylate and one showed temporary stabilization with thalidomide. Imatinib mesylate represents a new opportunity in GIST therapy, targeting the specific molecular alteration. It seems to be superior to conventional intra arterial hepatic chemotherapy.

  18. Improved oral absorption of cilostazol via sulfonate salt formation with mesylate and besylate

    Seo JH

    2015-07-01

    Full Text Available Jae Hong Seo, Jung Bae Park, Woong-Kee Choi, Sunhwa Park, Yun Jin Sung, Euichaul Oh, Soo Kyung Bae College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea Objective: Cilostazol is a Biopharmaceutical Classification System class II drug with low solubility and high permeability, so its oral absorption is variable and incomplete. The aim of this study was to prepare two sulfonate salts of cilostazol to increase the dissolution and hence the oral bioavailability of cilostazol.Methods: Cilostazol mesylate and cilostazol besylate were synthesized from cilostazol by acid addition reaction with methane sulfonic acid and benzene sulfonic acid, respectively. The salt preparations were characterized by nuclear magnetic resonance spectroscopy. The water contents, hygroscopicity, stress stability, and photostability of the two cilostazol salts were also determined. The dissolution profiles in various pH conditions and pharmacokinetic studies in rats were compared with those of cilostazol-free base.Results: The two cilostazol salts exhibited good physicochemical properties, such as nonhygroscopicity, stress stability, and photostability, which make it suitable for the preparation of pharmaceutical formulations. Both cilostazol mesylate and cilostazol besylate showed significantly improved dissolution rate and extent of drug release in the pH range 1.2–6.8 compared to the cilostazol-free base. In addition, after oral administration to rats, cilostazol mesylate and cilostazol besylate showed increases in Cmax and AUCt of approximately 3.65- and 2.87-fold and 3.88- and 2.94-fold, respectively, compared to cilostazol-free base.Conclusion: This study showed that two novel salts of cilostazol, such as cilostazol mesylate and cilostazol besylate, could be used to enhance its oral absorption. The findings warrant further preclinical and clinical studies on cilostazol mesylate and

  19. An estimation of Iodine 131 intakes for occupational workers of nuclear medicine group at the Instituto Nacional de Cancerologia, Bogota, Colombia

    Nino, Nelcy Yasmin; Lagares, Luis Carlos; Veloza, Luz Stella; Martinez, Maria Cristina; Reyes, Amelia de los

    2008-01-01

    Full text: In nuclear medicine, unsealed radioactive substances are administered to patients for diagnosis, treatment or research. The manipulation of these radionuclides, particularly those volatile, like iodine 131 (I-131), generates a risk of internal contamination by ingestion and inhalation. The inhaled radioactive particles are retained in the lungs or uptake by the thyroid tissue and could produce health effects. The IAEA provides regulatory practices in handling radioactive material to reduce internal contamination in the staff, based on the radiation protection principle to achieve occupational doses as low as reasonably achievable (ALARA). A quality assurance program in radioprotection should include the monitoring of occupational intakes. This paper describes a pilot study which determined quantitative methods to monitoring the nuclear medicine staff. The estimates of intakes and doses of I-131 were derived from the review and interpretation of urine monitoring data, using a Ludlum model 203 Shielded Well Scintillator (2 inches diameter x 1.8 inches thick), with a ratemeter model 2200. This study included workers occupationally exposed to I-131: physicians, technicians, radio pharmacists and physicists. The initial tests of the activity levels of I-131 in urine showed an average MPBB (Maximum Permissible Body Burden) of 0.035%, i.e. 0.025 μCi. Comparing with the maximum value of whole body 0.7μCi, the percentages of I-131 MPBB indicate the presence of small activities of I-131 in the urine, suggesting low-level chronic exposures from occupational workers in Nuclear Medicine. The higher values are the medical personnel who perform treatments for thyroid disorders. Conclusion: To do statistically significant the sampling and to protect individuals in each area it should be considered the daily urinary excretion, which is due to implement a protocol for regular assessment of the levels of incorporation of iodine 131 for jobs and activities, personnel in

  20. Atmospheric Dispersion of Various Types of Iodine in UAE in February and August

    Kim, Sungyeop; Beeley, Philip A. [Khalifa Univ. of Science, Abu Dhabi (United Arab Emirates); Kim, Sungyeop; Chang, Soonheung; Lee, Kunjai [Korea Advanced Institute of Science and Technology, Daejeon (Korea, Republic of)

    2013-05-15

    The distribution ratio of these three types of iodine being released to the atmosphere under accident scenario is still not clearly reported because of its complex kinetics of chemical and physical process in the accidental condition. In this research, the dispersion behaviors of three kinds of iodine in the atmosphere have been considered in the UAE environment in winter and summer situations. Higher ground level concentration on the same downwind distance from the source appears in summer because of lower wind speed than that of winter. More lateral spreading of vertical downwind direction in summer has been confirmed because of less stable air than that of winter. Higher ground level concentrations have been appeared in order of particle type, organic gas type and elemental gas type of I-131 with given assumptions.

  1. An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.

    Zhang, Yan; Fang, Lin; Zhang, Quan'an; Zheng, Qin; Tong, Jinlong; Fu, Xiaohui; Jiang, Xiaoqing; Su, Changqing; Zheng, Junnian

    2013-06-01

    Gene therapy and antibody approaches are crucial auxiliary strategies for hepatocellular carcinoma (HCC) treatment. Previously, we established a survivin promoter-regulated oncolytic adenovirus that has inhibitory effect on HCC growth. The human sulfatase-1 (hSulf-1) gene can suppress the growth factor signaling pathways, then inhibit the proliferation of cancer cells and enhance cellular sensitivity to radiotherapy and chemotherapy. I(131)-metuximab (I(131)-mab) is a monoclonal anti-HCC antibody that conjugated to I(131) and specifically recognizes the HAb18G/CD147 antigen on HCC cells. To integrate the oncolytic adenovirus-based gene therapy and the I(131)-mab-based radioimmunotherapy, this study combined the CArG element of early growth response-l (Egr-l) gene with the survivin promoter to construct a radiation-inducible enhanced promoter, which was used to recombine a radiation-inducible oncolytic adenovirus as hSulf-1 gene vector. When I(131)-mab was incorporated into the treatment regimen, not only could the antibody produce radioimmunotherapeutic effect, but the I(131) radiation was able to further boost adenoviral proliferation. We demonstrated that the CArG-enhanced survivin promoter markedly improved the proliferative activity of the oncolytic adenovirus in HCC cells, thereby augmenting hSulf-1 expression and inducing cancer cell apoptosis. This novel strategy that involved multiple, synergistic mechanisms, including oncolytic therapy, gene therapy and radioimmunotherapy, was demonstrated to exert an excellent anti-cancer outcome, which will be a promising approach in HCC treatment. Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

  2. Iodine deficiency and iodine excess in Jiangsu Province, China

    Zhao, J.

    2001-01-01

    Keywords:
    iodine deficiency, iodine excess, endemic goiter, drinking water, iodine intake, thyroid function, thyroid size, iodized salt, iodized oil, IQ, physical development, hearing capacity, epidemiology, meta-analysis, IDD, randomized trial, intervention, USA, Bangladesh,

  3. The treatment of iodine and chlorine chemistry in the risk assessment of deep radioactive waste disposal

    Jones, Michael A.

    1992-01-01

    The predicted contribution from 129 I, 131 I and 36 Cl to the radiological risk from a radioactive waste repository may be enhanced by the assumption of limited retardation in the near field and geosphere. However, migration of these radionuclides may be affected by their chemical speciation and retarded by a range of sorption processes. The chemical behaviour of iodine and chlorine is determined emphasizing i) aqueous speciations, ii) sorption onto inorganic substrates, and iii) the role of organic matter and microbes. Recommendations to enhance the methodology include i) consideration of aqueous speciation of iodine, both metal and organic complexes, ii) mechanistic simulation of iodine sorption by ion exchange and electrostatic/covalent adsorption, iii) simulation of enzymatically enhanced sorption of iodine and chlorine onto organic substrates, iv) enhancement of HMIP K d databases to include iodine and chlorine data for the geosphere and biosphere. A well defined programme of additional data collection, modelling studies and experimental investigations is recommended to achieve these enhancements. (author)

  4. Experience of iodine, caesium and noble gas release from AGR failures

    Chapman, C.J.; Harris, A.M.; Phillips, M.E.

    1985-01-01

    In the event of a fuel failure in an Advanced Gas Cooled Reactor (AGR), the quantity of fission products available for release to the environment is determined by the transport of fission products in the UO 2 fuel, by the possible retention of fission products in the fuel can interspace and by the deposition of fission products on gas circuit surfaces ('plate-out'). The fission products of principal radiological concern are radioactive caesium (Cs-137 and Cs-134) and iodine (principally I-131). Results are summarised of a number of experiments which were designed to study the release of these fission products from individual fuel failures in the prototype AGR at Windscale. Results are also presented of fission product release from failures in commercial AGRs. Comparisons of measured releases of caesium and iodine relative to the release of the noble gas fission products show that, for some fuel failures, there is a significant retention of caesium and iodine within the fuel can interspace. Under normal conditions circuit deposition reduces caesium and iodine gas concentrations by several orders of magnitude. Differing release behaviour of caesium and iodine from the failures is examined together with subsequent deposition within the sampling equipment. These observations are important factors which must be considered in developing an understanding of the mechanisms involved in circuit deposition. (author)

  5. Iodine deficiency disorders

    Ali, S M [Pakistan Council for Science and Technology, Islamabad (Pakistan)

    1994-12-31

    Iodine deficiency (IDD) is one of the common problem in the diet. Iodine deficiency as prevalence of goiter in population occurs in the mountainous areas. There is consensus that 800 million people are at risk of IDD from living in iodine deficient area and 190 million from goiter. Very high prevalence of IDD in different parts of the world are striking. It has generally observed that in iodine-deficient areas about 50% are affected with goiter, 1-5% from cretinsim and 20% from impaired mental and/or mortor function. (A.B.).

  6. Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?

    Olga Meltem Akay

    2016-05-01

    Full Text Available Objective: The aim of this study was to investigate the effects of imatinib mesylate on platelet aggregation and adenosine triphosphate (ATP release in chronic myeloid leukemia patients. Materials and Methods: Platelet aggregation and ATP release induced by 5.0 mM adenosine diphosphate, 0.5 mM arachidonic acid, 1.0 mg/ mL ristocetin, and 2 µg/mL collagen were studied by whole blood platelet lumi-aggregometer in 20 newly diagnosed chronic myeloid leukemia patients before and after imatinib mesylate treatment. Results: At the time of diagnosis, 17/20 patients had abnormal platelet aggregation results; 8 (40% had hypoactivity, 6 (30% had hyperactivity, and 3 (15% had mixed hypo- and hyperactivity. Repeat platelet aggregation studies were performed after a mean of 19 months (min: 5 months-max: 35 months in all patients who received imatinib mesylate during this period. After therapy, 18/20 (90% patients had abnormal laboratory results; 12 (60% had hypoactive platelets, 4 (20% had mixed hypo- and hyperactive platelets, and 2 (10% had hyperactive platelets. Three of the 8 patients with initial hypoactivity remained hypoactive, while 2 developed a mixed picture, 2 became hyperactive, and 1 normalized. Of the 6 patients with initial hyperactivity, 4 became hypoactive and 2 developed a mixed pattern. All of the 3 patients with initial hypo- and hyperactivity became hypoactive. Finally, 2 of the 3 patients with initial normal platelets became hypoactive while 1 remained normal. There was a significant decrease in ristocetin-induced platelet aggregation after therapy (p0.05. Conclusion: These findings indicate that a significant proportion of chronic myeloid leukemia patients have different patterns of platelet function abnormalities and imatinib mesylate has no effect on these abnormalities, with a significant impairment in ristocetin-induced platelet aggregation.

  7. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

    Desjardins, Annick; Quinn, Jennifer A; Vredenburgh, James J; Sathornsumetee, Sith; Friedman, Allan H; Herndon, James E; McLendon, Roger E; Provenzale, James M; Rich, Jeremy N; Sampson, John H; Gururangan, Sridharan; Dowell, Jeannette M; Salvado, August; Friedman, Henry S; Reardon, David A

    2007-05-01

    Recent reports demonstrate the activity of imatinib mesylate, an ATP-mimetic, tyrosine kinase inhibitor, plus hydroxyurea, a ribonucleotide reductase inhibitor, in patients with recurrent glioblastoma multiforme. We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG). Patients with grade III MG at any recurrence, received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for patients on enzyme inducing anti-epileptic drugs (EIAEDs) and 400 mg once a day for those not on EIAEDs. Clinical assessments were performed monthly and radiographic assessments were obtained at least every 2 months. The primary endpoint was 6-month progression-free survival (PFS) rate. Thirty-nine patients were enrolled. All patients had progressive disease after prior radiotherapy and at least temozolomide-based chemotherapy. The median number of episodes of prior progression was 2 (range, 1-7) and the median number of prior treatment regimens was 3 (range, 1-8). With a median follow-up of 82.9 weeks, 24% of patients were progression-free at 6 months. The radiographic response rate was 10%, while 33% achieved stable disease. Among patients who achieved at least stable disease at first evaluation, the 6-month and 12-month PFS rates were 53% and 29%, respectively. The most common grade 3 or greater toxicities were hematologic and complicated less than 4% of administered courses. Imatinib mesylate plus hydroxyurea, is well tolerated and associated with anti-tumor activity in some patients with recurrent grade 3 MG.

  8. Management of CML in the Pediatric Age Group: Imatinib Mesylate or SCT.

    El-Alfy, Mohsen S; Al-Haddad, Alaa M; Hamed, Ahmed A

    2010-12-01

    Management of CML has changed markedly since the introduction of tyrosine kinase inhibitors (TKIs). However stem cell transplantation (SCT) remains a valid therapeutic modality especially in developing countries due to its relatively lower cost. We aim to compare between imatinib mesylate and SCT as regard outcome in CML in the pediatric age group. Forty-eight patients with newly diagnosed CML in the chronic phase, aged 3 to 18 years were enrolled in this prospective study. Patients without a matched donor (Group I; N=30) were assigned to receive imatinib mesylate at a dose of 340mg÷m2÷day, while patients with a fully matched related donor (Group II; N=18), were offered SCT. Response (hematologic, cytogenetic and molecular), side effects and survival were analyzed. Complete hematologic response was obtained in 97% of the patients in group I and 94% in group II. Major cytogenetic response (CyR) was obtained in 80% of patients in group I and 100% in group II. Complete CyR was 57% in group I and 64% in group II. Major molecular response (MMR) was 36% in group I and 50% in group II with no significant difference between both groups. Six years overall survival (OS) was 87% in the 1st group and 61% in the 2nd group (pSCT group (55% had GVHD and 78% had infection). Imatinib mesylate has a superior OS and EFS than SCT in children. It is generally safe and well tolerated. Imatinib mesylate should be the 1st line treatment of pediatric patients with CML in the chronic phase. CML- Imatinib- SCT- Pediatrics.

  9. Homologous recombination induced by doxazosin mesylate and saw palmetto in the Drosophila wing-spot test.

    Gabriel, Katiane Cella; Dihl, Rafael Rodrigues; Lehmann, Mauricio; Reguly, Maria Luiza; Richter, Marc François; Andrade, Heloisa Helena Rodrigues de

    2013-03-01

    Benign prostatic hyperplasia (BPH) is the most common tumor in men over 40 years of age. Acute urinary retention (AUR) is regarded as the most serious hazard of untreated BPH. α-Blockers, such as doxazosin mesylate, and 5-α reductase inhibitors, such as finasteride, are frequently used because they decrease both AUR and the need for BPH-related surgery. An extract of the fruit from American saw palmetto plant has also been used as an alternative treatment for BPH. The paucity of information available concerning the genotoxic action of these compounds led us to assess their activity as inducers of different types of DNA lesions using the somatic mutation and recombination test in Drosophila melanogaster. Finasteride did not induce gene mutation, chromosomal mutation or mitotic recombination, which means it was nongenotoxic in our experimental conditions. On the other hand, doxazosin mesylate and saw palmetto induced significant increases in spot frequencies in trans-heterozygous flies. In order to establish the actual role played by mitotic recombination and by mutation in the genotoxicity observed, the balancer-heterozygous flies were also analyzed, showing no increment in the total spot frequencies in relation to the negative control, for both drugs. Doxazosin mesylate and saw palmetto were classified as specific inducers of homologous recombination in Drosophila proliferative cells, an event linked to the loss of heterozygosity. Copyright © 2011 John Wiley & Sons, Ltd.

  10. Marking with radioactive iodine of a plasma substitute and preliminary essays of his kinetic behaviour in rats

    Cova, Wilma Guimaraes

    1973-01-01

    A blood plasma substitute (Haem accel - PGO), which has as a base a degraded and polymerized gelatin, was labelled with radioactive iodine (I-131) and preliminary essays of its kinetic behavior was done. We have used the labelling method of McFarlaner. The results obtained - radiochemical yield and purity - were favorable. The kinetic behaviour the residual radioactivity studied by measuring the residual radioactivity of the body and excreta in groups of male Wistar rats for a maximum period of 150 hours. These results have shown and excellent correlation for a two components exponential function's adjustment, suggesting therefore a bi compartmental mathematical model. (author)

  11. I-124 PET/CT to Predict the Outcome of Blind I-131 Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer : Results of a Multicenter Diagnostic Cohort Study (THYROPET)

    Kist, Jakob W.; de Keizer, Bart; van der Vlies, Manfred; Brouwers, Adrienne H.; Huysmans, Dyde A.; van der Zant, Friso M.; Hermsen, Rick; Stokkel, Marcel P. M.; Hoekstra, Otto S.; Vogel, Wouter V.

    Patients with suspected recurrence from differentiated thyroid carcinoma, based on an increased thyroglobulin (Tg) level and negative neck ultrasound (US), pose a clinical dilemma. Because standard imaging has a low yield identifying potential recurrence, blind I-131 treatment is often applied.

  12. Marine geochemistry of iodine

    Kennedy, H.; Elderfield, H.

    1985-01-01

    Iodine has long been classified as a biophilic element with analyses showing that iodine is strongly enriched, relative to seawater concentrations in both plankton and particulate matter and that the concentration of iodine found in surface sediments is still further enriched relative to that found in the sedimenting particulate matter. The extent of enrichment of iodine relative to carbon in deep sea surface sediments has been shown to depend on the carbon accumulation rate. Iodine decomposition rates have been calculated and are shown to vary with the sedimentation rate in the same manner as has been shown for organic carbon. Vertical profiles of total dissolved iodine, iodate and iodide in interstitial waters of sediments from the north east Atlantic are characterised by three zones of reaction as identified by changes in the concentration of iodate and iodide. These reaction zones represent (i) iodide production (ii) iodide oxidation and (iii) iodate reduction. Pore water and solid phase iodine profiles from cores containing turbidite units have shown that iodine, released to pore waters as iodide during the oxidation of the organic matter, has been scavenged after diffusing upwards into a less reducing region of the sediment. (author)

  13. The iodine reactivity

    2003-01-01

    The iodine is an important element because it has long life isotopes (such as iodine 129) and a great mobility in natural media. Iodine presents a complex chemistry because of its volatility and its strong redox reactivity. The S.E.C.R. works to better understand the reactivity of this element in different natural, industrial or biological environments. It plays a part in thermochemical sites as a possible way of hydrogen formation. This seminar gives some aspects relative to the chemical reactivity of iodine, since its thermochemistry in the I/S cycles to produce hydrogen to its reactivity in the natural medium and its potential radiological impact. This document includes 4 presentations transparencies) dealing with: the 129 I cycle rejected in the low radioactive gaseous and liquid effluents of the La Hague reprocessing plant (C. Frechou); a bibliographic review of iodine retention in soils (F. Bazer-Bachi); the hydrogen production and the iodine/sulfur thermochemical cycle (role of iodine in the process); and the direct characterization by electro-spray ionization mass spectroscopy of iodine fixation by fulvic acids (P. Reiller, B. Amekraz, C. Moulin, V. Moulin)

  14. Iodine-deficiency disorders

    Zimmermann, M.B.; Jooste, P.L.; Pandav, C.S.

    2008-01-01

    billion individuals worldwide have insufficient iodine intake, with those in south Asia and sub-Saharan Africa particularly affected. Iodine deficiency has many adverse effects on growth and development. These effects are due to inadequate production of thyroid hormone and are termed

  15. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M.; Vega Ramírez, J. L.

    2016-01-01

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  16. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    Apaza Veliz, D. G., E-mail: dgav02@gmail.com [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa, Perú, Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru); Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Urquizo Baldomero, R. M. [Hospital Nacional Carlos Alberto Seguin Escobedo, Servicio de Medicina Nuclear, Arequipa (Peru); Vega Ramírez, J. L. [Universidad Nacional de San Agustín de Arequipa, Escuela de Física, Arequipa (Peru)

    2016-07-07

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  17. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Vega Ramírez, J. L.; Urquizo Baldomero, R. M.

    2016-07-01

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  18. Iodine mineral waters

    Iluta Alexandru

    2011-11-01

    Full Text Available Iodine mineral waters are found especially in sub-Carpathian region, also in regions with Salif deposits. Waters are currently used iodine in drinking cure for chaps and Basedow. Are also indicated in balneology. Iodine water containing at least 1 mg L, there is pure iodine is usually given the nature of other types of mineral waters further: sodium chlorinated water (Bazna (50-70 mg iodine / l, Baile Govora (50 - 70 mg / l, Bălţăteşti (4-5 mg / l, salted Monteoru (30 mg / l, mine water mixed alkaline chlorination, sulphate, which are indicated for crenoterapie (hypo or isotonic to the bathrooms Olăneşti or Călimăneşti-Căciulata.

  19. A simple and rapid method for the determination of iodine in rice samples by radiochemical neutron activation analysis

    Takagi, Hiroyuki; Kimura, Toshimasa; Iwashima, Kiyoshi; Yamagata, Noboru.

    1983-01-01

    A simple and rapid method has been developed for the determination of iodine in rice samples by radiochemical neutron activation analysis. Irradiated rice powder was decomposed together with an iodide carrier solution containing I-131 on heating in a sodium hypochlorite solution. After decomposition, the solution was acidified with hydrochloric acid, and the insoluble residue was filtered off. To the filtrate sodium sulfite solution and palladium chloride solution were added, and the precipitate of palladium iodide was separated with a glass fiber filter paper. Iodine contents of rice were calculated from the peak areas under the 443 keV γ-ray of I-128 in the precipitate and comparative stand ard. Corrections for the chemical recovery were applied to them by means of the areas under the 365 keV γ-ray of I-131. This method was applied to the certified refe rece materials, IAEA wheat flour RM-V-5 and NBS orchard leaves SRM 1571. The results were in good agreement with the recommended values. Iodine contents of rice samples of two different origins in Japan were found to be of the order of 10 0 ng g -1 (dry weight base). The recovery of iodine in this procedure was about 80%. Decontamination factors for Mn, Cl, Na, and Br in the final fraction were 7 x 10 3 , 2 x 10 4 , 3 x 10 4 , and 2 x 10 2 , respectively. The time required for the chemical procedure was about 15 min, and the limit of determination was 0.7 ng of iodine in a sample of 1 g. (author)

  20. Treatment of hyperthyroidism with fixed dose form Iodine 131

    Pacheco Torres, P.; Cerquera, A.M.; Acosta, F.; Sierra, M.

    2007-01-01

    Full text: Objective: Evaluation of the response to therapy with fixed dose of Iodine-131 in patients with hyperthyroidism. One hundred seventeen patients with hyperthyroidism were tested and sent for treatment with Iodine-131. The dose of the therapy was calculated according to the pathology (Diffuser goiter (DG): Multinodular goiter (MNG) and Single toxic nodule (NST). Values of TSH confirmed hyperthyroidism by laboratory methods. The thyroid-blocking agents were discontinued: methimazole for five days and propylthiouracil two days prior to therapy. The pregnancy tests were routinely conducted in females of reproductive age group. Patients reported fasting for therapy. The doses were administered in capsule form after obtaining informed consent from the patients. The patients were normally instructed to eat only after two hours after administration of iodine to promote gastric absorption of the radionuclide. Normally a post therapy thyroid scan is performed four days after treatment. Patients are usually followed up by the endocrinologists. A three- month post therapy evaluation is done by the nuclear medicine physician by telephone. The demographic data of our patients treated are as follows: Total number of patients: 117 Female: 88 (75.21%) Male: 29 (24.79%) Age average: 45 years. Diffuse Goiter= 94 (80.34%), Multinodular Goiter= 17 (14.52%) and Toxic Adenoma (NST) = 6 (5.12%). The average administered dose was 22.5 mCi to DG, 41.8 mCi to MNG and 37.5 mCi to NST. 102 (87.14%) patients at the control at 2 years after treatment presented stable response to therapy, 15 (12.86%) required a second therapy, 11 (11.70%) with BD and 4 (23.52%) with BMN; and any patient with NST required a second therapy. 83 (88.29%) of the patients with BD; 13 (76.48%) with BMN and 6 (100%) with NST the therapy was successful. Conclusion: Fixed dose of I-131 in hyperthyroidism is useful in patients with DG (11.70%). In patients with MNG whom a fixed dose is supplied, 23.52% require a

  1. Iodine leaflets in chapter D5 'Distribution of iodine pills'

    1981-01-01

    Jodine leaflet A will be distributed together with iodine pills in a nuclear disaster. Iodine leaflet B is suitable for informing the public in advance. Iodine leaflet C informs physicians in a scientific way on the benefits and risk of iodine pills. (orig./HP) [de

  2. Iodine generator for reclaimed water purification

    Wynveen, R. A.; Powell, J. D.; Schubert, F. H. (Inventor)

    1977-01-01

    The system disclosed is for controlling the iodine level in a water supply in a spacecraft. It includes an iodine accumulator which stores crystalline iodine, an electrochemical valve to control the input of iodine to the drinking water and an iodine dispenser. A pump dispenses fluid through the iodine dispenser and an iodine sensor to a potable water tank storage. The iodine sensor electronically detects the iodine level in the water, and through electronic means, produces a correction current control. The correction current control operates the electro-chemical iodine valve to release iodine from the iodine accumulator into the iodine dispenser.

  3. The synthesis of [[sup 2]H],[[sup 3]H], and [[sup 14]C]-labeled 8[beta]-[(methylthio)methyl]-6-propylergoline mesylate (pergolide mesylate), a potent, long-acting dopamine agonist

    Wheeler, W.J.; Kau, D.L.K.; Bach, N.J. (Lilly (Eli) and Co., Indianapolis, IN (United States). Lilly Research Labs.)

    1990-03-01

    The [[sup 3]H]- and two[[sup 14]C]-isopomers of 8[beta]-[(methylthio)methyl]-6-propylergoline mesylate (pergolide mesylate) have been synthesized. The [[sup 3]H]-derivative was synthesized by the palladium catalyzed tritiation of the corresponding 6-allyl derivative. Reaction of 8[beta]-[(methylthio)methyl]-ergoline with 1-[[sup 14]C]-1-propyl bromide yielded pergolide labeled in the 6-propyl group. Alternatively, reaction of 8[beta]-mesyloxy-6-propylergoline with [[sup 14]C]-sodium cyanide, followed by base hydrolysis, yielded 8 [beta]-carboxy-6-propylergoline-[[sup 14]C], which was subsequently converted to pergolide mesylate radiolabeled in the 17-position via a four step sequence. (Author).

  4. Is placental iodine content related to dietary iodine intake?

    Burns, R

    2011-08-01

    Delivery of iodine to the foetus depends not only on maternal dietary iodine intake but also on the presence of a functioning placental transport system. A role for the placenta as an iodine storage organ has been suggested, and this study compares the iodine content of placentas from women giving birth at term in Ireland and Iran, areas with median urinary iodine of 79 and 206 μg\\/l respectively.

  5. Exposure rates (versus time after administration), in relation with clinical factors, for thyroid carcinoma patients treated with Iodine-131

    Papadimitriou, D.; Oros, L.; Manetou, A.; Perris, A.; Molfetas, M.; Kottou, S.

    2002-01-01

    While the therapeutic use of iodine-131 for thyroid carcinoma patients offers enormous benefit to them, it contributes also significantly to the radiation exposure of individuals and population. A critical quantity for decisions relating radiation protection system based on restrictions recommended by authorities is the residual I-131 activity in patient's body. When this value is larger than a threshold level, it may keep the patient hospitalised for a short period of usually 2 to 3 days with an additional period of 7 days at home, where he must sleep separately and avoid close contact with other people. Essential for radiation protection issues is the careful collection of radioactive urine, radioactive waste and avoidance of any contaminations by perspiration and saliva. Longer hospital stay would increase the total cost of the treatment and limit the availability of the isolation room. So the patient has then to return home, having always in mind that in spite of the fast washout of the I-131 from his body, even the second week still contributes significantly to the total radiation burden to relatives and friends. Radiation hazards concerning relatives and friends can be kept to a truly negligible level (a small fraction of the annual dose limit of only 1mSv), only if it is provided that: a) reasonable standards of personal hygiene and cleanliness are followed, b) urine or saliva contaminations are avoided and c) patient's close contact with relatives or friends is kept to a minimum. These measures should be followed for a time period of 2-8 days after hospital discharge, a period that depends on administered and retained I-131 activity. This work tries to estimate the correlation between several clinical factors and the residual activity of I-131 in patient's body and proposes a method for a more simple measurement of the total body activity during patient's stay in the treatment centre - hospital

  6. Iodine in meat in Macedonia

    Bogdanov, Bogdan; Gonev, Mihajlo; Tadzher, Isak

    2000-01-01

    Iodine deficiency in Macedonia still persists in a mild form. In 1999 the iodination of salt rose to 20 m gr iodine in Kg salt. The consumption of salt diminished after the last war from 20-30 gr salt per day to 10-20 gr salt daily. This shows that the problem of the elimination of iodine deficiency is being vigorously tackled. Since 1956 the iodine in salt in Macedonia rose to 10 m gr KI/Kg salt. The content of iodine in the Macedonian diet seems to be important. The amount of iodine in milk, eggs and bread is low as found by the investigation of MANU. The content of iodine in meat is low, compared to British meat is 10 times lower. The average iodine content in Macedonian meat is 95.15 micro gr per Kg, whereas in British meat it is 850-1510 micro gr iodine per k gr meat. (Original)

  7. Controversies in urinary iodine determinations

    Soldin, Offie Porat

    2002-01-01

    Iodine deficiency (ID) is associated with increased prevalence of goiter, increased risk for neurodevelopmental disorders, and is the world’s leading cause of intellectual deficits. Iodine nutritional status of a population is assessed by measurements of urinary iodine concentrations which are also used to define, indicate, survey and monitor iodine deficiency and consequently its treatment. Several methods are available for urinary iodine determination. Discussed here are some of the limitat...

  8. Radiolytic oxidation of iodine in the containment at high temperature and dose rate

    Guilbert, S.; Bosland, L.; Jacquemain, D.; Clement, B.; Andreo, F.; Ducros, G.; Dickinson, S.; Herranz, L.; Ball, J.

    2007-01-01

    Iodine Chemistry is one of the areas of top interest in the field of nuclear power plants (NPP) severe accidents studies. The strong radiological impact of iodine on man health and environment, mostly through its isotope I-131, has made it a key point to get an accurate prediction of the potential iodine release from the NPP containment to the environment in the low probable event of an accident leading to core melt. Released from the fuel as a gaseous form, iodine enters the containment in gaseous or particulate form and undergoes deposition processes that eventually take it to the containment surfaces and sump. Once in the sump, iodine, when present as soluble compounds, gets dissolved as non volatile iodide (I-). Nonetheless, in the presence of radiation and particularly in acidic sumps, iodine can be oxidized to volatile forms such as molecular iodine (I 2 ) and can escape from the sump to the containment atmosphere (sump radiolysis process), thus increasing its potential contribution to the iodine source term. Iodine sump radiolysis has been extensively studied experimentally in the past decades. Experiments have revealed that parameters such as pH, temperature and total iodine concentration have a large impact on iodine volatility. However, experimental data at elevated temperatures (> 80 O C) and elevated dose rates (> 1 kGy.h -1 ) anticipated in containment during a postulated severe accident are too scarce to provide for these relevant conditions an accurate determination of the volatile iodine fractions. Furthermore, some data were obtained from post-irradiation analysis and iodine concentration may be underestimated at the time of measurements compared with that during irradiation, due to post-irradiation reactions. To complete the existing database, the EPICUR program was launched by IRSN (Institut de Radioprotection et de Surete Nucleaire) and experiments have been performed in the frame of the International Source Term Program (ISTP) to provide on

  9. Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event

    Yan ZhongShu

    2011-11-01

    Full Text Available Abstract Background Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia, advanced and metastatic gastrointestinal stromal tumor (GIST. It is well tolerated with mild adverse effects. Gynecomastia development during the course of treatment has been rarely reported. Methods Ninety-eight patients with advanced or recurrent GIST were treated with imatinib mesylate. Among the fifty-seven male patients six developed gynecomastia during the treatment. The lesions were confirmed by sonography. Sex hormone levels were determined in six patients with and without the presence of gynecomastia respectively. The patients with gynecomatia were treated with tamoxifene and the sex hormones were assayed before and after tamoxifene treatment. Results In patients with gynecomastia the lump underneath the bilateral nipples was 2.5 to 5 centimeters in diameter. Their serum free testosterone levels ranged between 356.61 and 574.60 ng/dl with a mean ± SD of 408.64 ± 82.06 ng/dl (95% CI 343.03~474.25 ng/dl, which is within the normal range. The level of serum estradiol was 42.89 ± 16.54 pg/ml (95% CI 29.66~56.12 pg/ml. Three patients had higher levels (43.79~71.21 pg/ml and the others' were within normal range of 27.00~34.91 pg/ml. Six patients without the development of gynecomastia had normal free testosterone. One patient died because of large tumor burden. The sex hormones had no significant changes before and after tamoxifene treatment.(P > 0.05 Conclusions Testosterone levels were not decreased in the six GIST patients with gynecomastia. Three patients had increased serum estradiol level which suggests that imbalance of sex hormones may be the cause of gynecomastia during treatment with imatinib mesylate.

  10. Electrochemistry of iodine

    Yaraliev, Ya.A. (AN Azerbajdzhanskoj SSR, Baku. Inst. Neorganicheskoj i Fizicheskoj Khimii)

    1982-06-01

    The review is devoted to investigations into oxidation-reduction processes in different systems including iodine. The data on adsorption of iodine on metals are discussed; the connection between the nature of iodine adsorption and the mechanism of its electrode reactions is considered. The metals studied can be placed in the following series taking into account the degree of I sorption on them: Cd approximately Tl < Sn approximately Pb < Ga < Bi < Hg < Co approximately Ni < Fe < Ag approximately Rh approximately Pd approximately Ir < Pt. The data are given of standard and equilibrium potentials in iodine systems. Electric oxidation and electric reduction of iodide ions is investigated using the methods of Faraday impedance and rectification, methods of voltamperometry and oscillopolarography, rotating disc electrode, chronopotentiometry. Anode and cathode processes of oxidation-reduction reactions in I/sup -//IO/sub 3//sup -/, I/sub 2//IO/sub 3//sup -/ and I/sub 2//I/sup +/ systems are analyzed.

  11. Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet

    Kadivar, Ali; Kamalidehghan, Behnam; Javar, Hamid Akbari; Davoudi, Ehsan Taghizadeh; Zaharuddin, Nurul Dhania; Sabeti, Bahareh; Chung, Lip Yong; Noordin, Mohamed Ibrahim

    2015-01-01

    Introduction Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent administration to keep the plasma drug level at an effective range. This might cause side effects, reduced effectiveness and poor therapeutic management. Therefore, floating sustained-release Imatinib tablets were developed to allow the tablets to be released in the upper part of the GIT and overcome the inadequacy of conventional tablets. Methodology Floating sustained-release Imatinib mesylate tablets were prepared using the wet granulation method. Tablets were formulated using Hydroxypropyl Methylcellulose (HPMC K4M), with Sodium alginate (SA) and Carbomer 934P (CP) as release-retarding polymers, sodium bicarbonate (NaHCO3) as the effervescent agent and lactose as a filler. Floating behavior, in vitro drug release, and swelling index studies were conducted. Initial and total drug release duration was compared with a commercial tablet (Gleevec) in 0.1 N HCl (pH 1.2) at 37 ± 0.5°C for 24 hours. Tablets were then evaluated for various physical parameters, including weight variation, thickness, hardness, friability, and drug content. Consequently, 6 months of physical stability studies and in vitro gastro-retentive studies were conducted. Results and Discussion Statistical data analysis revealed that tablets containing a composition of 14.67% w/w HPMC K4M, 10.67%, w/w Na alginate, 1.33%, w/w Carbomer 934P and 9.33%, w/w NaHCO3 produced the most favorable formulation to develop 24-hour sustained-release tablets with optimum floating behavior and satisfactory physicochemical characteristics. Furthermore, in vitro release study revealed that the formulated SR tablet had significantly lower Cmax and higher Tmax compared to the conventional tablet (Gleevec). Thus, formulated SR tablets preserved persistent

  12. Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet.

    Ali Kadivar

    Full Text Available Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT. Conventional imatinib mesylate (Gleevec tablets produce rapid and relatively high peak blood levels and requires frequent administration to keep the plasma drug level at an effective range. This might cause side effects, reduced effectiveness and poor therapeutic management. Therefore, floating sustained-release Imatinib tablets were developed to allow the tablets to be released in the upper part of the GIT and overcome the inadequacy of conventional tablets.Floating sustained-release Imatinib mesylate tablets were prepared using the wet granulation method. Tablets were formulated using Hydroxypropyl Methylcellulose (HPMC K4M, with Sodium alginate (SA and Carbomer 934P (CP as release-retarding polymers, sodium bicarbonate (NaHCO3 as the effervescent agent and lactose as a filler. Floating behavior, in vitro drug release, and swelling index studies were conducted. Initial and total drug release duration was compared with a commercial tablet (Gleevec in 0.1 N HCl (pH 1.2 at 37 ± 0.5°C for 24 hours. Tablets were then evaluated for various physical parameters, including weight variation, thickness, hardness, friability, and drug content. Consequently, 6 months of physical stability studies and in vitro gastro-retentive studies were conducted.Statistical data analysis revealed that tablets containing a composition of 14.67% w/w HPMC K4M, 10.67%, w/w Na alginate, 1.33%, w/w Carbomer 934P and 9.33%, w/w NaHCO3 produced the most favorable formulation to develop 24-hour sustained-release tablets with optimum floating behavior and satisfactory physicochemical characteristics. Furthermore, in vitro release study revealed that the formulated SR tablet had significantly lower Cmax and higher Tmax compared to the conventional tablet (Gleevec. Thus, formulated SR tablets preserved persistent concentration of plasma up to 24 hours

  13. Iodine Hall Thruster

    Szabo, James

    2015-01-01

    Iodine enables dramatic mass and cost savings for lunar and Mars cargo missions, including Earth escape and near-Earth space maneuvers. The demonstrated throttling ability of iodine is important for a singular thruster that might be called upon to propel a spacecraft from Earth to Mars or Venus. The ability to throttle efficiently is even more important for missions beyond Mars. In the Phase I project, Busek Company, Inc., tested an existing Hall thruster, the BHT-8000, on iodine propellant. The thruster was fed by a high-flow iodine feed system and supported by an existing Busek hollow cathode flowing xenon gas. The Phase I propellant feed system was evolved from a previously demonstrated laboratory feed system. Throttling of the thruster between 2 and 11 kW at 200 to 600 V was demonstrated. Testing showed that the efficiency of iodine fueled BHT-8000 is the same as with xenon, with iodine delivering a slightly higher thrust-to-power (T/P) ratio. In Phase II, a complete iodine-fueled system was developed, including the thruster, hollow cathode, and iodine propellant feed system. The nominal power of the Phase II system is 8 kW; however, it can be deeply throttled as well as clustered to much higher power levels. The technology also can be scaled to greater than 100 kW per thruster to support megawatt-class missions. The target thruster efficiency for the full-scale system is 65 percent at high specific impulse (Isp) (approximately 3,000 s) and 60 percent at high thrust (Isp approximately 2,000 s).

  14. Study on Radioecology and Tracer of Iodine-129

    Xiaolin, Hou

    2004-01-01

    Iodine-129 (15.7 Ma) is a naturally occurring radioisotope of iodine. The ratio of 129 I/ 127 I was estimated to be ∼ 10 -12 in the ocean and 10 -11 in the territorial environment in pre-nuclear era, releases from nuclear weapon tests have increased this ratio to ∼ 10 -10 . However, a large amount of iodine-129 was released from various nuclear facilities, and the greatest releases of 129 I are from two European reprocessing plants, especially in recent years. By 1998, 2600 Kg and 220 Kg 129 I have been discharged to the marine environment and atmosphere from La Hague (France) and Sellafield reprocessing plants, respectively. This amount is tens times larger than the total 129 I inventory in the pre-nuclear ocean and weapon test releases. Although there is no significant radiation risk for the human health at present level of 129 I, the continuously increasing production and release of 129 I make the accumulation of 129 I in the environment, immigration, cycle and long term radioecological risk should be give more attention due to its long half-life, high accumulation in human thyroid and high mobility. Iodine is a conservative element in the ocean, the large amount of iodine-129 discharged to the marine system can therefore be used as a oceanographic tracer to study the physical dispersion, mixing and circulative processes of water mass in the ocean. In Riso national laboratory, a radiochemical neutron activation analysis method was developed, using this method the radioecology and tracer of iodine-129 was studied. Some representative works are presented below. (1) Evaluation of radiation exposure of humans to iodine-129. The human and animal thyroids collected from different places, such as Tianjin in China, Gemol in Belarus, Ribe in Denmark, human urine in Denmark, seafood in China were analysed for iodine-129 concentration and 129 I/ 127 I ratio, the exposure level were compared with other places. (2) Reconstruction of radiation dose from I-131 in the

  15. Iodine deficiency and thyroid disorders.

    Zimmermann, Michael B; Boelaert, Kristien

    2015-04-01

    Iodine deficiency early in life impairs cognition and growth, but iodine status is also a key determinant of thyroid disorders in adults. Severe iodine deficiency causes goitre and hypothyroidism because, despite an increase in thyroid activity to maximise iodine uptake and recycling in this setting, iodine concentrations are still too low to enable production of thyroid hormone. In mild-to-moderate iodine deficiency, increased thyroid activity can compensate for low iodine intake and maintain euthyroidism in most individuals, but at a price: chronic thyroid stimulation results in an increase in the prevalence of toxic nodular goitre and hyperthyroidism in populations. This high prevalence of nodular autonomy usually results in a further increase in the prevalence of hyperthyroidism if iodine intake is subsequently increased by salt iodisation. However, this increase is transient because iodine sufficiency normalises thyroid activity which, in the long term, reduces nodular autonomy. Increased iodine intake in an iodine-deficient population is associated with a small increase in the prevalence of subclinical hypothyroidism and thyroid autoimmunity; whether these increases are also transient is unclear. Variations in population iodine intake do not affect risk for Graves' disease or thyroid cancer, but correction of iodine deficiency might shift thyroid cancer subtypes toward less malignant forms. Thus, optimisation of population iodine intake is an important component of preventive health care to reduce the prevalence of thyroid disorders. Copyright © 2015 Elsevier Ltd. All rights reserved.

  16. Tratamiento de la Enfermedad de Graves con I131: Primeros casos en la Unidad de Endocrinología Pediátrica del Hospital Nacional Cayetano Heredia, Lima-Perú: Case Report.

    Javier Ernesto SÁNCHEZ POVIS

    2006-01-01

    Full Text Available Objetivo: Describir la respuesta al tratamiento con I131 y sus complicaciones, en niños y adolescentes con enfermedad de Graves. Material y Métodos: Se estudiaron retrospectivamente las historias clínicas de los pacientes con diagnóstico de enfermedad de Graves y que recibieron tratamiento con I131 atendidos hasta 1999 en la Unidad de Endocrinología Pediátrica del Hospital Nacional Cayetano Heredia. Se registraron datos demográficos, peso tiroideo, captación de yodo, dosis de I131 recibida y evolución clínica y de función tiroidea. Resultados: Se incluyeron 13 pacientes: 1 varón y 12 mujeres. El peso glandular promedio obtenido fue 47,56 +10,70 gramos. La dosis inicial calculada fue 3,92 + 0,95 mCi, con un total de 4,47 + 1,66 mCi y tiempo medio de seguimiento de 2,76 años. Diez pacientes recibieron 1 sola dosis, 2 pacientes dos dosis y un paciente tres dosis, remitiendo el 100%. Los pacientes que recibieron una sola dosis, mostraron remisión del cuadro en 13,13 semanas y el tiempo promedio de remisión de toda la muestra fue 24,62 semanas. La prevalencia de hipotiroidismo a los 6 meses de iniciado el tratamiento fue 66,66%, y 83,33% a las 257 semanas. Conclusión: I131 fue 100% eficaz en el tratamiento de la enfermedad de Graves de los niños y adolescentes en esta pequeña serie de casos. (Rev Med Hered 2006;17:8-14.

  17. The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.

    Yu, Yao; Zhao, Wei; Zhu, Chunpeng; Kong, Zhiping; Xu, Yan; Liu, Guangzhi; Gao, Xuguang

    2015-01-01

    It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption after ICH. From February 2013 to May 2014, spontaneous ICH patients diagnosed by computed tomography (CT) within 18 hours of onset were evaluated. Patients were randomly divided into two groups: an experimental group and a control group. The treatment of the two groups was similar except that the experimental group received deferoxamine mesylate. Patients were evaluated by CT and neurology scale at the time of admission, and on the fourth, eighth, and fifteenth day (or at discharge) after admission. Patients were followed up for the first 30 days and clinical data of the two groups were compared. Forty-two patients completed 30 days of follow-up by May 2014; 21 cases in the experimental group and 21 cases in the control group. The control group's relative edema volume on the fifteenth day (or discharge) was 10.26 ± 17.54, which was higher than the experimental group (1.91 ± 1.94; P edema volume on the fourth, eighth, and fifteenth day (or discharge) was higher than the experimental group (P edema after ICH, although further investigation is required to form definitive conclusions. Chinese Clinical Trial Registry ChiCTR-TRC-14004979.

  18. Axillary iodine-131 accumulation due to perspiration

    Camponovo, E.J.; Goyer, P.F.; Silverman, E.D.; Kistler, A.M.; Yudt, W.M.

    1989-01-01

    A case of spurious axillary uptake of I-131 proven to be caused by perspiration is presented. False-positive localizations of radioiodine, both pathologic and physiologic, are reviewed to avoid confusion of these entities with functioning thyroid carcinoma metastases

  19. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography

    Nagasawa, Haruo; Kogure, Kyuya; Kawashima, Koichiro; Ido, Tatsuo; Itoh, Masatoshi; Hatazawa, Jun.

    1990-01-01

    Three female patients aged from 74 to 79 with multi-infarct dementia were studied using positron emission tomography (PET) to assess the effect of co-dergocrine mesylate (Hydergine) on cerebral glucose metabolism. The cerebral glucose utilization (CMRGlc) of each patient was evaluated by PET scan using 2-deoxy-[ 18 F]-2-fluoro-D-glucose (FDG). Following the first PET study, 0.04 mg/kg of co-dergocrine mesylate was injected intravenously with 250 ml saline solution, and then the second PET study was performed. The CMRGlc was determined from the images of the PET scan and the radioactivity of 18 F in the plasma. After the administration of co-dergocrine mesylate, the value of CMRGlc increased significantly in the cerebral cortex (p<0.01 and p<0.05) and basal ganglia (p<0.05) compared with values before the administration, but no significant increase was found in the centrum semiovale. These results suggest that co-dergocrine mesylate stimulates glucose metabolism of neurons in the human brain. (author)

  20. [Metabolic therapy with iodine 131 in patients with chronic renal failure. Clinical case].

    Vázquez-Rodríguez Barbero, Inmaculada; Espadas-Maeso, María José; Muñoz-Morales, Ana; Flores-Gómez, Pilar; Serrano-Carretero, María Belén; Castedo-Sal, Juan José; Sánchez Rey-Castro, Elena; Zamorano-Córdoba, Antonio

    2015-01-01

    62 year-old male with CKD stage 5 in dialysis program since 2012 who underwent surgery for papillary thyroid carcinoma with lymph node metastasis. Subsequently, the patient was admitted to the Unit of Metabolic Therapy at his reference hospital, where he is administered 80 millicuries of iodine-131 as a treatment associated with the surgery, unable to have his conventional dialysis, nursing interventions required in various stages of implementation of the continuous extrarenal clearance techniques (TCDE) were performed. The following care values were addressed targeted to patients undergoing treatment with I(131): specific equipment, personal protective measures and major diagnoses and nursing interventions. TCDE, despite being attributed to very critical patients, they can be extrapolated to other patients in a given time. TCDE allowed these patients to undergo dialysis in a safe environment for staff, ensuring proper disposal of contaminated liquids. TCDE were an effective treatment for the removal of I131, a single ssesion being necessary to normalize the levels of radioactivity. Coordination between services allewed ensure proper and effective treatment for the patient. Copyright © 2015 Elsevier España, S.L.U. All rights reserved.

  1. Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

    2018-05-14

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; CD45-Positive Neoplastic Cells Present; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts; Refractory Anemia With Ring Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts

  2. Volatilization of iodine from vegetation

    Amiro, B.D.; Johnston, F.L.

    1989-01-01

    Gaseous emissions of iodine were measured from bean plant foliage. A gamma-emitting iodine tracer, Na 125 I, was taken up by the plants from a hydroponic growth medium and released to a cuvette atmosphere. The dynamics of the flux were studied using a flow-through gamma detector. The relationship between leaf radioactive tracer activity and growth-medium activity was linear, as was the relationship between the iodine flux and both leaf and growth-medium activity. Iodine flux and leaf conductance to water responded similarly to changes in light levels, suggesting that the stomata may partially control the flux. The flux was inhibited by aeration of the hydroponic growth media, and we postulate that methylation causes the iodine flux. Iodine emissions from living vegetation probably contribute < 0.1% to the stable iodine concentration in the atmosphere above terrestrial areas. However, this pathway may be a direct route for radioactive iodine transport from contaminated soils to the atmosphere. (author)

  3. Radioactive iodine intake through foodstuff

    Omomo, Yoichiro

    1974-01-01

    The transition of radioactive iodine to human bodies is affected by the amount of coexisting stable iodine. The intake of stable iodine through foodstuffs was studied from the stand point of I) discussion of the literature which states the approximate amounts of stable iodine contained in environmental materials, and II) the authors' research on the consumption of foodstuffs. For example, the amounts of iodine intake of fishermen living in Kuji-cho (Ibaragi Prefecture) was estimated from I and II, and was revealed as 2704p. The national average iodine intake was about 800p indicating that the former estimated value was remarkably high. Eighty Four per cent of the 2.7 mg iodine intake was taken from marine products, indicating that marine products are important sources of iodine supply. (Tsukamoto, Y.)

  4. Mock iodine-125 radiation source

    Coffey, D.L.

    1976-01-01

    An intimate mixture of americium-241 and iodine-129 provides an energy spectrum that reliably simulates the spectrum of iodine-125 in a well-type detector. As such, it may be used as a long-lived standard to calibrate instruments such as well scintillation spectrometers in which measurements are to be made involving iodine-125

  5. Behaviour of short-lived iodines in operating UO2 fuel elements

    Lipsett, J.J.; Hastings, I.J.; Hunt, C.E.L.

    1984-11-01

    Sweep gas experiments have been done to determine the behaviour of short-lived fission products within operating UO 2 fuel elements at linear powers of 45, 54, and 60 KW/m, and to burnups of 70, 80, and 50 MWh/kgU respectively. Although radioiodine transport was not observed directly during normal operation, equilibrium gap inventories for I-131 were deduced from the shutdown decay behaviour of the fission gases. These inventories were a strong function of fuel power and ranged from 10 GBq (0.27 Ci) to 100 GBq (2.7 Ci) over the range tested. We conclude that the iodine inventory was adsorbed onto the fuel and/or sheath surfaces with a volatile fraction of less than 10 -2 and a charcoal-filter-penetrating fraction of less than 2x10 -4

  6. Iodine-131 imaging using 284 keV photons with a small animal CZT-SPECT system dedicated to low-medium-energy photon detection.

    Kojima, Akihiro; Gotoh, Kumiko; Shimamoto, Masako; Hasegawa, Koki; Okada, Seiji

    2016-02-01

    Iodine-131 is widely used for radionuclide therapy because of its β-particle and for diagnostic imaging employing its principal gamma ray. Since that principal gamma ray has the relatively high energy of 364 keV, small animal single-photon emission computed tomography (SPECT) imaging systems may be required to possess the ability to image such higher energy photons. The aim of this study was to investigate the possibility of imaging I-131 using its 284 keV photons instead of its 364 keV photons in a small animal SPECT imaging system dedicated to the detection of low-medium-energy photons (below 300 keV). The imaging system used was a commercially available preclinical SPECT instrument with CZT detectors that was equipped with multi-pinhole collimators and was accompanied by a CT imager. An energy window for I-131 imaging was set to a photopeak of 284 keV with a low abundance compared with 364 keV photons. Small line sources and two mice, one of each of two types, that were injected with NaI-131 were scanned. Although higher counts occurred at the peripheral region of the reconstructed images due to the collimator penetration by the 364 keV photons, the shape of the small line sources could be well visualized. The measured spatial resolution was relatively poor (~1.9 mm for full width at half maximum and ~3.9 mm for full width at tenth maximum). However, a good linear correlation between SPECT values and the level of I-131 radioactivity was observed. Furthermore, the uptake of NaI-131 to the thyroid gland for the two mice was clearly identified in the 3D-SPECT image fused with the X-ray CT image. We conclude that the use of an energy window set on the photopeak of 284 keV and the multi-pinhole collimator may permit I-131 imaging for a preclinical CZT-SPECT system that does not have the ability to acquire images using the 364 keV photons.

  7. Organ S values and effective doses for family members exposed to adult patients following I-131 treatment: A Monte Carlo simulation study

    Han, Eun Young [Department of Radiation Oncology, University of Arkansas Medical Sciences, Little Rock, Arkansas 72205 (United States); Lee, Choonsik [Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20852 (United States); Mcguire, Lynn; Brown, Tracy L. Y. [Department of Radiology, Division of Nuclear Medicine, University of Arkansas Medical Sciences, Little Rock, Arkansas 72205 (United States); Bolch, Wesley E. [J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, Florida 32611 (United States)

    2013-08-15

    Purpose: To calculate organ S values (mGy/Bq-s) and effective doses per time-integrated activity (mSv/Bq-s) for pediatric and adult family members exposed to an adult male or female patient treated with I-131 using a series of hybrid computational phantoms coupled with a Monte Carlo radiation transport technique.Methods: A series of pediatric and adult hybrid computational phantoms were employed in the study. Three different exposure scenarios were considered: (1) standing face-to-face exposures between an adult patient and pediatric or adult family phantoms at five different separation distances; (2) an adult female patient holding her newborn child, and (3) a 1-yr-old child standing on the lap of an adult female patient. For the adult patient model, two different thyroid-related diseases were considered: hyperthyroidism and differentiated thyroid cancer (DTC) with corresponding internal distributions of {sup 131}I. A general purpose Monte Carlo code, MCNPX v2.7, was used to perform the Monte Carlo radiation transport.Results: The S values show a strong dependency on age and organ location within the family phantoms at short distances. The S values and effective dose per time-integrated activity from the adult female patient phantom are relatively high at shorter distances and to younger family phantoms. At a distance of 1 m, effective doses per time-integrated activity are lower than those values based on the NRC (Nuclear Regulatory Commission) by a factor of 2 for both adult male and female patient phantoms. The S values to target organs from the hyperthyroid-patient source distribution strongly depend on the height of the exposed family phantom, so that their values rapidly decrease with decreasing height of the family phantom. Active marrow of the 10-yr-old phantom shows the highest S values among family phantoms for the DTC-patient source distribution. In the exposure scenario of mother and baby, S values and effective doses per time-integrated activity to

  8. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy

    Zechmann, Christian M.; Afshar-Oromieh, Ali; Mier, Walter; Armor, Tom; Joyal, John; Stubbs, James B.; Hadaschik, Boris; Kopka, Klaus; Debus, Juergen; Babich, John W.; Haberkorn, Uwe

    2014-01-01

    Since the prostate-specific membrane antigen (PSMA) is frequently over-expressed in prostate cancer (PCa) several PSMA-targeting molecules are under development to detect and treat metastatic castration resistant prostate cancer (mCRPC). We investigated the tissue kinetics of a small molecule inhibitor of PSMA ((S)-2-(3-((S)-1-carboxy-5-(3-(4-[ 124 I]iodophenyl)ureido)pentyl)ureido) pentan edioicacid; MIP-1095) using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131 I-MIP-1095 in men with mCRPC. We also report preliminary safety and efficacy of the first 28 consecutive patients treated under a compassionate-use protocol with a single cycle of 131 I-MIP-1095. Sixteen patients with known prostate cancer underwent PET/CT imaging after i.v. administration of 124 I-MIP-1095 (mean activity: 67.4 MBq). Each patient was scanned using PET/CT up to five times at 1, 4, 24, 48 and 72 h post injection. Volumes of interest were defined for tumor lesions and normal organs at each time point followed by dose calculations using the OLINDA/EXM software. Twenty-eight men with mCRPC were treated with a single cycle of 131 I-MIP-1095 (mean activity: 4.8 GBq, range 2 to 7.2 GBq) and followed for safety and efficacy. Baseline and follow up examinations included a complete blood count, liver and kidney function tests, and measurement of serum PSA. I-124-MIP-1095 PET/CT images showed excellent tumor uptake and moderate uptake in liver, proximal intestine and within a few hours post-injection also in the kidneys. High uptake values were observed only in salivary and lacrimal glands. Dosimetry estimates for I-131-MIP-1095 revealed that the highest absorbed doses were delivered to the salivary glands (3.8 mSv/MBq), liver (1.7 mSv/MBq) and kidneys (1.4 mSv/MBq). The absorbed dose calculated for the red marrow was 0.37 mSv/MBq. PSA values decreased by >50 % in 60.7 % of the men treated. Of men with bone pain, 84.6 % showed complete or moderate reduction in pain

  9. Organ S values and effective doses for family members exposed to adult patients following I-131 treatment: A Monte Carlo simulation study

    Han, Eun Young; Lee, Choonsik; Mcguire, Lynn; Brown, Tracy L. Y.; Bolch, Wesley E.

    2013-01-01

    Purpose: To calculate organ S values (mGy/Bq-s) and effective doses per time-integrated activity (mSv/Bq-s) for pediatric and adult family members exposed to an adult male or female patient treated with I-131 using a series of hybrid computational phantoms coupled with a Monte Carlo radiation transport technique.Methods: A series of pediatric and adult hybrid computational phantoms were employed in the study. Three different exposure scenarios were considered: (1) standing face-to-face exposures between an adult patient and pediatric or adult family phantoms at five different separation distances; (2) an adult female patient holding her newborn child, and (3) a 1-yr-old child standing on the lap of an adult female patient. For the adult patient model, two different thyroid-related diseases were considered: hyperthyroidism and differentiated thyroid cancer (DTC) with corresponding internal distributions of 131 I. A general purpose Monte Carlo code, MCNPX v2.7, was used to perform the Monte Carlo radiation transport.Results: The S values show a strong dependency on age and organ location within the family phantoms at short distances. The S values and effective dose per time-integrated activity from the adult female patient phantom are relatively high at shorter distances and to younger family phantoms. At a distance of 1 m, effective doses per time-integrated activity are lower than those values based on the NRC (Nuclear Regulatory Commission) by a factor of 2 for both adult male and female patient phantoms. The S values to target organs from the hyperthyroid-patient source distribution strongly depend on the height of the exposed family phantom, so that their values rapidly decrease with decreasing height of the family phantom. Active marrow of the 10-yr-old phantom shows the highest S values among family phantoms for the DTC-patient source distribution. In the exposure scenario of mother and baby, S values and effective doses per time-integrated activity to the

  10. Identifying best practice in relation to Iodine-131 ablation discharges to sewers in Ireland

    Ryan, Thomas P.; Fennell, Stepehn; McGarry, Ann; Punt, Adrian

    2008-01-01

    Full text: In line with a commitment in Ireland's strategy on the implementation of the Oslo-Paris Convention (OSPAR) as well as recent developments in the provision of national oncology services, best practice in relation to Iodine-131 (I-131) ablation discharges to sewers in Ireland is under review. Preparatory to this review the Radiological Protection Institute of Ireland (RPII) commissioned a study of current practices in Ireland and associated doses as well as a review of international best practice and advice. Currently, there are three hospitals in Ireland at which thyroid ablation therapy procedures (large therapeutic administrations of I-131 for thyroid cancer treatment) are carried out. Only one facility has a limited capacity for delay and decay storage prior to discharge. Based on current administrations and discharges, the potentially most exposed workers comprises hospital plumbers dealing with specific incidents with estimated doses in the order of 50 to 70 μSv per incident. Doses to sewage workers and fishing communities are estimated at less than 4 μSv y -1 and 0.4 μSv y -1 respectively. Based on anticipated future service requirements in Ireland, a marginal increase in doses to some of these groups is estimated. Iodine-131 discharges to the environment and associated doses to workers and members of the public may be significantly reduced by the introduction of state-of-the-art delay and decay tanks using multi-tank vacuum systems. The justification for the introduction of a regulatory requirement to install such systems is examined taking account of: discharges to the environment, concentrations in the environment, doses to workers and members of the public, best available techniques (BAT), international best practice and advice as well as the financial implications for medical facilities. The case for retrofitting delay and decay tanks to existing medical facilities is also examined as well as the option of including such tanks in the

  11. Iodine in soil

    Johanson, Karl Johan

    2000-12-01

    A literature study of the migration and the appearance of iodine isotopes in the bio-sphere particularly in soil is presented. Some important papers in the field of iodine appearance in soil and the appearance of 129 I in the surroundings of reprocessing plants are discussed. The most important conclusions are: 1. Iodine binds to organic matter in the soil and also to some oxides of aluminium and iron. 2. If the iodine is not bound to the soil a large fraction of added 129 I is volatilized after a rather short period. 3. The binding and also the volatilisation seems to be due to biological activity in the soil. It may take place within living microorganisms or by external enzymes excreted from microorganisms. 4. Due to variations in the composition of soil there may be a large variation in the distribution of 129 I in the vertical profile of soil - usually most of the 129 I in the upper layer - which also results in large variations in the 129 I uptake to plants

  12. Iodine in soil

    Johanson, Karl Johan [Swedish Univ. of Agricultural Sciences, Uppsala (Sweden). Dept. of Forest Mycology and Pathology

    2000-12-01

    A literature study of the migration and the appearance of iodine isotopes in the bio-sphere particularly in soil is presented. Some important papers in the field of iodine appearance in soil and the appearance of {sup 129}I in the surroundings of reprocessing plants are discussed. The most important conclusions are: 1. Iodine binds to organic matter in the soil and also to some oxides of aluminium and iron. 2. If the iodine is not bound to the soil a large fraction of added {sup 129}I is volatilized after a rather short period. 3. The binding and also the volatilisation seems to be due to biological activity in the soil. It may take place within living microorganisms or by external enzymes excreted from microorganisms. 4. Due to variations in the composition of soil there may be a large variation in the distribution of {sup 129}I in the vertical profile of soil - usually most of the {sup 129}I in the upper layer - which also results in large variations in the {sup 129}I uptake to plants.

  13. Iodine filters in nuclear installations

    Wilhelm, J.G.

    1982-01-01

    The present report discusses the significance for environmental exposure of the iodine released with the gaseous effluents of nuclear power stations and reprocessing plants in relation to releases of other airborne radionuclides. Iodine filtration processes are described. The release pathways and the composition of airborne fission product iodine mixtures and their bearing on environmental exposure are discussed on the basis of measured fission product iodine emissions. The sorbents which can be used for iodine filtration, their removal efficiencies and range of applications are dealt with in detail. The particular conditions governing iodine removal, which are determined by the various gaseous iodine species, are illustrated on the basis of experimentally determined retention profiles. Particular attention is given to the limitations imposed by temperature, humidity, radiation and filter poisoning. The types of filter normally used are described, their advantages and drawbacks discussed, the principles underlying their design are outlined and the sources of error indicated. The methods normally applied to test the efficiency of various iodine sorbents are described and assessed. Operating experience with iodine filters, gathered from surveillance periods of many years, is supplemented by a large number of test results and the findings of extensive experiments. Possible ways of prolonging the permissible service lives of iodine filters are discussed and information is given on protective measures. The various iodine removal processes applied in reprocessing plants are described and compared with reference to efficiency and cost. The latest developments in filter technology in reprocessing plants are briefly outlined

  14. Identification of cysteine-644 as the covalent site of attachment of dexamethasone 21-mesylate to murine glucocorticoid receptors in WEHI-7 cells

    Smith, L.I.; Bodwell, J.E.; Mendel, D.B.; Ciardelli, T.; North, W.G.; Munck, A.

    1988-01-01

    Dexamethasone 21-mesylate is a highly specific synthetic glucocorticoid derivative that binds covalently to glucocorticoid receptors via sulfhydryl groups. The authors have identified the amino acid that reacts with the dexamethasone 21-mesylate by using enzymatic digestion and microsequencing for radiolabel. Nonactivated glucocorticoid receptors obtained from labeling intact WEHI-7 mouse thymoma cells with [ 3 H]dexamethasone 21-mesylate were immunopurified and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Trypsin digestion followed by reversed-phase high-performance liquid chromatography (reversed-phase HPLC) produced a single [ 3 H]dexamethasone 21-mesylate labeled peptide. Automated Edman degradation of this peptide revealed that the [ 3 H]dexamethasone 21-mesylate was located at position 5 from the amino terminus. Dual-isotope labeling studies with [ 3 H]dexamethasone 21-mesylate and [ 35 S]methionine demonstrated that this peptide contained methionine. Staphylococcus aureus V8 protease digestion of [ 3 H]dexamethasone 21-mesylate labeled steroid-binding subunits generated a different radiolabeled peptide containing label at position 7 from the amino terminus. On the basis of the published amino acid sequence of the murine glucocorticoid receptor, their data clearly identify cysteine-644 as the single residue in the steroid-binding domain that covalently binds dexamethasone 21-mesylate. They have confirmed this finding by demonstrating that a synthetic peptide representing the amino acid sequence 640-650 of the murine glucocorticoid receptor behaves in an identical manner on reversed-phase HPLC as the trypsin-generated peptide from intact cells

  15. Cytoprotective effect of imatinib mesylate in non-BCR-ABL-expressing cells along with autophagosome formation

    Ohtomo, Tadashi; Miyazawa, Keisuke; Naito, Munekazu; Moriya, Shota; Kuroda, Masahiko; Itoh, Masahiro; Tomoda, Akio

    2010-01-01

    Treatment with imatinib mesylate (IM) results in an increased viable cell number of non-BCR-ABL-expressing cell lines by inhibiting spontaneous apoptosis. Electron microscopy revealed an increase of autophagosomes in response to IM. IM attenuated the cytotoxic effect of cytosine arabinoside, as well as inhibiting cell death with serum-deprived culture. Cytoprotection with autophagosome formation by IM was observed in various leukemia and cancer cell lines as well as normal murine embryonic fibroblasts (MEFs). Complete inhibition of autophagy by knockdown of atg5 in the Tet-off atg5 -/- MEF system attenuated the cytoprotective effect of IM, indicating that the effect is partially dependent on autophagy. However, cytoprotection by IM was not mediated through suppression of ROS production via mitophagy, ER stress via ribophagy, or proapoptotic function of ABL kinase. Although the target tyrosine kinase(s) of IM remains unclear, our data provide novel therapeutic possibilities of using IM for cytoprotection.

  16. Synthesis of chitosan-PEO hydrogels via mesylation and regioselective Cu(I)-catalyzed cycloaddition.

    Tirino, Pasquale; Laurino, Rosaria; Maglio, Giovanni; Malinconico, Mario; d'Ayala, Giovanna Gomez; Laurienzo, Paola

    2014-11-04

    In this work, a well-defined hydrogel was developed by coupling chitosan with PEO through "click chemistry". Azide functionalities were introduced onto chitosan, through mesylation of C-6 hydroxyl groups, and reacted with a di-alkyne PEO by a regioselective Cu(I)-catalyzed cycloaddition. This synthetic approach allowed us to obtain a hydrogel with a controlled crosslinking degree. In fact, the extent of coupling is strictly dependent on the amount of azido groups on chitosan, which in turn can be easily modulated. The obtained hydrogel, with a crosslinking degree of around 90%, showed interesting swelling properties. With respect to chitosan hydrogels reported in literature, a considerably higher equilibrium uptake was reached (940%). The possibility to control the crosslinking degree of hydrogel and its capability to rapidly absorb high amounts of water make this material suitable for several applications, such as controlled drug release and wound healing. Copyright © 2014. Published by Elsevier Ltd.

  17. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.

    Stagno, Fabio; Stella, Stefania; Spitaleri, Antonio; Pennisi, Maria Stella; Di Raimondo, Francesco; Vigneri, Paolo

    2016-01-01

    The tyrosine kinase inhibitor Imatinib Mesylate has dramatically improved the clinical outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease, generating unprecedented rates of complete hematologic and cytogenetic responses and sustained reductions in BCR-ABL transcripts. Here, we present an overview on the efficacy and safety of Imatinib and describe the most important clinical studies employing this drug for the frontline treatment of chronic phase CML. We also discuss recent reports describing the long-term outcome of patients receiving Imatinib for their disease. The imminent availability of generic forms of Imatinib coupled with the approval of expensive second-generation tyrosine kinase inhibitors underlines an unmet need for early molecular parameters that may distinguish CML patients likely to benefit from the drug from those that should receive alternative forms of treatment.

  18. Acute exposure to Iodine-125: a case study

    Kol, R; Canfi, A; Dukhan, N; Pelled, O; Brikner, D; Laichter, Y; Gold, B [Israel Atomic Energy Commission, Beersheba (Israel). Nuclear Research Center-Negev

    1996-12-01

    Radioiodines I-125 and I-131 are extremely volatile even in the form of the relatively stable Iodine anion. This property renders frequent airborne contamination and sometimes accidental inhalation of the radioiodine by personnel heavily involved with it`s handling. In order to detect radioiodine contamination as early as possible, the laboratory and its surroundings are constantly air monitored, surfaces are monitored according to a predetermined regime and personnel is being checked upon completion of a job or upon leaving the laboratory. Follow-up, routine or in special occasions, is performed by health-physics personnel who reports to the radiation medicine department. We report here the measures and means used to monitor a case of an accidental inhalation of I-125 due to an externally contaminated NaI[I-125] commercial package. The monitoring of the contamination is described, the dose to the thyroid and the Committed Effective Dose Equivalent (CEDE) are reported, and the medical evaluation is presented (authors).

  19. Sorption Coefficients for Iodine, Silver, and Cesium on Dust Particles

    Stempniewicz, M.M.; Goede, P.

    2014-01-01

    This paper describes the work performed to find relevant experimental data and find the sorption coefficients that represent well the available data for cesium, iodine, and silver on dust particles. The purpose of this work is to generate a set of coefficients that may be recommended for the computer code users. The work was performed using the computer code SPECTRA. Calculations were performed for the following data: • I-131 on AVR dust; • Ag-110m on AVR dust; • Cs-13 and Cs-137 on AVR dust. Available data was matched using the SPECTRA Sorption Model. S = A(T) · C_V-B(T) · C_d. The results are summarized as follows: • The available data can be correlated. The data scatter is about 4 orders of magnitude. Therefore the coefficients of the Langmuir isotherms vary by 4 orders of magnitude. • Sorption rates are higher at low temperatures and lower at high temperatures. This tendency has been observed in the data compiled at Oak Ridge. It is therefore surmised that the highest value of the sorption coefficients are appropriate for the low temperatures and the lowest value of the sorption coefficients are appropriate for the high temperatures. The recommended sorption coefficients are presented in this paper. • The present set of coefficients is very rough and should be a subject for future verification against experimental data. (author)

  20. Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein

    Sohn, Eun Jeong; Kim, Dae Won; Kim, Young Nam; Kim, So Mi; Lim, Soon Sung; Kang, Tae-Cheon; Kwon, Hyeok Yil; Kim, Duk-Soo; Cho, Sung-Woo; Han, Kyu Hyung; Park, Jinseu; Eum, Won Sik; Hwang, Hyun Sook; Choi, Soo Young

    2011-01-01

    Research highlights: → We studied effects of pergolide mesylate (PM) on in vitro and in vivo transduction of PEP-1-catalase. → PEP-1-catatase inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation. → PM enhanced the transduction of PEP-1-catalase into HaCaT cells and skin tissue. → PM increased anti-inflammatory activity of PEP-1-catalase. → PM stimulated therapeutic action of anti-oxidant enzyme catalase in oxidative-related diseases. -- Abstract: The low transduction efficiency of various proteins is an obstacle to their therapeutic application. However, protein transduction domains (PTDs) are well-known for a highly effective tool for exogenous protein delivery to cells. We examined the effects of pergolide mesylate (PM) on the transduction of PEP-1-catalase into HaCaT human keratinocytes and mice skin and on the anti-inflammatory activity of PEP-1-catatase against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation using Western blot and histological analysis. PM enhanced the time- and dose-dependent transduction of PEP-1-catalase into HaCaT cells without affecting the cellular toxicity. In a mouse edema model, PEP-1-catalase inhibited the increased expressions of inflammatory mediators and cytokines such as cyclooxygenase-2, inducible nitric oxide synthase, interleukin-6 and -1β, and tumor necrosis factor-α induced by TPA. On the other hand, PM alone failed to exert any significant anti-inflammatory effects. However, the anti-inflammatory effect of co-treatment with PEP-1-catalase and PM was more potent than that of PEP-1-catalase alone. Our results indicate that PM may enhance the delivery of PTDs fusion therapeutic proteins to target cells and tissues and has potential to increase their therapeutic effects of such drugs against various diseases.

  1. Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein

    Sohn, Eun Jeong; Kim, Dae Won; Kim, Young Nam; Kim, So Mi [Department of Biomedical Science and Research Institute of Bioscience and Biotechnology, Hallym University, Chunchon 200-702 (Korea, Republic of); Lim, Soon Sung [Department of Food Science and Nutrition and RIC Center, Hallym University, Chunchon 200-702 (Korea, Republic of); Kang, Tae-Cheon [Department of Anatomy and Neurobiology, College of Medicine, Hallym University, Chunchon 200-702 (Korea, Republic of); Kwon, Hyeok Yil [Department of Physiology, College of Medicine, Hallym University, Chunchon 200-702 (Korea, Republic of); Kim, Duk-Soo [Department of Anatomy, College of Medicine, Soonchunhyang University, Cheonan-Si 330-090 (Korea, Republic of); Cho, Sung-Woo [Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Seoul 138-736 (Korea, Republic of); Han, Kyu Hyung; Park, Jinseu; Eum, Won Sik [Department of Biomedical Science and Research Institute of Bioscience and Biotechnology, Hallym University, Chunchon 200-702 (Korea, Republic of); Hwang, Hyun Sook, E-mail: wazzup@hallym.ac.kr [Department of Biomedical Science and Research Institute of Bioscience and Biotechnology, Hallym University, Chunchon 200-702 (Korea, Republic of); Choi, Soo Young, E-mail: sychoi@hallym.ac.kr [Department of Biomedical Science and Research Institute of Bioscience and Biotechnology, Hallym University, Chunchon 200-702 (Korea, Republic of)

    2011-03-18

    Research highlights: {yields} We studied effects of pergolide mesylate (PM) on in vitro and in vivo transduction of PEP-1-catalase. {yields} PEP-1-catatase inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation. {yields} PM enhanced the transduction of PEP-1-catalase into HaCaT cells and skin tissue. {yields} PM increased anti-inflammatory activity of PEP-1-catalase. {yields} PM stimulated therapeutic action of anti-oxidant enzyme catalase in oxidative-related diseases. -- Abstract: The low transduction efficiency of various proteins is an obstacle to their therapeutic application. However, protein transduction domains (PTDs) are well-known for a highly effective tool for exogenous protein delivery to cells. We examined the effects of pergolide mesylate (PM) on the transduction of PEP-1-catalase into HaCaT human keratinocytes and mice skin and on the anti-inflammatory activity of PEP-1-catatase against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation using Western blot and histological analysis. PM enhanced the time- and dose-dependent transduction of PEP-1-catalase into HaCaT cells without affecting the cellular toxicity. In a mouse edema model, PEP-1-catalase inhibited the increased expressions of inflammatory mediators and cytokines such as cyclooxygenase-2, inducible nitric oxide synthase, interleukin-6 and -1{beta}, and tumor necrosis factor-{alpha} induced by TPA. On the other hand, PM alone failed to exert any significant anti-inflammatory effects. However, the anti-inflammatory effect of co-treatment with PEP-1-catalase and PM was more potent than that of PEP-1-catalase alone. Our results indicate that PM may enhance the delivery of PTDs fusion therapeutic proteins to target cells and tissues and has potential to increase their therapeutic effects of such drugs against various diseases.

  2. Perchlorate, iodine supplements, iodized salt and breast milk iodine content

    Kirk, Andrea B. [Department of Epidemiology, School of Public Health, University of North Texas Health Sciences Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107 (United States); Kroll, Martina; Dyke, Jason V.; Ohira, Shin-Ichi; Dias, Rukshan A.; Dasgupta, Purnendu K. [Department of Chemistry and Biochemistry, 700 Planetarium Place, University of Texas at Arlington, Arlington, TX 76019 (United States)

    2012-03-15

    This study was undertaken to determine if increasing maternal iodine intake through single dose tablets will decrease breast milk concentrations of the iodine-uptake inhibitor, perchlorate, through competitive inhibition. We also sought to determine if the timing of supplementation influences the fraction of iodine excreted in milk versus urine and to compare the effectiveness of iodized salt as a means of providing iodine to breastfed infants. Thirteen women who did not use supplements, seven of whom used iodized salt and six of whom used non-iodized salt, submitted four milk samples and a 24-h urine collection daily for three days. Women repeated the sampling protocol for three more days during which {approx} 150 {mu}g of iodine were taken in the evening and again for three days with morning supplementation. Samples were analyzed using isotope-dilution inductively-coupled plasma-mass spectrometry for iodine and isotope-dilution ion chromatography-tandem mass spectrometry for perchlorate. No statistically significant differences were observed in milk iodine or perchlorate concentrations during the two treatment periods. Estimated perchlorate intake was above the U.S. National Academy of Sciences suggested reference dose for most infants. Single daily dose iodine supplementation was not effective in decreasing milk perchlorate concentrations. Users of iodized salt had significantly higher iodine levels in milk than non-users. Iodized salt may be a more effective means of iodine supplementation than tablets. - Highlights: Black-Right-Pointing-Pointer Estimated infant exposures to perchlorate were, on a {mu}g/kg basis, {approx} 5 Multiplication-Sign higher than those of mothers. Black-Right-Pointing-Pointer Daily supplements are less effective than iodized salt in providing iodine to lactating women. Black-Right-Pointing-Pointer Low iodine and high perchlorate in milk may place infants at risk of iodine deficiency.

  3. Iodine Status in Pregnant & Breastfeeding Women

    Andersen, Stine Linding

    Iodine is required for the synthesis of thyroid hormones, which are crucial regulator of early brain development. The source of iodine in the fetus and the breastfed infant is maternal iodine, and adequate iodine intake in pregnant and breastfeeding is of major concern. Severe iodine deficiency can...... cause irreversible brain damage, whereas the consequences of mild to moderate iodine deficiency are less clear. Denmark was previously iodine deficient with regional differences (mild iodine deficiency in East Denmark and moderate iodine deficiency in West Denmark), and also pregnant and breastfeeding...... women suffered from iodine deficiency. A mandatory iodine fortification of household salt and salt used for commercial production of bread was introduced in Denmark in the year 2000. The PhD thesis investigates intake of iodine supplements and urinary iodine status in Danish pregnant and breastfeeding...

  4. The speciation of iodine in the environment

    Bulman, R.A.

    1986-01-01

    The speciation of iodine in the environment is discussed under the following topics: (i) sea surface to atmosphere, (ii) chemistry in bulk seawater, (iii) iodine in rocks, (iv) iodine in soils, (v) iodine in plants and (vi) iodine in solidified wastes. (author)

  5. Fractional release of short-lived noble gases and iodine from HTGR fuel compact containing a fraction of coated fuel particles with through-coating defects

    Ogawa, Toru; Fukuda, Kosaku; Kobayashi, Fumiaki; Kikuchi, Teruo; Tobita, Tsutomu; Kashimura, Satoru; Kikuchi, Hironobu; Yamamoto, Katsumune.

    1986-10-01

    Fractional release (R/B) data of short-lived noble gases and iodine from sweep-gas irradiated HTGR fuel compacts were analyzed. Empirical formulas to predict R/B of 88 Kr as a function of temperature and fraction through-coating defects, and to calculate ratios of R/B's of other shortlived gases to that of 88 Kr were proposed. A method to predict R/B of iodine was also proposed. As for 131 I, a fission product of major safety concern, (R/B) I 131 ≅ (R/B) Xe 133 was predicted. Applying those methods, R/B from OGL-1 fuel element (5th and 6th) was predicted to show a good agreement with observation. (author)

  6. Long-term remission in BCR/ABL-positive AML-M6 patient treated with Imatinib Mesylate.

    Pompetti, Franca; Spadano, Antonio; Sau, Antonella; Mennucci, Antonio; Russo, Rosa; Catinella, Virginia; Franchi, Paolo Guanciali; Calabrese, Giuseppe; Palka, Giandomenico; Fioritoni, Giuseppe; Iacone, Antonio

    2007-04-01

    BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/die) and within 4 months achieved a cytogenetic and molecular complete response. After more than 4 years of continuous Imatinib therapy, nested RT-PCR for BCR/ABL is persistently negative. The case reported shows that the response obtained with Imatinib Mesylate in BCR/ABL-positive AML may be long lasting, offering a chance of successful treatment for this poor prognosis group of patients.

  7. Disposal of Iodine-129

    Morgan, M.T.; Moore, J.G.; Devaney, H.E.; Rogers, G.C.; Williams, C.; Newman, E.

    1978-01-01

    One of the problems to be solved in the nuclear waste management field is the disposal of radioactive iodine-129, which is one of the more volatile and long-lived fission products. Studies have shown that fission products can be fixed in concrete for permanent disposal. Current studies have demonstrated that practical cementitious grouts may contain up to 18% iodine as barium iodate. The waste disposal criterion is based on the fact that harmful effects to present or future generations can be avoided by isolation and/or dilution. Long-term isolation is effective in deep, dry repositories; however, since penetration by water is possible, although unlikely, release was calculated based on leach rates into water. Further considerations have indicated that sea disposal on or in the ocean floor may be a more acceptable alternative

  8. Atomic iodine laser

    Fisk, G.A.; Gusinow, M.A.; Hays, A.K.; Padrick, T.D.; Palmer, R.E.; Rice, J.K.; Truby, F.K.; Riley, M.E.

    1978-05-01

    The atomic iodine photodissociation laser has been under intensive study for a number of years. The physics associated with this system is now well understood and it is possible to produce a 0.1 nsec (or longer) near-diffraction-limited laser pulse which can be amplified with negligible temporal distortion and little spatial deformation. The output of either a saturated or unsaturated amplifier consists of a high-fidelity near-diffraction-limited, energetic laser pulse. The report is divided into three chapters. Chapter 1 is a survey of the important areas affecting efficient laser operation and summarizes the findings of Chap. 2. Chapter 2 presents detailed discussions and evaluations pertinent to pumps, chemical regeneration, and other elements in the overall laser system. Chapter 3 briefly discusses those areas that require further work and the nature of the work required to complete the full-scale evaluation of the applicability of the iodine photodissociation laser to the inertial confinement program

  9. Hyperthyroidism and radioactive iodine

    Corstens, F.H.M.

    1980-01-01

    The study details the results of treatment of patients with hyperthyroidism using a combination of fractionated low doses radioactive iodine and anthithyroid drug therapy. The patients studied were treated according to this regimen after August 1968 and all reached euthyroidism before March 1979. None of the patients had been treated with radioactive iodine prior to the start of the protocol. A subgroup of the patients had received an unsuccessfull course with antithyroid drug therapy and, or, surgical therapy before the start of the protocol. Patients who had never been treated for hyperthyroidism were given antithyroid drug therapy for at least 6 months in an attempt to reach euthryroidism without the use of 131 I therapy. Therefore, all patients had experienced a course of unsuccessfull therapy prior to the start of the treatment protocol using combined fractionated low doses of 131 I and antithyroid drug therapy. (Auth.)

  10. Simultaneous quantification of iodine and high valent metals via ICP-MS under acidic conditions in complex matrices.

    Brix, Kristina; Hein, Christina; Sander, Jonas Michael; Kautenburger, Ralf

    2017-05-15

    The determination of iodine as a main fission product (especially the isotopes I-129 and I-131) of stored HLW in a disposal beside its distribution as a natural ingredient of many different products like milk, food and seawater is a matter of particular interest. The simultaneous ICP-MS determination of iodine as iodide together with other elements (especially higher valent metal ions) relevant for HLW is analytically very problematic. A reliable ICP-MS quantification of iodide must be performed at neutral or alkaline conditions in contrast to the analysis of metal ions which are determined in acidic pH ranges. Herein, we present a method to solve this problem by changing the iodine speciation resulting in an ICP-MS determination of iodide as iodate. The oxidation from iodide to iodate with sodium hypochlorite at room temperature is a fast and convenient method with flexible reaction time, from one hour up to three days, thus eliminating the disadvantages of quantifying iodine species via ICP-MS. In the analysed concentration range of iodine (0.1-100µgL -1 ) we obtain likely quantitative recovery rates for iodine between 91% and 102% as well as relatively low RSD values (0.3-4.0%). As an additional result, it is possible to measure different other element species in parallel together with the generated iodate, even high valent metals (europium and uranium beside caesium) at recovery rates in the same order of magnitude (93-104%). In addition, the oxidation process operates above pH 7 thus offering a wide pH range for sample preparation. Even analytes in complex matrices, like 5M saline (NaCl) solution or artificial cement pore water (ACW) can be quantified with this robust sample preparation method. Copyright © 2017 Elsevier B.V. All rights reserved.

  11. Iodine immobilization in apatites

    Audubert, F.; Lartigue, J.E.

    2000-01-01

    In the context of a scientific program on long-lived radionuclide conditioning, a matrix for iodine 129 immobilization has been studied. A lead vanado-phosphate apatite was prepared from the melt of lead vanado-phosphate Pb 3 (VO 4 ) 1.6 (PO 4 ) 0.4 and lead iodide PbI 2 in stoichiometric proportions by calcination at 700 deg. C during 3 hours. Natural sintering of this apatite is not possible because the product decomposition occurs at 400 deg. C. Reactive sintering is the solution. The principle depends on the coating of lead iodide with lead vanado-phosphate. Lead vanado-phosphate coating is used as iodo-apatite reactant and as dense covering to confine iodine during synthesis. So the best condition to immobilize iodine during iodo-apatite synthesis is a reactive sintering at 700 deg. C under 25 MPa. We obtained an iodo-apatite surrounded with dense lead vanadate. Leaching behaviour of the matrix synthesized by solid-solid reaction is under progress in order to determine chemical durability, basic mechanisms of the iodo-apatite alteration and kinetic rate law. Iodo-apatite dissolution rates were pH and temperature dependent. We obtained a rate of 2.5 10 -3 g.m -2 .d -1 at 90 deg. C in initially de-ionised water. (authors)

  12. Separation and retention of iodine

    Thomas, T.R.

    1976-01-01

    Caustic and mercuric nitrate scrubbers have been used for iodine recovery from process offgas, but they exhibit low decontamination factors for organic iodide removal and produce liquid wastes that are unsuitable for final storage. The Iodox process gives high decontamination factors for both organic iodides and elemental iodine. The liquid waste can be evaporated to a solid or concentrated and fixed in cement. Efficient separation and retention of gaseous iodine species can be obtained with silver-loaded adsorbents. The waste is a dry solid easily handled and stored. Adsorbents containing cheaper metals appear to have lower iodine-loading capacities and may be unsuitable for bulk iodine removal from process offgas because of the large amounts of solid waste that would be generated. A potential method for regenerationg and recycling silver-loaded adsorbents is being evaluated. In conjunction with the regeneration, lead-exchanged zeolite is used as a secondary adsorbent for the final fixation and storage of the iodine

  13. Iodine-131 dose dependent gene expression in thyroid cancers and corresponding normal tissues following the Chernobyl accident.

    Michael Abend

    Full Text Available The strong and consistent relationship between irradiation at a young age and subsequent thyroid cancer provides an excellent model for studying radiation carcinogenesis in humans. We thus evaluated differential gene expression in thyroid tissue in relation to iodine-131 (I-131 doses received from the Chernobyl accident. Sixty three of 104 papillary thyroid cancers diagnosed between 1998 and 2008 in the Ukrainian-American cohort with individual I-131 thyroid dose estimates had paired RNA specimens from fresh frozen tumor (T and normal (N tissue provided by the Chernobyl Tissue Bank and satisfied quality control criteria. We first hybridized 32 randomly allocated RNA specimen pairs (T/N on 64 whole genome microarrays (Agilent, 4×44 K. Associations of differential gene expression (log(2(T/N with dose were assessed using Kruskall-Wallis and trend tests in linear mixed regression models. While none of the genes withstood correction for the false discovery rate, we selected 75 genes with a priori evidence or P kruskall/P trend <0.0005 for validation by qRT-PCR on the remaining 31 RNA specimen pairs (T/N. The qRT-PCR data were analyzed using linear mixed regression models that included radiation dose as a categorical or ordinal variable. Eleven of 75 qRT-PCR assayed genes (ACVR2A, AJAP1, CA12, CDK12, FAM38A, GALNT7, LMO3, MTA1, SLC19A1, SLC43A3, ZNF493 were confirmed to have a statistically significant differential dose-expression relationship. Our study is among the first to provide direct human data on long term differential gene expression in relation to individual I-131 doses and to identify a set of genes potentially important in radiation carcinogenesis.

  14. Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma; Obstrucao de vias lacrimais associada ao tratamento radioiodoterapico de carcinoma de tireoide

    Fonseca, Fabricio Lopes da; Lunardelli, Patricia; Matayoshi, Suzana, E-mail: suzana.matayoshi@gmail.com [Setor de Plastica Ocular, Divisao de Clinica Oftalmologica, Universidade de Sao Paulo (HC/FM/USP), Sao Paulo (SP) (Brazil)

    2012-03-15

    Purpose: To report the finding of nasolacrimal drainage system obstruction associated with radio iodine therapy and to review clinical data and the surgical treatment outcome of this rare complication. Methods: We retrospectively analyzed ophthalmological data of patients with history of thyroid carcinoma that underwent radioactive iodine I-131 therapy and were referred to lacrimal surgery. Results: 17 patients with thyroid cancer treated with thyroidectomy and radioactive iodine I-131 therapy presented symptomatic nasolacrimal duct obstruction after 13.2 months following cancer treatment. 11 patients presented bilateral epiphora, 8 had lacrimal sac mucocele. Age range was 30 to 80 years, 10 patients had less than or equal to 49 years. The mean cumulative dose of radioiodine was 571mCi (range: 200-1200 mCi). Nasal obstruction symptoms and increased salivary glands were also present in 53% of patients. All subjects underwent dacryocystorhinostomy. Dilation of the lacrimal sac and increased intraoperative bleeding was also observed in 3 younger patients. Complete epiphora and dacryocystitis resolution after surgery occurred in 82.4%, and partial in 17.6% (3 patients that still presented unilateral relapse after correction of bilateral obstruction). Mean follow-up was 6 months (range: 2-24 months). Conclusions: Cumulative high dose of radioiodine, nasal and salivary gland dysfunction are associated with lacrimal drainage obstruction. We observed a great percentage of younger patients presenting dacryocystitis when compared to the idiopathic dacryostenosis. Radioactive iodine uptake by nasolacrimal duct mucosa with subsequent inflammation, edema and fibrosis seems to have a relationship to lacrimal duct obstruction. The knowledge of this complication is important for the study and proper management of these patients (author)

  15. Immobilization of iodine in concrete

    Clark, W.E.; Thompson, C.T.

    1977-01-01

    A method for immobilizing fission product radioactive iodine recovered from irradiated nuclear fuel comprises combining material comprising water, Portland cement and about 3 to 20 wt percent iodine as Ba(IO 3 ) 2 to provide a fluid mixture and allowing the fluid mixture to harden, said Ba(IO 3 ) 2 comprising said radioactive iodine. An article for solid waste disposal comprises concrete prepared by this method. 10 claims, 2 figures

  16. Iodine neutron capture therapy

    Ahmed, Kazi Fariduddin

    A new technique, Iodine Neutron Capture Therapy (INCT) is proposed to treat hyperthyroidism in people. Present thyroid therapies, surgical removal and 131I treatment, result in hypothyroidism and, for 131I, involve protracted treatment times and excessive whole-body radiation doses. The new technique involves using a low energy neutron beam to convert a fraction of the natural iodine stored in the thyroid to radioactive 128I, which has a 24-minute half-life and decays by emitting 2.12-MeV beta particles. The beta particles are absorbed in and damage some thyroid tissue cells and consequently reduce the production and release of thyroid hormones to the blood stream. Treatment times and whole-body radiation doses are thus reduced substantially. This dissertation addresses the first of the several steps needed to obtain medical profession acceptance and regulatory approval to implement this therapy. As with other such programs, initial feasibility is established by performing experiments on suitable small mammals. Laboratory rats were used and their thyroids were exposed to the beta particles coming from small encapsulated amounts of 128I. Masses of 89.0 mg reagent-grade elemental iodine crystals have been activated in the ISU AGN-201 reactor to provide 0.033 mBq of 128I. This activity delivers 0.2 Gy to the thyroid gland of 300-g male rats having fresh thyroid tissue masses of ˜20 mg. Larger iodine masses are used to provide greater doses. The activated iodine is encapsulated to form a thin (0.16 cm 2/mg) patch that is then applied directly to the surgically exposed thyroid of an anesthetized rat. Direct neutron irradiation of a rat's thyroid was not possible due to its small size. Direct in-vivo exposure of the thyroid of the rat to the emitted radiation from 128I is allowed to continue for 2.5 hours (6 half-lives). Pre- and post-exposure blood samples are taken to quantify thyroid hormone levels. The serum T4 concentration is measured by radioimmunoassay at

  17. Chemical generation of iodine atoms

    Hewett, Kevin B. [Directed Energy Directorate, Air Force Research Laboratory, 3550 Aberdeen Avenue SE, Kirtland AFB, NM 87117-5776 (United States)]. E-mail: kevin.hewett@kirtland.af.mil; Hager, Gordon D. [Directed Energy Directorate, Air Force Research Laboratory, 3550 Aberdeen Avenue SE, Kirtland AFB, NM 87117-5776 (United States); Crowell, Peter G. [Northrup Grumman Information Technology, Science and Technology Operating Unit, Advanced Technology Division, P.O. Box 9377, Albuquerque, NM 87119-9377 (United States)

    2005-01-10

    The chemical generation of atomic iodine using a chemical combustor to generate the atomic fluorine intermediate, from the reaction of F{sub 2} + H{sub 2}, followed by the production of atomic iodine, from the reaction of F + HI, was investigated. The maximum conversion efficiency of HI into atomic iodine was observed to be approximately 75%, which is in good agreement with the theoretical model. The conversion efficiency is limited by the formation of iodine monofluoride at the walls of the combustor where the gas phase temperature is insufficient to dissociate the IF.

  18. Iodine removal from a gas phase

    Vikis, A. Ch.

    1982-01-01

    Iodine, e.g. radioactive iodine, present as one or more organic iodides, optionally with elemental iodine, in a gas phase (e.g. air) are removed by photochemically decomposing the organic iodides to elemental iodine, reacting the iodine produced, and any initially present with excess ozone, preferably photochemically produced in situ in the gas phase to produce solid iodine oxides, and removing the solid oxides from the gas phase. (author)

  19. Iodine removal from a gas phase

    Vikis, A.C.

    1984-01-01

    Iodine, e.g. radioactive iodine, present as one or more organic iodides, optionally with elemental iodine, in a gas phase (e.g. air) are removed by photochemically decomposing the organic iodides to elemental iodine, reacting the iodine produced, and any initially present with excess ozone, preferably photochemically produced in situ in the gas phase to produce solid iodine oxides, and removing the solid oxides from the gas phase

  20. The Status of Iodine Nutrition and Iodine Deficiency Disorders ...

    Background: Iodine deficiency disorders are serious public health problems in Ethiopia. The aim of this study was to measure the prevalence and severity of iodine deficiency disorders among school children in Metekel Zone. Methods: A cross-sectional school based descriptive study was conducted between February 2011 ...

  1. Marking with radioactive iodine of a plasma substitute and preliminary essays of his kinetic behaviour in rats; Marcacao com radioiodo de um sucedaneo do plasma e ensaios preliminares de seu comportamento cinetico em ratos

    Cova, Wilma Guimaraes

    1973-07-01

    A blood plasma substitute (Haem accel - PGO), which has as a base a degraded and polymerized gelatin, was labelled with radioactive iodine (I-131) and preliminary essays of its kinetic behavior was done. We have used the labelling method of McFarlaner. The results obtained - radiochemical yield and purity - were favorable. The kinetic behaviour the residual radioactivity studied by measuring the residual radioactivity of the body and excreta in groups of male Wistar rats for a maximum period of 150 hours. These results have shown and excellent correlation for a two components exponential function's adjustment, suggesting therefore a bi compartmental mathematical model. (author)

  2. Marking with radioactive iodine of a plasma substitute and preliminary essays of his kinetic behaviour in rats; Marcacao com radioiodo de um sucedaneo do plasma e ensaios preliminares de seu comportamento cinetico em ratos

    Cova, Wilma Guimaraes

    1973-07-01

    A blood plasma substitute (Haem accel - PGO), which has as a base a degraded and polymerized gelatin, was labelled with radioactive iodine (I-131) and preliminary essays of its kinetic behavior was done. We have used the labelling method of McFarlaner. The results obtained - radiochemical yield and purity - were favorable. The kinetic behaviour the residual radioactivity studied by measuring the residual radioactivity of the body and excreta in groups of male Wistar rats for a maximum period of 150 hours. These results have shown and excellent correlation for a two components exponential function's adjustment, suggesting therefore a bi compartmental mathematical model. (author)

  3. Modelling the chemistry of iodine

    Paquette, J.

    1989-01-01

    We have assembled a kinetic model, based on elementary chemical reactions, that describes the chemical behaviour of iodine in aqueous solution as a function of time and various parameters such as pH, concentration and radiation field. The model is conceptually divided into six section: aqueous iodine chemistry, aqueous organic iodide chemistry, water radiolysis, radiolysis of iodine solutions, radiolysis of organic iodide solutions and mass transfer. The model indicates that, in the absence of a radiation field, the rate of production of volatile iodine species is controlled by the rate of oxidation of the iodide ion. The volatile iodine species are dominated by organic iodides if organic impurities are present. The single most important parameter controlling iodine volatility is the pH of the solution; high pH values tend to minimize iodine volatility. In the presence of a radiation field, the volatility of iodine is controlled by the radiation-induced oxidation of the iodide ion. Again, iodine volatility is dominated by organic iodides if organic impurities are present. High pH values minimize iodine volatility. A sensitivity analysis has been performed on some sections of the model to identify reactions to which the volatility of iodine is most sensitive. In the absence of a radiation field, the volatility is most sensitive, first, to the rate of oxidation of the iodide ion, and, second, to the rate of mass transfer of volatile species between the aqueous and the gaseous phases. This approach should be useful in identifying reactions for which accurate rate constants are required and in decreasing the complexity of the model. 37 refs

  4. Volatilization of iodine from vegetation

    Amiro, B D; Johnston, F L [Atomic Energy of Canada Ltd., Pinawa, MB (Canada). Whiteshell Nuclear Research Establishment

    1989-01-01

    Gaseous emissions of iodine were measured from bean plant foliage. A gamma-emitting iodine tracer, Na {sup 125}I, was taken up by the plants from a hydroponic growth medium and released to a cuvette atmosphere. The dynamics of the flux were studied using a flow-through gamma detector. The relationship between leaf radioactive tracer activity and growth-medium activity was linear, as was the relationship between the iodine flux and both leaf and growth-medium activity. Iodine flux and leaf conductance to water responded similarly to changes in light levels, suggesting that the stomata may partially control the flux. The flux was inhibited by aeration of the hydroponic growth media, and we postulate that methylation causes the iodine flux. Iodine emissions from living vegetation probably contribute < 0.1% to the stable iodine concentration in the atmosphere above terrestrial areas. However, this pathway may be a direct route for radioactive iodine transport from contaminated soils to the atmosphere. (author).

  5. Iodine metabolism and food needs

    Mornex, R.

    1992-01-01

    Iodine is an element that is necessary for the growth and mental development of a child and for the maintenance of the activity of all cells at all ages. In this article, the author recalls the iodine sources, its metabolism and the food needs and contributions

  6. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

    Grunberg, Steven M; Rolski, Janusz; Strausz, Janos

    2009-01-01

    in the control group. The most common serious adverse events were neutropenia (n=5 [3%] in the control group, n=3 [1%] in the single-dose oral casopitant mesylate group, and n=11 [4%] in the 3-day intravenous plus oral casopitant mesylate group), febrile neutropenia (n=1 [

  7. Spectrophotometric Determination of Gemifloxacin Mesylate in Pharmaceutical Formulations Through Ion-Pair Complex Formation

    Marothu Vamsi Krishna

    2008-01-01

    Full Text Available Four simple and sensitive ion-pairing spectrophotometric methods have been described for the assay of gemifloxacin mesylate (GFX either in pure form or in pharmaceutical formulations. The developed methods involve formation of colored chloroform extractable ion-pair complexes of the drug with safranin O (SFN O and methylene blue (MB in basic medium; Napthol blue 12BR (NB 12BR and azocaramine G (AG in acidic medium. The extracted complexes showed absorbance maxima at 525, 650, 620 and 540 nm for SFN O, MB, NB 12BR and AG, respectively.Beer's law is obeyed in the concentration ranges 3-15, 4-20, 2-10 and 2-10 μg/mL with molar absorptivity of 2.81 × 104, 2.20 x 104, 4.02 × 104 and 4.15 × 104 L mole−1 cm−1 and relative standard deviation of 0.077, 0.104, 0.080 and 0.103% for SFN O, MB, NB 12BR and AG, respectively. These methods have been successfully applied for the assay of drug in pharmaceutical formulations. No interference was observed from common pharmaceutical adjuvants. Results of analysis were validated statistically and through recovery studies.

  8. Spectrophotometric Determination of Gemifloxacin Mesylate, Moxifloxacin Hydrochloride, and Enrofloxacin in Pharmaceutical Formulations Using Acid Dyes

    Ayman A. Gouda

    2014-01-01

    Full Text Available Simple, rapid, and extractive spectrophotometric methods were developed for the determination of some fluoroquinolones antibiotics: gemifloxacin mesylate (GMF, moxifloxacin hydrochloride (MXF, and enrofloxacin (ENF in pure forms and pharmaceutical formulations. These methods are based on the formation of ion-pair complexes between the basic drugs and acid dyes, namely, bromocresol green (BCG, bromocresol purple (BCP, bromophenol blue (BPB, bromothymol blue (BTB, and methyl orange (MO in acidic buffer solutions. The formed complexes were extracted with chloroform and measured at 420, 408, 416, 415, and 422 nm for BCG, BCP, BPB, BTB, and MO, respectively, for GMF; at 410, 415, 416, and 420 nm for BCP, BTB, BPB, and MO, respectively, for MXF; and at 419 and 414 nm for BCG and BTB, respectively, in case of ENF. The analytical parameters and their effects are investigated. Beer’s law was obeyed in the ranges 1.0–30, 1.0–20, and 2.0–24 μg mL−1 for GMF, MXF, and ENF, respectively. The proposed methods have been applied successfully for the analysis of the studied drugs in pure forms and pharmaceutical formulations. Statistical comparison of the results with the reference methods showed excellent agreement and indicated no significant difference in accuracy and precision.

  9. Effect of gamma-irradiation on biodegradable microspheres loaded with rasagiline mesylate

    Fernandez, Marcos; Barcia, Emilia; Negro, Sofia

    2016-01-01

    In the present study, the influence of gamma-irradiation was evaluated on the physicochemical characteristics and in vitro release of rasagiline mesylate (RM), a selective MAO-B inhibitor used in Parkinson's disease, from poly(D,L-lactide-co-glycolide) (PLGA) microspheres. Microspheres were prepared using PLGA 50:50 by the solvent evaporation technique (O/W emulsion). Microspheres were sterilized by gamma-irradiation and their influence was assessed by scanning electron microscopy (SEM), laser light diffraction, differential scanning calorimetry (DSC), X-ray diffraction (XRD), gel permeation chromatography (GPC), encapsulation efficiency (EE) and in vitro drug release. Gamma-irradiation of RM-loaded microspheres did not affect EE, DSC and XRD patterns. After gamma-irradiation, changes on the surface were observed by SEM, but no significant difference in mean particle size was observed. GPC measurements showed a decrease in molecular weight of the polymer after five days of in vitro release. The similarity factor value between irradiated and non-irradiates microspheres was <50, indicating the non-similarity of the release profiles. The sterilization technique had an effect on the integrity of polymeric system, significantly affecting in vitro release of RM from PLGA microspheres. Therefore, from our results we conclude that gamma-irradiation is not a suitable sterilization procedure for this formulation

  10. Quantitative determination of pefloxacin mesylate by residual-base neutralisation method

    HULIKALCHANDRA SHEKAR PRAMEELA

    2004-05-01

    Full Text Available This work describes two procedures based on residual base determination for the quantification of pefloxacin mesylate (PFM in bulk drug and in pharmaceutical products. In the first method involving titrimetry, the drug solution is treated with a measured excess of sodium hydroxide followed by back titration of the residual base with hydrochloric acid using a phenol red-bromothymol blue mixed indicator. The second spectrophotometrie method involves treatment of a fixed amount of sodium hydroxide – phenol red mixture with varying amounts of the drug, and measuring the decrease in the absorbance of the dye at 560 nm. In the titrimetric method, a reaction stoichiometry of 1:1 was found in the quantification range of 4–20 mg of drug. The spectrophotometric method allows the determination of PFM in the 5–40 mg ml-1 range. The molar absorptivity is 5.91¤103 l mol-1 cm-1 and the Sandell sensitivity is 56.37 ng cm-2. The methods were applied successfully to the determination of PFM in pharmaceutical preparations.

  11. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

    Weigel, Marion T; Maass, Nicolai; Mundhenke, Christoph; Dahmke, Linda; Schem, Christian; Bauerschlag, Dirk O; Weber, Katrin; Niehoff, Peter; Bauer, Maret; Strauss, Alexander; Jonat, Walter

    2010-01-01

    Breast cancer treatment is based on a combination of adjuvant chemotherapy followed by radiotherapy effecting intracellular signal transduction. With the tyrosine kinase inhibitors new targeted drugs are available. Imatinib mesylate is a selective inhibitor of bcr-abl, PRGFR alpha, beta and c-kit. The purpose of this study was to determine whether Imatinib has an influence on the effectiveness of radiotherapy in breast cancer cell lines and if a combination of imatinib with standard chemotherapy could lead to increased cytoreduction. Colony-forming tests of MCF 7 and MDA MB 231 were used to study differences in cell proliferation under incubation with imatinib and radiation. Changes in expression and phosphorylation of target receptors were detected using western blot. Cell proliferation, migration and apoptosis assays were performed combining imatinib with doxorubicin. The combination of imatinib and radiotherapy showed a significantly stronger inhibition of cell proliferation compared to single radiotherapy. Differences in PDGFR expression could not be detected, but receptor phosphorylation was significantly inhibited when treated with imatinib. Combination of imatinib with standard chemotherapy lead to an additive effect on cell growth inhibition compared to single treatment. Imatinib treatment combined with radiotherapy leads in breast cancer cell lines to a significant benefit which might be influenced through inhibition of PDGFR phosphorylation. Combining imatinib with chemotherapy enhances cytoreductive effects. Further in vivo studies are needed to evaluate the benefit of Imatinib in combination with radiotherapy and chemotherapy on the treatment of breast cancer

  12. Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor

    Kim, Hawk; Chang, Heung-Moon; Ryu, Min-Hee; Kim, Tae-Won; Sohn, Hee-Jung; Kim, So-Eun; Kang, Hye-Jin; Park, Sarah; Lee, Jung-Shin

    2005-01-01

    We report a gastrointestinal stromal tumor (GIST) patient with male gynecomastia and testicular hydrocele after treatment with imatinib mesylate. A 42 yr-old male patient presented for management of hepatic masses. Two years earlier, he had undergone a small bowel resection to remove an intraabdominal mass later shown to be a GIST, followed by adjuvant radiation therapy. At presentation, CT scan revealed multiple hepatic masses, which were compatible with metastatic GIST, and he was prescribed imatinib 400 mg/day. During treatment, he experienced painful enlargement of the left breast and scrotal swelling. Three months after cessation of imatinib treatment, the tumors recurred, and, upon recommencing imatinib, he experienced painful enlargement of the right breast and scrotal swelling. He was diagnosed with male gynecomastia caused by decreased testosterone and non-communicative testicular hydrocele. He was given androgen support and a hydrocelectomy, which improved his gynecomastia. The mechanism by which imatinib induces gynecomastia and hydrocele is thought to be associated with an inhibition of c-KIT and platelet-derive growth factor. This is the first report, to our knowledge, describing concurrent male gynecomastia and testicular hydrocele after imatinib treatment of a patient with GIST. PMID:15953881

  13. Enhanced Silver Nanoparticle Chemiluminescence Method for the Determination of Gemifloxacin Mesylate using Sequential Injection Analysis

    Alarfaj, N.A.; Aly, F.A.; Tamimi, A.A.

    2013-01-01

    A sequential injection analysis (SIA) with chemiluminescence detection has been proposed for the determination of the antibiotic gemifloxacin mesylate (GFX). The developed method is based on the enhancement effect of silver nanoparticles (Ag NPs) on the chemiluminescence (CL) signal of luminol-potassium ferricyanide reaction in alkaline medium. The introduction of gemifloxacin in this system produced a significant decrease in the CL intensity in presence of (Ag NPs). The optimum conditions for CL emission were investigated. Linear relationship between the decrease in CL intensity and concentration was obtained in the range 0.01-1000 ng mL-1, (r = 0.9997) with detection limit of 2.0 pg mL-1 and quantification limit of 0.01 pg mL-1. The relative standard deviation was 1.3 %. The proposed method was employed for the determination of gemifloxacin in bulk drug, in its pharmaceutical dosage forms and biological fluids such as human serum and urine. The interference of some common additive compounds such as glucose, lactose, starch, talc and magnesium stearate was investigated, and no interference was found from these excipients. The obtained SIA results were statistically compared with those obtained from a reported method and did not show any significant difference at confidence level 95%. (author)

  14. Breastfeeding and maternal and infant iodine nutrition.

    Azizi, Fereidoun; Smyth, Peter

    2009-05-01

    The aim of this review is to explore information available regarding iodine secretion in milk, both mothers and infants iodine nutrition during breastfeeding and to make recommendations for appropriate iodine supplementation during lactation. MEDLINE was queried for studies between 1960 and 2007 that included lactation and breastfeeding with iodine and iodine deficiency. Studies were selected if they studied (i) Secretion of iodine in breast milk; (ii) breastfeeding and iodine nutrition; (iii) factors affecting maternal iodine metabolism and (iv) recommendations for iodine supplementation during breastfeeding. Thirty-six articles met the selection criteria. The iodine content of breast milk varies with dietary iodine intake, being lowest in areas of iodine deficiency with high prevalence of goitre. Milk iodine levels are correspondingly higher when programs of iodine prophylaxis such as salt iodization or administration of iodized oil have been introduced. The small iodine pool of the neonatal thyroid turns over very rapidly and is highly sensitive to variations in dietary iodine intake. Expression of the sodium iodide symporter is up-regulated in the lactating mammary gland which results in preferential uptake of iodide. In areas of iodine sufficiency breast milk iodine concentration should be in the range of 100-150 microg/dl. Studies from France, Germany, Belgium, Sweden, Spain, Italy, Denmark, Thailand and Zaire have shown breast milk concentrations of nutrition. The current WHO/ICCIDD/UNICEF recommendation for daily iodine intake (250 microg for lactating mothers) has been selected to ensure that iodine deficiency dose not occur in the postpartum period and that the iodine content of the milk is sufficient for the infant's iodine requirement.

  15. Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know.

    Ali, Mohammad Javed

    2016-01-01

    The aims of the current review are to summarize the etiopathogenesis, symptomatology, management, complications, and outcomes of iodine-131-induced nasolacrimal duct obstructions, to propose a screening protocol and elucidate the potential avenues of future research. The authors performed an electronic database (PubMed, MEDLINE, EMBASE, and Cochrane Library) search of all articles published in English on nasolacrimal duct obstructions following radioiodine therapy. These articles were reviewed along with their relevant cross references. Data reviewed included demographics, presentations, investigations, management, complications, and outcomes. In addition, based on relevant unanswered questions and current lacunae in literature, potential avenues for further research have been elucidated. The frequency of nasolacrimal duct obstruction is reported to range from 2.2% to 18% following I-131 therapy. They are mostly bilateral and noted in patients who receive more than 150 mCi radioiodine. Exact etiopathogenesis is unknown but radiotoxicity to lacrimal sac and nasolacrimal duct is believed to be mediated through a sodium-iodine symporter protein. Although uncommon, it is important to increase awareness among treating physicians and patients receiving radioiodine therapy about the potential side effect of nasolacrimal duct obstruction. Imaging modalities are useful adjuncts in the diagnosis. Dacryocystorhinostomy is the most common modality of management with good outcomes. Nasolacrimal duct obstruction following radioiodine treatment is a distinct clinical entity. Increased awareness would facilitate timely diagnosis, management, and an enhanced quality of life for the patients.

  16. Experimental dosimetry and kinetics of radioactive tracers for human applications: example of therapeutic injection of Lipiodol labelled with Iodine 131

    Ahmed Mahidi, N.

    1992-10-01

    We have evaluated the radiation dose received by the liver and lungs for 10 patients with a hepatic carcinoma after surgical operation followed by a therapeutic dose of Lipiodol labelled with iodine 131. The cumulated activities have been obtained by using a calibrated gamma camera. Fixation and kinetics of the I 131 Lipiodol in normal and cancers livers have been measured with the determination of the effective and biological half-lives. The calculated doses are based on the MIRD method. Results confirm that Lipiodol fixation is important in the liver at J1 (about 74% of the injected activity). Its elimination is essentially urinary, pulmonary fixation remained low, the dose received by the healthy part of liver is acceptable. These values have been compared with those obtained by another method using a thermoluminescent dosimeter (LiF) installed on the skin over the liver. Comparison between results obtained by the 2 methods shows a good correlation

  17. Radiation dose to the thyroid due to incorporation of iodine isotopes: Age dependence and reliability of dose factors

    Henrichs, K.; Mueller-Brunecker, G.; Paretzke, H.G.

    1983-08-01

    This is the first time that dose factors are published in the literature, together with an assessment of their reliability with regard to the quantification of the dose received by the population in the Federal Republic of Germany due to incorporation if iodine isotopes, taking into account the given age distribution among the population. The calculation of dose factors is based on the latest dosimetric and metabolic models issued by the ICRP (ICRP-30), and the impact of the various parameters and their variability on the accuracy of dose factor determination is assessed. The procedure followed to calculate the dose due to incorporation on the basis of metabolic models (ICRP 1978 and ICRP 1979) is explained. The main data (such as half life, mean frequency per decay, mean energy in keV) are given for I-123, I-125, I-129, I-131, I-132, I-133, I-134, and I-135 (ICRP-30) and listed in tables. (orig./HP) [de

  18. Iodine removing means

    Takeshima, Masaki.

    1975-01-01

    Object: To employ exhaust gas from an incinerator to effect regeneration of an adsorbent such as active carbon which has adsorbed a radioactive gas such as iodine contained in the ventilating system exhaust gas of a boiling water reactor power plant. Structure: Radioactive exhaust gas such as iodine, xenon and krypton is led to an active carbon adsorbing means for removal through adsorption. When the adsorbing function of the active carbon adsorption means is reduced, the exhaust gas discharged from the incinerator is cooled down to 300 0 C and then caused to flow into the active carbon layer, and after depriving it of sulfur dioxide gas, oxides of nitrogen, daughter nuclides resulting from attenuation of radioactive gas and so forth, these being adsorbed by the carbon active layer, it is led again to the incinerator, whereby the radioactivity accompanying the regenerated gas is sealed as ash within the incinerator. Further, similarly accompanying fine active carbon particles and the like are utilized as a heat source for the incinerator. (Kamimura, M.)

  19. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131 KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

    Sultana, Asma; Garvey, Conall; Sutton, Robert; Neoptolemos, John P; Ghaneh, Paula; Shore, Susannah; Raraty, Michael GT; Vinjamuri, Sobhan; Evans, Jonathan E; Smith, Catrin Tudur; Lane, Steven; Chauhan, Seema; Bosonnet, Lorraine

    2009-01-01

    Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome. This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I 131 in pancreatic cancer (ISRCTN 16857581). Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route. The dose limiting toxicities within each group were determined. Patients were assessed for safety and efficacy and followed up until death. Between February 2003 and July 2005, 25 patients were enrolled. Nineteen patients were randomised, 9 to the intravenous and 10 to the intra-arterial arms. In the intra-arterial arm, dose limiting toxicity was seen in 2/6 (33%) patients at 50 mCi whereas in the intravenous arm, dose limiting toxicity was noted in 1/6 patients at 50 mCi, but did not occur at 75 mCi (0/3). The overall response rate was 6% (1/18). Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9 months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79). One patient was still alive at the time of this analysis. Dose limiting toxicity for KAb201 with I 131 by the intra-arterial route was 50 mCi, while dose limiting toxicity was not reached in the intravenous arm

  20. Effectiveness and risks of stable iodine prophylaxis

    Waight, P.J.

    1995-01-01

    The factors upon which the efficacy of stable iodine prophylaxis depends are reviewed, with particular reference to the dose of stable iodine, the timing of the dose, the influence of dietary iodine and the impact of the other prospective actions. The risks of stable iodine ingestion are estimated, and their application to the principle of Justification in outlined. (Author)

  1. Iodine in the environment revisited

    Christiansen, J.V.; Carlsen, L.

    1989-05-01

    The report gives an overview of the environmental cycle of iodine, especially focusing on the possible reactions being responsible for the retention of iodine in the terrestrial environment. During the last two decades evidence for the presence of iodine in soil as organically bound has been presented. The major part of inorganic iodine in the terrestrial environment will, under physical and chemical conditions normally prevailing, exist as iodide. No evidence for a direct reaction between iodide and organic material has been presented, whereas strong support for the engagement of microbial activity in the formation of organic iodine compounds in soil has been obtained. Incorporation of iodine in humic substances as a result of enzymatic catalysis, involving an enzyme of the perozidase group apperas reasonable. It is concluded that microbiological activity involving extracellular enzymes most probably is responsible for the possible retention of iodine in the terrestrial environment. It is suggested that these reactions in detail should be studied experimentally. (author) 3 tabs., 2 ills., 51 refs

  2. Therapeutic applications of radioactive 131iodine: Procedures and incidents with capsules

    Al Aamri, Marwa; Ravichandran, Ramamoorthy; Binukumar, John Pichy; Al Balushi, Naima

    2016-01-01

    Treatments for thyrotoxicosis and carcinoma thyroid are carried out by oral administration of radioactive iodine ( 131 I) in the form of liquid or capsules. The liquid form of 131 I has higher risk factors such as vapourization, spillage and need for management of higher activity wastes. Use of 131 I in capsule form simplify procedures of handling compared to liquid form of 131 I. The guidelines of safe handling and quality assurance aspects for therapeutic use 131 I are well outlined by International Atomic Energy Agency (IAEA) reports. A few unusual incidents with I-131 capsules encountered in the past need to be highlighted from health physics point of view. In Royal Hospital, Oman, I-131 is imported in capsules, and the total activity handled/year steadily increased over 10 years. Discrete activities range from 185 MBq (5 mCi) up to 7.4 GBq (200 mCi). In four incidents deviations in standard operational procedures were recorded. Nature of incidents is described as follows: (1) After assay of activity, the capsule was directly put in the lead container with missing of inner cap. (2) Patient poured water in the Perspex tube, when the capsule was handed over to her, making an emergency situation. (3) In 3 high activity capsules (2 nos 2.96 GBq, 1 no. 4.26 GBq), observed sticky behavior in capsule holder on the 2 nd day post receipt, which were in order on the 1 st day. (4) A capsule could not be swallowed by a patient, which was taken back from the mouth. Monitoring of patient later did not show residual ingested activity. The report documents some of the unusual incidents for information to other centers engaged in such radioactive administrations

  3. Iodine deficiency and nutrition in Scandinavia

    Manousou, Sofia; Dahl, Lisbeth; Heinsbaek Thuesen, Betina

    2017-01-01

    Iodine nutrition is a result of geological conditions, iodine fortification and monitoring strategies within a country together with the dietary habits of the population. This review summarizes the basis for the current iodine situation in the Scandinavian countries in order to identify gaps...... strategies have been used in Scandinavia to improve iodine nutrition. The major source of iodine is iodized salt in Sweden and from milk and dairy products in Norway. In Denmark, drinking water, milk, dairy products and iodized salt used in commercial production of bread are the important sources of iodine....... The current iodine status in Scandinavia is not optimal and action is ongoing to increase iodination in Denmark, where there is mild iodine deficiency in the general population. Data from all three countries indicate insufficient iodine nutrition during pregnancy and there is a need for data from children...

  4. Iodine excretion in school children in Copenhagen

    Rasmussen, Lone B.; Kirkegaard-Klitbo, Ditte Marie; Laurberg, Peter

    2016-01-01

    INTRODUCTION: Studies of dietary habits show a high iodine intake in children in Denmark. Iodine excretion in children has not previously been assessed. Iodine excretion in adults is below the recommended threshold, and it is therefore being discussed to increase the fortification level. The main...... objective of this study was to assess iodine excretion in children living in Copenhagen to establish whether a moderate increase in iodine fortification would lead to excess iodine intake in this group. METHODS: Children in first and fifth grade were recruited through schools in Copenhagen. In total, 244...... children de-ivered a urine sample. Urine samples were analysed for iodine and creatinine, and the results were expressed as urinary iodine concentration (UIC) and as estimated 24-h iodine excretion. Iodine excretion in children was also compared with that of adults living in the same area, investigated...

  5. Iodine isotopes and radiation safety

    Styro, B.; Nedvekajte, T.; Filistovich, V.

    1992-01-01

    Methods of concentration determination of stable and radioactive iodine isotopes in the Earth's different geospheres are described. Iodine isotopes concentration data, chemical forms and transformations as well as their exchange among separate geospheres of their global biochemical circulation (ocean, atmosphere, lithosphere and biosphere) are presented. Information on iodine isotopes as after-effects of nuclear installations accident (in particular, the Chernobyl accident) is generalized. The book is intended for scientists and practical workers in ecology and radioactivity protection and for a students of physics. 442 refs.; 82 figs.; 36 tabs

  6. "Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: An open-label non-randomized, uncontrolled clinical trial"

    Elmholdt, Tina Rask; Olesen, Anne Braae

    2011-01-01

    Background Nephrogenic systemic fibrosis is a disease affecting the connective tissue of the skin and internal organs in patients with renal failure. No effective treatments are available. Objectives To investigate if the tyrosine kinase inhibitor, imatinib mesylate was effective in patients...... Imatinib mesylate may be an effective drug in the treatment of skin fibrosis in moderate to severe NSF cases, even at reduced doses. We found a positive clinical effect on the skin, but no convincing improvement of the joint mobility. Only few patients could be recruited limiting the interpretation...

  7. Radiochemistry of iodine

    Kahn, M.; Kleinberg, J.

    1977-09-01

    The preparation of isotopes of the element, with selected procedures for its determination in or separation from various media is described along with the separating of iodine species from each other. Each part of the introductory section is referenced separately from the remainder of the monograph. For the preparative and analytical sections there is an extensive, indexed bibliography which was developed from the indexes of Volumes 19 to 30 inclusive (1965-1974) of Nuclear Science Abstracts (NSA). From these indexes the NSA abstracts of possible pertinent references were selected for examination and a choice was made of those references which were to be included in the bibliography. The bibliography has both primary and secondary references. Although the monograph does not cover hot atom chemistry, the kinetics of exchange reactions, decay schemes, or physiological applications, papers in these areas were examined as possible sources of useful preparative and analytical procedures. (JRD)

  8. Radiochemistry of iodine

    Kahn, M.; Kleinberg, J.

    1977-09-01

    The preparation of isotopes of the element, with selected procedures for its determination in or separation from various media is described along with the separating of iodine species from each other. Each part of the introductory section is referenced separately from the remainder of the monograph. For the preparative and analytical sections there is an extensive, indexed bibliography which was developed from the indexes of Volumes 19 to 30 inclusive (1965-1974) of Nuclear Science Abstracts (NSA). From these indexes the NSA abstracts of possible pertinent references were selected for examination and a choice was made of those references which were to be included in the bibliography. The bibliography has both primary and secondary references. Although the monograph does not cover hot atom chemistry, the kinetics of exchange reactions, decay schemes, or physiological applications, papers in these areas were examined as possible sources of useful preparative and analytical procedures

  9. Current iodinated contrast media

    Stacul, F.

    2001-01-01

    The number of scientific papers on iodinated contrast media is declining. Indeed, comparative trials between high-osmolality and low-osmolality agents largely showed the higher safety and tolerability of the latter, and this is no longer a matter of discussion. Only financial constraints could prevent a total conversion to low-osmolality agents. Research comparing low-osmolality (nonionic monomers, ionic dimer) and iso-osmolality contrast media (nonionic dimers) are still ongoing. Both classes of nonionic compounds proved safer than the ionic dimer. The relative merits of nonionic monomers and nonionic dimers are a matter for debate, and criteria for a selective use of different agents for different procedures could be discussed. (orig.)

  10. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.

    Basciani, Sabrina; Brama, Marina; Mariani, Stefania; De Luca, Gabriele; Arizzi, Mario; Vesci, Loredana; Pisano, Claudio; Dolci, Susanna; Spera, Giovanni; Gnessi, Lucio

    2005-03-01

    Leydig cell tumors are usually benign tumors of the male gonad. However, if the tumor is malignant, no effective treatments are currently available. Leydig cell tumors express platelet-derived growth factor (PDGF), kit ligand and their respective receptors, PDGFR and c-kit. We therefore evaluated the effects of imatinib mesylate (imatinib), a selective inhibitor of the c-kit and PDGFR tyrosine kinases, on the growth of rodent Leydig tumor cell lines in vivo and in vitro, and examined, in human Leydig cell tumor samples, the expression of activated PDGFR and c-kit and the mutations in exons of the c-kit gene commonly associated with solid tumors. Imatinib caused concentration-dependent decreases in the viability of Leydig tumor cell lines, which coincided with apoptosis and inhibition of proliferation and ligand-stimulated phosphorylation of c-kit and PDGFRs. Mice bearing s.c. allografts of a Leydig tumor cell line treated with imatinib p.o., had an almost complete inhibition of tumor growth, less tumor cell proliferation, increased apoptosis, and a lesser amount of tumor-associated mean vessel density compared with controls. No drug-resistant tumors appeared during imatinib treatment but tumors regrew after drug withdrawal. Human Leydig cell tumors showed an intense expression of the phosphorylated form of c-kit and a less intense expression of phosphorylated PDGFRs. No activating mutations in common regions of mutation of the c-kit gene were found. Our studies suggest that Leydig cell tumors might be a potential target for imatinib therapy.

  11. Reversal of soft-tissue local anesthesia with phentolamine mesylate in adolescents and adults.

    Hersh, Elliot V; Moore, Paul A; Papas, Athena S; Goodson, J Max; Navalta, Laura A; Rogy, Siegfried; Rutherford, Bruce; Yagiela, John A

    2008-08-01

    The authors conducted two multicenter, randomized, double-blinded, controlled Phase III clinical trials to study the efficacy and safety of phentolamine mesylate (PM) in shortening the duration and burden of soft-tissue anesthesia. The study involved 484 subjects who received one of four commercially available local anesthetic solutions containing vasoconstrictors for restorative or scaling procedures. On completion of the dental procedure, subjects randomly received a PM or a sham injection (an injection in which a needle does not penetrate the soft tissue) in the same site as the local anesthetic injection. The investigators measured the duration of soft-tissue anesthesia by using standardized lip- and tongue-tapping procedures every five minutes for five hours. They also evaluated functional measures and subject-perceived altered function, sensation, appearance and safety. Median recovery times in the lower lip and tongue for subjects in the PM group were 70 minutes and 60 minutes, respectively. Median recovery times in the lower lip and tongue for subjects in the sham group were 155 minutes and 125 minutes, respectively. Upper lip median recovery times were 50 minutes for subjects in the PM group and 133 minutes for subjects in the sham group. These differences were significant (P < .0001). Recovery from actual functional deficits and subject-perceived altered function, sensation and appearance also showed significant differences between the PM and the sham groups. PM was efficacious and safe in reducing the duration of local anesthetic- induced soft-tissue numbness and its associated functional deficits. Clinicians can use PM to accelerate reversal of soft-tissue anesthesia and the associated functional deficits.

  12. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.

    Tas, Cetin; Joyce, Jessica C; Nguyen, Hiep X; Eangoor, Padmanabhan; Knaack, Jennifer S; Banga, Ajay K; Prausnitz, Mark R

    2017-12-28

    Migraine is a widespread neurological disease with negative effects on quality of life and productivity. Moderate to severe acute migraine attacks can be treated with dihydroergotamine mesylate (DHE), an ergot derivative that is especially effective in non-responders to triptan derivatives. To overcome limitations of current DHE formulations in subcutaneous injection and nasal spray such as pain, adverse side effects and poor bioavailability, a new approach is needed for DHE delivery enabling painless self-administration, quick onset of action, and high bioavailability. In this study, we developed a dissolving microneedle patch (MNP) made of polyvinylpyrrolidone, due to its high aqueous solubility and solubility enhancement properties, using a MNP design previously shown to be painless and simple to administer. DHE-loaded MNPs were shown to have a content uniformity of 108±9% with sufficient mechanical strength for insertion to pig skin ex vivo and dissolution within 2min. In vivo pharmacokinetic studies were carried out on hairless rats, and DHE plasma levels were determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The area under curve (AUC) value after DHE delivery by MNP (1259±917ng/mL min) was not significantly different (p>0.05) as compared to subcutaneous injection, with a relative bioavailability of 97%. Also, appreciable plasma levels of DHE were seen within 5min for both delivery methods and t max value of MNPs (38±23min) showed no significant difference (p>0.05) compared to subcutaneous injection (24±13min). These results suggest that DHE-loaded MNPs have promise as an alternative DHE delivery method that can be painlessly self-administered with rapid onset and high bioavailability. Copyright © 2017 Elsevier B.V. All rights reserved.

  13. In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow

    P.B. Soares

    2013-01-01

    Full Text Available Imatinib mesylate (IM is used to treat chronic myeloid leukemia (CML because it selectively inhibits tyrosine kinase, which is a hallmark of CML oncogenesis. Recent studies have shown that IM inhibits the growth of several non-malignant hematopoietic and fibroblast cells from bone marrow (BM. The aim of the present study was to evaluate the effects of IM on stromal and hematopoietic progenitor cells, specifically in the colony-forming units of granulocyte/macrophage (CFU-GM, using BM cultures from 108 1.5- to 2-month-old healthy Swiss mice. The results showed that low concentrations of IM (1.25 µM reduced the growth of CFU-GM in clonogenic assays. In culture assays with stromal cells, fibroblast proliferation and α-SMA expression by immunocytochemistry analysis were also reduced in a concentration-dependent manner, with a survival rate of approximately 50% with a dose of 2.5 µM. Cell viability and morphology were analyzed using MTT and staining with acrydine orange/ethidium bromide. Most cells were found to be viable after treatment with 5 µM IM, although there was gradual growth inhibition of fibroblastic cells while the number of round cells (macrophage-like cells increased. At higher concentrations (15 µM, the majority of cells were apoptotic and cell growth ceased completely. Oil red staining revealed the presence of adipocytes only in untreated cells (control. Cell cycle analysis of stromal cells by flow cytometry showed a blockade at the G0/G1 phases in groups treated with 5-15 µM. These results suggest that IM differentially inhibits the survival of different types of BM cells since toxic effects were achieved.

  14. Immobilization of iodine in concrete

    Clark, Walter E.; Thompson, Clarence T.

    1977-04-12

    A method for immobilizing fission product radioactive iodine recovered from irradiated nuclear fuel comprises combining material comprising water, Portland cement and about 3-20 wt. % iodine as Ba(IO.sub.3).sub.2 to provide a fluid mixture and allowing the fluid mixture to harden, said Ba(IO.sub.3).sub.2 comprising said radioactive iodine. An article for solid waste disposal comprises concrete prepared by this method. BACKGROUND OF THE INVENTION This invention was made in the course of, or under a contract with the Energy Research and Development Administration. It relates in general to reactor waste solidification and more specifically to the immobilization of fission product radioactive iodine recovered from irradiated nuclear fuel for underground storage.

  15. Clinical factors affecting the outcome in postradioactive iodine (RAI) therapy patients - Philippine Heart Center experience

    Quinon, A.; Oabel, E.; Jimeno, C.

    2007-01-01

    Full text: Clinical factors such as patient's age, duration of the underlying autoimmune thyroid stimulus and anti-thyroid drug therapy may affect the outcome of patients who underwent RAI therapy. Objective: To evaluate the clinical factors affecting the outcome of RAI therapy. Methodology: Patients (n=41) with Graves' disease treated with anti-thyroid drugs were followed up after Radioactive Iodine therapy treatment. Thyroid scan, 2 and 24 hours radioactive iodine uptake were taken to compute for the therapy dose (120 uci) (computed thyroid weight in gms) (24-hour I 131 uptake). Patients were then divided into groups (Group 1= hypothyroid, Group 2= euthyroid, Group 3 hyperthyroid) based on their thyroid function results (FT3, FT4, TSH) after 2, 4, 6, 12 months post-therapy. Clinical and physiologic factors were then correlated with the outcome. Results: The population consisted of 41 patients (male=8, female=33) with an overall incidence of Group 1= 17%, Group 2= 54% and Group 3= 29% posttherapy. Factors such as age, with their means (Groups 134, 2= 39, 3=39 p= 0.42) and gland uptake (24-hour Groups 1= 53, 2= 61 358, p= 0.41) were not associated with the remission rate. Other factors that were related to the length of the disease such as duration of symptoms (Groups 121, 2=24, 3= 29 months p0.68), duration of medicine prior to RAI therapy (Group 1= 10, 2= 15, 3= 18 months p=0.306) and gland weight (Groups 1=40 2=42 3=46 grams p=0.78) tends to have a higher mean values in therapy failure patients. Conclusion: Clinical factors studied showed no significant differences among patients developing hypothyroid, euthyroid or hyperthyroid state. The data suggested that treatment failures in patients with Graves' disease could be improved by lessening the time interval between the diagnosis and radioactive iodine therapy. (author)

  16. Milk Iodine Content in Slovakia

    I. Paulíková

    2008-01-01

    Full Text Available The aim of this work was to map actual iodine status and its seasonal differences in raw milk of dairy cows, sheep, and goats in various regions of Slovakia. Iodine concentrations were determined in 457 samples of raw milk from dairy cows, 78 samples of sheep, and 16 samples of goat milk collected in various regions of Slovakia from 2002 to 2007. Among all the 457 samples of bovine milk, iodine content below 50 μg l-1 was recorded in 114 samples (24.94%; 294 samples (64.33% ranged between 50 and 200 μg l-1; 19 samples (4.16% from 200 to 500 μg l-1; 17 samples (3.72% between 500 and 1 000 μg l-1, and 13 samples (2.85% showed iodine concentrations over 1 000 μg l-1. regional concentrations showed the highest values in the Western, then Middle and Eastern Slovakia, and the lowest values in Northern Slovakia (p p -1 in 49 sheep (62.8% and in 6 goats below 60 μg l-1 (37.5%, which are indicative of iodine deficiency. When comparing seasonal differences, sheep and goat milk had higher iodine content during the winter feeding period, however, in dairy cows we recorded the opposite ratio. Except for goat milk (p < 0.01 the seasonal differences were not significant.

  17. Iodine filters in nuclear power stations

    Wilhelm, J.G.

    1977-04-01

    On the basis of calculated and recorded release rates of nuclear power plants, the significance of iodine releases in the invironmental impact relative to other nuclides is discussed. The release pathways for iodine in LWR-type reactors and the efficiency of various methods to lower the activity release are given. The airborne species of iodine are discussed with regard to their removal in iodine sorption filters and environmental impact. The technical status of iodine removal by means of iodine sorption filters is studied for normal operation and accident conditions in nuclear power stations on the basis of the data given in the relevant literature for the efficiency of a number of iodine sorption materials. The applicability of concepts for ventilation and containment and their influence on iodine filter systems are discussed. Design, structure, and testing of iodine sorption filters are treated in detail; recommendations for design are given, and failure sources are mentioned. (orig.) [de

  18. Iodine status in neonates in Denmark

    Nøhr, S B; Laurberg, Peter; Børlum, K G

    1994-01-01

    Iodine status of 147 neonates born in five different regions of Denmark was evaluated in relation to the iodine content of breast milk and iodine supplementation taken by the mother. Approximately two-thirds of the women had not received iodine supplementation. They had low iodine concentrations...... in breast milk and urinary iodine concentrations of the neonates at day 5 were low. The median values (milk/urine) were 33.6/31.7 micrograms/l (Randers 22/26, Ringkøbing 29/16, Aalborg 36/31. Arhus 54/41 and Copenhagen 55/59 micrograms/l). Higher values were found in the group where tablets containing...... iodine had been taken (milk/urine: 57.0/61.0 micrograms/l). In general, the values are low compared with internationally recommended levels. We suggest that mothers without autoimmune thyroid disease should receive iodine supplementation in the form of vitamin/mineral tablets containing iodine (150...

  19. Radioiodine treatment of hyperthyroidism in patients with low thyroid iodine uptake

    Ruchala, M.; Sowinski, J.; Dolata, M.; Skiba, A.; Gembicki, M.; Junik, R.

    2005-01-01

    Ci, as compared to the sub-groups as a whole, specifically,15.7 mCi. The mean age of patients in the control group was slightly less than that of the study group (50.8 and 60, respectively). The results of the treatment of patients with a low iodine uptake are similar to the results obtained in the group of patients with iodine uptake above 30% and therefore low iodine uptake should not be a contraindication for isotope I-131 therapy. Additionally, we have demonstrated that a statistically significant decrease in thyroid volume is observed in all patients after the iodine isotope treatment which indirectly proves the effectiveness of the prescribed treatment, and that low thyroid iodine uptake is more frequently observed in elderly patients and in patients treated with iodine or anti-thyroid drugs. (author)

  20. Role of single photon emission computed tomography/computed tomography in diagnostic iodine-131 scintigraphy before initial radioiodine ablation in differentiated thyroid cancer

    Agrawal, Kanhaiyalal; Bhattacharya, Anish; Mittal, Bhagwant Rai

    2005-01-01

    The study was performed to evaluate the incremental value of single photon emission computed tomography/computed tomography (SPECT/CT) over planar radioiodine imaging before radioiodine ablation in the staging, management and stratification of risk of recurrence (ROR) in differentiated thyroid cancer (DTC) patients. Totally, 83 patients (21 male, 62 female) aged 17–75 (mean 39.9) years with DTC were included consecutively in this prospective study. They underwent postthyroidectomy planar and SPECT/CT scans after oral administration of 37–114 MBq iodine-131 (I-131). The scans were interpreted as positive, negative or suspicious for tracer uptake in the thyroid bed, cervical lymph nodes and sites outside the neck. In each case, the findings on planar images were recorded first, without knowledge of SPECT/CT findings. Operative and pathological findings were used for postsurgical tumor–node–metastasis staging. The tumor staging was reassessed after each of these two scans. Single photon emission computed tomography/computed tomography localized radioiodine uptake in the thyroid bed in 9/83 (10.8%) patients, neck nodes in 24/83 (28.9%) patients and distant metastases in 8/83 (9.6%) patients in addition to the planar study. Staging was changed in 8/83 (9.6%), ROR in 11/83 (13.2%) and management in 26/83 (31.3%) patients by the pretherapy SPECT/CT in comparison to planar imaging. SPECT/CT had incremental value in 32/83 patients (38.5%) over the planar scan. Single photon emission computed tomography/computed tomography is feasible during a diagnostic I-131 scan with a low amount of radiotracer. It improved the interpretation of pretherapy I-131 scintigraphy and changed the staging and subsequent patient management

  1. Determination of Therapeutic Dose of I-131 for First High Dose Radioiodine Therapy in Patients with Differentiated Thyroid Cancer: Comparison of Usefulness between Pathological Staging, Serum Thyroglobulin Level and Finding of I-123 Whole Body Scan

    Jeong, Hwan Jeong; Lim, Seok Tae; Youn, Hyun Jo; Sohn, Myung-Hee

    2008-01-01

    Recently, a number of patients needed total thyroidectomy and high dose radioiodine therapy (HD-RAI) get increased more. The aim of this study is to evaluate whether pathological staging (PS) and serum thyroglobulin (sTG) level could replace the diagnostic I-123 scan for the determination of therapeutic dose of HD-RAI in patients with differentiated thyroid cancer. Fifty eight patients (M:F=13;45, age 44.5±11.5 yrs) who underwent total thyroidectomy and central or regional lymph node dissection due to differentiated thyroid cancer were enrolled. Diagnostic scan of I-123 and sTG assay were also performed on off state of thyroid hormone. The therapeutic doses of I-131 (TD) were determined by the extent of uptakes on diagnostic I-123 scan as a gold standard. PS was graded by the criteria recommended in 6th edition of AJCC cancer staging manual except consideration of age. For comparison of the determination of therapeutic doses, PS and sTG were compared with the results of I-123 scan. All patients were underwent HD-RAI. Among them, five patients (8.6%) were treated with 100 mCi of I-131, forty three (74.1%) with 150 mCi, six (10.3%) with 180 mCi, three (5.2%) with 200 mCi, and one (1.7%) with 250 mCi, respectively. On the assessment of PS, average TDs were 154±25 mCi in stage I (n=9), 175±50 mCi in stage II (n=4), 149±21 mCi in stage III (n=38), and 161±20 mCi in stage IV (n=7). The statistical significance was not shown between PS and TD (p=0.169). Among fifty two patients who had available sTG, 25 patients (48.1%) having below 2 ng/mL of sTG were treated with 149±26 mCi of I-131, 9 patients (17.3%) having 2≤ sTG <5 ng/mL with 156±17 mCi, 5 patients (9.6%) having 5≤ sTG <10 ng/mL with 156±13 mCi, 7 patients (13.5%) having 10≤ sTG <50 ng/mL with 147±24 mCi, and 6 patients (11.5%) having above 50 ng/mL with 175±42 mCi. The statistical significance between sTG level and TD (p=0.252) was not shown. In conclusion, PS and sTG could not replace the

  2. Chemisorption of organic iodine compounds forming from fission isotopes of radioactive iodine

    Tot, G.; Galina, F.; Zel'd, E.

    1977-01-01

    Studied is ethyl iodine adsorption, labelled by iodine 131, on palladium black and on aluminium oxide activized by palladium. The desorption of adsorbed iodine in the temperature range of 20-600 deg C by the mass spectroscopy and thermal gravimetric methods was investigated. At the ethyl iodine and palladium interaction the bond between carbon and iodine in the ethyl iodine molecule breaks down and extracting iodine reacts with palladium, forming a stable compound at high temperatures. Desorption of adsorbed iodine is insignificant up to the temperatures of 250-300 deg C. Thus, sorbents, containing palladium, may be successfully applied for iodine absorption from the organic iodine compounds. These compounds spontaneously appear from the iodine fragment ratio isotopes during their interaction with some environmental organic impurities

  3. The radiotoxicology of iodine

    Taylor, D.M.

    1981-01-01

    Thirty radioisotopes of iodine are known but only those with mass numbers from 123 to 135 are of major radiotoxicological interest. Exposure of animals or man to inorganic 131 I or 125 I may result in the induction of benign or malignant thyroid tumors or depression of thyroid function; Bq for Bq 125 I is less toxic than 131 I. However, the shorter lived radioiodines 132 I, 133 I, and 135 I appear to be 10 to 100 times more toxic than 131 I alone. Little information is available about the toxicity of radioiodine containing organic compounds. The DNA precursor, iododeoxyuridine when labelled with 125 I becomes incorporated into the cell nucleus and produces severe and often irreparable damage due to the emission of Auger electrons. The risk estimate for the induction of thyroid carcinoma or adenoma by inorganic 131 I is considered to be 10 to 20x10 -6 persons Gy -1 y -1 , but may be up to 100 times larger for persons exposed to mixtures of short-lived radioiodines. (author)

  4. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

    Millot, F; Guilhot, J; Nelken, B; Leblanc, T; De Bont, ES; Bekassy, AN; Gadner, H; Sufliarska, S; Stary, J; Gschaidmeier, H; Guilhot, F; Suttorp, M

    A multicentric phase 2 study was conducted to determine the efficiency and the tolerance of imatinib mesylate in children with chronic myelogenous leukemia (CML) in advanced phase of the disease, in relapse after stem cell transplantation, or in case of failure to an interferon a-based regimen. In

  5. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.

    Menon-Andersen, Divya; Mondick, John T; Jayaraman, Bhuvana; Thompson, Patrick A; Blaney, Susan M; Bernstein, Mark; Bond, Mason; Champagne, Martin; Fossler, Michael J; Barrett, Jeffrey S

    2009-01-01

    Imatinib mesylate (Gleevec) is a small molecule tyrosine kinase inhibitor approved for use in the management of chronic myeloid leukemia in adults and children and in gastrointestinal stromal tumors in adults. Population pharmacokinetic (PPK) studies evaluating the effect of population covariates on the pharmacokinetics of imatinib and its active metabolite have been developed in adults with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). However, this still remains to be described in children. The objectives of the analysis were to develop a PPK model of imatinib and its active metabolite, CGP74588, to describe exposure in children and young adults and to identify covariates that are predictors of variability in disposition. Plasma concentrations from 26 subjects with Philadelphia (Ph+) leukemia (Phase I study) and 15 subjects with refractory solid tumors (Phase II study), who received oral imatinib at doses ranging from 260 to 570 mg/m(2), were available for the PPK analysis in NONMEM. Blood samples were drawn prior to dosing and over 24-48 h on days 1 and 8 of the studies. Covariates studied included weight, age, albumin, alanine aminotransferase and the study population. The pharmacokinetics of imatinib and CGP 74588 were well described by one and two compartment models, respectively. Total body weight was the only covariate found to significantly affect Cl/F and V/F. The final imatinib-CGP 74588 model is summarized as follows: CL/F (imatinib) (L/h) = 10.8 x (WT/70)(0.75), V/F (imatinib) (L) = 284 x (WT/70) and D1(duration of zero order absorption,imatinib) (h) = 1.67 and CL/F (CGP 74588) (L/h) = 9.65 x (WT/70)(0.75), V1/F (CGP 74588) (L) = 11.6 x (WT/70), Q (CGP 74588) (L/h) = 2.9 x (WT/70)(0.75) and V2/F (CGP 74588) (L) = 256*(WT/70). Model evaluation indicated that the final model was robust and satisfactory. Current imatinib dosing guidelines in pediatrics is based on the achievement of exposures consistent with doses known to be

  6. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

    Waring Paul

    2004-10-01

    Full Text Available Abstract Background The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs has previously been difficult as they are resistant to conventional chemotherapy and radiation. The development of imatinib mesylate has made a major impact on the management of advanced GISTs. It is apparent that there are sanctuary sites such as the central nervous system where imatinib does not achieve adequate concentrations. We describe the case of a man with metastatic GIST who experienced multiple cerebral relapses of disease while systemic disease progression appeared to be controlled by imatinib. Case presentation A 47-year-old man presented in July 1999 with a jejunal GIST with multiple hepatic metastases. The jejunal primary was resected and after unsuccessful cytoreductive chemotherapy, the liver metastases were also resected in December 1999. The patient subsequently relapsed in August 2001 with symptomatic hepatic, subcutaneous gluteal, left choroidal and right ocular metastases all confirmed on CT and PET scanning. Biopsy confirmed recurrent GIST. MRI and lumbar puncture excluded central nervous system involvement. The patient was commenced on imatinib 400 mg bd in September 2001 through a clinical trial. The symptoms improved with objective PET and CT scan response until December 2002 when the patient developed a right-sided foot drop. MRI scan showed a left parasagittal tumor which was resected and confirmed histologically to be metastatic GIST. Imatinib was ceased pre-operatively due to the trial protocol but recommenced in February 2003 on a compassionate use program. The left parasagittal metastasis recurred and required subsequent re-excision in September 2003 and January 2004. Control of the systemic GIST was temporarily lost on reduction of the dose of imatinib (due to limited drug supply but on increasing the dose back to 800 mg per day, systemic disease was stabilized for a period of time before generalised progression

  7. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report

    Hughes, Brett; Yip, Desmond; Goldstein, David; Waring, Paul; Beshay, Victoria; Chong, Guan

    2004-01-01

    The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs) has previously been difficult as they are resistant to conventional chemotherapy and radiation. The development of imatinib mesylate has made a major impact on the management of advanced GISTs. It is apparent that there are sanctuary sites such as the central nervous system where imatinib does not achieve adequate concentrations. We describe the case of a man with metastatic GIST who experienced multiple cerebral relapses of disease while systemic disease progression appeared to be controlled by imatinib. A 47-year-old man presented in July 1999 with a jejunal GIST with multiple hepatic metastases. The jejunal primary was resected and after unsuccessful cytoreductive chemotherapy, the liver metastases were also resected in December 1999. The patient subsequently relapsed in August 2001 with symptomatic hepatic, subcutaneous gluteal, left choroidal and right ocular metastases all confirmed on CT and PET scanning. Biopsy confirmed recurrent GIST. MRI and lumbar puncture excluded central nervous system involvement. The patient was commenced on imatinib 400 mg bd in September 2001 through a clinical trial. The symptoms improved with objective PET and CT scan response until December 2002 when the patient developed a right-sided foot drop. MRI scan showed a left parasagittal tumor which was resected and confirmed histologically to be metastatic GIST. Imatinib was ceased pre-operatively due to the trial protocol but recommenced in February 2003 on a compassionate use program. The left parasagittal metastasis recurred and required subsequent re-excision in September 2003 and January 2004. Control of the systemic GIST was temporarily lost on reduction of the dose of imatinib (due to limited drug supply) but on increasing the dose back to 800 mg per day, systemic disease was stabilized for a period of time before generalised progression occurred. This case illustrates that the brain can be a

  8. Iodine behaviour in severe accidents

    Dutton, L M.C.; Grindon, E; Handy, B J; Sutherland, L [NNC Ltd., Knutsford (United Kingdom); Bruns, W G; Sims, H E [AEA Technology, Harwell (United Kingdom); Dickinson, S [AEA Technology, Winfrith (United Kingdom); Hueber, C; Jacquemain, D [IPSN/CEA, Cadarache, Saint Paul-Lez-Durance (France)

    1996-12-01

    A description is given of analyses which identify which aspects of the modelling and data are most important in evaluating the release of radioactive iodine to the environment following a potential severe accident at a PWR and which identify the major uncertainties which affect that release. Three iodine codes are used namely INSPECT, IODE and IMPAIR, and their predictions are compared with those of the PSA code MAAP. INSPECT is a mechanistic code which models iodine behaviour in the aqueous aerosol, spray water and sump water, and the partitioning of volatile species between the aqueous phases and containment gas space. Organic iodine is not modelled. IODE and IMPAIR are semi-empirical codes which do not model iodine behaviour in the aqueous aerosol, but model organic iodine. The fault sequences addressed are based on analyses for the Sizewell `B` design. Two types of sequence have been analysed.: (a) those in which a major release of fission products from the primary circuit to the containment occur, e.g. a large LOCAS, (b) those where the release by-passes the containment, e.g. a leak into the auxiliary building. In the analysis of the LOCA sequences where the pH of the sump is controlled to be a value of 8 or greater, all three codes predict that the oxidation of iodine to produce gas phase species does not make a significant contribution to the source term due to leakage from the reactor building and that the latter is dominated by iodide in the aerosol. In the case where the pH of the sump is not controlled, it is found that the proportion of gas phase iodine increases significantly, although the cumulative leakage predicted by all three codes is not significantly different from that predicted by MAAP. The radiolytic production of nitric acid could be a major factor in determining the pH, and if the pH were reduced, the codes predict an increase in gas phase iodine species leaked from the containment. (author) 4 figs., 7 tabs., 13 refs.

  9. Up regulation of K A I 1 gene expression and apoptosis effect of imatinib mesylate in gastric adenocarcinoma (AGS cell line

    eyed Ataollah Sadat Shandiz

    2016-02-01

    Full Text Available Objective: To evaluate the effect of imatinib mesylate on KAI1 gene expression and apoptosis properties in human gastric carcinoma AGS cell line. Methods: Cell viability was assessed by MTT assay and quantitative real time PCR method was applied for investigation of Bax, Bcl-2, and KAI1 gene expression in AGS cells. The quantity of KAI1, Bax, and Bcl-2 compared to GAPDH gene expressions were examined using the formula 2-∆∆Ct. Furthermore, cell apoptosis/necrosis was carried out by annexin V/PI staining and quantified with flow cytometry after treatment with imatinib. Results: Imatinib mesylate was showed to have a dose-dependent toxicity effect against AGS cells. KAI1/GAPDH gene expression ratios were 1.07 ± 0.02 (P > 0.05, 1.68 ± 0.19 (P > 0.05, 3.60 ± 0.55 (P < 0.05, 6.54 ± 0.27 (P < 0.001 for 20, 50, 80 and 100 μmol/L of imatinib concentrations. The mRNA levels of Bax detected by real-time PCR after treatment with imatinib mesylate were significantly increased. Also, the number of apoptotic cells was increased from 3.72% (statistically significant; P < 0.05 in untreated AGS cells to 21.72%, 83.04% and 85.80%, respectively, following treatment with 20, 40, and 60 μmol/L imatinib mesylate. Conclusions: The results suggest that imatinib mesylate can induce apoptosis pathway in a dose-dependent mode and might modulate metastasis by up regulating KAI1 gene expression in human gastric carcinoma AGS cell line.

  10. [Assessment of dietary iodine intake of population in non-high-iodine areas in China].

    Song, Xiaoyu; Li, Fengqin; Liu, Zhaoping; He, Yuna; Sui, Haixia; Mao, Weifeng; Liu, Sana; Yan, Weixing; Li, Ning; Chen, Junshi

    2011-03-01

    To assess the potential risk of dietary iodine insufficiency of population in non-high-iodine areas (water iodine China. The dietary iodine intake of 13 age-sex population groups were estimated by combining the data of iodine intake from food, table salt and drinking water. Two conditions were considered: consuming iodized salt or non-iodized salt. The data of food and table salt consumption were derived from the Chinese National Nutrition and Health Survey in 2002. Water consumption was calculated as the recommended water intake. Iodine contents of food, table salt and water were calculated from China Food Composition Table and iodine surveillance data. Under the condition of consuming iodized salt, the average iodine intake of all population groups was higher than the Recommended Nutrient Intake (RNI), while the iodine intakes of individuals above Upper Limits (UL) and below RNI were 5.8% and 13.4% respectively, and the iodine intake of individuals lower than the Estimated Average Requirement (EAR) was 9.4% in adults above 18 years of age (including pregnant and lactating women). If non-iodized salt was consumed, the average iodine intake of most sex-age population groups was higher than RNI, but the iodine intake of 97.6% of individuals would be lower than RNI, while the iodine intake of 97.4% of adults would be lower than EAR. The contribution of iodine from table salt was much higher than that from drinking water and food in the condition of consuming iodized salt, while food was the predominant contributor of dietary iodine in the condition of consuming non-iodized salt. The health risk of iodine deficiency was higher than that of iodine excess in areas where water iodine was China, and the risk of iodine insufficiency was much higher if non-iodized salt was consumed. Iodized salt should be the main sources of dietary iodine intake for population in areas where water iodine was China.

  11. Urinary Iodine Concentrations Indicate Iodine Deficiency in Pregnant Thai Women but Iodine Sufficiency in Their School-Aged Children

    Gowachirapant, S.; Winichagoon, P.; Wyss, L.; Tong, B.; Baumgartner, J.; Boonstra, A.; Zimmermann, M.B.

    2009-01-01

    The median urinary iodine concentration (UI) in school-aged children is recommended for assessment of iodine nutrition in populations. If the median UI is adequate in school-aged children, it is usually assumed iodine intakes are also adequate in the remaining population, including pregnant women.

  12. Iodinated contrast media nephrotoxicity

    Meyrier, A.

    1994-01-01

    In the late seventies, iodinated contrast agents (ICA) were considered to be a major cause of acute iatrogenic renal failure. Over the last decade new contrast agents have been synthesized, nonionic and less hyperosmolar. The incidence of acute renal failure due to ICAs, varies from 3.7 to 70% of cases according to the series, with an average figure of 10.2%. The pathophysiology of ICA nephrotoxicity was mainly studied in laboratory animal models. Three main factors are involved in an inducing ICA-mediated decrease in glomerular filtration rate: reduction of the renal plasma flow, a direct cytotoxic effect on renal tubular cells and erythrocyte alteration leading to intra-renal sludge. Excluding dysglobulinemias with urinary excretion of immunoglobulin light chains, which represent a special case of maximum nephrotoxicity, 4 main risk factors of renal toxicity have been identified in nondiabetic subjects: previous renal failure with serum creatinine levels greater than 140 μmol per liter, extracellular dehydration, age over 60 and use of high doses of ICA and/or repeated ICA injections before serum creatinine levels return to baseline. Preventive measures for avoiding ICA nephrotoxicity are threefold: maintain or restore adequate hydration with saline infusion, stop NSAID treatment several days before ICA administration, and allow a 5 day interval before repeating contrast media injections. New, nonionic and moderately hyperosmolar contrast agents appear to be much less nephrotoxic than conventional ICAs in laboratory animals and in high-risk patients. It is advisable to select such contrast media for investigating high-risk patients. This approach was recently substantiated in well designed, randomized clinical studies which included more than 2 000 patients. (author)

  13. Intercomparison Of Activity Measurements Of Co-58, Y-88, Ho-166m, Tc-99m, dan I-131 Between P3KRBiN and Laboratory Within BATAN And Hospitals

    Nazaroh; Ermi-Juita; Hermawan-Candra

    2003-01-01

    One way to maintain traceability and to keep consistency of the measurement result of radioactivity was intercomparison program. According with Surat Keputusan Kepala BATAN No.73/KA/IV/99, one of tasks and functions of standardization laboratory is to coordinate an intercomparison program of radioactivity measurement. In the year of 2000, intercomparison program of activity measurements between P3KRBiN and 10 laboratories within BATAN and 12 hospitals were carried out. For intercomparison of Co-58, Y-88, and Ho-166m, there were 3 laboratories within BATAN which have more than 50% difference compared with P3KRBiN measurements and for intercomparison of Tc-99m, dan I-131, there were 2 Dose-Calibrators belongs to hospitals which have more than 30% difference compared with P3KRBiN measurements. From that result it can be concluded that intercomparison of activity measurements are very important and needs continuously to maintain traceability and to keep consistency of measurement result. (author)

  14. Experimental reproduction of iodine deficiency in cattle.

    McCoy, M A; Smyth, J A; Ellis, W A; Arthur, J R; Kennedy, D G

    1997-11-22

    The role of iodine deficiency in stillbirth/perinatal weak calf syndrome was investigated in pregnant heifers. Five heifers were fed an iodine deficient diet (mean [sd] iodine concentration 0.06 [0.01] mg/kg dry matter [DM]) and six received an iodine sufficient diet (mean [sd] iodine concentration 1.45 [0.27] mg/kg DM). The diets consisted of wheat and soyabean meal with added minerals and vitamins (with or without iodine) and were fed to the heifers over the final four to five months of pregnancy. The iodine deficient diet produced clinicopathological changes and pathological changes in the thyroid glands of both the heifers and their offspring. However, all the calves in the iodine deficient group were born clinically normal.

  15. Thyroid disorders in mild iodine deficiency

    Laurberg, P; Nøhr, S B; Pedersen, K M

    2000-01-01

    Comparative epidemiologic studies in areas with low and high iodine intake and controlled studies of iodine supplementation have demonstrated that the major consequence of mild-to-moderate iodine deficiency for the health of the population is an extraordinarily high occurrence of hyperthyroidism...... endangered but the consequences of severe iodine deficiency for brain development are grave and a considerable safety margin is advisable. Moreover, a shift toward less malignant types of thyroid cancer and a lower radiation dose to the thyroid in case of nuclear fallout support that mild-to-moderate iodine...... deficiency should be corrected. However, there is evidence that a high iodine intake may be associated with more autoimmune hypothyroidism, and that Graves' disease may manifest at a younger age and be more difficult to treat. Hence, the iodine intake should be brought to a level at which iodine deficiency...

  16. Effect of iodine solutions on polyaniline films

    Ayad, M.M.; Amer, W.A.; Stejskal, J.

    2009-01-01

    Polyaniline (PANI) emeraldine-base films have been exposed to iodine solutions. The interaction between the films and the iodine solution was studied using the quartz-crystal microbalance (QCM) technique and the UV-visible absorption spectroscopy. The iodine-treated film of emeraldine base was subjected to dedoping process using 0.1 M ammonia solution. The resulting film was exposed again to the previously used iodine solution. Iodine was found to play multiple roles: the ring-iodination of PANI film, the oxidation of PANI to pernigraniline base, and iodine doping to PANI salt. A sensor based on PANI-coated electrode of QCM was developed to monitor the presence of iodine in solution.

  17. Biological dosimetry of patients with differenced carcinoma of thyroid treated with Iodine-131

    Vallerga, M. B.; Rojo, A.M.; Taja, M.R.; Deluca, G.; Di Giorgio, M.; Fadel, A.; Cabrejas, M.; Valdivieso, C.

    2006-01-01

    The administration of I-131 to patient with Differentiated Thyroid Carcinoma (CaDiT) it is used inside the therapeutic outline as later step to the thyroidectomy. However, the good activity to give is of difficult determination due to factors such as, the variability in the capacity of tumoral reception of the I-131, distribution of the pharmaceutical, physiologic status, other associate pathologies, grade of advance of the illness, and previous treatments. Additionally, the activity to administer is dependent of the dose of tolerance in the healthy tissues; superior dose to 2 Gy in bone marrow, its could drive to myelotoxicity. At the moment, the form more extended of administration it is the empiric prescription that considers clinical parameters and of laboratory for their determination. Presently work, the protocol of applied treatment incorporates the evaluation for internal dosimetry and biological dosimetry to estimate absorbed dose in bone marrow. The biological estimate of the dose of these patients is based on the quantification of chromosomal aberrations whose frequency is referred to a curve-dose response in which the lymphocytes is irradiated in vitro with I-131, allowing to determine the in vivo dose to the patient's circulating lymphocytes. The objective of the present work is to determine the applicability of different cytogenetic essays in the estimate of the absorbed dose to the whole body or specific organs. Three patients were evaluated with CaDiT. Their treatment protocol consisted on a tracer administration of radioactive iodine of 74 - 111 MBq (2 - 3 mCi) and a therapy 7,4 - 11,1 GBq (200 - 300 mCi). Previous to the tracer administration and 8 days post-therapeutic administration took samples of veined blood that were evaluated by biological dosimetry by means of the application of the techniques: conventional cytogenetic Micronucleus and FISH (Hybridization in situ by Fluorescence). Starting from the frequencies of observed chromosomal

  18. Contrast induced hyperthyroidism due to iodine excess

    Mushtaq, Usman; Price, Timothy; Laddipeerla, Narsing; Townsend, Amanda; Broadbridge, Vy

    2009-01-01

    Iodine induced hyperthyroidism is a thyrotoxic condition caused by exposure to excessive iodine. Historically this type of hyperthyroidism has been described in areas of iodine deficiency. With advances in medicine, iodine induced hyperthyroidism has been observed following the use of drugs containing iodine—for example, amiodarone, and contrast agents used in radiological imaging. In elderly patients it is frequently difficult to diagnose and control contrast related hyperthyroidism, as most...

  19. Formation and behaviour of organic iodine

    Zilliacus, R.; Koukkar, P.; Karjunen, T.; Sjoevall, H.

    2002-01-01

    The report presents experimental studies on the formation of organic iodine in severe reactor accidents. The analyses were performed to evaluate the amount of alkaline chemical needed for effective pH control of containment water during the accidents. The formation of organic iodine in solutions used in the filtered venting system and the absorption of iodine compounds in the solutions were studied. Experiments for the formation of organic iodine on painted surfaces were also performed. (au)

  20. Mineral resource of the month: iodine

    Polyak, Désirée E.

    2009-01-01

    The article focuses on iodine, its benefits and adverse effects, and its production and consumption. It states that iodine is essential to humans for it produces thyroid hormones to nourish thyroid glands but excessive intake could cause goiter, hyperthyroidism or hypothyroidism. U.S. laws require salt iodization to help prevent diseases. Chile and Japan are the world's leading iodine producer while in the U.S. iodine is mined from deep well brines in northern Oklahoma.

  1. Iodine Prophylaxis and Nuclear Accidents

    Franic, Z.

    1998-01-01

    Iodine is a highly volatile element therefore being very mobile in the environment. It enters the metabolism of living organisms and is selectively taken up and concentrated in the thyroid gland. The plume (cloud-like formation) of radioactive material that might be released in the environment in the case of a serious nuclear accident, primarily consists of the radioactive isotopes of iodine. Among those, due to its decay properties, is the most important 131 I. The effective means of protecting the thyroid gland against exposure to radioactive iodine is an intake of stable iodine. Therefore, one of the central issues in the emergency planning is to determine whether and at which projected thyroid radiation dose stable iodine should be given to the population. The International Atomic Energy Agency (IAEA) set the generic optimized intervention value for iodine prophylaxis to 100 mGy of avertable committed dose to a thyroid.The prophylaxis is implemented by utilizing the pills of pills of potassium iodine (KI). The efficacy of KI in protecting the thyroid gland depends upon the time of intake relative to the start of exposure to radioactive iodine. The best results are obtained if KI is taken 1-2 hours before or immediately after the start of exposure. The recommended dosage, based upon the study performed by Il'in et.al. is 130 mg/day. KI should be taken at least three days after the acute exposure to radioiodine, to prevent accumulation in a thyroid gland of radioiodine excreted from the other compartments of the body. The largest epidemiological study on the effects of KI prophylaxis ever performed was the one in Poland after the Chernobyl accident. Stable iodine was given as single dose of KI solution to 10.5 million of children and 7 millions of adults. Among children no serious side effects were seen while only two adults (with previously recorded iodine sensitivity) had severe respiratory distresses. Polish experiences showed that rapid response to such

  2. Department of Homeland Security (DHS I-131)

    Social Security Administration — This identifies resident aliens who should have their Supplemental Security Income benefit payment suspended because they have voluntarily left the United States for...

  3. Management modes for iodine-129

    White, I.F.; Smith, G.M.

    1984-01-01

    This study completes a two-stage programme, supported by the Commission of the European Communities, on management modes for iodine-129. The models for the radiological assessment of iodine-129 management modes have been reviewed and, where necessary, revised, and a generic radiological assessment has been carried out using these models. Cost benefit analysis has been demonstrated for a variety of iodine-129 management modes; for a wide range of assumptions, the costs of abatement of atmospheric discharges would be outweighed by the radiological benefits. The cost benefit analysis thus complements and confirms the preliminary conclusion of the previous study: iodine-129 should be trapped to a large extent from the off-gases of a large reprocessing plant and disposed of by other suitable means, in order to ensure that all exposures from this radionuclide are as low as reasonably achievable. Once the major fraction of the iodine-129 throughput of a reprocessing plant has been trapped from the dissolver off-gases, there are unlikely to be strong radiation protection incentives either for further trapping from the dissolver off-gases or for trapping from the vessel off-gases. In a generic study it is not possible to state an optimum choice of process(es) for abatement of atmospheric discharges of iodine-129. This choice must be determined by assessments in the specific context of a particular reprocessing plant, its site, the waste disposal routes that are actually available, and also in the wider context of the management plans for all radioactive wastes at the plant in question

  4. The importance of iodine nutrition during pregnancy.

    Glinoer, Daniel

    2007-12-01

    To examine the importance of iodine nutrition during pregnancy. Review of existing literature of iodine in pregnancy. Population surveys and metabolic studies. Pregnant women. The main changes in thyroid function associated with pregnancy are due to an increase in hormone requirements that begin in the first trimester of gestation. This increase can only be met by a proportional increase in hormone production, something that depends directly upon the availability of iodine. When dietary iodine is lacking, an adequate physiological adaptation is difficult to achieve and is progressively replaced by pathological alterations that occur in parallel with the degree and duration of iodine deprivation. Iodine prophylaxis should be given systematically to women during pregnancy. In most public health programmes dealing with the correction of iodine deficiency disorders, iodised salt has been used as the preferred means to deliver iodine to households. Iodised salt, however, is not the ideal means of delivering iodine in the specific instances of pregnancy, breast-feeding and complementary feeding because of the need to limit salt intake during these periods. In European countries, presently it is proposed that iodine is given to pregnant women and breast-feeding mothers by systematically administering multivitamin tablets containing iodine in order to reach the recommended dietary allowance of 250 microg iodine day-1.

  5. Iodine in Enteral and Parenteral Nutrition

    Zimmermann, M.B.; Crill, C.M.

    2010-01-01

    Iodine deficiency (ID) has multiple adverse effects on growth and development due to inadequate thyroid hormone production. Methods for assessment of iodine nutrition in individuals include the urinary iodine concentration (UI), thyroid size and thyroid function tests. The UI measured in several

  6. Industrial system for producing iodine-123

    Brantley, J.C.

    1985-01-01

    An industrial system to produce iodine-123 required a complex set of steps involving new approaches by the Food and Drug Administration, difficult distribution procedures, and evidence from potential users that either very pure iodine-123 or inexpensive iodine-123 is needed. Industry has shown its willingness to invest in new radionuclides but needs strong evidence as to product potential to justify those investments

  7. Iodine excretion in school children in Copenhagen

    Rasmussen, Lone B; Kirkegaard-Klitbo, Ditte Marie; Laurberg, Peter

    2016-01-01

    INTRODUCTION: Studies of dietary habits show a high iodine intake in children in Denmark. Iodine excretion in children has not previously been assessed. Iodine excretion in adults is below the recommended threshold, and it is therefore being discussed to increase the fortification level. The main...

  8. MARGINAL IODINE DEFICIENCY EXACERBATES PERCHLORATE THYROID TOXICITY.

    The environmental contaminant perchlorate disrupts thyroid homeostasis via inhibition of iodine uptake into the thyroid. This work tested whether iodine deficiency exacerbates the effects of perchlorate. Female 27 day-old LE rats were fed a custom iodine deficient diet with 0, 50...

  9. Chemical species of iodine in some seaweeds. Pt. 2. Iodine-bound biological macromolecules

    Xiaolin Hou; Chifang Chai; Xiaojun Yan

    2000-01-01

    The distribution of iodine in various biological macromolecules in Sargassum kjellmanianum was studied using neutron activation analysis combined with chemical and biochemical separation techniques. The results indicate that iodine is mainly bound with protein, part of iodine with pigment and polyphenol, and little with polysaccharides, such as algin, fucoidan and cellulose. This result is significant for the mechanism of enriching iodine of algae and utilization of alga iodine. (author)

  10. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-01-01

    In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow's milk are considerably less . Detailed

  11. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-07-01

    In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow

  12. Combined derivatization and high-performance liquid chromatography with fluorescence and ultraviolet detection for simultaneous analysis of octreotide and gabexate mesylate metabolite in human pancreatic juice samples.

    Carlucci, Giuseppe; Selvaggi, Federico; Sulpizio, Sara; Bassi, Claudio; Carlucci, Maura; Cotellese, Roberto; Ferrone, Vincenzo; Innocenti, Paolo; Locatelli, Marcello

    2015-06-01

    A simple and sensitive method based on the combination of derivatization and high-performance liquid chromatography with ultraviolet and fluorimetric detection was developed for the simultaneous determination of octreotide and gabexate mesylate metabolite in human pancreatic juice samples. Parameters of the derivatization procedure affecting extraction efficiency were optimized. The developed method was validated according to the International Conference on Harmonization guidelines. The calibration curves were linear over a range of 0.1-15 µg/mL for octreotide and 0.20-15 µg/mL for gabexate mesylate metabolite. Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C18 column (4.6 × 250 mm; 5 µm particle size) using a gradient with a run time of 36 min, without further purification. The limits of detection were 0.025 and 0.05, respectively, for octreotide and gabexate mesylate metabolite. This paper reports the validation of a quantitative high performance liquid chromatography-photodiode array-fluorescence (HPLC-PDA-FL) method for the simultaneous analysis of octreotide and gabexate mesylate metabolite in pancreatic juice by protein precipitation using zinc sulfate-methanol-acetonitrile containing the derivatizing reagent, 4-fluoro-7-nitro-[2,1,3]-benzoxadiazole (NBD-F). Derivatized products of octreotide and gabexate mesylate metabolite were separated on a Luna C18 column (4.6 × 250 mm; 5 µm particle size) using a gradient with a run time of 36 min, without further purification. The method was validated over the concentration ranges 0.1-15 and 0.2-15 µg/mL for octreotide and gabexate mesylate metabolite, respectively, in human pancreatic juice. Biphalin and methyl-p-hydroxybenzoate were used as the internal standards. This method was successfully utilized to support clinical studies in humans. The results from assay validations show that the method is selective, sensitive and robust. The limit

  13. Transfer of gaseous iodine to Tradescantia

    Nakamura, Yuji; Ohmomo, Yoichiro.

    1984-01-01

    Transfer rates of gaseous elemental iodine and methyliodide from atmosphere to Tradescantia were investigated in relation to supposed genetic mutation due to radioactive iodine released from nuclear facilities. The estimated transfer rate of elemental iodine to the young buds of Tradescantia, which was given as the ratio of iodine uptake rate per unit weight of the plant to the concentration of the element in the air, was approximately 7 x 10 -2 cm 3 /g.sec, about 30 to 40 times higher than that of methyliodide. The contribution of direct deposition of elemental iodine was suggested to be significant, although methyliodide was mainly absorbed by respiration through stomata of the plant. (author)

  14. Dietary flavonoids and iodine Metabolism

    Elst, van der J.P.; Smit, J.W.A.; Romijn, H.A.; Heide, van der D.

    2003-01-01

    Flavonoids have inhibiting effects on the proliferation of cancer cells, including thyroidal ones. In the treatment of thyroid cancer the uptake of iodide is essential. Flavonoids are known to interfere with iodide organification ill vitro, and to cause goiter. The influence of flavonoids on iodine

  15. Thyroid disorders in mild iodine deficiency.

    Laurberg, P; Nøhr, S B; Pedersen, K M; Hreidarsson, A B; Andersen, S; Bülow Pedersen, I; Knudsen, N; Perrild, H; Jørgensen, T; Ovesen, L

    2000-11-01

    Comparative epidemiologic studies in areas with low and high iodine intake and controlled studies of iodine supplementation have demonstrated that the major consequence of mild-to-moderate iodine deficiency for the health of the population is an extraordinarily high occurrence of hyperthyroidism in elderly subjects, especially women, with risk of cardiac arrhythmias, osteoporosis, and muscle wasting. The hyperthyroidism is caused by autonomous nodular growth and function of the thyroid gland and it is accompanied by a high frequency of goiter. Pregnant women and small children are not immediately endangered but the consequences of severe iodine deficiency for brain development are grave and a considerable safety margin is advisable. Moreover, a shift toward less malignant types of thyroid cancer and a lower radiation dose to the thyroid in case of nuclear fallout support that mild-to-moderate iodine deficiency should be corrected. However, there is evidence that a high iodine intake may be associated with more autoimmune hypothyroidism, and that Graves' disease may manifest at a younger age and be more difficult to treat. Hence, the iodine intake should be brought to a level at which iodine deficiency disorders are avoided but not higher. Iodine supplementation programs should aim at relatively uniform iodine intake, avoiding deficient or excessive iodine intake in subpopulations. To adopt such a strategy, surveillance programs are needed.

  16. Iodine tablets and a nuclear accident

    Paile, W.

    1992-01-01

    Radioactive iodine is one of the major substances released during severe nuclear accidents. Radioactive iodine is easily gasified, and if present in fallout it can enter the lungs, and thereby the circulatory system, with the inhalation of air. Once in a body, radioactive iodine accumulates in the thyroid and may result in tumours in the thyroid and, in extreme cases, impaired thyroid function. Accumulation of radioactive iodine can be prevented by taking non-radioactive, 'cold' iodine as tablets. Iodine tablets dilute the radioactive iodine that has entered the body. A dose of iodine also paralyses the thyroid temporarily by saturating its iodine-carrying capacity. To be useful iodine tablets should be taken immediately when a radioactive emission has occurred. If the tablets are taken too early or too late, they give little protection. Iodine tablets should not be taken just to be on the safe side, since their use may involve harmful side effects. Dosing instructions should also be followed with care. (orig.)

  17. Iodine removing method in organic solvent

    Suzuki, Takeo; Sakurai, Manabu

    1988-01-01

    Purpose: To effectively remove iodine in an organic solvent to thereby remove iodine in the solvent that can be re-used or put to purning treatment. Method: Organic solvent formed from wastes of nuclear facilities is mixed with basic lead acetate, or silica gel or activated carbon incorporated with such a compound to adsorb iodine in the organic solvent to the basic lead acetate. Then, iodine in the organic solvent is removed by separating to eliminate the basic lead acetate adsorbing iodine from the organic solvent or by passing the organic solvent through a tower or column charged or pre-coated with silica gel or activated carbon incorporated with lead acetate. By using basic lead acetate as the adsorbents, iodine can effective by adsorbed and eliminated. Thus, the possibility of circumstantial release of iodine can be reduced upon reusing or burning treatment of the organic solvent. (Kamimura, M.)

  18. Prophylactic iodine treatment in radiation protection

    Oberhausen, E.

    1980-01-01

    Prophylactic iodine treatment is to prevent accumulation of radioactive iodine in the thyroid. This is done by administering a large amount of stable iodine before uptake of radioactive iodine so that further accummulation of iodine in the thyroid will be impossible. This blocking effect should be as complete as possible. This is achieved by administering an initial dose of 200 mg potassium iodide. As the release of radioactive iodine may last several hours or even days; for this reason, maintenance doses of 100 mg potassium iodide should be administered in 8-hour intervals. The risk of prophylactiv iodine treatment is rather low; however, provocation of latent hyperthyreoses must be expected in, at the most, 0.2% of the exposed population. (orig./MG) [de

  19. Iodine status in neonates in Denmark: regional variations and dependency on maternal iodine supplementation

    Nøhr, S B; Laurberg, P; Børlum, K G

    1994-01-01

    Iodine status of 147 neonates born in five different regions of Denmark was evaluated in relation to the iodine content of breast milk and iodine supplementation taken by the mother. Approximately two-thirds of the women had not received iodine supplementation. They had low iodine concentrations...... in breast milk and urinary iodine concentrations of the neonates at day 5 were low. The median values (milk/urine) were 33.6/31.7 micrograms/l (Randers 22/26, Ringkøbing 29/16, Aalborg 36/31. Arhus 54/41 and Copenhagen 55/59 micrograms/l). Higher values were found in the group where tablets containing...... iodine had been taken (milk/urine: 57.0/61.0 micrograms/l). In general, the values are low compared with internationally recommended levels. We suggest that mothers without autoimmune thyroid disease should receive iodine supplementation in the form of vitamin/mineral tablets containing iodine (150...

  20. Diagnosis and treatment of a carcinoid tumor using iodine-131 meta-iodobenzylguanidine

    Hoefnagel, C.A.; Den Hartog Jager, F.C.; Van Gennip, A.H.; Marcuse, H.R.; Taal, B.G.

    1986-01-01

    Scintigraphy using I-131 meta-iodobenzylguanidine has been introduced as an effective method to detect pheochromocytomas and neuroblastomas, and the radiopharmaceutical also is applied in therapy of these tumors. The authors present a case of a metastatic gastric carcinoid tumor, another neural crest tumor, concentrating I-131 MIBG, which was documented by conventional scintigraphy and SPECT in correlation with CT scans and colloid scintigrams of the liver. Two therapeutic attempts in this patient, using I-131 MIBG, are described. The metabolic basis of this phenomenon is discussed, and the importance of I-131 MIBG imaging in the detection of neural crest tumors is underlined

  1. A Spectroscopic Method for Determining Free Iodine in Iodinated Fatty-Acid Esters

    Klyubin, V. V.; Klyubina, K. A.; Makovetskaya, K. N.

    2018-01-01

    It is shown that the concentration of free iodine in samples of iodinated fatty-acid esters can be measured using the electronic absorption spectra of their solutions in ethanol. The method proposed is rather simple in use and highly sensitive, allowing detection of presence of less than 10 ppm of free iodine in iodinated compounds. It is shown using the example of Lipiodol that this makes it possible to easily detect small amounts of free iodine in samples containing bound iodine in concentrations down to 40 wt %.

  2. Separation of iodine-131 from water using isotopic exchange with iodine-starch compound

    Ignatov, V.P.; Kolomejtseva, I.V.

    1990-01-01

    Conditions of iodine isotopic exchange with iodine-starch compound (ISC) were studied with the aim of compound utilizatoin for radioactive iodine separation from solution. It is shown that in pH range from 2 to 7 the degree of iodine extraction and coefficient of its distribution practically do not depend on pH, at pH>7 ISC destruction (decolorizing) starts and iodine extraction decreases. Rapid method of iodine separation from solution is suggested. The method can be used in radiochemical techniques. The degree of extraction equals 80 %, a higher degree of extraction can not be achieved owing to ISC formation peculiarities

  3. Radioactive iodine absorbing properties of tetrathiafulvalene

    Ito, Tomiyasu; Nakamura, Asao (Ajinomoto Co. Inc., Kawasaki, Kanagawa (Japan). Central Research Labs.); Nogawa, Norio; Oohashi, Kunio; Morikawa, Naotake

    1989-05-01

    For the purpose of searching some effective absorbents of gaseous radioactive iodine, 16 substances considered as having an affinity for iodine were investigated with regular iodine and /sup 125/I. In a preliminary survey, only tetrathiafulvalene (TTF) was found to have satisfactory absorbing properties comparable to activated charcoal. A further detailed comparison of the properties between TTF and activated charcoal led us to the conclusion that the former has more preferable properties as absorbent of radioactive iodine than the latter in all points studied. The results are summarized as follows: (1) The absorption of iodine on TTF in atmosphere was about twice as much as that on activated charcoal. Desorption of iodine from saturatedly absorbed iodine on TTF was practically negligible except trace amount of initial desorption, while that on activated charcoal was considerable (3%/50h) even in the air at room temperature. (2) Absorbed amount of iodine on activated charcoal decreased with increasing gaseous iodine concentration, air flow rate, on humidity of flowing-air. On the other hand, those factors scarcely affected that on TTF. Under an air flow rate of 1m/s, activated charcoal absorbs only 80% of iodine, while TTF absorbs more than 99%. (3) In flowing-air saturated with water vapor, iodine absorbed on activated charcoal was gradually liberated although by small amount (0.08%/100h), while that on TTF was much more stable for a long period (0.004%/100h). As a conclusion, TTF is considered to be useful as a quite effective radioactive iodine absorbent, especially in the case where protection from radioactive iodine should be serious, though it is expensive now. (author).

  4. Radioactive iodine absorbing properties of tetrathiafulvalene

    Ito, Tomiyasu; Nakamura, Asao; Nogawa, Norio; Oohashi, Kunio; Morikawa, Naotake.

    1989-01-01

    For the purpose of searching some effective absorbents of gaseous radioactive iodine, 16 substances considered as having an affinity for iodine were investigated with regular iodine and 125 I. In a preliminary survey, only tetrathiafulvalene (TTF) was found to have satisfactory absorbing properties comparable to activated charcoal. A further detailed comparison of the properties between TTF and activated charcoal led us to the conclusion that the former has more preferable properties as absorbent of radioactive iodine than the latter in all points studied. The results are summarized as follows: (1) The absorption of iodine on TTF in atmosphere was about twice as much as that on activated charcoal. Desorption of iodine from saturatedly absorbed iodine on TTF was practically negligible except trace amount of initial desorption, while that on activated charcoal was considerable (3%/50h) even in the air at room temperature. (2) Absorbed amount of iodine on activated charcoal decreased with increasing gaseous iodine concentration, air flow rate, on humidity of flowing-air. On the other hand, those factors scarcely affected that on TTF. Under an air flow rate of 1m/s, activated charcoal absorbs only 80% of iodine, while TTF absorbs more than 99%. (3) In flowing-air saturated with water vapor, iodine absorbed on activated charcoal was gradually liberated although by small amount (0.08%/100h), while that on TTF was much more stable for a long period (0.004%/100h). As a conclusion, TTF is considered to be useful as a quite effective radioactive iodine absorbent, especially in the case where protection from radioactive iodine should be serious, though it is expensive now. (author)

  5. Geochemical Cycling of Iodine Species in Soils

    Hu, Q.; Moran, J.E.; Blackwood, V.

    2007-01-01

    Iodine is an important element in studies of environmental protection and human health, global-scale hydrologic processes and nuclear nonproliferation. Biogeochemical cycling of iodine in soils is complex, because iodine occurs in multiple oxidation states and as inorganic and organic species that may be hydrophilic, atmophilic, and biophilic. In this study, we applied new analytical techniques to study the content and speciation of stable iodine in representative surface soils, and sorption and transport behavior of iodine species (iodide, iodate, and 4-iodoaniline) in sediments collected at numerous nuclear facilities in the United States, where anthropogenic 129 I from prior nuclear fuel processing activities poses an environmental risk. The surface soil samples were chosen for their geographic locations (e.g., near the ocean or nuclear facilities) and for their differing physico-chemical characteristics (organic matter, texture, etc). Extracted solutions were analyzed by IC and ICP-MS methods to determine iodine concentrations and to examine iodine speciation (iodide, iodate, and organic iodine). In natural soils, iodine is mostly (nearly 90% of total iodine) present as organic species, while inorganic iodine becomes important (up to 50%) only in sediments with low organic matter. Results from laboratory column studies, aimed at examining transport of different iodine species, showed much greater retardation of 4-iodoaniline than iodide or iodate. Careful attention must be given to potential interconversion among species when interpreting the biogeochemical behavior of iodine in the environment. In addition to speciation, input concentration and residence time effects will influence the biogeochemical cycling of anthropogenic 129I deposited on surface soils

  6. Recovery of iodine as iodine-125 from biological materials prior to assay

    Jones, G.B.; Belling, G.B.; Buckley, R.A.

    1979-01-01

    In biological tissues iodine is usually present as iodoamino acids or iodoproteins. The organic material must be oxidised and the iodine converted into iodate prior to the final spectrophotometric determination. At parts per billion (10 9 ) levels, recoveries of added iodine are difficult to measure precisely as iodine can easily be lost from the sample and added inorganic iodine may not be recovered in the same proportions as the naturally occurring iodine. Iodine-125 provides a much more sensitive, specific and accurate means of testing the recovery of nanogram amounts of iodine from biological tissues and it can be incorporated into tissues in the naturally occurring compounds. Plants can be grown in a solution culture containing iodine-125 and animals can be injected with iodine-125 to provide tissues where naturally occurring iodine compounds are labelled with radioactive iodine. These tissues can be used to examine the recovery of iodine after oven drying, freeze drying, alkali ashing and acid digestion of the samples. Experimental details are given for spinach, tobacco, oats, cauliflower and thyroid. Results are given and discussed. (author)

  7. Nighttime atmospheric chemistry of iodine

    Saiz-Lopez, Alfonso; Plane, John M. C.; Cuevas, Carlos A.; Mahajan, Anoop S.; Lamarque, Jean-François; Kinnison, Douglas E.

    2016-12-01

    Little attention has so far been paid to the nighttime atmospheric chemistry of iodine species. Current atmospheric models predict a buildup of HOI and I2 during the night that leads to a spike of IO at sunrise, which is not observed by measurements. In this work, electronic structure calculations are used to survey possible reactions that HOI and I2 could undergo at night in the lower troposphere, and hence reduce their nighttime accumulation. The new reaction NO3+ HOI → IO + HNO3 is proposed, with a rate coefficient calculated from statistical rate theory over the temperature range 260-300 K and at a pressure of 1000 hPa to be k(T) = 2.7 × 10-12 (300 K/T)2.66 cm3 molecule-1 s-1. This reaction is included in two atmospheric models, along with the known reaction between I2 and NO3, to explore a new nocturnal iodine radical activation mechanism. The results show that this iodine scheme leads to a considerable reduction of nighttime HOI and I2, which results in the enhancement of more than 25 % of nighttime ocean emissions of HOI + I2 and the removal of the anomalous spike of IO at sunrise. We suggest that active nighttime iodine can also have a considerable, so far unrecognized, impact on the reduction of the NO3 radical levels in the marine boundary layer (MBL) and hence upon the nocturnal oxidizing capacity of the marine atmosphere. The effect of this is exemplified by the indirect effect on dimethyl sulfide (DMS) oxidation.

  8. New iodine filter pack design

    Blackbee, B.A.

    1977-10-01

    To enable Naval Emergency Monitoring Teams to fulfil their role in the field it was necessary to locate or design a replacement filter pack for the collection of radioactive iodine air samples. Collaboration with the Berkeley Laboratories of the Central Electricity Generating Board provided the necessary starting point for a suitable type of package. Further development by NGTE (West Drayton) yielded the improved filter pack which is the subject of this memorandum. (author)

  9. Iodine frequency references for space

    Schuldt, Thilo; Braxmaier, Claus; Döringshoff, Klaus; Peters, Achim; Oswald, Markus; Johann, Ulrich

    2017-01-01

    Optical frequency references are a key element for the realization of future space missions. They are needed for missions related to tests of fundamental physics, gravitational wave detection, Earth observation and navigation and ranging. In missions such as GRACE follow-on or LISA the optical frequency reference is used as light source for high-sensitivity inter-satellite distance metrology. While cavity-based systems are current baseline e.g. for LISA, frequency stabilization on a hyperfine transition in molecular iodine near 532 nm is a promising alternative. Due to its absolute frequency, iodine standards crucially simplify the initial spacecraft acquisition procedures. Current setups fulfill the GRACE-FO and LISA frequency stability requirements and are realized near Engineering Model level. We present the current status of our developments on Elegant Breadboard (EBB) and Engineering Model (EM) level taking into account specific design criteria for space compatibility such as compactness (size iodine spectroscopy EM: 38 × 18 × 10 cm 3 ) and robustness. Both setups achieved similar frequency stabilities of ∼ 1 · 10 −14 at an integration time of 1 s and below 5 · 10 −15 at integration times between 10 s and 1000 s. Furthermore, we present an even more compact design currently developed for a sounding rocket mission with launch in 2017. (paper)

  10. Iodine Absorption Cells Purity Testing

    Jan Hrabina

    2017-01-01

    Full Text Available This article deals with the evaluation of the chemical purity of iodine-filled absorption cells and the optical frequency references used for the frequency locking of laser standards. We summarize the recent trends and progress in absorption cell technology and we focus on methods for iodine cell purity testing. We compare two independent experimental systems based on the laser-induced fluorescence method, showing an improvement of measurement uncertainty by introducing a compensation system reducing unwanted influences. We show the advantages of this technique, which is relatively simple and does not require extensive hardware equipment. As an alternative to the traditionally used methods we propose an approach of hyperfine transitions’ spectral linewidth measurement. The key characteristic of this method is demonstrated on a set of testing iodine cells. The relationship between laser-induced fluorescence and transition linewidth methods will be presented as well as a summary of the advantages and disadvantages of the proposed technique (in comparison with traditional measurement approaches.

  11. Experimental determination of the transfer functions feed/beaf, feed/pork, feed/milk for Cs-137, Co-60, Mu-54, Na-22, I-131, and Tc-95m

    Voigt, G.; Henrichs, K.; Proehl, G.; Paretzke, H.G.

    1986-05-01

    After the Chernobyl reactor accident, experimental studies have been made with a group of animals, and the results measured are presented in tabular form. The transfer factors of Na-22 have been found to be affected by the daily amount of stable sodium content in the feed. Mn-54 quantities in the feed have been too low to be measured. For two different feeding modes, equilibrium transfer factors of Co and Cs have been determined in pork. As to cereals and potatoe diets, upper limits of transfer have been found. The data obtained for the transfer factor of iodine to milk are in good agreement with published data. (DG) [de

  12. Iodine chemistry in a reactor regulation

    Powers, D.A.

    1996-01-01

    Radioactive iodine has always been an important consideration in the regulation of nuclear power reactors to assure the health and safety of the public. Regulators adopted conservatively bounding predictions of iodine behavior in the earliest days of the development of nuclear power because there was so little known about either accidents or the chemistry of iodine. Today there is a flood of new information and understanding of the chemistry of iodine under reactor accident conditions. This paper offers some thoughts on how the community of scientists engaged in the study of iodine chemistry can present the results of their work so that it is more immediately adopted by the regulator. It is suggested that the scientific community consider the concept of consensus standards so effectively used within the engineering community to define the status of the study of radioactive iodine chemistry for reactor safety. (author) 9 refs

  13. Iodine chemistry in a reactor regulation

    Powers, D A [Nuclear Regulatory Commission, Washington, DC (United States). Advisory Committee on Reactor Safeguards

    1996-12-01

    Radioactive iodine has always been an important consideration in the regulation of nuclear power reactors to assure the health and safety of the public. Regulators adopted conservatively bounding predictions of iodine behavior in the earliest days of the development of nuclear power because there was so little known about either accidents or the chemistry of iodine. Today there is a flood of new information and understanding of the chemistry of iodine under reactor accident conditions. This paper offers some thoughts on how the community of scientists engaged in the study of iodine chemistry can present the results of their work so that it is more immediately adopted by the regulator. It is suggested that the scientific community consider the concept of consensus standards so effectively used within the engineering community to define the status of the study of radioactive iodine chemistry for reactor safety. (author) 9 refs.

  14. Application of radiopharmaceuticals in iodine disorder studies

    Rajurkar, N.S.

    2015-01-01

    Iodine is an essential trace element and is of much interest in nutritional research. It is essential for the production of the hormones in the thyroid gland. However, deficiency or excess of iodine can cause disorders, commonly known as iodine disorders. Total quantity of iodine present in the body is 15-20 mg, mostly in thyroid gland and the safe and adequate intake of iodine is in the range of 50-200 μg.d -1 . Most of the iodine taken from food is accumulated in thyroid glands which plays a vital role in the well being as it controls growth and metabolism. In some people gland becomes over active (hyper thyroiditis) and in some people gland becomes sluggish (hypo thyroiditis). However, both the conditions are unhealthy and lead to serious consequences. The condition can be detected and treated with the help of radioiodine

  15. Criteria for safe working with iodine-125

    Linsley, G.S.

    1977-01-01

    Radio-immunoassay and other saturation assay tests involving the use of iodine-125 are finding wide application for the determination of hormone concentrations in biological fluids. In such tests, iodinations involving concentrations of a milli-curie per micro-litre are common. Iodine-125 presents a problem from the monitoring standpoint because of its low energy photon emission (27 and 35 keV). Iodine is preferentially taken up by the thyroid gland and work involving moderate amounts of radio-iodine may give rise to a significant hazard in an accident situation. The general precautions which should be taken in work with unsealed radioactive substances are briefly summarized, working limits for iodine-125 are identified, and methods of personal protection and monitoring in an emergency situation described. (author)

  16. Local radiolytic effectiveness of Auger electrons of iodine-125 in benzene-iodine solutions

    Uenak, P.; Uenak, T.

    1987-01-01

    High radiotoxicity of iodine-125 has been mainly attributed to the local radiolytic effects of Auger electrons on biological systems. In the present study, experimental and theoretical results are compared. The agreement between the experimental and theoretical results explains that the energy absorption of iodine aggregates has an important role in the radiolytic effectiveness of Auger electrons and iodine-125 in benzene-iodine solutions. (author) 18 refs.; 3 figs

  17. Measurement of thyroid volume, iodine concentration and total iodine content by CT and its clinical significance

    Nakaji, Shunsuke; Imanishi, Yoshimasa; Okamoto, Kyouko; Shinagawa, Toshihito

    2007-01-01

    Recently, Imanishi et al have developed new CT software for quantitative in vivo measurement of thyroid iodine. Using a CT system with the software, we measured volume, iodine concentration and total iodine content of thyroids in 63 controls and 435 patients with various diffuse thyroid diseases and thyroid nodules. In controls, all of them showed no difference between the sexes. Although the iodine concentration of the thyroid showed no difference among children, adults and seniles, the volume and total iodine content of the thyroid appeared smaller in children and seniles than in adults. In addition, although the volume and iodine concentration of the thyroid had two peaks in distribution, the total iodine content had almost normal distribution. Normal range of volume, iodine concentration and total iodine content in adults were 5.2-15.5 cm 3 , 0.28831-0.85919 mg/cm 3 and 2.35-11.69 mg, respectively. In thyroid nodule, there is no significant difference in volume, iodine concentration and total iodine content between benign and malignant nodules. All nodules with iodine concentration of less than 0.00007 mg/cm 3 were benign. No thyroid was higher in iodine concentration than the normal range although the thyroid was lower in 78.7% of patients with diffuse thyroid diseases. In all thyroids with increasing iodine concentration and total iodine content in medication course, thyroidal symptoms and signs were uncontrollable by the medication. In 43.8% of patients with long-period systemic diseases, the thyroid showed abnormality in any of the three. We concluded that quantitative in vivo measurement of thyroid iodine by CT could assist the diagnosis of thyroid diseases and decision of therapeutic methods. (author)

  18. Equine goiter associated with excess dietary iodine.

    Eroksuz, H; Eroksuz, Y; Ozer, H; Ceribasi, A O; Yaman, I; Ilhan, N

    2004-06-01

    Naturally occurring goiter cases are described in 2 newborn Arabian foals whose mares were supplemented with excess iodine during the final 24 w of the pregnancy. Six nursing foals and 2 mares were also affected clinically with thyroid hypertrophy. At least 12 times the maximum tolerable level of iodine supplementation was given, as the daily iodine intake for each mare was 299 mg. The prevalence of goiter cases was 2 and 9% in the mares and foals, respectively.

  19. Salivary gland dysfunction following radioactive iodine therapy

    Wiesenfeld, D.; Webster, G.; Cameron, F.; Ferguson, M.M.; MacFadyen, E.E.; MacFarlane, T.W.

    1983-01-01

    Radioactive iodine is used extensively for the treatment of thyrotoxicosis and thyroid carcinoma. Iodine is actively taken up by the salivary glands and, following its use, salivary dysfunction may result as a consequence of radiation damage. The literature is reviewed and a case is reported in which a patient presented with a significant increase in caries rate attributed to salivary dysfunction following radioactive iodine therapy for a thyroid carcinoma

  20. Estimation of iodine intake from various urinary iodine measurements in population studies

    Vejbjerg, P.; Knudsen, N.; Perrild, H.

    2009-01-01

    Background: Iodine intake is often measured by a surrogate measure, namely urine iodine excretion as almost all ingested iodine is excreted in the urine. However, the methods for urine collection and the reporting of the results vary. These methods, and their advantages and disadvantages, are con...

  1. Molecular environment of iodine in naturally iodinated humic substances: Insight from X-ray absorption spectroscopy

    Schlegel, Michel L.; Mercier-Bion, Florence; Barre, Nicole; Reiller, Pascal; Moulin, Valerie

    2006-01-01

    The molecular environment of iodine in reference inorganic and organic compounds, and in dry humic and fulvic acids (HAs and FAs) extracted from subsurface and deep aquifers was probed by iodine L-3-edge X-ray absorption spectroscopy. The X-ray absorption near-edge structure (XANES) of iodine spectra from HAs and FAs resembled those of organic references and displayed structural features consistent with iodine forming covalent bonds with organic molecules. Simulation of XANES spectra by linear combination of reference spectra suggested the predominance of iodine forming covalent bonds to aromatic rings (aromatic-bound iodine). Comparison of extended X-ray absorption fine structure (EXAFS) spectra of reference and samples further showed that iodine was surrounded by carbon shells at distances comparable to those for references containing aromatic-bound iodine. Quantitative analysis of EXAFS spectra indicated that iodine was bound to about one carbon at a distance d(I-C) of 2.01(4)-2.04(9) angstrom, which was comparable to the distances observed for aromatic-bound iodine in references (1.99(1)-2.07(6) angstrom), and significantly shorter than that observed for aliphatic-bound iodine (2.15(2)-2.16(2) angstrom). These results are in agreement with previous conclusions from X-ray photoelectron spectroscopy and from electro-spray ionization mass spectrometry. These results collectively suggest that the aromatic-bound iodine is stable in the various aquifers of this study. (authors)

  2. 127I Moessbauer study of some oxygen bonded iodine(I) and iodine(III) complexes

    Bardhan, M.; Birchall, T.; Frampton, C.; Kapoor, P.

    1988-01-01

    127 I Moessbauer spectra have been recorded at 4.2 0 K for a series of oxygen bonded iodine(I) and iodine(III) complexes. The sign of the quadrupole coupling constant is dependant only on the primary arrangement of ligands about the central iodine nucleus whereas the magnitude and the asymmetry parameter are more sensitive to ligand electronegativity and type. (orig.)

  3. Iodine deficiency in pregnancy and the effects of maternal iodine supplementation on the offspring: a review

    Zimmermann, M.B.

    2009-01-01

    The World Health Organization (WHO) recently increased their recommended iodine intake during pregnancy from 200 to 250 µg/d and suggested that a median urinary iodine (UI) concentration of 150-249 µg/L indicates adequate iodine intake in pregnant women. Thyrotropin concentrations in blood collected

  4. Iodine requirements and the risks and benefits of correcting iodine deficiency in populations

    Zimmermann, M.B.

    2008-01-01

    Iodine deficiency has multiple adverse effects on growth and development due to inadequate thyroid hormone production that are termed the iodine deficiency disorders (IDD). IDD remains the most common cause of preventable mental impairment worldwide. IDD assessment methods include urinary iodine

  5. Absorption spectrum of Iodine around 5915 A

    1990-01-01

    The iodine absorption spectrum around 5915 A is of interest for many authors especially the hyperfine structure of the iodine line. Lodine absorption spectrum was obtained due to the interaction of iodine vapour with dye laser [(R6G) (0.5A) scanning range around 5915 A] which is pumped by(Ar + )laser absorption spectrum. The decrease in the peak of the transmission line around 5915 A shows the signal futher decreased by heating the iodine cell. This analysis has been done using a monochromator

  6. Hygienic assessment of radioactive iodine isotopes

    Vasilenko, I.Ya.

    1987-01-01

    Sources of radioactive iodine isotopes and their biological significance depending on the way of intake are discussed. The degree of food contamination by radioactive iodine as well as products, which serve as the source of its intake into the human body, and results of their processing are considered. The danger of radioactive iodine intake by different groups of population as well as thyroid irradiation effects are discussed. Description of activities, directed to the human body protection against radioactive iodine and assessment of these protection measures efficiency is presented

  7. Iodine-129 in thyroids of grazing animals

    Ballad, R.V.; Holman, D.W.; Hennecke, E.W.; Johnson, J.E.; Manuel, O.K.; Nicholson, L.M.

    1976-01-01

    A combination of neutron activation and mass spectrometry has been used to determine the concentrations of fissiogenic 129 I and stable 127 I in thyroids of grazing animals and in mineral iodine. The 129 I/ 127 I ratios are lowest in mineral iodine and in a given area lower in cow thyroids than in deer thyroids. Near saturation levels of mineral iodine in commercial feeds and salt licks may account for differences in the 129 I levels of cows and deer. Values of the 129 I/ 127 I ratio in deer appear to vary inversely with the iodine concentration of the thyroid. (author)

  8. Photochemistry of DNA containing iodinated cytosine

    Rahn, R O; Stafford, R S [Oak Ridge National Lab., TN (USA)

    1979-10-01

    Irradiation at 313 nm of compounds containing iodinated cytosine moieties results in the photolysis of iodine. Photolysis occurs with a quantum yield of 0.022-0.024 for 5-iododeoxycytidine and 5-iododeoxycytidine monophosphate, and 0.004-0.008 for iodinated DNA as well as for iodinated polycytidylate. Photodegradation of the cytosine moiety occurs when air is present during irradiation, presumably due to the reaction of oxygen with the cytosyl radical formed when iodine is lost. This oxygen promoted photodegradation destroys the cytosine chromophore and is complete in the monomers but occurs to only a limited extent in the polymers. In the absence of oxygen or in the presence of ethanol, photodegradation is prevented and the loss of iodine leads exclusively to the formation of the cytosine chromophore. In DNA, the loss of iodine is accompanied by the formation of sugar damage and/or chain breaks. As measured by sedimentation in alkaline sucrose gradients, approximately one break is made for every six iodines lost in denatured DNA. The frequency of chain breakage per iodine photolyzed is reduced 2-fold in renatured DNA. Analysis in neutral gradients suggests that half of the breaks observed in alkali are alkali-labile bonds. Both ethanol and cysteamine reduce the number of chain breaks in alkali by approximately 3-fold.

  9. Iodine: It's Important in Patients that Require Parenteral Nutrition

    Zimmermann, M.B.

    2009-01-01

    Iodine deficiency has multiple adverse effects on growth and development because of inadequate thyroid hormone production. Four methods are generally recommended for assessment of iodine nutrition: urinary iodine concentration, thyroid size, and blood concentrations of thyroid-stimulating hormone

  10. FDA regulations regarding iodine addition to foods and labeling of foods containing added iodine12

    Trumbo, Paula R

    2016-01-01

    The US Food and Drug Administration (FDA) regulates the addition of iodine to infant formulas, the iodization of salt, and the addition of salt and iodine to foods. The required amount of iodine in infant formulas is based on caloric content, and the label must provide the iodine content per 100 kcal. Cuprous iodide and potassium iodide may be added to table salt as a source of dietary iodine at a maximum amount of 0.01%; if added, the label must indicate that the salt is iodized. Table salt to which iodine has not been added must bear the statement, “This salt does not supply iodide, a necessary nutrient.” If a nutrient is to be appropriately added to a food for the purpose of correcting a dietary insufficiency, there should be sufficient scientific information available to demonstrate a nutritional deficiency and/or identify a public health problem. Furthermore, the population groups that would benefit from the proposed fortification should be identified. If iodine is added to a food, the percent Daily Value of iodine must be listed. There are no FDA regulations governing ingredient standards for dietary supplements. As a result, some dietary supplements include iodine and others do not. If a supplement contains iodine, the Supplement Facts label must list iodine as a nutrient ingredient. If iodine is not listed on the Supplement Facts label, then it has not been added. There are similarities between the FDA, which establishes US food regulations and policies, and the Codex Alimentarius (Codex), which develops international food standards and guidelines under the aegis of the FAO and the WHO. Both the FDA and Codex call for the labeling of table salt to indicate fortification with iodine, voluntary labeling of iodine on foods, and a Daily Value (called a Nutrient Reference Value by Codex) of 150 μg for iodine. PMID:27534626

  11. Serum thyroglobulin and urinary iodine concentration are the most appropriate indicators of iodine status and thyroid function under conditions of increasing iodine supply in schoolchildren in Benin

    van den Briel, T.; West, C. E.; Hautvast, J. G.; Vulsma, T.; de Vijlder, J. J.; Ategbo, E. A.

    2001-01-01

    Iodine deficiency control programs have greatly reduced iodine deficiency disorders worldwide. For monitoring changes in iodine status, different indicators may be used. The aim of this study was to evaluate the suitability of indicators of iodine status and thyroid function, thyroglobulin (Tg),

  12. Consuming iodine enriched eggs to solve the iodine deficiency endemic for remote areas in Thailand

    Teeyapant Punthip

    2010-12-01

    Full Text Available Abstract Background Evidence showed that the occurrence of iodine deficiency endemic areas has been found in every provinces of Thailand. Thus, a new pilot programme for elimination of iodine deficiency endemic areas at the community level was designed in 2008 by integrating the concept of Sufficient Economic life style with the iodine biofortification of nutrients for community consumption. Methods A model of community hen egg farm was selected at an iodine deficiency endemic area in North Eastern part of Thailand. The process for the preparation of high content iodine enriched hen food was demonstrated to the farm owner with technical transfer in order to ensure the sustainability in the long term for the community. The iodine content of the produced iodine enriched hen eggs were determined and the iodine status of volunteers who consumed the iodine enriched hen eggs were monitored by using urine iodine excretion before and after the implement of iodine enrichment in the model farm. Results The content of iodine in eggs from the model farm were 93.57 μg per egg for the weight of 55 - 60 g egg and 97.76 μg for the weight of 60 - 65 g egg. The biological active iodo-organic compounds in eggs were tested by determination of the base-line urine iodine of the volunteer villagers before and after consuming a hard boiled iodine enriched egg per volunteer at breakfast for five days continuous period in 59 volunteers of Ban Kew village, and 65 volunteers of Ban Nong Nok Kean village. The median base-line urine iodine level of the volunteers in these two villages before consuming eggs were 7.00 and 7.04 μg/dL respectively. After consuming iodine enriched eggs, the median urine iodine were raised to the optimal level at 20.76 μg/dL for Ban Kew and 13.95 μg/dL for Ban Nong Nok Kean. Conclusions The strategic programme for iodine enrichment in the food chain with biological iodo-organic compound from animal origins can be an alternative method to

  13. Evaluating complications of local anesthesia administration and reversal with phentolamine mesylate in a portable pediatric dental clinic.

    Boynes, Sean G; Riley, Amah E; Milbee, Sarah; Bastin, Meghan R; Price, Maylyn E; Ladson, Andrea

    2013-08-01

    This study sought to identify and quantify complications with local anesthetic administration and reversal on consecutive patients seen for comprehensive dental care in a school-based, portable dental clinic, and includes data on the patients seen by the participating portable dental providers. In 923 dental visits where local anesthetic was administered, a standardized form was used to gain further information and identify any complications; this was accompanied by a questionnaire for the student's teacher, in order to quantify the student's distraction and disruption ratings following the dental visit. After statistical analysis of the 923 consecutive cases, the overall complication rate was 5.3%. All of the complications were considered to be mild or moderate, and there were no severe event reports. The complications encountered most frequently (n = 49) were associated with self-inflicted soft tissue injury. The results of this study indicate that comprehensive care with local anesthesia delivered by a school-based portable dental clinic has a low risk of complications. Whereas safe administration of dental care is achievable with or without phentolamine mesylate as a local anesthetic reversal agent, its use was determined to improve safety outcomes. Three factors appeared to directly increase the incidence of complications: the administration of an inferior alveolar nerve block, attention deficit disorder, and obesity. Teacher evaluations demonstrated that children receiving care by a portable dental team were able to reorient back to classwork and were not disruptive to classmates.

  14. Thermodynamic solution properties of pefloxacin mesylate and its interactions with organized assemblies of anionic surfactant, sodium dodecyl sulphate

    Usman, Muhammad; Rashid, Muhammad Abid; Mansha, Asim; Siddiq, Mohammad

    2013-01-01

    Graphical abstract: - Highlights: • Free energy of adsorption is more negative than free energy of micellization. • Micellization becomes more spontaneous at high temperature. • There is strong interaction between PFM and SDS. - Abstract: This manuscript reports the physicochemical behavior of antibiotic amphiphilic drug pefloxacin mesylate (PFM) and its interaction with anionic surfactant, sodium dodecyl sulfate (SDS). The data of surface tension and electrical conductivity are helpful to detect the CMC as well as to calculate surface parameters, i.e. surface pressure, π, surface excess concentration, Γ, area per molecule of drug and standard Gibbs free energy of adsorption, ΔG ads and thermodynamic parameters like standard free energy of micellization, ΔG m , standard enthalpy of micellization, ΔH m and standard entropy of micellization, ΔS m . The interaction of this drug with anionic surfactant, sodium dodecyl sulfate (SDS) was studied by electrical conductivity and UV/visible spectroscopy. This enabled us to compute the values of partition coefficient (K x ), free energy of partition, ΔG p , binding constant, K b , free energy of binding, ΔG b , number of drug molecules per micelle, n, and thermodynamic parameters of drug–surfactant interaction

  15. Measurement and prediction of dabigatran etexilate mesylate Form II solubility in mono-solvents and mixed solvents

    Xiao, Yan; Wang, Jingkang; Wang, Ting; Ouyang, Jinbo; Huang, Xin; Hao, Hongxun; Bao, Ying; Fang, Wen; Yin, Qiuxiang

    2016-01-01

    Highlights: • Solubility of DEM Form II in mono-solvents and binary solvent mixtures was measured. • Regressed UNIFAC model was used to predict the solubility in solvent mixtures. • The experimental solubility data were correlated by different models. - Abstract: UV spectrometer method was used to measure the solubility data of dabigatran etexilate mesylate (DEM) Form II in five mono-solvents (methanol, ethanol, ethane-1,2-diol, DMF, DMAC) and binary solvent mixtures of methanol and ethanol in the temperature range from 287.37 K to 323.39 K. The experimental solubility data in mono-solvents were correlated with modified Apelblat equation, van’t Hoff equation and λh equation. GSM model and Modified Jouyban-Acree model were employed to correlate the solubility data in mixed solvent systems. And Regressed UNIFAC model was used to predict the solubility of DEM Form II in the binary solvent mixtures. Results showed that the predicted data were consistent with the experimental data.

  16. Spectrofluorimetric determination of gemifloxacin mesylate and linezolid in pharmaceutical formulations: Application of quinone-based fluorophores and enhanced native fluorescence

    Moussa Bahia Abbas

    2014-03-01

    Full Text Available Quinone-based fluorophores and enhanced native fluorescence techniques were applied for a fast quantitative analysis of gemifloxacin mesylate (GEM and linezolid (LIN in pharmaceutical formulations. For this purpose, three sensitive, accurate and precise spectrofluorimetric methods were developed. GEM, as an n-electron donor, reacts with 7,7,8,8-tetracyanoquinodimethane (method A and 2,5-dichloro-3,6-dihydroxy-p-benzoquinone (method B as п-electron acceptors, forming charge transfer complexes that exhibit high fluorescence intensity at 441 and 390 nm upon excitation at 260 and 339 nm, respectively. Method C depends on measurement of enhanced native fluorescence of LIN in phosphate buffer (pH 5 at 380 nm upon excitation at 260 nm. Experimental factors affecting fluorescence intensity were optimized. Linearity was obtained over concentration ranges 50-500, 10-60 and 20-400 ng mL-1 for methods A, B and C, respectively. The developed methods were validated and successfully applied for determination of the cited drugs in tablets.

  17. Electroanalytical Determination of Gemifloxacin Mesylate in Bulk, Tablets and Human Urine Using Gold Nanoparticles Modified Carbon Paste Electrode

    Ali Attia

    2014-12-01

    Full Text Available A simple, precise, inexpensive and sensitive voltammetric method has been developed for the determination of gemifloxacin mesylate (GEM in the presence of tween 80 in the bulk, farmaceutical dosage forms and human urine at gold nanoparticles modified carbon paste electrode (GNCPE. The electrochemical behavior of GEM has been investigated by using cyclic voltammetry (CV and differential pulse voltammetry (DPV techniques. The electrochemical oxidation of GEM was an irreversible process which exhibited adsorption-diffusion controlled process behavior in Britton-Robinson (BR buffer over the entire pH range of values from 2 to 9. The adsorptive stripping response was evaluated as a function of some variables such as pH, type of surfactant, scan rate and accumulation time. The anodic peak current varied linearly over the range from 8.0 × 10-7 to 2.8 × 10-5 M. The limits of detection and quantification were 7.32 × 10-8 M and 2.44 × 10-7 M, respectively. The relative standard deviations and the percentage recoveries were found in the following ranges: 0.58-1.35% and 99.37-101.76%, respectively.

  18. Experimental study on iodine chemistry (EXSI) - Containment experiments with elemental iodine

    Kaerkelae, T.; Auvinen, A.; Holm, J.; Ekberg, C.; Glaenneskog, H.

    2009-10-01

    The behaviour of iodine during a severe accident has been studied in several experimental programs, ranging from the large-scale PHEBUS FP tests and intermediate-scale ThAI tests to numerous separate effect studies. Oxidation of iodine in gas phase has been one of the greatest remaining uncertainties in iodine behaviour during a severe accident. In this study the possible formation of iodine oxide aerosol due to radiolytic oxidation of gaseous iodine is experimentally tested and the reaction products are analysed. The experimental facility applied in this study is based on the sampling system built at VTT for ISTP program project CHIP conducted IRSN. The experimental facility and the measuring technology are sophisticated and unique in the area of nuclear research as well as in the field of aerosol science. The results from the experiments show an extensive particle formation when ozone and gaseous iodine react with each other. The formed particles were collected on filters, while gaseous iodine was trapped into bubbles. The particles were iodine oxides and the size of particles was approximately 100 nm. The transport of gaseous iodine through the facility decreased when both gaseous iodine and ozone were fed together into facility. Experimental study on radiolytic oxidation of iodine was conducted in co-operation between VTT and Chalmers University of Technology as a part of the NKS-R programs. (author)

  19. Experimental study on iodine chemistry (EXSI) - Containment experiments with elemental iodine

    Kaerkelae, T.; Auvinen, A. (VTT Technical Research Centre of Finland (Finland)); Holm, J.; Ekberg, C. (Chalmers Univ. of Technology (Sweden)); Glaenneskog, H. (Vattenfall Power Consultant (Sweden))

    2009-10-15

    The behaviour of iodine during a severe accident has been studied in several experimental programs, ranging from the large-scale PHEBUS FP tests and intermediate-scale ThAI tests to numerous separate effect studies. Oxidation of iodine in gas phase has been one of the greatest remaining uncertainties in iodine behaviour during a severe accident. In this study the possible formation of iodine oxide aerosol due to radiolytic oxidation of gaseous iodine is experimentally tested and the reaction products are analysed. The experimental facility applied in this study is based on the sampling system built at VTT for ISTP program project CHIP conducted IRSN. The experimental facility and the measuring technology are sophisticated and unique in the area of nuclear research as well as in the field of aerosol science. The results from the experiments show an extensive particle formation when ozone and gaseous iodine react with each other. The formed particles were collected on filters, while gaseous iodine was trapped into bubbles. The particles were iodine oxides and the size of particles was approximately 100 nm. The transport of gaseous iodine through the facility decreased when both gaseous iodine and ozone were fed together into facility. Experimental study on radiolytic oxidation of iodine was conducted in co-operation between VTT and Chalmers University of Technology as a part of the NKS-R programs. (author)

  20. Altering iodine metabolism in the calf by feeding iodine-binding agents

    Miller, J.K.; Swanson, E.W.; Lyke, W.A.; Byrne, W.F.

    1975-01-01

    Effects of feeding cottonseed meal and anion-exchange resin on iodine absorption and excretion by calves were investigated. Each additional amount of resin fed from 0.3 to 3.5 g/kg body weight further increased fecal excretion from single oral iodine-131 and intravenous iodine-125 doses. By feeding 3 to 10 g cottonseed meal/kg body weight, excretion of oral iodine-131 given daily was increased 7 to 94 percent in feces and reduced as much as 35 percent in urine, but plasma iodine-131 was not changed. Introducing 1 g resin/kg body weight daily into the diet increased fecal iodine-131 excretion three to five times that with cottonseed meal alone and reduced both plasma and urinary iodine-131. The same amount of resin fed daily had similar effects on excretion of iodine-131 injected subcutaneously each day. Although iodine depletion by a highly efficient iodine binder (resin) in the gastrointestinal tract is probable, iodine binding by a natural feed constituent (cottonseed meal) was relatively inefficient. (U.S.)